




TEXTBOOK OF MEDICINAL CHEMISTRY



VOLUME
I

V. Alagarsamy

TEXTBOOK OF MEDICINAL CHEMISTRY

Volume I

"This page intentionally left blank"

TEXTBOOK OF MEDICINAL CHEMISTRY

Volume I


V. Alagarsamy

M Pharm, PhD, FIC, DOMH

Professor and Principal

MNR College of Pharmacy, Sangareddy

Gr. Hyderabad



ELSEVIER

A division of

Reed Elsevier India Private Limited

Textbook of Medicinal Chemistry, Volume I

Alagarsamy

ELSEVIER

A division of

Reed Elsevier India Private Limited

Mosby, Saunders, Churchill Livingstone, Butterworth Heinemann and Hanley & Belfus are the Health Science imprints of Elsevier.

© 2010 Elsevier

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopying, recording, or any information storage and retrieval system without the prior written permission from the publisher and the copyright holder.

ISBN: 978-81-312-2189-1

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors, editors, contributors and the publisher have, as far as it is possible, taken care to ensure that the information given in this text is accurate and up-to-date. However, readers are strongly advised to confirm that the information, especially with regard to drug dose/usage, complies with current legislation and standards of practice. ***Please consult full prescribing information before issuing prescriptions for any product mentioned in the publication.***

Published by Elsevier, a division of Reed Elsevier India Private Limited

Registered Office: Gate No. 3, Building No. A-1, 2 Industrial Area, Kalkaji, New Delhi-110019

Corporate Office: 14th Floor, Building No. 10B, DLF Cyber City, Phase II,
Gurgaon-122002, Haryana, India

Commissioning Editor: Nimisha Goswami

Development Editor: Subodh K. Chauhan

Manager Publishing Operations: Sunil Kumar

Manager Production: N.C. Pant

Typeset by Televijay Technologies (P) Ltd., Chennai.

Printed and bound at Rajkamal Electric Press, Kundli, Haryana.

Preface

Medicinal chemistry emerged as a specialized area due to the development in chemistry and biology, hence it is considered as a highly interdisciplinary science combining a wide variety of subjects such as organic chemistry, pharmacology, biochemistry, toxicology, pharmacognosy, molecular biology, genomics, proteomics, computational chemistry, physical chemistry and statistics. Now, the growth of medicinal chemistry has reached a stage where the activity-guided synthesis of compounds is possible rather than screening of synthesized compounds for different biological activities. This field also penetrates into the areas of gene therapy and biochemistry-based virtual drug receptors with the help of computer-aided molecular modeling techniques.

This book is an upshot of my vision to discover the best book on medicinal chemistry, which deals about the concise description of diseases, clear classification of drugs with their chemical structures, synthesis of each drug with different routes, mode of action, metabolism, physical and pharmacological properties along with their therapeutic uses, assay technique, dose, official dosage forms and summary of structure–activity relationship (SAR) studies. Swathing the entire features of medicinal chemistry, first of its kind, is the unique feature of this book. It facilitates the students to understand the subject more easily and interestingly.

While writing this book, I felt that the book will bring about a re-orientation in the teaching and learning process of medicinal chemistry. Academic community in India is faced with scarcity of books to cater to their needs. Numerous foreign writers' books deal well about basics and pharmacological aspects related to medicinal chemistry, but lack two major requirements, i.e. synthesis and clear classification of drugs used. Some Indian authors filled this lacuna to a certain extent by including the synthesis, but failed to give a clear classification of drugs with their chemical structure. For this, the content of this book has been carefully tailored to cater the needs of the academicians belonging to all Indian universities, pharmacologists, clinical and industrial pharmacists by incorporating the missing links between general synthetic organic chemistry and medicinal chemistry.

This *Textbook of Medicinal Chemistry* is presented in two volumes. Volume I consists of six sections. The first section is devoted to the physicochemical properties and their relation to biological activities and the second section provides the framework of drug design, which together form the basic aspects of medicinal chemistry. The remaining sections, III to VI, deal with chemical, pharmacological, biochemical and toxicological aspects of organic medicinal compounds used in various diseases associated with different systems of the human body such as CNS, ANS, CVS and urinary system.

We hope that this special volume will be a good source of information and reference for not only graduate and postgraduate students but also basic and applied researchers in this field. Moreover, it will also be of interest to a wide range of scientists, including organic chemists, biochemists, pharmacologists and clinicians, who are interested in drug research. I welcome suggestions and constructive criticism from all corners of scientific community.

V. Alagarsamy

Acknowledgements

I wish to place on record my heartfelt thanks to everyone who have made this book possible, especially my beloved teachers from first standard to doctoral programme guides, Dr Rajani Giridhar and Dr M.R. Yadav.

I am immensely grateful to Dr B. Suresh and Dr R.K. Goyal for inspiring and initiating me to write the book.

I am grateful to Shri M.N. Raju, Chairman, and Mr Ravi Varma, Director, MNR Educational Trust, Hyderabad, for providing constant encouragement and moral support to achieve this goal.

I express my sincere appreciation to my students, Dr V. Raja Solomon (postdoctoral researcher, Laurentian University, Canada), Mr J.C. Hanish Singh, Mr P. Parthiban, Mr S. Thiru Senthil Murugan and Ms J. Rajeshwari, for helping me author this book. I also thank my colleagues, especially, Mr S. Satheesh Kumar, Mr B. Subba Rao, Mr R. Chandrasekar and Mr M. Shahul Hameedh, for their untiring support in making this book.

The friendly interaction I had experienced with the Elsevier team, Ms Ritu Sharma, Ms Nimisha Goswami, Mr Subodh K. Chauhan, and Televijay Technologies Project Manager Ms Usha K. Nair, offered a plenty of energy to eliminate the fatigue during the preparation of this book. If the author gets such a cooperative and energetic publication team, publishing any number of books will not be a difficult task. I thank them wholeheartedly for helping me reach this target and am requesting them to continue their service to the author community in the same intensity.

The stimulation I got from my father, mother, sister, brothers and wife to reach this target is more than analeptics, and the patience and cooperation extended by my children, Aish and Abhi, made me think of the goal without any diversion. To express my thankfulness, I pray The Almighty to bless my children with teachers like those I got in my life so that they too are inspired by their teachers and dedicate to the field of medicinal chemistry and, in turn, serve for the suffering humanity.

V. Alagarsamy

"This page intentionally left blank"

Contents

<i>Preface</i>		v
<i>Acknowledgements</i>		vii
	Introduction to Medicinal Chemistry	1
	• Processes of Drug Discovery • Drug Discovery and Design—A Historical Outline • Modern Drug Discovery • Screening and Designing • Nature as a Source of Drug Compounds • Drug Designing	
SECTION I	Physicochemical Factors in Relation to Biological Activity of Drugs	9
Chapter 1	Physicochemical Properties	11
Chapter 2	Ferguson Principle	13
Chapter 3	Hydrogen Bonding	15
Chapter 4	Ionization and pKa Value	19
Chapter 5	Redox Potential	22
Chapter 6	Surface Tension	25
Chapter 7	Complexation	27
Chapter 8	Steric Features of Drugs	30
Chapter 9	Bioisosterism	36
SECTION II	Drug Design	41
Chapter 1	Concepts of Drug Design	43
	• Design of Analogues and Pro-drugs • Design of Lead and Lead Discovery • Rational Approach to Drug Design	

Chapter 2	Receptors	49
	• Types of Receptors • Theories of Receptors • Forces Involved in Drug Receptors Interaction • Factors Affecting the Drug-Receptors Interaction	
Chapter 3	Computer-Aided Drug Design	54
	• Bioinformatics Hub	
Chapter 4	Structure–Activity Relationship and Quantitative Structure–Activity Relationship	56
	• Historical Development of QSAR • Basic Requirements for QSAR Analysis • Model Development Procedures	
Chapter 5	Combinatorial Chemistry	66
	• Combinatorial Compound Libraries	
Chapter 6	Pro-Drugs	71
	• Classification of Pro-drugs • Application of Pro-drugs	
SECTION III	Drugs Acting on Central Nervous System	83
Chapter 1	Central Nervous System	85
Chapter 2	Sedatives and Hypnotics	88
	• Molecular Basis of Inhibitory Neurotransmitters • Classification • Synthesis and Drug Profile • SAR of Barbiturates; SAR of Benzodiazepines	
Chapter 3	General Anaesthetics	130
	• Stages of Anaesthesia • Classification • Synthesis and Drug Profile	
Chapter 4	Local Anaesthetics	150
	• Classification • Synthesis and Drug Profile • SAR of Benzoic Acid Derivatives • SAR of Anilides	
Chapter 5	Tranquillizers	178
	• General Mode of Action • Classification • Synthesis and Drug Profile • SAR of Phenothiazines; SAR of Butyrophenones	

Chapter 6	Antidepressants	204
	• Classification • Synthesis and Drug Profile • SAR of Dibenzazepines; SAR of Dibenzocycloheptane Derivatives	
Chapter 7	CNS Stimulants	229
	• Classification • Synthesis and Drug Profile	
Chapter 8	Narcotic Analgesics	247
	• Synthesis and Drug Profile • SAR of Morphine Derivatives; SAR of Meperidine Analogues; SAR of Methadone Derivatives; SAR of Benzomorphan Derivatives • Narcotic Antagonists • Classification • Synthesis and Drug Profile	
Chapter 9	Anticonvulsants	286
	• Classification • Synthesis and Drug Profile • SAR of Hydantoins; SAR of Oxazolidine Diones; SAR of Phenacemide Analogues	
Chapter 10	Anti-Prakinsonism Agents	317
	• Classification • Synthesis and Drug Profile	
Chapter 11	Skeletal Muscle Relaxants	329
	• Classification • Synthesis and Drug Profile	
Chapter 12	Alzheimer's Disease	344
	• Pathogenesis; Treatment	
SECTION IV	Drugs Acting on Autonomic Nervous System	349
Chapter 1	Autonomic Nervous System	351
Chapter 2	Adrenergic Drugs	356
	• Physiological Basis of Adrenergic Receptors Function • General Classification of Adrenergic Agonists • Synthesis and Drug Profile • Structural–Activity Relationship	
Chapter 3	Cholinergic Drugs	378
	• Spectrum of Cholinomimetic Drugs • Classification • Synthesis and Drug Profile • Structure–Activity Relationship	

Chapter 4	Adrenergic Blockers	398
	• Physiological Basis of Adrenergic Receptor Antagonists • Classification • Synthesis and Drug Profile • Structure–Activity Relationship	
Chapter 5	Anticholinergic Drugs	419
	• Difference Between the Quaternary and the Tertiary Antimuscarinics • Classification • Synthesis and Drug Profile • SAR of Atropine Analogues; SAR of Muscarinic Antagonists	
SECTION V	Drugs Acting on Cardiovascular System	445
Chapter 1	Cardiovascular System	447
Chapter 2	Antihypertensive Drugs	449
	• Classification • Synthesis and Drug Profile	
Chapter 3	Antiarrhythmic Drugs	476
	• Classification • Synthesis and Drug Profile	
Chapter 4	Antihyperlipidaemic Agents	499
	• Classification • Synthesis and Drug Profile	
Chapter 5	Antianginals	520
	• Principles of Therapy for Angina • Classification • Synthesis and Drug Profile • SAR of Dihydropyridine Derivatives	
SECTION VI	Drugs Acting on Urinary System	547
Chapter 1	Urinary System	549
Chapter 2	Diuretics	551
	• Classification • Synthesis and Drug Profile; SAR of Thiazide Derivatives; SAR Carbonic Anhydrase Inhibitors; SAR of Loop Diuretics	

Contents of Medicinal Chemistry, Volume II

SECTION I	Drugs Acting on Inflammation/Allergy	1
Chapter 1	Antihistamines	3
	• Structure Activity Relationship—H ₁ Receptor Antagonists • Classification • Synthesis and Drug Profile	
Chapter 2	Prostaglandins	46
	• Functions of PGs • Biosynthesis • Synthesis and Drug Profile	
Chapter 3	Analgesics, Antipyretics and NSAIDs	56
	• Classification • SAR of Salicylates; Synthesis and Drug Profile; SAR of <i>p</i> -Amino Phenol Derivatives; SAR of 3,5-Pyrazolidine Diones; SAR of Anthranilic Acid Derivatives; SAR of Aryl Alkanoic Acid Derivatives; SAR of Indole Acetic Acid Derivatives; SAR of Oxicams	
SECTION II	Drugs Acting on Respiratory System	107
Chapter 1	Expectorants and Antitussives	109
	• Introduction to Respiratory System • Expectorants and Antitussives • Classification • Synthesis and Drug Profile	
Section III	Drugs Acting on Digestive System	119
Chapter 1	Antiulcer Agents	121
	• Classification • Synthesis and Drug Profile • SAR of H ₂ -Receptor Antagonists	
Chapter 2	Antidiarrhoeals	137
	• Synthesis and Drug Profile	

SECTION IV	Drugs Acting on Blood and Blood-Forming Organs	143
Chapter 1	Coagulants	145
	• Classification • Anticoagulants; Classification; Synthesis and Drug Profile	
Chapter 2	Plasma Expanders	160
SECTION V	Drugs Acting on Endocrine System	163
Chapter 1	Oral Hypoglycaemic Drugs	165
	• Classification • Synthesis and Drug Profile • SAR of Sulphonyl Ureas	
Chapter 2	Steroids	192
	• Steroid Nomenclature and Structure • Progestogens • Oestrogens • Androgens and Anabolic Agents	
Chapter 3	Antithyroid Drugs	215
	• Classification • Synthesis and Drug Profile	
SECTION VI	Chemotherapy	221
Chapter 1	History and Development of Chemotherapy	223
	• Historical Background • Spectrum of Activity of Chemotherapeutic Agents	
Chapter 2	Antibacterial Sulphonamides	229
	• SAR of Sulphonamides • Classification • Synthesis and Drug Profile	
Chapter 3	Quinolone Antibacterials	254
	• Effective Antibacterial Quinolone Derivatives • Synthesis and Drug Profile • SAR of Quinolones	
Chapter 4	Antibiotics	265
	• Classification • Penicillins; Cephalosporins; Amino Glycoside Antibiotics; Tetracyclins; Polypeptide Antibiotics; Macrolide Antibiotics; Lincomycins; Other Antibiotics	

Chapter 5	Antitubercular Agents	331
	• Synthesis and Drug Profile	
Chapter 6	Antifungal Agents	344
	• Classification • Synthesis and Drug Profile	
Chapter 7	Antiviral Agents	364
	• Classification • Synthesis and Drug Profile	
	• SAR of Amantadine Analogues	
Chapter 8	Antiamoebic Agents	401
	• Classification of Amoebicides • Synthesis and Drug Profile	
Chapter 9	Antimalarials	409
	• Life Cycle of Plasmodium • Classification	
	• Synthesis and Drug Profile • Structure–Activity Relationship	
Chapter 10	Anthelmintics	435
	• Classification • Synthesis and Drug Profile	
Chapter 11	Antineoplastic Agents	455
	• Classification • Synthesis and Drug Profile	
Chapter 12	Antileprotic Drugs	511
	• Classification • Synthesis and Drug Profile	

"This page intentionally left blank"

Introduction to Medicinal Chemistry

Medicinal chemistry is a discipline at the intersection of chemistry and pharmacology that involves the identification, synthesis, and development of new chemical entities that are suitable for medical or pharmaceutical use. Medicinal chemistry is an interdisciplinary science combining variety of subjects such as organic chemistry, phytochemistry, pharmacology, toxicology, molecular biology, biochemistry, computational chemistry, physical chemistry, and statistics. It also includes the study of existing drugs, their pharmacological properties, toxic effects, and their quantitative structure-activity relationships (QSARs).

Majority of the medicinal compounds, which are used as medicines are natural products and synthetic organic compounds. However, metal-containing compounds are also found to be useful as drugs. For example, cisplatin series of platinum-containing complexes are used as anticancer agents. These compounds are known as metal-based drugs.

PROCESSES OF DRUG DISCOVERY

Discovery

The initial step of drug discovery involves the identification of new active compounds, often called 'hits or leads', which are found by screening many compounds of synthetic or natural sources, such as plants, animals, or microorganisms for their targeted biological properties. More often, the hits use to come from synthetic sources, such as historical compound collections and combinatorial chemistry.

Optimization

The second step in drug discovery involves further chemical alterations on structure activity relationship (SAR) basis to enhance the biological and physicochemical properties of a given candidate compound library. The chemical modifications can improve the binding property and interaction (pharmacophores) of the drug candidate compounds, their affinities, and pharmacokinetics, or indeed, their reactivity and stability during their metabolic degradation. Among the methods that have contributed to the quantitative metabolic prediction, a recent example is substrate product occurrence ratio calculator (SPORCalc).

The identified pharmacophores play an important role in finding the lead compounds, which exhibit the most potency, the best pharmacokinetics, and the least toxicity. The QSAR molecular modelling tools, such as comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA), which leads to tabulated data and first- and second-order equations. Among the theories related to these, the most relevant being Hansch's analysis that involves Hammett electronic parameters, steric parameters, and LogP (lipophilicity) parameters.

Development

The final step involves rendering the lead compounds that are suitable for use in the clinical trials after their successful pharmacodynamic optimization in clinical trials, the optimization of the synthetic route for bulk production, and the preparation of a suitable drug formulation.

DRUG DISCOVERY AND DESIGN—A HISTORICAL OUTLINE

Many years ago peoples used a wide range of natural products for medicinal purpose. These products obtained from animals, vegetables and mineral sources were sometimes very effective. But, many of the products were found to be toxic and it is interesting note that the Greeks used the same word *pharmakon* for both poisons and medicinal products. Literatures about the ancient remedies was not readily available for use until the invention of the printing press in the 15th century.


In the 19th century, extraction procedures and pure isolated entities (i.e. pure form of substances, such as alkaloids, carbohydrates, etc.) were reported to be in existence. Some of the isolated compounds were proved to be satisfactory as therapeutic agents. The majority of the plant or natural products were believed to be too toxic, such as morphine and cocaine, which was extensively prescribed by physicians.

In the search of finding less toxic medicines than these, on the basis of natural sources, resulted in the introduction of synthetic substances such as drugs in the late 19th century. These improvements were based on the structures of the known biologically active compounds, now referred to as 'leads'. By adopting this approach, structurally related compounds were developed for the targeted activity. These lead-related compounds are referred to as analogues.

In 1910, Paul Ehrlich and Saccachiro Hata synthesized the first synthetic drug, Arsphenamine, by combining synthesis with reliable biological screening and evaluation procedures. At the beginning of 19th century, Ehrlich recognized the fact that expected biological and toxic properties of drugs were important in their screening. He demonstrated that the more effective drugs showed a greater selectivity for target microorganism than its host. Consequently, to compare the effectiveness of different compounds, he expressed drug selectivity by a term known as chemotherapeutic index, which he defined as follows:

Chemotherapeutic index = Minimum effective dose/maximum tolerable dose

On the basis of this concept, over 600 structurally related arsenic compounds were tested and catalogued in terms of the therapeutic index by Paul and Hata. This has led to the discovery of Arsphenamine (Salvarsan, Hoechst, German) in 1909, that could cure mice infected with syphilis. This drug was found to be effective in humans, but it must be used with extreme care, as it is very toxic. However, it was replaced by penicillin in mid-1940s.



Ehrlich's method of approach is still one of the basic techniques used to design and evaluate new drugs in medicinal chemistry. Recently, chemotherapeutic index has been updated to take into account the variability of individuals, and is now defined as its reciprocal, therapeutic index or ratio.

$$\text{Therapeutic index} = \text{LD}_{50}/\text{ED}_{50}$$

where LD_{50} is the lethal dose that is required to kill 50% of the test animals or microorganisms, and ED_{50} is the effective dose that is required to produce a therapeutic response in 50% of the test animals or microorganisms. However, the therapeutic index values can only be used as a limited guide of relative usefulness for the different compounds.

Apart from this, serendipity has played a large part in the discovery of drugs. For example, the development of penicillin by Florey and Chain was possible only because of Alexander Fleming, who noted the inhibition of *Staphylococcus* by *Penicillium notatum*. Despite our increased knowledge base, it is still necessary to pick a correct starting point for an investigation, if a successful outcome is to be achieved. However, modern techniques, such as computerized molecular modelling and combinatorial chemistry introduced in 1970s and 1990s, respectively, are likely to reduce the number of intuitive discoveries.

MODERN DRUG DISCOVERY

A new approach to drug discovery is to understand how the diseases and infections are controlled at the molecular and physiological level and to target specific entities based on this knowledge. This process of drug discovery involves the identification of the candidates, synthesis, characterization, screening, and assays for its therapeutic efficacy. Once a compound has proved its value in these tests, the process of drug development starts prior to the clinical trials.

Despite the advances in technology and understanding of the biological systems, drug discovery is still a long process with a low rate of new therapeutic discoveries. Information on the human genome, its sequence, and what it encodes has been hailed as a potential windfall for drug discovery, promising to virtually eliminate the bottlenecks in therapeutic targets that have been one of the limiting factors on the rate of therapeutic discovery.

Targets—New and Established

Those targets for which there is good scientific understanding, supported by lengthy publication history of both as to how the target functions in normal physiology and how it is involved in human pathology are called as 'established targets'. It is directed to the extent of background information available on a target, in particular, functional information and does not imply that the mechanism of the action of drugs that are thought to act through particular established targets is fully understood. Less investment is, generally, required to develop a therapeutic directed against the target for which more such information is available. The process of gathering such functional information is called 'target validation' in pharmaceutical industry parlance. Established targets provide information on the chemical feasibility of developing a small molecular therapeutic against the target, and can provide licensing opportunities and freedom to operate indicators with respect to small molecule therapeutic candidates.

In general, 'new targets' are those targets that are not 'established targets', but which have been or are the subject of drug discovery campaigns. These typically include newly discovered proteins or proteins

whose functions have now become clear as a result of basic scientific research. The majority of the targets currently selected for drug discovery efforts are proteins. Two classes of proteins predominate: G-protein-coupled receptors (GPCRs) and protein kinases.

SCREENING AND DESIGNING

The process of finding a new drug against a desired target for a particular disease usually involves high-throughput screening (HTS), wherein large libraries of compounds are tested for their ability to modify the target. For example, if the target is a novel GPCR, compounds will be screened for their ability to inhibit or stimulate that receptor. If the target is a protein kinase, the chemicals will be tested for their ability to inhibit that kinase.

Another important function of HTS is to show the selectivity of compounds for the desired target. The idea is to find a molecule that will interfere with only the chosen target, but not the other related targets. For this, other screening runs will be performed to see whether the 'hits' against the chosen target will interfere with other related targets. This process is called cross-screening. More unrelated targets a compound hits, the more likely it is that off-target toxicity will occur with that compound, hence cross-screening is important.

Although HTS is a commonly used method for novel drug discovery. It is often possible to start from a molecule, which already has some of the desired properties. Such a molecule might be extracted from a natural product or even be a drug on the market, which could be improved upon (called 'me too' drugs). Other methods, such as virtual HTS, where screening is done using the computer-generated models and attempting to 'dock' virtual libraries to a target, are also often used.

Another important method for drug discovery is drug designing, whereby the biological and physical properties of the target are studied, and a prediction is made about the sort of chemicals that might fit into an active site. From these exercises, novel pharmacophores can emerge very rapidly.

Once a lead-compound series has been established with sufficient target potency, selectivity, and favourable drug-like properties one or two compounds will then be proposed for drug development. The best of these is generally called the lead compound, while the other will be designated as the 'backup'.

NATURE AS A SOURCE OF DRUG COMPOUNDS

Despite the rise of combinatorial chemistry as an integral part of lead-discovery process, the natural products still play a major role as starting materials for drug discovery. A recent study suggested that 974 small molecule new chemical entities were developed in the past 25 years; among these, 63% were natural, derived, or semisynthetic derivatives of natural products. For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive, and anti-inflammatory drugs, natural products may be useful as a source of novel chemical structures for modern techniques of development.

Plant-Derived Bioactive Materials

Before Paracelsus, vast majority of the traditionally used crude drugs in Western medicine were plant-derived extracts. This has resulted in an inherited pool of information of the healing potential of plant

species, thus making them an important source of starting materials for drug discovery. A different set of metabolites is sometimes produced in the different anatomical parts of the plant (i.e. roots, leaves, and flowers), and botanical knowledge is crucial also for the correct identification of bioactive plant materials.

Microbial Species with Bioactive Metabolites

Microbes have to compete for living space and nutrients. To survive in these conditions, many microbes have developed abilities to prevent the competing species from proliferation. This phenomenon has led to the microbes being the main source of antimicrobial drugs. *Streptomyces* species have been a source of antibiotics. The classical example of an antibiotic discovered as a defence mechanism against another microbe is the discovery of penicillin in bacterial cultures contaminated by penicillium fungi in 1928.

Marine Invertebrates as a Source of Bioactive Compounds

Marine environments are potential sources of new bioactive agents. Arabinose nucleosides discovered from marine invertebrates in 1950s, demonstrated that sugar moieties other than ribose and deoxyribose can yield bioactive nucleoside structures. However, it was in 2004, when the first marine-derived drug was approved. The cone snail toxin, ziconotide, also known as Prialt, was approved by Food and Drug Administration (FDA, USA) to treat severe neuropathic pain. Several other marine-derived agents are now in clinical trials for indications, such as cancer, inflammation, and pain. One class of these agents are bryostatin-like compounds, under investigation as anticancer agent.

Chemical Diversity of Natural Products

As mentioned earlier, combinatorial chemistry was a key technology enabling the efficient generation of large screening libraries for the needs of HTS. It has been pointed out that, despite the increased efficiency in chemical synthesis, no increase in lead or drug candidates have been reached even after two decades of combinatorial chemistry. This has led to an analysis of the chemical characteristics of combinatorial chemistry products, as compared to the existing drugs and the natural products. The chemoinformatics is a concept of chemical diversity depicted as the distribution of compounds in the chemical space on the basis of their physicochemical characteristics, and is often used to describe the difference between combinatorial chemistry libraries and natural products. The synthetic, combinatorial library compounds seem to cover only a limited and quite uniform chemical space, whereas existing drugs, particularly, natural products exhibit much greater chemical diversity, distributing more evenly to the chemical space. The most prominent differences between natural products and compounds in combinatorial chemistry libraries are the number of chiral centres (much higher in natural compounds), structure rigidity (higher in natural compounds), and number of aromatic moieties (higher in combinatorial chemistry libraries). Other chemical differences between these two groups include the nature of heteroatoms (O and N enriched in natural products; S and halogen atoms more often present in synthetic compounds), as well as level of nonaromatic unsaturation (higher in natural products). As both structure rigidity and chirality are well-established factors in medicinal chemistry and are known to enhance compounds specificity and efficacy as a drug, it has been suggested that natural products compare favourably to today's combinatorial chemistry libraries as potential lead molecules.

Methodologies in Natural Product Drug Discovery

IDENTIFICATION OF BIOLOGICALLY ACTIVE MATERIAL

Random collection or screening of material, or exploitation of ethnopharmacological knowledge in the selection are the main approaches exist for the finding of new bioactive chemical entities from natural sources. The former approach is based on the fact that only a small part of Earth's biodiversity has ever been tested for biological activity, and organisms living in a species-rich environment need to evolve defence and competition mechanism to survive. A collection of plant, animal, and microbial samples from rich ecosystems might give rise to novel biological activities. One example of a successful use of this strategy is the screening for antitumour agents, by the National Cancer Institute in USA, started in 1960s. Paclitaxel was identified from Pacific yew tree *Taxus brevifolia*. Paclitaxel showed antitumour activity through a previously undescribed mechanism (stabilization of microtubules), and is now approved for clinical use for the treatment of lung, breast, and ovary cancer, as well as for Kaposi's sarcoma.

The selection of the starting materials may be done by collecting knowledge about the use of plants and the other natural products as herbal medicines, and thereby getting an idea of their potential biological activities. Ethnobotany, the study of the use of plants in the society, and particularly, ethnopharmacology, an area inside ethnobotany, focused on medicinal use of plants. Artemisinin, an antimalarial agent, from sweetworm tree, *Artemisia annua*, used in Chinese medicine since 200 BC is one of the drugs used as a part of combination therapy for multiresistant, *Plasmodium falciparum*.

STRUCTURAL ELUCIDATION

The elucidation of the chemical structure is critical to avoid double hits (i.e. the identification of a chemical agents that are already known for its structure and chemical activity), and for a long time remained as the most time-consuming step in the natural product drug discovery process. Mass spectrometry (MS) is a method in which individual compounds are identified based on their mass/charge ratio, after ionization and it has contributed to the enhanced ease of structure determination. Chemical compounds exist in nature as mixtures, therefore, the combination of liquid chromatography and mass spectrometry (LC-MS) is often used to separate the individual chemicals. Mass spectral databases for known compounds are available. Apart from MS, nuclear magnetic resonance (NMR) spectroscopy is another important technique for determining chemical structures of natural products. NMR yields information about individual hydrogen and carbon atoms in the structure, allowing detailed reconstruction of the molecule's architecture.

DRUG DESIGNING

It is an approach of finding drugs by designing, based on their biological targets. Typically, a drug target is a key molecule that is involved in a particular metabolic or signalling pathway that is specific to a disease condition or pathology, or to the infectivity or survival of a microbial pathogen. Some approaches attempt to inhibit the functioning of the pathway in the diseased state by causing a key molecule to stop functioning. Drugs may be so designed that they bind to the active region and inhibit this key molecule. However, these drugs would also have to be designed in such a way as not to affect any other important molecules that may be similar in appearance to the key molecules. Sequence homologies are often used to identify

such risks. Other approaches may be to enhance the normal pathway by promoting specific molecules, which are affected in the diseased state.

Using computational tools the structure of the drug molecule that can specifically interact with the biomolecules can be modelled. These tools can allow a drug molecule to be constructed within the biomolecule, using the knowledge of its structure and the nature of its active site. Depending on whether the core or the R-groups are chosen first, construction of the drug molecule can be made inside or outside. However, many of these approaches are plagued by the practical problems of chemical synthesis. Newer approaches have also suggested the use of drug molecules that are large and proteinaceous in nature, rather than small molecules. There have also been suggestions to make these using messenger ribonucleic acid (mRNA). Gene silencing may also have therapeutic applications.

Rational Drug Design

Rational drug design begins with a knowledge of the specific chemical responses in the body or the target organism, and tailoring the combinations to fit a treatment profile in contrast to the historical method of drug discovery, by trial-and-error testing of chemical substances on cultured cells or animals and matching the apparent effects to treatments. In drug metabolism, knowledge of the stability and the reactivity of libraries of potential drug compounds, the predicted metabolic and toxicological outcomes, and rational redesign of possible drug candidates is essential. Due to the complexity of the drug design process, two terms of interest are still serendipity and bounded rationality. These challenges are caused by the large chemical space describing potential new drugs without side-effects.

Typical example of rational drug design involves the use of three-dimensional information about biomolecules obtained from such techniques as X-ray crystallography and NMR spectroscopy. This approach to drug discovery is called as structure-based drug design. The first example of the application of structure-based drug design leading to an approved drug is the carbonic anhydrase inhibitor dorzolamide, which was approved in 1995.

Another important candidate discovered in rational drug design is a tyrosine kinase inhibitor imatinib, designed specifically for the bcr-abl fusion protein that is characteristic for Philadelphia chromosome-positive leukaemias (chronic myelogenous leukaemia and occasionally, acute lymphocytic leukaemia). Imatinib is substantially different from the earlier drugs for cancer, as most of the agents of chemotherapy simply target on the rapidly dividing cells not differentiating between cancer cells and other tissues.

The activity of a drug at its binding site is only one part of its design. Another part to be taken into account is the molecule's drug likeness, which summarizes the necessary physical properties for effective absorption. One way of estimating drug likeness is by Lipinski's rule of five.

Computer-Assisted Drug Design

Computational chemistry is used to discover, enhance, and study drugs and related biologically active molecules in computer-assisted drug design. Methods used typically include molecular modelling and simple methods from machine learning and statistics. In QSAR of candidate drugs regression is heavily used. Molecular mechanics, molecular dynamics, semiempirical quantum chemistry methods, ab initio quantum chemistry methods, and density functional theory are also used. The purpose is to reduce the cost and time necessary for the development of a new drug.

"This page intentionally left blank"

PHYSICOCHEMICAL FACTORS IN RELATION TO BIOLOGICAL ACTIVITY OF DRUGS

1	Physicochemical Properties	11
2	Ferguson Principle	13
3	Hydrogen Bonding	15
4	Ionization and pKa Value	19
5	Redox Potential	22
6	Surface Tension	25
7	Complexation	27

10	Physicochemical Factors in Relation to Biological Activity of Drugs
----	---

8	Steric Features of Drugs	30
---	--------------------------	----

9	Bioisosterism	36
---	---------------	----

Chapter 1

Physicochemical Properties

INTRODUCTION

The biological activity of a targeted drug molecule is solely dependent on its physicochemical characteristics, essentially the nature and type of functional moieties, and also the spatial arrangement of such group in the molecule. Modulating the structure of a drug implies introduction, elimination, or substitution of certain groups in the drug. This may lead to the development of a parallel drug with the characteristic similar to the lead compound. Hence, the activity is maintained, although the structure is changed. This can be expressed by an idea of bioisosteric groups that generally have similar biological activity. Physicochemical properties play an important role in modifying the biological activities of many compounds. Thus, pharmacological or therapeutic effects of a drug also relate to its biodistributions or physicochemical parameters of a drug such as:

- hydrogen bonding
- chelation
- oxidation–reduction potential
- dissociation constant
- bioisosterism
- surface activity

Medicinal chemistry undoubtedly rests its main focus on the broad-based variations embracing the influence of numerous possible manipulations with regard to the chemical structure on the biological activity. In the light of the above statement of facts supported by copious volumes of scientific evidence reported in many of the literatures, it is almost important and necessary for the medicinal chemist to decipher and logically understand not only the ‘mechanism of drug action’ in vivo by which a drug substance exert its effect, but also the overall physicochemical properties of the molecule. In a rather most recent conceptualized theoretical basis, the terminology physicochemical characteristics invariably refer to the cognizable influence of the plethora of organic functional moieties strategically positioned within a drug substance. It is, however, pertinent to mention here that most of the aforesaid properties covertly

and overtly exert a significant influence on the various biological phenomenon in vivo, such as absorption, distribution, metabolism, and excretion of newer targeted drug molecules.

Therefore, a creative medicinal chemist should ponder over the intricacies, complexities, and legitimate presence of each functional moiety to the overall physical and chemical properties of the targeted drug molecule with a view to arrive at or design safer, better, and efficacious medicinal agents. Nevertheless, such critical studies have to be carried out in a rather methodical and systematic manner *vis-à-vis* their effects upon biological activities.

Chapter 2

Ferguson Principle

INTRODUCTION

The observation that many compounds containing diverse chemical groups exhibit narcotic or anaesthetic action is indicative of the fact that mainly physical rather than chemical properties are involved. The fact that narcotic action is attained rapidly and remains at the same level as long as reservoir or critical concentration of the drug is maintained, but quickly disappears when the supply of drug is removed suggests that equilibrium exists between the external phase and the biophase.

According to Ferguson, it is unnecessary neither to define the nature of the biophase or the receptor nor to measure the concentration of the drug at this site. If equilibrium conditions exist between the drug in molecular biophase and in extracellular fluids, the tendency to escape from each phase is the same, even though the concentrations in the two phases are different. This tendency is called thermodynamic activity. It is approximately equivalent to the degree of saturation of each phase. Since, the thermodynamic activity is the same in both the biophase and the extracellular phase, measurements made in the extracellular phase, which is measurable, may be directly equated with biophase, which is not possible to be measured.

On the basis of the mode of action, drugs are divided into two categories (Table 2.1):

1. structurally nonspecific drugs
2. structurally specific drugs

The thermodynamic activity of nonvolatile drugs may be calculated from the expression S/S_0 , where S = molar concentration of the drug and S_0 = solubility of the drug.

In the case of volatile drugs, their thermodynamic activity is calculated by using the formula p_t/p_s , where p_t = partial pressure of the substance in solution,

$$p_t = 760 \times (C/100)$$

$$p_s = \text{saturated vapour pressure}$$

$$C = \text{concentration}$$

For example,

Saturated vapour pressure of CHCl_3 (p_s) = 324

Narcotic concentration C = 0.5

Table 2.1 Differences between structurally nonspecific drugs and structurally specific drugs.

S. No.	Structurally Nonspecific Drugs	Structurally Specific Drugs
1.	Their biological action is directly related to the thermodynamic activity	Their biological action does not depend on the thermodynamic activity
2.	Thermodynamic activity value varied from 0.01 to 1	Thermodynamic activity value is below 0.01
3.	High doses are needed for biological activities	They are effective in low concentrations
4.	Chemical structures are different, but they produce similar biological responses	They have some structural characteristics in common to produce the biological response
5.	Slight modifications in their chemical structure do not result in pronounced changes in biological action	Slight modifications in their chemical structure may result in substantial changes in biological activity

$$\begin{aligned}
 \text{Partial pressure of CHCl}_3 (p_r) &= 760 \times (C/100) \\
 &= 760 \times (0.5/100) \\
 &= 760 \times 0.005 \\
 &= 3.8 \approx 4
 \end{aligned}$$

$$\begin{aligned}
 \text{Approximate thermodynamic activity} &= p_r/p_s \\
 &= 4/324 \\
 &= 0.01
 \end{aligned}$$

The isoanaesthetic concentration of gases and vapours are given in Table 2.2.

Table 2.2 Isoanaesthetic concentration of gases and vapours in man at 37°C.

Substance	Vapour Pressure (mm-Hg) p_s	Anaesthetic Concentration (C)	Partial Pressure at Anaesthetic Concentration p_t $760 \times (C/100)$	Approximate Thermodynamic Activity (p_t/p)
Nitrous oxide	59,300	100	760	0.01
Ethylene	49,500	80	610	0.01
Acetylene	51,700	65	495	0.01
Ethyl chloride	1780	5	38	0.02
Ethyl ether	830	5	38	0.05
Vinyl ether	760	4	30	0.04
Ethyl bromide	725	1.9	14	0.02
1, 2-Dichloroethylene	450	0.95	7	0.02
Chloroform	324	0.5	4	0.01

These findings coined the Ferguson's principle, which states that 'substances that are present at the same proportional saturation in a given medium have the same degree of biological action'.

Chapter 3

Hydrogen Bonding

INTRODUCTION

Hydrogen bond (H-bond) is a bond in which a hydrogen atom serves to hold two other atoms together. The H-bond usually is formed only between hydrogen and electronegative atoms. In addition, the atoms capable of forming H-bonds have at least one unshared pair of electrons. The most common atoms capable of forming H-bonds are F, O, N, and to a lesser extent Cl and S.


The compounds that are capable of forming hydrogen bonding are only soluble in water. Proteins are held in a specific configuration by H-bonds, and denaturations of proteins involve the treating of some bonds.

CLASSIFICATION



Generally, hydrogen bonding is classified into two types:

1. intermolecular hydrogen bonding
2. intramolecular hydrogen bonding

Intermolecular hydrogen bonding: Hydrogen bonding occurs between two or more molecules



Intramolecular hydrogen bonding: Hydrogen bonding occurs within the molecules



There is also some evidence that the hydrogen attached to a triple bond carbon (e.g. HCN and CHCl_3) forms a H-bond. The strength of H-bonds ranges from 1 to 10 kcal/mol, and usually is about 5 kcal/mol. The distance between the electronegative elements in a H-bond is usually in the range of 2.5–2.7 Å. At distance greater than 3 Å, there is very little interaction (Table 3.1). The stability of H-bonds falls roughly in the following order, $\text{OHO} > \text{OHN} > \text{NHN}$.


Table 3.1 H-bond and its bond strength.

H-bond	Bond Strength (kcal/mol)
F–H.....F	7
O–H.....O	4.5–7.6
O–H.....N	4–7
C–H.....pi electrons	2–4
C–H.....O	2–3
N–H.....O	2–3
N–H.....N	1.3


H-bonds may occur between molecules (intermolecular H-bond), within one molecule (intramolecular H-bond), or as a combination of these two. Intermolecular bonds are frequently much weaker than the intramolecular bonds. Multiple hydrogen bonding groups in any drug molecule would greatly increase its potential for aqueous solubility. Minimal aqueous solubility is essential for all the drug molecules to transport to the site of action on a receptor.

Generally, the more H-bonds that are possible, the greater the water solubility of the molecule. The strength of the H-bond depends on the solvent as well as on the physical state. For example, the H-bond strength of $\text{O–H} \cdots \text{O}$ for CH_3COOH dimer in vapour state is 7.64 kcal/mol, but CH_3COOH dimer in benzene is 4.85 kcal/mol. In water, the H-bond strength is 4.5 kcal/mol; in ice, the bond strength is 6 kcal/mol.


Intramolecular hydrogen bonding




Intermolecular hydrogen bonding



The description of the drug receptor interaction based on hydrogen bonds is closely related to the importance of these bonds in maintaining the integrity of biological systems and in determining the physicochemical properties of drug molecules. The physical state of substances, such as water, DNA, protein, and various drug molecules, are maintained by hydrogen bonding. The most frequently observed H-bonds in biological systems are between the hydroxyl (OH) and amino (NH) groups. In the DNA helix, hydrogen bonding links the complementary base pairs of adenine-thymine and guanine-cytosine.



Adenine–thymine



Guanine–cytosine

Since the physical and chemical properties of a compound may be greatly altered by hydrogen bonding, it is reasonable to expect that it may also have a significant effect and some correlation with biological properties. In a number of cases, such a correlation is present (Tables 3.2 and 3.3).


Table 3.2 Differences between 1-phenyl-3-methy-5-pyrazolone and 1-phenyl-2, 3-dimethy-5-pyrazolone (antipyrine).

1-Phenyl-3-methy-5-pyrazolone	1-Phenyl-2, 3-dimethy-5-pyrazolone (antipyrine)
No analgesic property	Good analgesic agent
Melting point 127°C	Melting point 112°C
Insoluble in water	Soluble in water
Slightly soluble in ether	Moderately soluble in ether
Forms intermolecular hydrogen bonding	Does not form intermolecular hydrogen bonding

Table 3.3 Differences between *o*-hydroxybenzoic acid and *p*-hydroxybenzoic acid.



<i>o</i> -Hydroxybenzoic acid (Salicylic acid)	<i>p</i> -Hydroxybenzoic acid
pKa 3.0	pKa 4.5
Less soluble in water	More soluble in water
Low melting point	High melting point
Good antibacterial action	Low antibacterial action
Forms intramolecular hydrogen bonding	Forms intermolecular hydrogen bonding

1-Phenyl-3-methyl-5-pyrazolone forms intermolecular hydrogen bonding





The alkylating agents (nitrogen mustards) are thought to act by replacing the weak and reversible H-bonds between adjacent nucleic acid strands with strong and relatively irreversible covalent bonds. In this way, nucleic acid regeneration and cell division in the rapidly proliferating cancer cells may be inhibited.

Antipyrine, 1-phenyl-2,3-dimethyl-5-pyrazolone has analgesic activity, but 1-phenyl-3-methyl-5-pyrazolone is inactive. This is due to the formation of hydrogen bonding in the 1-phenyl-3-methyl-5-pyrazolone and gives rise to a linear polymer, which cannot pass through biomembranes.



Salicylic acid (*o*-hydroxy benzoic acid) has antibacterial activity, but not the *p*-isomer and *m*-isomers, that is, *p* and *m*-hydroxy benzoic acids are inactive. This is because salicylic acid form intramolecular hydrogen bonding, therefore, it is less water-soluble and its partition coefficient is also greater.

The *m*- and the *p*-isomer can form intermolecular H-bonds, results in dimer, and does not easily pass through the biomembranes. The partition coefficient of it is also less, and hence, low antibacterial action.



Chapter 4

Ionization and pKa Value

INTRODUCTION

If the biological activity of a drug results from ions, the activity intensifies with increase in the degree of ionization. However, if the activity results from undissociated molecules, increase in the degree of ionization of active compounds causes a decrease in activity.

Increase in ionization intensifies a drug's water solubility and decreases its liposolubility. In general, drugs cross cellular membranes in undissociated forms as intact molecules and act in dissociated forms as ions. This happens because the passage of ions across the cellular membrane is prevented by two factors.

1. The cellular membrane is made up of layers of electrically charged macromolecules (lipids, proteins, and muco polysaccharide) that attract or repel ions.
2. Hydration of ions increases their volumes rendering difficult their diffusion through pores.

Weakly acidic drugs are predominantly of the unionized form at lower pH of the gastric fluid, and absorbed from the stomach as well as intestine. Some very weak acidic drugs, such as phenytoin and many barbiturates, whose pKa values are greater than 7, are essentially unionized at all pH values. Therefore, for these weak acidic drugs transport is more rapid and independent of pH.

Most weak bases are poorly absorbed in the stomach since they are present largely in the ionized form at low pH. Strong base, those with pKa values between 5 and 11, shows pH dependent absorption. Stronger base, such as guanithidine (pKa > 11), are ionized throughout the gastrointestinal tract and tend to be poorly absorbed.

pKa VALUE

The partially lipidic nature of cellular membranes, such as the ones that enwrap the stomach, small intestine, mucosa, and nervous tissue facilitate the passage of drugs with high liposolubility across them. The liposolubility is affected by pH of the environmental medium and by the degree of dissociation pKa. Usually, drugs are weak acids or weak base. The degree of dissociation, pKa, is calculated from the following Henderson–Hasselbalch equation.

In the case of acid,

$$\text{pH} = \text{pK}_a + \log \frac{\text{Ionized drug concentration}}{\text{Unionized drug concentration}}$$

$$\text{Percentage of drug ionized} = \frac{10^{\text{pH} - \text{pK}_a}}{1 + 10^{\text{pH} - \text{pK}_a}} \times 100$$

In the case of base,

$$\text{pH} = \text{pK}_a + \log \frac{\text{Unionized drug concentration}}{\text{Ionized drug concentration}}$$

$$\text{Percentage of drug ionized} = \frac{10^{\text{pK}_a - \text{pH}}}{1 + 10^{\text{pK}_a - \text{pH}}} \times 100$$

The biological activity of certain acids and bases is directly related to their degree of ionization. Whereas some (e.g. phenols, carboxylic acids) act in the molecular form, others (quaternary ammonium salts) act in an ionized form. In these cases, the pH plays an important role, that is, acids are more active at lower pH; bases are more active at higher pH.

- Strong acid has low pK_a value
- Weak acid has high pK_a value
- Strong base has high pK_a value
- Weak base has low pK_a value

Drug Exerting Action as Undissociated Molecules

In a large number of potent medical compounds, the dissociation plays a vital role for their respective biological characteristics. The unusual structural grouping in the tetracycline results in three distinct acidity constants in aqueous solutions of the acid salts. The particular functional groups responsible for each of the thermodynamic pK_a value have been determined by Lessen et al, as described in Figure 4.1.




Figure 4.1 Functional groups responsible for each of the thermodynamic pK_a value.

The approximate pKa values for each of these groups in the four commonly used tetracyclines are shown in Table 4.1.

Table 4.1 pKa values of tetracyclines.

S. No.	Name	pKa ₁	pKa ₂	pKa ₃
1.	Tetracycline	3.3	7.7	9.5
2.	Chlorotetracycline	3.3	7.4	9.3
3.	Demeclocycline	3.3	7.2	9.3
4.	Oxytetracycline	3.3	7.3	9.1

Besides the activities of several local anaesthetics, *d*-tubocurarine and phenol have also been proved to be related to their degree of ionization.

Drug Exerting Action as Ionized Molecules

A plethora of medicinal compound exerts their pharmacodynamic action exclusively as the ionized molecule, namely, acetylcholine, quaternary salts as ganglionic blocking agents, muscle relaxants, and antiseptics.

Chapter 5

Redox Potential

INTRODUCTION

The redox potential may be defined as a quantitative expression of the tendency of a compound that has to give or receive electrons. The redox potential may be compared with an acid-base reaction. In the case of acid–base reaction, there is the transfer of a proton from an atom in one molecule to the atom in another molecule, while in the case of oxidation–reduction reaction there is an electron transfer. Since living organisms function at an optimum redox potential range, which varies with the organism, it might be assumed that the redox potential of the compounds of a certain type would correlate with the observed biological effect. This correlation is applicable for all compounds of similar structure and physical properties.

The redox potential of a system may be calculated from the following equation: $E_h = E_o^1 - 0.06/n$ (concentration of reductant/concentration of oxidant), where


E_h : redox potential of the system being studied

E_o^1 : standard potential at given pH

n : number of electrons transferred


However, there are a number of reasons why only a few satisfactory correlations have been observed.

- The redox potential applies to a single reversible ionic equilibrium, which does not exist in a living system.
- A living cell carries on many reactions simultaneously involving oxidation of ionic and a nonionic character, some of which are reversible and others are irreversible.
- The access of a drug to the sites of oxidation-reduction reactions in the intact animal is hindered by the complex competing events occurring during absorption, distribution, metabolism, and excretion.
- Therefore, it is to be expected that correlations between redox potential and biological activity, generally, hold only for compounds of very similar structure and physical properties. In such series, variations in the route of distribution and in steric factors, which might modify the redox system interaction, would be minimized.




When Riboflavin (I) accepts electrons, it is converted into its dihydro (II) form. This reaction has a redox potential $E_0 = -0.185$ volt. Kuhn (1943) prepared the analogue in which the two methyl groups of riboflavin were replaced by chlorine. The resulting compound had a potential of $E_0 = -0.095$ volt, and its antagonistic properties were suggested as being due to the dichloro-dihydro form being a weaker reducing agent than the dihydro form of riboflavin. It may be absorbed at the specific receptor site, but may not have a negative potential to carry out the biological reductions of riboflavin.

Reist et al (1960) prepared the nonredox analogues of riboflavin as potential anticancer agents. Replacement of the N_5 -nitrogen of dihydroriboflavin (1,5-dihydro-7,8-dimethyl-10-ribitylisoalloxazine) by a methylene group (III) would be expected to have a profound effect on the redox potential as compared to riboflavin. Similarly, replacement of the N_5 -nitrogen of dihydroriboflavin by an isopropylidene group (IV) fixes the molecule in the dihydro form, thus, eliminating the redox system completely.



Although (IV) is derived from dihydroriboflavin (II) rather than from riboflavin, the redox enzyme system employing riboflavin coenzymes utilizes both the oxidized and reduced forms; thus, analogues of either I or II should be effective antagonists.

Craig et al (1960), studied a series of substituted phenothiazine with regard to potentiometric titration, electrode potentials, and their correlation with anthelmintic activity and measured them in the biological assay using mixed infestation of *Syphacia obvelata* and *Aspicularis tetraptera* in mice. From these studies, it appeared that two factors were necessary for their activity, namely, the ability to form a high proportion of a stable semiquinone radical (as measured by the index potential in aqueous CH_3COOH) and the presence of free 3 or 7 position.



In addition to the two factors mentioned above, Craig et al (1960) also noted that only these compounds with electrode potential in the range of 550–850 mV in aqueous CH_3COOH had significant activity. If the toxic or paralyzing effect of the phenothiazines were due to an inhibition by the semiquinone of the

oxidation–reduction system in the parasite, it would seem reasonable that active phenothiazines would have reduction potentials corresponding to these of oxidation–reduction enzyme system or the system which they inhibit. At similar potentials, the semiquinone concentration would be maximal, and thus, facilitate or compete with the electron transfers in the enzyme system involved.

For example, it has been suggested that the semiquinone of chlorpromazine is responsible for the inhibition of certain oxidoreductase *in vitro* and some of the biological activities of phenothiazines correlates with the formation of their semiquinones *in vivo*.

Chapter 6

Surface Tension

INTRODUCTION

A surfactant is defined as a material that can reduce the surface tension of water at lower concentrations. This molecule is made up of water-soluble and water insoluble components. Surface agent may enhance or retard the drug absorption, which depends upon the chemical nature of surfactant, its concentration, its effect on biological membrane, and micelle formation.

At lower concentrations, the surfactant enhances the absorption rate; the same in higher concentrations reduce the absorption rate. In lower concentrations, they reduce the surface tension and bring about better absorption through better contact of the molecules with absorbing membrane, but when the concentration crosses the critical micelle concentration, the surfactant aligns them at the surface so that the hydrophilic end is towards the water and hydrophobic is squeezed away from the water. These molecular aggregates are called micelle, which entrap the drug molecule in their hydrophobic core, and result in the retardation of the rate of absorption (Fig. 6.1).




Figure 6.1 Micelle formation.

The orientation of surface active molecules at the surface of water or at the interface of polar and nonpolar liquids takes place with the nonpolar (hydrocarbon) portion of the molecule oriented towards the nonpolar liquid or vapour phase and polar groups (e.g. $-\text{COOH}$, $-\text{OH}$, $-\text{NH}_2$, $-\text{NO}_2$, etc.) towards the polar liquid. Three forces are involved in the orientations of this type, namely, van der Waals forces, hydrogen bonds, and ion dipoles.

A surfactant molecule exhibits two distinct regions of lipophilic and hydrophilic character, and such compounds are commonly categorized as amphiphilic or as amphiphils. Molecules of this type may vary markedly from predominantly hydrophilic to predominantly lipophilic, depending on the relative ratio of polar to nonpolar groups present.

CLASSIFICATION

Surface-active agents are classified as follows:

- Anionic surfactants: Ordinary soaps, salts of bile acids, salts of the sulphate or phosphate esters of alcohols, salts of sulphonic acids.
- Cationic surfactants: High molecular weight aliphatic amines, quaternary ammonium derivatives.
- Nonionic surfactants: Polyethylene ethers, glycol esters of fatty acids.
- Amphoteric surfactants

Applications

The bactericidal activity of cationic quaternary ammonium compounds, such as benzalkonium chloride, cetrimide, cetyl pyridinium chloride, etc. is explained through their surface-active property. Many compounds, such as detergents, disinfectants, and antibiotics act through the surface phenomenon.

The anthelmintic activity of hexylresorcinols is reported to be increased by low concentrations of soap and decreased by high concentrations of soap. If the soap concentration is kept below critical micelle concentration (CMC), a 1:1 association of phenol and soap occurs, which facilitates the penetration of phenol through the surface of the worm. If the CMC is exceeded, the micelle competes favourably with the worms for phenol and there is decreased activity.

Compounds showing pronounced surface activity usually are unsuited for use in the animal body. Such compounds are lost through their adsorption by proteins, and they also have an undesirable feature of disorganizing the cell membrane and producing haemolysis of red blood cells. In general, highly surface-active agents are not used internally, but only topically, as skin disinfectants or sterilizers for sterilization of instruments. This is the case for ionic surfactants. Nonionic surfactants are largely employed in pharmaceutical preparations for oral (sometimes even parenteral) use as solubilizing agents of water insoluble or slightly soluble drugs.

Surface-active agents can be expected to have a pronounced effect on the permeability of a cell. Mildly surface-active agents may be adsorbed by cell membranes, and thereby interfere with the absorption of other compounds through this membrane or may alter membrane structure and function. Many central nervous system depressant drugs, such as sedative-hypnotic, anticonvulsant, and central relaxant agents possess the general structure of nonionic surface-active compounds.

The most commonly used surfactants are anionic and nonionic surfactants. Since the process of solubilization occurs due to the presence of micelles, generally, high concentrations of surfactants are needed to improve drug solubility significantly. One example of a surfactant based solution is Taxol (paclitaxel, Sigma-Aldrich, USA), an anticancer drug that is solubilized in 50% solution of Cremophor. Other examples include Valrubicin in 50% Cremophor and Cyclosporin in 65% Cremophor.

Surfactant preparations are used as replacement therapy for the treatment of premature infants suffering from neonatal respiratory distress syndrome (also known as hyaline membrane disease). A substantial deficiency in the endogenous lung surfactant is the principal factor contributing to the pathology of respiratory distress syndrome. The lung surfactant preparations are used in combination with supplemental oxygen and mechanical ventilation to facilitate gas exchange. The exogenous surfactants are either derived from animal or synthesized. For example, Beractant (modified bovine extract), Calfactant (extracted from the lungs of calves), and Poractant alfa (extract of porcine lung).

Chapter 7


Complexation

INTRODUCTION

Complexes or coordination results from a donor-acceptor mechanism (donating accepting electron or rather an electron pair) or Lewis acid–base reaction (donating accepting protons). Since complex drugs cannot cross the natural membranous barriers, they reduce the rate of absorption of the drug. The compounds that are obtained by donating electrons to metal ions with the formation of ring structures are called chelates. The compounds that are capable of forming a ring structure with metal atoms are termed as ligands.

Both biological molecules and medicinal agents may develop chelate structures by forming a ring structure with a metal through coordinate bonds (i.e. bonds in which electrons pairs are from the same atom).

Example: Glycine forms complex with Cu^{2+}




The stability constant (K_s) reflects the strength of the interaction, and larger the constant the greater the stability.

$$K_s = \frac{[\text{Complex}]}{[\text{Glycine}][\text{Cu}^{2+}]}$$

Two coordinate covalent bonds are formed between glycine and copper in the complex. The nitrogen and oxygen atoms of glycine serve as the electron donating groups, each supplying an electron pair, whereas the cupric ion is the electron acceptor.

Electron donating groups are almost always limited to O, N, and S atoms; electron acceptors include various bivalent and trivalent metals particularly those of the transition group. Stability of the metal ions in the complex:



A ligand, such as ammonia, that has a single basic group capable of bonding to the metal ion is a unidentate ligand. A ligand having more than one accessible basic binding site is multidentate, for example, ethylenediamine, $\text{NH}_2\text{CH}_2\text{CH}_2\text{NH}_2$, is a bidentate ligand form, and chelates with $\text{Cu}(\text{II})$.

Some important multidentates are listed in Table 7.1.






Table 7.1 Multidentates


Ethylenediamine




Ethylenediamine tetra acetic acid




Dimethylglyoxime




2, 2'-Bipyridine



1, 10-Phenanthroline



8-Hydroxyquinoline





The number of rings formed in the chelate depends on the electron donating groups. S can form the stable four-member rings, O and N can form five and six member rings, but five member rings are generally more stable. Heavy metals are required for the following enzymes and biomacromolecular components (Table 7.2).

Important metal binding hormones are thyroxine, insulin, histamine, epinephrine, and norepinephrine. In clinical practice, chelating agents have been used primarily as antidotes in heavy metal poisoning. In principle, any chelating agent with a sufficiently high K_s value in vitro could be used as an antidote, but some limitations are there. For example, ethylene diamine tetra acetic acid (EDTA), because of its powerful chelating effect can displace toxic heavy metals, such as lead and mercury from cellular

Table 7.2 Metals required for enzymes and biomacromolecular components.

S. No.	Metal	Cellular Components
1.	Cobalt	Vitamin B ₁₂ , carboxypeptidase
2.	Copper	Oxidase enzymes
3.	Iron	Porphyrin enzymes, haemoglobin Iron storage molecules (ferritin, haemosiderin)
4.	Magnesium	Chlorophyll
5.	Manganese	Chloroplasts
6.	Molybdenum	Xanthine oxidase, aldehyde oxidase
7.	Nickel	Urease
8.	Zinc	Carbonic oxidase, alcohol dehydrogenase

layer, but EDTA is not highly selective in its action, it tightly binds some essential metals, including calcium. To prevent excessive loss of calcium from the body during EDTA therapy, it is necessary to administer this antidote as disodium calcium salt. Iron deficiency, anaemia, may be treated using the iron complex of EDTA in the place of ferrous sulphate or ferrous gluconate. Pernicious anaemia is treated effectively using Vitamin B₁₂, a naturally occurring cobalt complex. Deferoxamine is a highly selective antidote, which strongly chelates iron in iron poisoning. Dimercaprol (BAL) is used in the treatment of lead poisoning. L-Penicillamine is used in the treatment of copper and Wilson's disease.



Numerous antimicrobial and antineoplastic agents are believed to exert their action by means of complex formations with DNA base pairs. These drug molecules are large planar aromatic compounds, and they can be inserted between the planar base pair assemblies on the DNA double helix. This type of inserted molecular interaction is called intercalation. Intercalating drugs include ethidium, quinacrine, proflavin, daunorubicin, adriamycin, and actinomycin D.

Undesirable side effects are caused by drugs that chelates with metals. A side effect of hydralazine, an antihypertensive agent, is the formation of anaemia, and this is due to chelation of the drug with iron. 8-Hydroxy quinoline and its analogues acts as antibacterial and antifungal agents by complexing with iron or copper.

Chapter 8


Steric Features of Drugs

INTRODUCTION

The potential biological activity of a targeted drug molecule solely depends on its physicochemical characteristics, and essentially comprises the nature and type of functional moieties and also the spatial arrangement of such groups in the molecules. Interestingly, the human body itself represents an asymmetric environment, wherein drug molecules interact with proteins and biological macromolecules (receptors). Hence, it is virtually important and necessary that the decisive functional moieties must be strategically located with respect to exact spatial region encircling the targeted drug molecule, so as to enable the crucial and productive bonding interactions particularly with the receptor, thereby potentially accomplishing the desired pharmacologic effect. It is, however, pertinent to state here that the right fitment of correct 3D-orientation of the functional moieties in a drug substance may ultimately result in the formation of an extremely viable and reasonably strong interaction with its receptor.

Steric factors determined by the stereochemistry of the receptor site surface and that of the drug molecules are, therefore, of primary importance in determining the nature and the efficiency of the drug-receptor interaction. The drug must approach and fit closely into the receptor surface to evoke the pharmacological action. Hence, the drug must possess a high degree of structural specificity or stereo selectivity. Many drugs show stereo selectivity because mostly receptor binds are optically active biological macromolecules, such as protein, polynucleotide, or glycolipids.

For example, diethyl stilboesterol exists in two fixed stereo isomeric forms and *trans*-diethylstilboesterol is oestrogenic, whereas *cis*-isomer is only 7% as active. In *trans*-diethylstilboesterol, resonance interaction and minimal stearic interference tend to hold the two aromatic ring and connecting ethylene carbon atom in the same plane.




In geometric isomers, *cis*- and *trans*-isomers differ in their physical and chemical properties. Therefore, distribution in the biological medium is different.


Conformational Isomers

Different arrangements in the space for atoms or groups in single bonds are called conformations. Rotations about the bonds allow interconversion of conformers (conformational isomers). The energy barrier between isomers is often high enough for their independent existence and reaction. Differences in the reactivity of functional groups or interaction with biological receptors may be due to differences in steric requirements of the receptors.

Open chains of atoms form an important part of many of the drug molecules. Energy barrier to the free rotations of the chains are present because of the interactions of nonbonded atoms, for example, the atoms tend to position themselves in space so that they occupy staggered positions with no two atoms directly facing each other (eclipsed). Nonbonded interactions in polymethylene chains tend to favour the most extended anticonformations, although some of the partially extended gauche conformations also exist. The conformational isomers show significant differences in biological activities.




n-Butane anti conformation




3-Amino-*n*-propanol eclipsed conformation


Stabilized planar structure of esters



Antistabilized




Resonance stabilized




Gauche


Stabilized planar structure of amides



Antistabilized




Resonance stabilized



Gauche

The potential interaction energy of trimethyl ammonium ion and acetoxy group is lowest in the staggered (also called, though erroneously, *trans* or *transoid*) conformation, and highest when the two groups are eclipsed (*cis* or *cisoid* conformation). It has been suggested that acetylcholine interacts with the muscarinic receptor in fully extended staggered conformation and interacts with nicotinic receptor in folded (gauche)

conformation. To study the relationship between the possible conformations of rigid analogues of acetylcholine and their biological effects conformationally rigid analogues of acetylcholine have been used. The *cis* and *trans* isomers of 2-acetoxy cyclopropyl trimethyl ammonium iodide are two such compounds. The (+) – *trans*-isomer in which the quaternary nitrogen atom and acetoxy groups are held apart in a shape approximating that of extended conformation of acetylcholine was found to be almost equipped with acetylcholine at the muscarinic receptor, but shows little nicotinic activity. It is easily hydrolyzed by acetyl cholinesterase. In contrast (+) – *cis*-isomer showed practically no activity at the nicotinic or muscarinic receptor. The results indicate that acetylcholine assumes staggered conformation at the muscarinic receptors.




Optical Isomers

Optical isomers were further categorized as enantiomers and diastereoisomers.

ENANTIOMERS


If four different atoms or groups are attached at the four corners of a regular tetrahedron, then the molecule is asymmetric and can exist in two forms. The three-dimensional structure cannot be superimposed on each other, and hence, are different, even though they represent the same structural arrangement of atoms. They bear a relationship to each other corresponding to what exists between an object and its mirror image. Mirror image molecules are not superimposable and are called enantiomers.

A tetrahedral carbon atom carrying four groups that are all different, therefore, must invariably constitute a centre of asymmetry and permits two arrangements of the groups in space. This asymmetry calls for the existence of two isomers identical in all respects except optical properties. For example, lactic acid—2-hydroxy propanoic acid.



A chiral compound containing one asymmetric centre has two enantiomers. Although each enantiomer has identical chemical and physical properties, they may have different physiological activities such as the interaction with receptor, metabolism, and protein binding.

Examples of enantiomers possessing varying biological activity are the following:




Many optical isomers exhibit variation in the intensity of their biological properties. For example,

- (-)-Hyoscyamine is 15–20 times more active as a mydriatic than (+) Hyoscyamine.
- (-)-Hyoscine is 16–18 times as active as (+) hyoscine.
- (-)-Epinephrine is 12–15 times more active as vasoconstrictor than (+) epinephrine.
- (-)-Isoprenaline is 800 times more active bronchodilator than (+) isoprenaline.
- (+)Nor homoepinephrine is 160 times more active as a pressor than (-) nor homoepinephrine.
- (+)Amino acids are sweet, whereas (-) -amino acids are either sweetless or bitter.
- (+)Ascorbic acid has good antiscorbutic properties, whereas (-) ascorbic acid has none.
- (S)Thalidomide is more teratogenic than (R) thalidomide.



DIASTEREOMERS

Tartaric acid is an example of a compound having two similar asymmetric carbon atoms since each carbon atom has attached hydrogen atom, a hydroxyl group, a carboxyl group (CH OH COOH group). If we represent the configurations of two mirror images' about each asymmetric carbon atom, then the structures are represented as enantiomers of d- and l-tartaric acid.

A third structure is possible, which possess a plane of symmetry (achiral) and is, therefore, optically inactive. Such molecules are designated as mesoforms. The relationship of stereoisomers (1) and (2) are enantiomers, but (1) and (3) are not enantiomers, they are called diastereomers. These stereoisomers are not



mirror images, unlike enantiomers, but diastereomers possess different physical and chemical properties. Examples of diastereomers possessing varying activity are the following:



Reasons Behind Varying Activity of Optical Isomers

The difference is due to the interaction of asymmetric carbon atom of the molecule with stereo specific receptors. According to Easson–Stedman hypothesis, if binding ions are specific for one enantiomer, then a three-point attachment must occur between the enantiomer and the asymmetric surface of the receptor, since only one of the enantiomers will fit, and the other one is only capable of a two-point attachment as shown in Figure 8.1.




Figure 8.1 Varying activity of optical isomers.

BINDING OF ENANTIOMERS TO RECEPTORS

The enantiomer (Fig. 8.2) that has a high affinity for receptor is called eutomer, whereas the one with a lower affinity is called distomer. The ratio of activity of the eutomer and distomer is called eudismic ratio.




Figure 8.2 Binding of epinephrine with receptor.

Examples of Easson–Stedaman principle: For epinephrine, the benzene ring, benzylic hydroxyl, and protonated amine binds with the hydrophobic or aromatic region, anionic site, and hydrogen bonding centre of the receptor.


Chapter 9

Bioisosterism


INTRODUCTION

Isosterism is of vital importance to the medicinal chemists because the biological characteristics of isosteres appear to be similar; more frequently than physical or chemical characteristics. Keeping in view the numerous advantageous application of isosterism in resolving biological problems effectively, Friedman proposed the following definition of bioisosterism—the phenomenon by which compounds usually fit the broadest definition of isosteres and possess the same type of biological activity.


For instance, among antihistamines it is always preferable to have small compact substituents on the terminal nitrogen.



(A) Pyrrolidone analogue



(B) Diethyl analogue



(C) Dimethyl analogue

In the above-mentioned three structural analogues, it has been observed that 'A' possesses twice the activity of 'C', whereas it showed an activity that is many times greater than that of the open-chain diethylamino analogue.

It has been duly observed that it is more or less difficult to correlate the biological properties *vis-à-vis* physicochemical properties inherited by specific individual atoms, functional groups, or entire molecule by virtue of the glaring and established fact that a host of physical and chemical parameters are involved simultaneously, and are, therefore, extremely difficult to quantify them justifiably.

Besides simpler relationships, for example, isosterism invariably do not delay across the several varieties of biological systems that are often encountered with medicinal agents. In other words, a specific isosteric replacement in one particular biological system may either work or fail in response to the other. Thus, bioisosteres were further explained as follows: bioisosteres are (functional) groups or molecules that have chemical and physical similarities producing broadly similar biological properties.

CLASSIFICATION

Bioisosteres are classified into the following two types:

1. Classical bioisosteres
2. Nonclassical bioisosteres

Classical bioisosteres: Classical bioisosteres have similarities in shape and electronic configuration of atoms, groups, and molecules, which they replace. Actual applications of bioisosteres in the successful design of a specific given molecule interacting with particular receptor is one glaring example, and very often either fails or negates the biological characteristics in another environment. Therefore, it is pertinent to state at this juncture that the logical use of biological replacement (classical or nonclassical) in the design of a new target drug molecules is solely and significantly depend on the specific biological system under critical investigation. Hence, there are no predetermined, well-established, predictable hard and fast guidelines, or laid generalized rules that may be useful to a medicinal chemist to affect bioisosteric replacement gainfully towards improved biological activity. Various classical bioisosteres with their appropriate examples are listed as follows:

i. Monovalent atoms and groups


F, H

OH, NH


F, OH, NH, or CH₃ for H

SH, OH


Cl, Br, and CF₃




Uracil




5-Fluorouracil




Hypoxanthine



6-Mercaptopurine




Folic acid




Aminopterin

ii. Divalent atoms and groups

—C=S,—C=O,—C=NH,—C=C—



Procaine



Procainamide

iii. Trivalent atoms and groups


$-\text{CH} =, -\text{N} =$

$-\text{P} =, -\text{As} =$

iv. Tetravalent atoms and groups

$=\text{N}^+ =, =\text{C} =, =\text{P}^+ =, =\text{As}^+ =$


v. Ring equivalents




Nonclassical bioisosteres: They do not obey the steric and electronic definition of classical isosteres. Also, they do not have the same number of atoms as replacement. Although, many of these functional moieties practically just behave as one, they have one of the following characteristic features, such as

- electronic properties
- physicochemical properties
- spatial arrangements
- functional moiety critical for biological activity


1. Exchangeable groups




Isoproterenol



Soterenol









Diphenhydramine



d-Carboxamine

2. Cyclic versus noncyclic structure



PROBABLE QUESTIONS

- Describe the importance of physicochemical properties on biological activity of drug molecules.
- Enumerate the different physicochemical properties of a drug molecule that influences the biological activity and describe in detail about the following
(a) Hydrogen bonding and (b) Ionization
- Write in brief about the following physicochemical properties and its influence on biological activity of drugs
(a) Redox potential (b) Surface activity
- What is bioisosterism? Write its applications in the design of a new and potent drug molecule.
- Write a brief note on the steric features of drugs and its effects on the biological activity.

SUGGESTED READINGS

- Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
- Block JH and Beale JM. *Wilson Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry* (11th edn). New York: Lippincott Williams and Wilkins, 2004.

3. Craig JC, Tate ME, Donovan FW, and Rogers WP. 'Chemical constitution and anthelmintic activity-V. Alkoxy and chlorophenothiazines'. *J Med Pharm Chem* 2: 669–90, 1960.
4. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2005.
5. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
6. Reist EJ, Hamlow HP, Junga IG, Silverstein RM, Baker BR. 'Potential anticancer agents.1 XXXIV. Nonredox analogs of riboflavin. Part I. Model studies'. *J Org Chem* 25: 1368–378, 1960.

DRUG DESIGN

1	Concepts of Drug Design	43
2	Receptors	49
3	Computer-Aided Drug Design	54
4	SAR and QSAR	56
5	Combinatorial Chemistry	66
6	Pro-Drugs	71

"This page intentionally left blank"

Chapter 1

Concepts of Drug Design

INTRODUCTION

The discovery or design of new drugs requires a design process along with the synthetic techniques, methods of administration, development of tests, and further procedures to establish pharmacodynamics and their toxicological assessment. The diversity in synthetic chemistry is ever increasing as a result of the increase in the number of chemical compounds, which requires a sequence of screening modules with appropriate time consumption and affords little success. These consequences made it necessary to find out the possibilities for the development of new, logical, and scientific approaches in the discovery of new molecules or drugs and came to be known as drug designing.

Drug design is an integrated advancing discipline, in which a biologically active molecule is produced by chemical synthesis followed by an evaluation of its activity and toxicological studies with the limitation of trial-and-error screening. In the broader sense, it implies the random evaluation of congeners produced from the lead molecule either by implementing tailor-made techniques or by applying the basic concepts of physicochemical properties to produce an able molecule.

DESIGN OF ANALOGUES AND PRODRUGS

Drug design involves the development of analogues and prodrugs by some chemical modifications from the lead molecule or from a parent compound by modifying the carbon skeletal transformation or by the synthesis of compounds of the same nucleus with various substitutions. Analogues can also be synthesized by changing the position of substitution group. For example, synthesis of *trans*-diethylstilbesterol by the modification of oestradiol produced better oestrogenic activity than the latter one.

The term prodrug implies an appropriate derivative of a drug. The prodrugs are discovered by the screening of active metabolites after in vivo biotransformation that are formed from parent compounds. For example, phenylbutazone is transformed into oxyphenbutazone by hydroxylation reaction mediated by phase I (nonsynthetic) metabolic reaction.

DESIGN OF LEAD AND LEAD DISCOVERY

The concept of lead discovery envisages two investigational processes. They are:

1. **Exploration of leads:** search of new molecules.
2. **Exploitation of leads:** assessment, chemical modelling, and extension of leads.

The drug discoveries without a lead are quiet few in number. The most prominent examples include penicillium and librium. Librium is the first benzodiazepine tranquillizer. A series of quinazoline-3-oxides were synthesized by Leo Sternbach at Roche in a new tranquilizer development programme. None of the molecules produced reliable pharmacological activity. One of the molecules that had been missed and identified while a laboratory clean up was happening, found to posses probable activity and chemically it was benzodiazepine-4-oxide. It produced chloromethyl quinazoline-3-oxide with methylamine. This lead identification was further exploited to develop potent analogues such as diazepam, which was found to be 10 times more potent than the lead.

Approaches to Lead Discovery

The lead identifications require a series of biological evaluation of the lead molecules. Once, after the identification, it can be structurally modified, the potency and the activity are improved.

RANDOM SCREENING

The entire synthesized compounds or any chemical constituents obtained from natural products are evaluated in a series for their biologically active components. Thus, random screening may produce unexpected active medicines. Antibiotics, such as streptomycin, tetracyclins, and fungal metabolites, such as lovastatin and cyclosporins, were found through this method. This approach needs more manpower, and it is expensive and time-consuming and the success rate is considerably low.

NONRANDOM SCREENING

In this method, only compounds that possess similar structural skeletons were evaluated from their particular properties.

PHARMACOKINETIC STUDIES

Biotransformation occurs as the fate by metabolizing enzymes. In order to develop new leads, the metabolites or biotransformed compounds are studied for their properties, and such studies are expected to assess the activity from a comparison with the parent molecule. For example, the discovery of sulphanilamide is reported through the metabolic studies of prontosil.

PHARMACODYNAMIC STUDIES


The effects apart from the therapeutic actions, that is, side effects may lead to the finding out of a new molecule with some appreciable structural modification. For example, sulphonamide used specifically for the treatment of typhoid, lowered the blood sugar levels drastically. This exerted action led to the finding of aryl sulphonyl thiourea moiety responsible for the lowering of blood glucose level. Amino alkyl derivatives of iminodibenzyl were synthesized as analgesic, sedative, and antihistamines that was found to possess antidepressive action. This led to the synthesis of many tricyclic antidepressants.

Drug Design Through Disjunction


Disjunction comes into the systemic formulation of analogues of a prototype agent, generally, towards structurally simpler products, which may be carried as quasi-replicas or partials of the prototype agent. This is employed by various methods, that is

- Unjoining of certain bonds.
- Substitution of aromatic cyclic system for saturated bonds.
- Elimination of the size of hydrocarbon portion of the parent molecule.
- Decyclization of any ring system.
- Cyclization of hydrocarbon chains.

For example, oestrogenic study of oestradiol through drug design by disjunction produced successful molecules of *trans*-diethylstilbesterol.



The disjunction of various steps in the design from II to III and to IV has not successively produced a reliable molecule, but it has succeeded in the total elimination of ring B and C in estradiol (I). By plotting the response curve, the maximal activity in the series was attributed to *trans*-diethylstilbosterol (D_1) and the possibility of reductions in activity depends on the distance between two hydroxyl groups.




Drug Design Through Conjunction

In this method, a systemic formulation of analogues of a prototype agent is employed. In general, principally mixed moieties are derived by conjunction of two pharmacophoreic molecules. An example for this is ganglionic blocking agents and its development is based on the principle of mixed moieties. Acetylcholine is a neurotransmitter, which acts as a parasympathetic muscarinic stimulant and produces appreciable changes in ganglionic functions; whereas, hexamethonium is a ganglionic blocker, and possesses only a slight action at postganglionic parasympathetic endings and produces a high degree of ganglionic blockade. The evaluation of Muscarinic moiety on being studied in relation with a particular bisquaternary type of structure, for example, hexamethonium, promptly suggests the following proposed design, thus, embodying the ganglionic moiety and Muscarinic moiety into a single molecule. It is, however, pertinent to mention here that the internitrogen distance essentially constitute an important factor in many of the series of *bis* quaternary salts possessing ganglionic blocking activity. It is worthwhile when the distance is more or less the same as that in hexamethonium. However, the actual synthesis and pharmacological evaluation of conjunctioned hexamethyl analogue reveals the presence of both a weak Muscarinic stimulant and possessing of a good ganglionic blocking action.


MOLECULAR HYBRIDIZATION IN DRUG DESIGN

Molecular hybridization essentially embodies the synthesis of strategically designed new breeds of bio-active agents from two or more compounds having different characteristic features with the aid of covalent-bond synthesis. In 1886, Necki exploited the beneficial properties of phenols and carboxylic acids possessing potent antibacterial characteristic feature into the design of newer drug molecules with better and improved pharmacological activities by simple esterification.

Example 1. A molecule of streptomycin and a molecule of isoniazid by means of a strong double bond between 'C' and 'N' forms a hybridized molecule through the elimination of a molecule of water. This hybridized molecule exhibits significant potentiated antibacterial and tuberculostatic activity.



2. Hybridization of acetyl salicylic acid (antipyretic) and quinine (antimalarial) to lose a molecule of water to form a hybridized molecule for a potent antimalarial drug with substantial antipyretic and analgesic activity.



RATIONAL APPROACH TO DRUG DESIGN

There are many approaches to drug designing in relation with physiochemical parameters and electronic features taken into consideration for designing a drug. These are as follows:

1. **Approach with quantum mechanics:** This, also called as wave mechanics, comprises the fundamental physical properties of a molecule. These include the properties of protons, neutrons, and electrons, which are explained by quantum mechanics. The basis of drug molecule nature is altered by chemical alterations of the electronic features.
2. **Approach with molecular orbital theory:** This approach depicts the change in properties that shall be made by the alteration of orbits. Based on this, the electrons present in the molecules are linked with orbitals to change the electronic feature. The molecular orbital approach is the change on electronic charges, evidenced from the investigation of three volatile inhalation anaesthetics, and also on molecular conformation, as studied with respect to acetylcholine, in regard to bond lengths and angles including torsional angles. These interpretations are carried out by computational methods in respect to structure activity relationship (SAR).
3. **Approach with molecular connectivity:** This is based on the structural features of a molecule. All steric and electronic parameters varies according to their configuration. These includes cyclization, unsaturation, presence of heteroatom, skeletal branching, and position in molecules with the aid of numerical indices and the series of functional attachments.
4. **Approach of linear free-energy:** Linear free energy approach was based on the selection of physiochemical parameters of a molecule with a specific biological activity. But the biological activity may vary in relation to the physiochemical properties of the drug or molecule and does not provide a prompt success, but it may reveal some beneficial features regarding the molecule.

Chapter 2

Receptors

INTRODUCTION

One of the basic tenets of pharmacology is that drug molecules exert some chemical influence on one or more constituents of the cells to produce a pharmacological response. Of course, the molecules in an organism are vastly outnumbered, but the drug molecules should be merely distributed at random to get a chance to interact with any particular class of proteins. The biological activity is studied by understanding the nature of binding sites and the mechanism by which the association of drug molecules take place. There are four primary target regulator proteins that are commonly involved in the drug interactions to produce pharmacological actions. They are enzymes, carrier molecules, ion channels, and receptors.

The term receptor or a receptive substance was used to denote a small region of macromolecule, which may be an isolable enzyme, a structural and functional compound of a cell membrane, or a specific intracellular substance, such as a protein or a nucleic acid. Occupation of a receptor by a drug molecule may or may not result in the activation of the receptor. Activations result in tissue responses. Binding and activation represent the two steps in the generation of receptor-mediated response by an agonist. If a drug binds to a receptor causing activation, and thereby prevents the agonist from binding, it is termed as a receptor antagonist, whereas the tendency for it once bound to activate the receptor is denoted by efficacy. Drugs with intermediate levels of efficacy produces submaximal response even at 100% receptor occupation are known as partial agonist. Those, which produce maximum response after 100% receptor occupation, are called full agonist.

TYPES OF RECEPTORS

Receptors elicit many different types of cellular effect. Some of them are very rapid, that is, those involved in synaptic transmission, operating within milliseconds, and other receptors for hormones that operates after hours and days. There are four types of receptors.

Type 1: Ligand-gated ion channels

Type 2: G-protein-coupled receptors

Type 3: Kinase-linked receptors

Type 4: Nuclear receptors

Ligand-gated ion channels: The ligand-gated ion channels are also known as ionotropic receptors. These are membrane proteins with a similar structure to other ion channels, but incorporating a ligand-binding site (receptor), usually in an extracellular domain. Typically, these are the receptors on which fast neurotransmitters act.

Examples: nicotinic acetylcholine receptor, GABA_A receptor, and glutamate receptor of *N*-methyl-*D*-aspartic acid (NMDA).

G-protein-coupled receptors: It is also called metabotropic receptors or seven-*trans* membrane spanning receptors that act through a second messenger, which elicits an action. Second messengers usually are *cyclic* adenosine monophosphate (cAMP) and inositol trisphosphate (IP₃).

Examples: muscarinic receptors, beta adrenergic receptors, serotonin receptors and opioid receptors.

Kinase-linked or enzyme-linked receptors: These constitute extracellular ligand-binding domain that is linked to an intracellular domain by a single transmembrane helix. In many cases, the intracellular domain is enzymatic in nature. Some times the receptor subunit may bind to an enzyme called *Janus-Kinase*. Type 3 receptors include those for insulin and various cytokines.

Nuclear receptors: The nuclear receptors regulate the gene transcriptions, are located in the cytosol, and migrate to the nuclear compartment when a ligand is present. The receptor protein is inherently capable of binding to specific genes. These include the receptors of glucocorticoids and thyroid hormone.

THEORIES OF RECEPTORS

Occupation Theory

Proposed by Gaddum and Clark, the theory states that the intensity of pharmacological effect is directly proportional to the number of receptors occupied by the drug. The pharmacological response of a drug molecule depends on the amount of dose, the total number of receptors available, and its intrinsic activity that can be expressed as $K_1[R] \times [A]$.

where K_1 = association constant

R = concentration of the receptors not occupied by drugs

A = concentration of drug molecules or dose

Similarly, the rate of dissociation of the drug receptor complex is given by the expression $K_2[RA]$.

K_2 = dissociation constant

$[RA]$ = concentration of receptors occupied by the drug

At equilibrium, $K_1[R] \times [A] = K_2[RA]$

$[R] + [RA]$ is equal to $[r]$ = total concentration of the receptors.

Thus, $K_1[A][r] - [RA] = K_2[RA]$ ----- (1)

or

$$[RA]/[r] = K_1[A]/K_1[A] + K_2 = 1/1 + K_2/K_1[A] \text{ ----- (2)}$$

K_2/K_1 can be replaced by KA = equilibrium constant.

It is the reciprocal of the drugs affinity for the receptors.

The term $[RA]/[r]$ represent the fraction of the total number of receptors occupied by the drug.

When $[RA] = [r]$, that is, all receptors are occupied and the response is, thus, proportional to its intrinsic activity X_n

$$\text{Relative response} = [RA]X/[r] = X/1 + KA/[A] \text{ ---- (3)}$$

This theory does not rationalize partial antagonists.

Rate Theory

The rate theory explains that the pharmacological activity is a function of the rate of association and dissociation of a drug with the receptor and is not the function of the number of occupied receptors.

At equilibrium, the rates of combination and dissociation of drug-receptor reactions are same and Eqn (1) can be written as

$$K_1[A] ([r] - [RA])/[r] = K_2 [RA]/[r] \text{ ---- (4)}$$

or

$$\text{Rate of receptor occupation} = K_2/1 + RA/[A] \text{ --- (5)}$$

When the response is proportional to the number of receptors occupied, Eqn (3) is important and when the response is proportional to the rate of receptors, Eqn (5) is important.

Induced Fit Theory

It is proposed by Koshland to give explanation for the action of enzymes and substrates. It explains that the receptor (enzyme) need not necessarily exist in the same conformation that is required to bind the drug (substrate). As the drug approaches the receptor, a conformational change is induced for binding, which initiates the pharmacological activity.

Example: Acetylcholine interacts with the regulating protein and alters the normal forces that stabilizes the structure of the protein and thereby producing a transient rearrangement in membrane structure and a consequent change in its ion regulating property. These receptors are suggested to be elastic and returns to the original conformation after the drug releases.

According to this theory, an agonist will bind by conformational change with intrinsic activity and elicit a response, but an antagonist will bind by conformational change without intrinsic activity.

Macromolecular Perturbation Theory

According to this theory, the drug interaction with a receptor leads either to specific conformational perturbations (SCPs) or to nonspecific conformational perturbations (NSCPs). An SCP will produce a specific response from an agonist in which the drug possesses intrinsic activity. In NSCP, no stimulant action, but may be antagonistic or blocking action will be produced. If a drug possesses SCP and NSCP features, an equilibrium mixture of two complexes may result and leads to partial agonistic action.

Example: Alkyl trimethyl ammonium ions

C_1 to C_6 —Alters receptor structure and produces muscarnic agonistic action

C_8 to C_{12} —Antagonistic action

Heptyl and octyl derivatives—Partial agonists (intermediate derivatives)

Activation–Aggregation Theory

According to this theory, even in the absence of drugs, a receptor is in a state of dynamic equilibrium between an activated form (R_o), which is responsible for biological responses and an inactive form (T_o). Agonists shift the equilibrium to activated form and antagonists shift the equilibrium to inactivated form. Partial agonists bind to both conformations during partial antagonistic action. The agonist-binding site and antagonist-binding site conformation may be different.

FORCES INVOLVED IN DRUG RECEPTORS INTERACTION

Covalent Bonding

Covalent bonds are the one which are produced by a strong energy. These are produced only when an irreversible antagonist inactivates the receptors. If a weak bond forms the drug receptor complex, the complex formed will be a reversible type.

Example: Acetylcholinesterase is irreversibly inactivated by a number of phosphate esters (organophosphorus compounds includes pesticides). The nitrogen mustards are irreversible inhibitors of certain receptors.

Dipole-Dipole and Ion-Dipole Interactions

It is associated with electrostatic bonding. Molecules in which there is a partial charge separation between adjacent atoms or functional groups can interact either with each other or with ions. The carbon-X bonds in drugs and receptors (where X is an electronegative atom) will have asymmetric distribution of electrons. This produces electronic dipoles. The dipoles in a drug molecule can be attracted by ions (ion-dipole interaction) or by other dipole-dipole interaction (Fig. 2.1). Ion dipole interactions are more powerful and has high energy.




Figure 2.1 Ion-dipole and dipole-dipole interactions.

Hydrogen Bonding

It forms a weak (energy from 7 to 40 KJ/mol) and easily breaking bond. Since drugs contain hydroxyl, amino, carboxyl, and carbonyl groups it can form H bonds with the receptors. H-bonding is a type of dipole-dipole interaction formed between the proton of a group X-H (X-is an electronegative atom) and other electronegative atoms (Y) containing pairs of nonbonded electrons. X removes electron density from hydrogen. Therefore, it has a partial positive charge, which is strongly attached to nonbonded electrons of Y. Hydrogen bonding usually stabilizes the structures by intramolecular bond formation. Such bond formation occurs in protein alpha helix and in base pair of DNA.

Electrostatic Bonding

The opposite charged compound will interact with the opposite charged part of the receptor. The positively charged quaternary *N*-acetylcholine may be attracted to the negative charge of an ionized carboxyl group in the receptor.

Charge Transfer Complex

A dipole-dipole interaction is produced and a charge transfer complex is formed when any molecule with electron-donating property comes near the electron-accepting group. Donor molecules are electrons rich in heterocycles, for example, furan, thiophene, and aromatics with electron-donating substituents, or compounds with free nonbonding electron pair. Acceptor molecules are electron deficient systems such as purines and pyrimidines or aromatics with electron-withdrawing substituents. Examples of charge transfer complex in drug receptor interaction are antimalarials with their receptors and antibiotics intercalating the DNA. The energy is not more than 30 KJ/mol.

Hydrophobic Forces

In the presence of nonpolar molecules, the surrounding water molecules orient themselves, and therefore, are in a high-energy state, when two nonpolar receptor groups (one from the drug and another from the receptor) approach disorder-ordered H_2O molecules in an attempt to associate with each other by increasing the enthalpy and decreasing the free energy to stabilize drug receptor-complex.

van der Waal's or London Dispersion Forces

Atoms in nonpolar molecular structure have a temporary nonsymmetrical distribution of electron density, which results in the generation of a temporary dipole that creates an intermolecule attraction called van der Waal's force. However, this is a weak bond.

FACTORS AFFECTING THE DRUG-RECEPTOR INTERACTION

Isosterism: Groups of atoms that possess similar physical or chemical properties of a molecule due to similarity in size, electronegativity, or stereochemistry are referred to as isosteres. The existences of such groups in molecules are termed isosterism. For example, N_2 and CO, both have 14 total electrons and no charges and show same physical properties. In sulphonamides, the replacement of atoms or groups with various isosters, other analogues are developed. Potency of these agents varied according their interaction with the target.

Steric features of a drug: The drug must possess stereoselective property to initiate a response at a particular receptor. For example, *trans*-diethylstilbesterol is oestrogenic while *cis*-isomer is almost inactive.

Optical isomerism: Enantiomers, asymmetry, and chirality are important concepts to give better receptor interaction with drugs. Although each enantiomer has some physical and chemical properties, they may act in different ways and in different sites to produce variable pharmacological action.

Chapter 3

Computer-Aided Drug Design

INTRODUCTION

Computer aided drug design (CADD) involves all the computer-assisted techniques that are used to discover, design, and optimize biologically active compounds with putative use as a drug having the desired structure and properties.

The process of drug discovery and development is a long, tedious, and difficult one with the high demand for drugs on one side and the complexity of various biological systems on the other side. Occasionally, new drugs are discovered by accident, more frequently, they are developed as a part of an organized effort to discover new ways to treat specific diseases. The trial-and-error method usually employed for new drug developments are highly uneconomical, as they require various predictions, such as pharmacokinetic, pharmacodynamic, and toxic properties before the synthesis of a chemical compound. Finally, after these, it is observed that out of the several thousand compounds synthesized and tested, hardly one, two, or even none clicks. Today, the emphasis is not just finding new ways to treat human disease, but also on improving the quality of life in general. Computer-based drug design techniques have the ability to accomplish both these goals and improve the efficiency of the process as well.

The drug discovery and lead optimization process is currently dominated by developments in two fields, a rational design based on structural information and sophisticated computational methods to elucidate the structural prerequisites that are important for binding to a particular target.

The rational drug design processes have changed the way in which potential new drugs are discovered. The rational drug design process starts with an understanding of the fundamental physiological and biochemical aspects of the disease or target, rather than random screening process. One method to bring about cost effectiveness in drug design process is by applying both the knowledge of mechanistic basis of a target disease and molecular characteristics of the compounds to have an effect on diseases state. This approach to therapeutic development is called *rational drug design approach*.

CADD is a specialized branch that covers computational methods of calculation, and graphics techniques gives information about drug-receptor interactions. CADD methods are closely linked to bioinformatics application and databases (Fig. 3.1).

BIOINFORMATICS HUB

Bioinformatics can be thought of as a central hub that unites several disciplines and methodologies.

On the support side of the hub, computational resources and other software technologies like information technology, information management, and databases, provide the infrastructure for bioinformatics.




Figure 3.1 Role of bioinformatics in computer-aided drug design.

On the scientific side of the hub, bioinformatic methods are used extensively in molecular biology, genomics, proteomics, and in CADD research.

Bioinformatics supports CADD research in the following aspects:

- Virtual high-throughput screening
- Sequence analysis
- Homology modelling
- Similarity searches
- Drug lead optimization
- Physicochemical modelling
- Drug bioavailability and bioactivity

Advantages of CADD

CADD methods and bioinformatics tools offer significant benefits for drug discovery programs.

Cost saving: The cost of drug discovery and development has reached \$800 million for a single drug to be successfully brought into the market. Recently, many pharmaceutical industry are focussing the CADD to reduce this cost burden.

Time-to-market: The predictive power of CADD can reduce the time period for drug development and optimization and avoids potential 'dead-end' compound on final stage. It can get drugs to the market more quickly and cost effectively.

Insight: The molecular graphics technique of CADD gives information about drug-receptor interaction and atomic scale binding properties to particular ligand or protein. It may give new ideas for researcher to modify the drug compounds for improved fit. Therefore, CADD and bioinformatics together are a powerful combination in drug research and development.

Chapter 4

Structure-Activity Relationship and Quantitative Structure-Activity Relationship

INTRODUCTION

Structure-activity relationship (SAR) and quantitative structure-activity relationship (QSAR) study, collectively referred to as (Q)SAR, are theoretical models that can be used to predict the physicochemical, biological, and environmental fate properties of molecules.

The aim of QSAR techniques is to develop correlations between any biological property form of activity, frequently *biological* activity, and their properties, usually, physicochemical properties of a set of molecules, in particular, substituent properties. However, in its most general form, QSAR has been adapted to cover correlations independent of actual physicochemical properties. QSAR started with similar correlations between chemical reactivity and structure. Ideally, the activities and properties are connected by some known mathematical function, F:

Biological activity = F (physicochemical properties)

Biological activity can be any measure of, such as C, K_p , IC_{50} , ED_{50} , and K_m .

Physicochemical properties can be broadly classified into three general types such as electronic, steric, and hydrophobic property of biologically active molecules, for which an enormous range of properties and physicochemical parameters have been defined. Ideally, the parameters selected should be orthogonal, that is, have minimal covariance. The relationship or function is usually (but not always) a mathematical expression derived by statistical and related techniques, for example, multiple linear regression (MLR). The parameters describing physicochemical properties are used as independent variables and the biological activities are dependent variables. In some cases, a function cannot be found, and this reflects the multivariate, nonlinear nature of biological and physical properties. Usage of such data may be possible with neural networks to deduce essential data for biological activities and then using them for prediction.

Usually, some data are used to generate a relationship (the training set), while another set of data is reserved as a test set on which predictions using the rule are made. In this manner, a model can be tested for validity. The complete range of techniques used to derive functional relationships between the data is collectively known as chemometrics.

HISTORICAL DEVELOPMENT OF QSAR

In early 1868, Crum-Brown and Fraser published an equation, which is considered to be the first general equation of QSAR. Richet discovered that the toxicity of organic compounds (aldehyde, alcohol, ethers, ketone, etc.) inversely follow their water solubility. Later, Meyer and Overton have worked independently and observed the linear relationships between lipophilicity (oil-water partition coefficients) and narcotic activities. Further, Fuhner has given the first evidence of additivity of groups contributing to biological activity values in a homologous series of compounds for their narcotic activity. Ferguson postulated that the thermodynamic principles could be related to drug activities.

After 1950, QSAR methodology has progressed remarkably. During this year, Bruice, Kharasch, and Winzler reported group contributions to biological activity values in a series of thyroid hormone analogues; this may be considered as a first Free-Wilson-type analysis. Zahradnik has tried to apply the concept of the Hammett equation. However, significant progress has occurred in the field of QSAR in 1960s through the research work of Bocek and Kopecky, Hansch, Free-Wilson and Fujita. Among these, only Bocek-Kopecky method has become unsuccessful due to the involvement of a number of parameters. Among the different methods, Hansch, Free-Wilson, and modified Free-Wilson approaches are the widely practiced ones for modelling the biological response. Also, QSAR is one of the approaches attracting increasing levels of interest in the pharmaceutical industry as a productive and cost-effective technology in the search for novel lead compounds.

Hansch Analysis

QSAR based on Hammett's relationship utilize electronic properties as the descriptors of structures. Difficulties were encountered when investigators attempted to apply Hammett-type relationships to biological systems, indicating that other structural descriptors were necessary. In 1962, Hansch et al entered the scenario with the numerical information on lipophilicity, electronic, and steric effect on the model development. The general form of Hansch equation is as follows:

$$\text{Log BA} = a \log p + b \sigma + c E_s + \text{constant (linear)}$$

$$\text{Log BA} = a \log p + b (\log p)^2 + c \sigma + d E_s + \text{constant (nonlinear)}$$

Hansch model correlates biological activity with physicochemical properties. The coefficients (a , b , c , d , and constant) are determined by multiple regression analysis.

Free-Wilson Analysis

It is also known as the additivity model or *de novo* approach. This method is based on the assumption that the introduction of a particular substituent at a particular molecular position always contributes in the same way to the biological potency of the whole molecule, as expressed by the equation:

$$\text{Log BA} = \text{contribution of unsubstituted parent compound} + \text{contribution of corresponding substituents}$$

$$\text{Log BA} = \mu + \sum a_i a_j$$

where a_i = number of positions at which substitution occurs

a_j = number of substituents at that position

μ = overall average.

The equation is solved by MLR using the presence (1) or absence (0) of the different substituents as independent parameters, while the measured activity serves as dependent variable.

Mixed Approach

Kubinyi has presented the combination of Hansch and Free-Wilson approach as mixed approach.

$$\text{Log BA} = k_1 \pi + k_2 \sigma + k_3 \text{Es} + k \text{ (Hansch analysis)}$$

$$\text{Log BA} = \mu + \sum a_i a_j \text{ (Free-Wilson approach)}$$

So, the mixed approach can be written as

$$\text{Log BA} = \sum a_i a_j + \sum k_i \phi_j + k$$

Where $\sum (a_i a_j)$ is the Free-Wilson part for the substituents

$\phi_j = \sigma, \pi$, and Es contribution of the parent skeleton.

Among the above-mentioned approaches, Hansch approach became the most popular approach in QSAR. The high-dimensional QSAR analyses (3D, 4D, and 5D) are developed to avoid pitfalls of classical method and to create the hypothetical drug receptor model.

ADVANTAGES OF QSAR

- It gives quantifying the relationship between structure and activity with their physiochemical property basis.
- Possible to make predictions of designed compounds before the chemical synthesis of novel analogues.
- It may help to understand the interactions between functional group of designed molecules and their activity of target enzyme or protein.

DISADVANTAGES OF QSAR

- Due to biological data experimental error it may give false correlations.
- If training set of molecule is less, the data may not reflect the complete property and it cannot be used to predict the most active compounds.
- In some 3D QSAR study ligands binding receptor or protein may not be available in that case the common approach result may not represent the reality.
- Cannot expect that the QSAR works all the time give successful applications.

A model perfectly predicts that the training data may not be good or even useless for prediction. The problem of QSAR is to find coefficients C_0, C_1, \dots, C_n such that

$$\text{Biological activity} = C_0 + (C_1 \times P_1) + \dots + (C_n \times P_n)$$

and the prediction error is minimized for a list of given compounds.

Partial least squares (PLSs) is a technique used for computation of the coefficients of structural descriptors.

BASIC REQUIREMENTS FOR QSAR ANALYSIS

Some basic requirements are very essential for best model development. They are the following:

- All analogues belong to a congeneric series (classical QSAR studies) exerting the same mechanism of action. This is a series of compounds with a similar basic structure, but with varying substituents. Noncongeneric series are widely used for higher dimensional (3D and 4D) studies.

- Also, the set of compounds with same mechanism of action is essential.
- Biological response should be distributed over a wide range.
- Observed biological activity should be in specific units (concentration in molar units or IC_{50} or percentage inhibition).
- A simple rule is that the total number of compounds in the training set divided by the number of variables in the final model should be greater than approximately five or six.

This will assure that a data set will not be 'over predicted' and that the model will have a better chance to retain the predictive value.

Steps Involved in QSAR Studies

The QSAR methodology enables the development of mathematical models, which can be used to predict the biological activity of newly designed compounds. There are three steps involved in this procedure; the first step is the creation of a database in which calculation of various physicochemical and structural parameters of a congeneric series takes place followed by regression analyses leading to model development between biological activities versus derived physiochemical descriptors. The third step involves the validation of the models and prediction of the biological activity of the designed compounds.

Statistical Methods Used in QSAR Analysis

Statistical methods are an essential component of QSAR work. They help to build models, estimate a model's predictive abilities, validate an already existing model, and find the relationships and co-relationship among the variables and the activities. Data analysis methods are used to recombine data into forms and groups and observations into hierarchies.

REGRESSION METHODS

It is a mathematical procedure, which co-relates dependent (X) variable with the independent (Y) variables. There can be different forms of regression analysis:

Simple linear regression analysis: An independent variable is correlated with a dependent variable and produces a linear one-term equation. It is useful for discovering some of the most important descriptors.

MLR analysis: More than one independent variable is correlated with a dependent variable and a single multiterm equation is formed. The number of variables should be one-fifth of the molecules in a series, that is, for each five molecules in the series one can have one variable.

Stepwise linear regression analysis: This is useful when the number of independent variables is very high and is thus correlated in a stepwise manner with the dependent variable producing a multiterm linear equation.

PARTIAL LEAST SQUARE (PLS)

Hundreds or even thousands of independent variables (X-block) can be correlated with one or several dependent variables (Y-block). PLS is used when X data contain co-linearities or when N is less than $5M$, where N is the number of compounds and M is the number of independent variables. Often perfect correlations are obtained in PLS analysis, due to the usually large number of X variables and cross-validation

procedure must be used to select the model that is having the highest predictive values. Several PLS are performed in which one or several objects are eliminated from the data set. It is the method of choice in 3D QSAR method.

GENETIC FUNCTION APPROXIMATION (GFA)

It provides multiple models that are created by evolving random initial models using a genetic algorithm. Models are improved by performing a cross over operation to recombine better sorting models. This method is used when dealing with a large numbers of descriptors.

GENETIC PARTIAL LEAST SQUARES (G/PLSs)

This method combines the best of GFA and PLS. Each generation has a PLS applied to it instead of MLR and so each model can have more terms in it without fear of overfilling. G/PLS retains the ease of interpretations of GFA by back transforming the PLS component to the original variable.

PRINCIPAL COMPONENT ANALYSIS (PCA)

PCA is a data reduction method, using mathematical techniques to identify the pattern in a data matrix. The main element of this approach consists of the construction of a small set of new orthogonal, that is, uncorrelated variables derived from a linear combination of the original variables.

Statistical Measures Commonly Used in Regression Analysis

Correlation coefficient (r)/Square of the correlation coefficient (r²): The correlation coefficient 'r' and square of the correlation coefficient (r²) are measures of the quality of the fit of the model. It is computed using the following equation

$$r = \sqrt{1 - \Sigma \Delta^2 / SSY}$$

$$r^2 = 1 - \Sigma \Delta^2 / SSY$$

$$\text{Where, } SSY = \Sigma (Y_{\text{obs}} - Y_{\text{mean}})$$

$$\Sigma \Delta^2 = \Sigma (Y_{\text{obs}} - Y_{\text{cal}})^2$$

Where SSY is the overall variance, that is, $S = \Sigma (Y_{\text{obs}} - Y_{\text{mean}})$ Y_{obs} is observed biological activities

Y_{mean} is mean of biological activities value

Y_{cal} is calculated biological activity used in the equation.

A high value of correlation coefficient (r) indicates the statistical significance of the regression equation and thereby the participating substituent constants. The squared correlation r² is a measure of the explained variance, most often presented as a percentage value, for example, $r = 0.8$, then $r^2 = 0.664$ or 66.4% as the variance accounted by regression parameters.

Standard error of the estimate (S): This is a measure of how well the function derived by the QSAR analysis predicts the observed biological activity. Its value considers the number of objects n and the number of variable k . Therefore, S depends not only on the quality of fit, but also on the number of degrees of freedom. The smaller the value of S the better is the QSAR.

$$DF = n - k - 1$$

$$S = \sqrt{\Sigma (Y_{\text{obs}} - Y_{\text{cal}})^2 / n - k - 1}$$

F-value: It is a measure of the statistical significance of the regression model, the influence of the number of variables included in the model is even larger than the standard deviation.

$$F\text{-value} = r^2 (n - k - 1) / k(1 - r^2)$$

Predicted sum of squares (PRESS): The sum of the overall compounds of the square difference between the actual and the predicted value of dependent variables.

$$P = \sum (Y_{\text{obs}} - Y_{\text{pred}})^2$$

Cross-validation r^2 (q^2): Cross-validation is an approach for assessing the predictive value of a model. The cross validation $r^2(q^2)$ is generated during a validation procedure. It is calculated using the formula

$$q^2 = 1.0 - \sum (Y_{\text{pred}} - Y_{\text{obs}})^2 / \sum (Y_{\text{obs}} - Y_{\text{mean}})^2$$

Where Y_{pred} is a predicted value; Y_{obs} is an actual value or experimental value; Y_{mean} is the best estimate of the mean of all values that might be predicted.

A cross-validated r^2 is usually smaller than the overall r^2 for a QSAR equation. It is used as a diagnostic tool to evaluate the predictive power of an equation. Cross-validation proceeds by omitting one or more rows of input data, re-deriving the model, and predicting the target property values of the omitted rows. The re-derivation and predicting cycle continues until all the target property values have been predicted at least once. The root mean square error of all the target predictions, the predictive sum of squares (PRESS) is the basis for evaluating the model.

Outliers: An outlier is defined as a structure with a residual greater than two times the standard deviation.

Bootstrapping: Bootstrapping is another technique for model validation. It is based on simulating a large number of data sets sampled from the original data set that are of the same size as the original. The same data can be sampled more than once. The statistical analysis is performed on each of the simulating data sets. The component model with consistent results is then chosen as the final model.

MODEL DEVELOPMENT PROCEDURES

Classical or 2D QSAR Analysis

2D descriptors are usually developed by using the atoms and connective information of the molecule, but 3D coordinates and individual conformations are not considered. In 2D QSAR, physicochemical parameters such as hydrophobic (π), steric (molar refractivity or MR), hydrogen acceptor (HA), hydrogen donor (HD), and electronic (field effect or F, resonance or R, Hammett's constant or σ) are normally used. In addition to these parameters, *de novo* constants or indicator variables with 0 or 1 values denoting the absence or presence of certain features (*cis/trans* ring atom and bridge atom or chain, different test model, etc) are also used to adequately parameterize the compounds. In all this, many topological indices are also considered as parameters for analysis.

Drug distribution and binding processes are equilibrium processes governed by the corresponding free energy differences, $K = e^{-\Delta G/RT} = e^{-(\Delta H - T\Delta S)/RT}$, such relationships should use logarithmic scale. For these the biological inhibitory values, that is, IC_{50} or ED_{50} or LD_{50} or Ki must be converted into logarithmic form, such as $\log(1/IC_{50})$ or $\log(1/ED_{50})$ or $\log(1/LD_{50})$ or $\log(1/Ki)$ values to obtain appropriate activity parameters for the QSAR study. The logarithmic scales also ensure a normal distribution for the experimental

error of biological tests, a requirement for regression-type statistical analyses. In some cases, the activity percentage (%) values (A) are converted to $\text{Log} \{A/(100 - A)\}$ as a binding equilibrium constant, which physicochemically is more meaningful than A alone for QSAR analysis.

3D-QSAR Analysis

Three-dimensional quantitative structure-activity relationships (3D-QSARs) are quantitative models that relate the biological activity of small molecules with their properties calculated in 3D space (Fig 4.1). Hence, 3D properties of a molecule are considered rather than that of the individual substituents. The 3D structures are usually generated from 2D or 2D with configurational information or 3D-structure database or X-ray crystallographic analysis or 2D NMR study. This structure is optimized to refine the geometry based on the size of the molecule such as molecular mechanics (large systems; thousands of atoms) or semi-empirical (medium size systems; hundreds of atoms) or *ab initio* (small systems; tens of atoms), in order to obtain one lowest energy structure per molecule. There are many 3D-QSAR techniques used for various purposes. A few of them are the following:

- Comparative molecular field analysis (CoMFA)
- Comparative molecular similarity indices analysis (CoMSIA)
- Molecular shape analysis (MSA)
- The distance geometry approach
- The binding site model approach
- COMPASS, the hypothetical active lattice method
- The molecular similarity approach
- Genetically evolved receptor models

Among all the 3D-QSAR techniques, CoMFA is the most widely used technique and has shown unprecedented accuracy in prediction. Some of these approaches to QSAR are based on the statistical analysis of the 3D interaction fields. These are generated by measuring over a regular 3D grid the interaction energy between a small probe atom or a group and the ligands. Initially, the 3D structures of the training set of compounds are aligned based on common molecular features, so as to occupy the same volume of space. The interaction energies of the small probe, usually, a methyl group and a proton, is measured with each of the training set compounds at each grid co-ordinates in space. The interaction energy at each grid point in space becomes a descriptor in a QSAR analysis. It results in a data table containing several hundreds or even thousands of descriptors for the analysis.

COMPARATIVE MOLECULAR FIELD ANALYSIS (CoMFA)

CoMFA is a 3D-QSAR technique employing both interactive graphics and statistical techniques for correlating the shapes and the biological properties of the molecules. It was proposed and developed by R.D. Cramer in 1988. The principle underlying CoMFA is that differences in a target property related to differences in the shapes of the noncovalent fields of tested molecules. The molecular shape of tested molecule field into a QSAR table and the magnitude of steric (Lennard-Jones) and electrostatic (Coulombic) fields are sampled at regular intervals throughout a defined region of rigid box.

To do so, bioactive conformation of each compound is chosen and they are superimposed in a manner defined by the supposed mode of interaction with the target receptor. Further, CoMFA compares the steric




Figure 4.1 Systematic methodology for 3D-QSAR analysis.

and the electrostatic fields calculated around the molecules with various probe groups in three dimensions and extract the important features related to the biological activity. With this information, CoMFA tries to identify the quantitative influence of the specific chemical features of the molecules on their potencies. In 3D space the contour plots result showing that biological activity important regions of designed or active molecules. Advantages of CoMFA technique include the prediction of activity of new compounds and representation of QSAR models in the form of contour maps.

There are many important aspects that need to be considered for developing a good CoMFA model. They include the following factors:

- Biological data, selection of compounds, and series design, generation of 3D structure of ligand molecules.
- Conformational analysis of each molecule.
- Establishment of bioactive conformation of each molecule, binding mode and superimposition of the molecules.
- Position of lattice points, choice of force fields and calculation of interaction energies.
- Statistical analysis of the data and selection of the 3D QSAR model.
- Display of results in contour plots and interpretation of them, design and forecasting the activity of unknown compounds.

COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS (CoMSIA)

The general methodology and crucial variables for CoMSIA are same as for CoMFA. The primary difference between them is that in case of CoMFA, the contribution due to dispersion forces between molecules are described by Lennard-Jones potential and electrostatic properties are characterized by Coulomb-type potential while in CoMSIA a special Gaussian function is considered for calculation of interaction energies. CoMSIA avoids some of the inherent deficiencies arising from the functional form of the Lennard-Jones and Coulomb potentials used in the original version of CoMFA. Both the potentials are very steep, close to the Vander Waal's surface and produce singularities at the atomic positions. As a consequence, the potential energy expressed at the grid points in the proximity of the surface changes dramatically. To avoid unacceptably large energy values, the potential evaluations are normally restricted to the regions outside the molecules and require the definition of some arbitrarily determined cutoff values. Due to the differences in the slope of the Lennard-Jones and Coulomb potentials, these cut-off values are exceeded at different distances from the molecules, requiring further arbitrary scaling of the two fields in a simultaneous evaluation, which can involve the loss of information about one of the fields. To overcome such problems, CoMSIA evaluates molecular similarity in space. Furthermore, in addition to the steric and electrostatic fields, CoMSIA defines explicit hydrophobic and hydrogen bond donor and acceptor descriptor fields, which are not available with standard CoMFA.

SUGGESTED READINGS

1. Abraham DJ. 'History of quantitative structure-activity relationships'. In *Burger's Medicinal Chemistry and Drug Discovery*, Vol I (6th edn), C. Selassie (ed). New York: John Wiley.
2. Hansch C, Leo A, and Hoekman D. *Exploring QSAR: Hydrophobic, Electronic, and Steric Constants*. Washington: American Chemical Society, 1995.
3. Kadam SS, Mahaik HR, and Bothara KG. 'Principles of medicinal chemistry'. *QSAR* 1: 435, 1986.
4. Marshall GR, Barry CD, Bosshard HE, Dammkoehler RA, and Dunn DA. 'The conformational parameter in drug design: The active analog approach'. In *Computer Assisted Drug Design*. ACS Symposia, 112. Olson EC and Christofferson RE (eds). Washington DC: American Chemical Society, 1979.
5. Martin YC. 'A practitioner's perspective of the role of quantitative structure activity analysis in medicinal chemistry'. *J Med Chem* 24: 229, 1981.

6. Robert FG (ed). *Biological Correlations: The Hansch Approach, Advances in Chemistry Series*, No. 114. Washington DC: American Chemical Society, 1972.
7. Schad LJ, Hess B Jr, Purcell WP, Cammarat A, Franke R, and Kubinyi H. 'Compatibility of the Free-Wilson and Hansch quantitative structure-activity relations'. *J Med Chem* 24: 900, 1981.
8. Stuper AJ, Brugger WE, and Jurs PC. *Chemometrics: Theory and Application*, Kowalski BR (ed). Washington DC: American Chemical Society, 1977.
9. Topliss JG. *Quantitative Structure-Activity Relationships of Drugs*. New York: Academic Press, 1983.

Chapter 5

Combinatorial Chemistry



INTRODUCTION

Combinatorial chemistry is a technique through which large numbers of structurally distinct molecules may be synthesized at a time and submitted for high throughput screening (HTS) assay. Combinatorial chemistry is one of the recent methodologies developed by researchers in the pharmaceutical industry to reduce the time and costs associated with producing successful and competitive new drugs. By accelerating the process of biologically active compounds, this method is having a profound effect on all the branches of chemistry, especially on drug discovery. Through the rapidly evolving technology of combinatorial chemistry, it is now possible to produce compound libraries to screen for novel bioactivities. This powerful new technology has begun to help pharmaceutical companies to find novel drug candidates quickly, save significant money in preclinical development costs, and ultimately change their fundamental approach to drug discovery.

The aim of this chapter is to provide a basic introduction to the field of combinatorial chemistry describing the development of major techniques and applications.

Principles of Combinatorial Chemistry

The key of combinatorial chemistry is that a large range of analogues are synthesized using the same reaction conditions and the same reaction vessels. In this way, the organic chemist can synthesize hundreds or thousands of compounds at one time instead of preparing only a few by a traditional methodology. For example, compound A would have been reacted with compound B to give product AB, which would have been isolated after reaction, work up, and purification.



In contrast to this approach, combinatorial chemistry offers the potential to make every combination of a compound A1 to An with compound B1 to Bn.

The range of combinatorial techniques is highly diverse, and these products could be made individually in a parallel or in mixtures, using either solution or solid-phase techniques. Whatever be the technique used, the common denominator is that productivity has been amplified beyond the levels that have been routine for the last hundred years.

COMBINATORIAL COMPOUND LIBRARIES

The origin of combinatorial chemistry lies in the use of solid supports for peptide synthesis. By coupling the growing peptide to a solid support, such as a polystyrene bead, it is possible to use excess reagents and so ensure that the reaction proceeds to completion. Any excess reagent is simply washed away. In the original applications of solid-phase chemistry to peptide synthesis the goal was generally the synthesis of a single molecular target. A key breakthrough was the recognition that this methodology could be used to generate large numbers of molecules using a scheme known as *split-mix* technique. This technique starts with a set of reagents (which we may also refer to as monomers), each of which is coupled to the solid support. These are then mixed together and divided into equal-sized aliquots for reaction with the second reagent. The products from this reaction are reacted with the third reagent, and so on. If the number of reagents at each step are n_1, n_2, n_3 , etc., then the total number of molecules produced is the product is $n_1 n_2 n_3$. The size of the library, thus, increases exponentially with the number of reagents—hence the use of the term ‘combinatorial’.

The original split-mix method is capable of producing extremely large libraries, but it does suffer from some drawbacks. A particular limitation is that due to the various mixing stages the identity of the product on each bead is unknown (except for the final reagent). It is important to note, however, that each bead contains just one discrete chemical entity. In the recent years, many progress has subsequently been made in the technology for automated synthesis and purification since the first reports were published. These developments have enabled many of the limitations of the early combinatorial techniques to be overcome, making automated synthesis methods a common place in both industrial and academic laboratories.

Combinatorial Synthesis on Solid Phase

In 1963, Merrifield pioneered the solid phase synthesis (SPS) work, which earned him a nobel prize. Merrifield’s SPS concept was first applied for a developed biopolymer, recently it has spread in every field where organic synthesis is involved. Nowadays, many academic laboratories and pharmaceutical companies focused on the development of the technologies and chemistry suitable for SPS. This resulted in the impressive outbreak of combinatorial chemistry, which profoundly changed the approach to new drugs, new catalyst, or new natural discovery.

The utilization of solid support for the organic synthesis relies on three interconnected requirements. These are as follows:

1. A cross-linked, insoluble polymeric material should be inert to the condition of synthesis.
2. The linking substrate (linker) to the solid phase that permits selective cleavage of some or all the products from the solid support during synthesis for analysis of the extent of reaction (s) and ultimately to give the final product of interest.
3. The chemical protection strategy must allow selective protection and deprotection of reactive groups.

ADVANTAGES AND DISADVANTAGES OF SOLID SUPPORT REAGENTS**Advantages**

- Solid-supported reagents are easily removed from reactions by filtration.
- Excess reagents can be used to drive reactions to completion without introducing difficulties in purification.
- Recycling of recovered reagents is economical, environmentally-sound, and efficient.
- Ease of handling is especially important when dealing with expensive or time-intensive catalysts, which can be incorporated into flow reactors and automated processes.
- Finely tune chemical properties by altering choice of support and its preparation.
- Toxic, explosive, and noxious reagents are often more safely handled when contained on solid support.
- Reagents on solid-support react differently, mostly more selectively, than their unbound counterparts.

Disadvantages

- Some reagents may not interact well with solid support.
- Ability to recycle reagents on solid support is not assured.
- Reactions may run more slowly due to diffusional constraints.
- Polymeric support materials can be very expensive to prepare.
- Stability of the support material can be poor under harsh reaction conditions.
- Side reactions with the polymer support itself may occur.

Resins for SPS

In solid phase synthesis, resin supports for SPS include spherical beads of lightly cross-linked gel type polystyrene (GPS) (1%–2% divinylbenzene) and poly(styrene-oxyethylene) graft copolymers, which are functionalized to allow attachment of linkers and substrate molecules. Each of these materials has advantages and disadvantages, depending on the particular application. There are several types of resins available for different type of reactions, which has been mentioned in Table 5.1.

Table 5.1 Types of resins and reactions.

Type of Resin	Chemical Structure of Resin	Protecting Group	Deprotecting Reagent
Rink amide resin		Fmoc	95% TFA








(Continued)

Table 5.1 (Continued)

Type of Resin	Chemical Structure of Resin	Protecting Group	Deprotecting Reagent
MBHA resin		Boc	HF, TFMSA
4-Sulfamylbutyryl AM resin		Fmoc	1. TMS-CHN ₂ 2. RSH/ NaSPhcat
Sieber Amide resin		Fmoc	95% TFA
DHP HM resin		Fmoc	95% TFA
HMBA-AM resin		Fmoc	NaBH ₄ /EtOH
4-(4-Formyl-3-methoxyphenoxy) butyryl AM resin		Fmoc	95% TFA
Brominated PPOA resin		Boc	NaOH/ Dioxane

(Continued)

Table 5.1 (Continued)

Type of Resin	Chemical Structure of Resin	Protecting Group	Deprotecting Reagent
Oxime resin		Boc	NaOH/ Dioxane
2-Chlorotrityl chloride resin		Fmoc	1% TFA in DCM, AcOH/ DCM/TFE
HMPB-AM resin		Fmoc	1% TFA in DCM
Merrifield resin		Boc	HF/TFMSA
PAM resins		Boc	HF/TFMSA
Wang resin		Fmoc	95% TFA
HMBA-AM resin			ROH/DIPEA/ DMF

Chapter 6

Pro-Drugs

INTRODUCTION

A pro-drug is a chemically modified inert precursor of the drug that on biotransformation liberates the pharmacologically active parent compound. A pro-drug is also called as pro-agent, bio-reversible derivative, or latentiated drug. The design of pro-drug approach is also called as drug latentiation.

Ideal Properties

The ideal properties of pro-drugs are as follows:


- Drug and the carrier linkage must be cleared in vivo.
- It should not have intrinsic pharmacologic activity.
- It should rapidly transform, chemically or enzymatically, into the active form where desired
- The metabolic fragments, apart from the active drug, should be nontoxic.

CLASSIFICATION OF PRO-DRUG


Depending on the constitution, lipophilicity, and method of bioactivation, pro-drugs are classified into two categories.

1. Carrier-linked pro-drugs
2. Bio-precursors

Carrier-linked pro-drug or simple pro-drugs: They are generally esters or amides. Carrier-linked pro-drugs are the ones where the active drug is covalently linked to an inert carrier or transport moiety. Such pro-drugs modify the lipophilicity due to the attached carrier. The active drug is released by hydrolytic cleavage, either chemically or enzymatically.

Examples:

Bioprecursors: They are inert molecules obtained by a chemical modification of the active drugs, but do not contain a carrier. For example, nonsteroidal anti-inflammatory drug, sulindac, is inactive as sulphoxide and must be reduced metabolically to active sulphide.




Pro-drugs are also classified according to the functional group. They are


- Carboxylic acids and alcohols
- Amines
- Azo linkages
- Carbonyl compounds

Carboxylic acid and alcohols: Pro-drugs of carboxylic acid and alcohol functionalities can be prepared by conversion to esters. The esters can be easily hydrolyzed by *esterase* enzymes (e.g. lipase, ester hydrolase, cholesterol esterase, acetyl cholinesterase, and carboxy peptidase) present in plasma and other tissues to give active drug.


Example:



Amines: Due to the high stability and lack of *amidase* enzyme necessary for hydrolysis, the conversion of amines to amide as a pro-drug is not been used for most of the drugs. A more common approach adopted is to use Mannich bases as pro-drug form of amines.




Hetacillin is a pro-drug form of ampicillin in which amide nitrogen and α amino functionalities have been allowed to react with acetone to give a Mannich base (imidazolidine ring system). This leads to decrease in the basicity and increase in the lipophilicity and absorption.




The basic pyrrolidine nitrogen increases water solubility of the parent drug rolitetracycline. The Mannich base hydrolyzes completely and rapidly in aqueous media to give the active tetracycline.

Azo linkage: Pro-drugs of amines are occasionally prepared by incorporating them in to an azo linkage. By the action of *azo reductase* the amino compounds are released in vivo.

- Prontosil drug is inactive in vitro, but it is active in vivo since it is converted to sulphanilamide by *azo reductase* enzymes.




- Sulphasalazine by the action of *azo reductase* releases the amino salicylic acid and sulphapyridine. The generation of anti-inflammatory salicylic acid prior to absorption prevents the systemic absorption of the agents and enhances the concentration of it in active site.



Carbonyl moiety: Conversion of carbonyl functionalities, such as aldehyde and ketone, to pro-drug have not been found wide clinical use. They are converted into derivatives in which the sp^2 carbonyl carbon is converted as sp^3 hybridized carbon attached to hetero-atoms. These pro-drugs are re-converted to carbonyl compound by hydrolysis.

For example, hexamine releases formaldehyde in the urine (acidic P^H), which acts as an antibacterial agent.



The differences between bioprecursors and carrier prodrugs are given in Table 6.1.

Table 6.1 Differences between bioprecursors and carrier prodrugs.

Characteristic	Carrier Pro-drugs	Bioprecursors
Constitution	Active principles + Carrier group	No carrier group
Bioactivation	Hydrolytic	Oxidative or reductive
Catalysis	Chemical or enzymic	Only enzymatic
Lipophilicity	Strongly modified	Slightly modified

APPLICATIONS OF PRO-DRUG

The aim of pro-drug development is, in most cases, to solve specific pharmaceutic or pharmacological and pharmacokinetic problems. The main objectives of pro-drug are as follows:

- Improvement of taste.
- Improvement of odour.
- Enhancement of bioavailability.
- Improvement of stability and solubility properties.
- Decreased toxicity and adverse reactions.
- Increased site specificity.
- Increased duration of pharmacological actions.
- Drug absorption, distribution, metabolism, and excretion affect pharmacokinetics.

Improvement of Taste


One of the reasons for poor patient compliance particularly in case of children is the bitterness, acidity, or causticity of the drug. Two approaches are adopted to overcome the bad taste of drug. The first is reduction of drug solubility in saliva and the other is to lower the affinity of drug towards taste receptors, thus, masking the bitterness. Some examples of drugs with improved taste are given in Table 6.2.

Table 6.2 Drugs with improved taste.

Parent drug	Pro-drug with improved taste
Chloramphenicol	Palmitate ester
Clindamycin	Palmitate ester
Sulfisoxazole	Acetyl ester
Erythromycin	Estolate

Improvement of Odour


The odour of a compound depends on its vapour pressure; a liquid with high vapour will have a strong odour. For example, ethyl mercaptan is a foul smelling liquid used in the treatment of leprosy. This is converted to phthalate ester, a diethyl dithioisophthalate that has higher boiling point and is odourless.



Enhancement of Bio-Availability (Lipophilicity)

Due to the presence of an amino group in the side chain, Ampicillin possesses low lipophilicity and is only 30%–40% absorbed when taken by oral route. Altering the polarity of this antibiotic, by esterifying the


free carboxyl group results in compounds that are completely absorbed, that is, with greater bio-availability than the parent ampicillin.



Improvement of Stability and Solubility

Stability: To improve their stability, prodrug approach is a good technique. Several drugs may decompose in their shelf life or in the gastro intestinal tract (GIT) when used orally. An antineoplastic drug, Azacytidine, hydrolyse readily in acidic pH, but the bisulphite prodrug of it is more stable.


Solubility: Hydrophilic or water-soluble drugs are needed when parenteral or ophthalmic formulation of such agents is desired. Drugs with hydroxyl functional group can be converted to their hydrophilic form through the use of half ester such as hemi-glutarate or hemi-phthalates, the other half of this acid carries sodium, potassium, or amine salts, and renders the moiety more soluble.



Parent drug	Pro-drug with enhanced hydrophilicity
Tocophenols	Sodium succinate ester
Metronidazole	Amino acid esters


Decreased Toxicity and Adverse Reactions

Carboxylic acids and phenols are sometimes too toxic to be employed as such in clinical practice. Ester pro-drugs of the acidic nonsteroidal anti-inflammatory drugs are devoid of gastric ulcerogenic activity and is considered as one of the responsible factors for the adverse reaction of these drugs.




Site-Specific Drug Delivery

Many pro-drugs could be so prepared that they will be delivered to a specific site, thus reducing the toxicity to other organs. The dihydropyridine/pyridinium redox chemical delivery system is very useful for the brain.



Increased duration of action


The pro-drug di-*p*-toluate ester of *N*-^tbutyl noradrenaline provides a longer duration of bronchodilator activity than the parent drug. The pro-drug is preferentially distributed into the lung tissues rather than into the plasma or the heart, so that the bronchodilator effect is exerted.




Bio-PRECURSOR PRODRUG

Bio-precursor pro-drug does not contain a carrier or a promoiety, but rather contains a latent functionality that is metabolically or chemically transformed into active drug molecule. The types of activation involves phase I, such as oxidation, reduction, phosphorylation, or chemical activation.


Bio-activation: Hydroxylation of cyclophosphamide followed by the metabolite decomposition converts the pro-drug into the cytotoxic phosphoxamide mustard.




N-dealkylation: Many drugs are transformed into their active metabolite form by *N*-dealkylation



Oxidation: The prodrug nabumetone in which the formyl group formed is oxidized into a carboxylate group and generating the active drug.



Reduction: The nonsteroidal anti-inflammatory drug sulindac is reduced in vivo to the active form.



PROBABLE QUESTIONS

1. Describe the various approaches of lead discovery.
2. What are the different types of receptors existing? Describe them with suitable examples.
3. What are the different forces involved in drug receptors interaction?
Explain any two of them.
4. Explain the various factors affecting the drug-receptor interaction.
5. Write in detail about computer aided drug design (CADD).
6. Define QSAR and explain about Hansch analysis and Free-Wilson analysis.

7. Write in detail about the steps involved in the QSAR studies.
8. Write a note on the following.
(a) Comparative Molecular Field Analysis (CoMFA) (b) Comparative Molecular Similarity Indices Analysis (CoMSIA)
9. What is combinatorial chemistry? Write its application in the drug discovery.
10. Write a note on combinatorial synthesis on solid phase.
11. What is pro-drug? Write their classification based on the functional group.
12. What are the advantages of pro-drugs? Explain with suitable examples.
13. Write a note on bioprecursor prodrug

SUGGESTED READINGS

1. Abedi J. HPLC method for purifying organic compounds (Raleigh, NC). US Patent 6413431, Application Number: 09/625606, Publication Date: 07/02/2002, Filing Date: 07/26/2000.
2. Abraham DJ. 'History of quantitative structure-activity relationships'. In *Burger's Medicinal Chemistry and Drug Discovery* (6th edn), C. Selassie (ed), Vol I. New York: John Wiley, 2003.
3. Bayer E, Hemmasi B, Alebert K, Rapp W, and Dengler M. 'Peptides, structure and function'. In *Proceeding of the Eighth American Peptide Symposium*, Hruby VJ and Rich DH (eds), p. 87. Rockford, IL: Pierce Chemical Company, 1983.
4. Block JH and Beale JM. *Wilson Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry* (11th edn). New York: Lippincott Williams and Wilkins, 2004.
5. Choi B and Zocchi G. 'Guanylate kinase, induced fit, and the allosteric spring probe'. *Biophys J* 92(5): 1651–658, 2007.
6. Eberle AN, Atherton E, Dryland A, and Sheppard RC. 'Peptide synthesis. IX: Solid-phase synthesis of melanin concentrating hormone using a continuous-flow polyamide method'. *J Chem Soc* 2: 361–67, 1986.
7. Gould RF (ed). *Biological Correlations: The Hansch Approach*. Advances in Chemistry Series, No. 114. Washington DC: American Chemical Society, 1972.
8. Hansch C, Leo C, and Hoekman D. *Exploring QSAR: Hydrophobic, Electronic, and Steric Constants*. Washington: American Chemical Society, 1995.
9. Houghten RA and Dooley CT. *Bio Med Chem Lett* 3. 405–12, 1993.
10. Kadam SS, Mahaik HR, and Bothara KG. 'Principles of medicinal chemistry'. *QSAR* 1: 435, 1986.
11. Lam KS, Salmon SE, Hersch EM, Hruby VJ, Kazmierski WM, and Knapp RJ. *Nature* 354. 82–84, 1991.
12. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
13. Maehle AH. 'The quantification and differentiation of the drug receptor theory'. *Ann Sci* 62(4): 479–500, 2005.
14. Marshall GR, Barry CD, Bosshard HE, Dammkoehler RA, and Dunn DA. 'The conformational parameter in drug design: The active analog approach, in computer assisted drug design'. ACS Symposia, 112, Olson EC and Christofferson RE (eds). Washington DC: American Chemical Society, 1979.

15. Martin YC. 'A practitioner's perspective of the role of quantitative structure activity analysis in medicinal chemistry'. *J Med Chem* 24: 229, 1981.
16. Merrifield RB. 'Solid phase peptide synthesis. I. The synthesis of a tetrapeptide'. *J Am Chem Soc* 85: 2149–154, 1963.
17. Merrifield RB. *Angew Chem Int Ed Engl* 24: 799, 1985.
18. Robert F Gould (ed). *Biological Correlations—The Hansch Approach. Advances in Chemistry Series*, No. 114. Washington DC: American Chemical Society, 1972.
19. Schaad LJ, Hess BA Jr, Purcell WP, Cammarata A, Franke R, and Kubinyi H. 'Compatibility of the Free-Wilson and Hansch quantitative structure-activity relations'. *J Med Chem* 24: 900, 1981.
20. Seydel JK. *QSAR and Strategies in the Design of Bioactive Compounds*. Weinheim: Wiley-VCH, 1985.
21. Sieber P and Riniker B. *Tetrahedron Lett* 28: 6031–6034, 1987.
22. Stuper AJ, Brugger WE, and Jurs PC. 'Computer assisted studies of chemical structure and genotoxic activity by pattern recognition techniques'. In *Chemometrics: Theory and Application*, Kowalski BR (ed). Washington, DC: American Chemical Society, 1977.
23. Thompson LA and Ellman JA. *Tetrahedron Lett* 35: 9333, 1994.
24. Topliss JG. *Quantitative Structure-Activity Relationships of Drugs*. New York: Academic Press, 1983.

"This page intentionally left blank"

DRUGS ACTING ON CENTRAL NERVOUS SYSTEM

1	Central Nervous System	85
----------	-------------------------------	-----------

2	Sedatives and Hypnotics	88
----------	--------------------------------	-----------

3	General Anaesthetics	130
----------	-----------------------------	------------

4	Local Anaesthetics	150
----------	---------------------------	------------

5	Tranquillizers	178
----------	-----------------------	------------

6	Antidepressants	204
----------	------------------------	------------

7	CNS Stimulants	229
8	Narcotic Analgesics	247
9	Anticonvulsants	286
10	Anti Parkinson's Agents	317
11	Muscle Relaxants	329
12	Alzheimer's Disease	344

Chapter 1

Central Nervous System

INTRODUCTION

The drugs that act on the central nervous system (CNS) influence the lives of everyone at all times. These drugs can selectively relieve pain, reduce fever, suppress disordered movement, induce sleep or arousal, and reduce the desire to eat or ally the tendency to vomit. Selectively, acting drugs can be used to treat anxiety, mania, depression, or schizophrenia and do so without altering consciousness.

Monoamines were the first identified central nervous system transmitters. The pathways of noradrenergic, dopaminergic, and serotonergic neurons in laboratory animals were produced and the same basic features have been confirmed in human brain. Neurotransmitters are categorized according to their chemical nature, that is, amino acids, amines, monoamine, and purines.

The electrophysiological signs of action in the CNS falls into two categories (i) excitatory (produce depolarization) and (ii) inhibitory (produces hyperpolarization) in the neurons. Some of these that modulate the CNS are called neuromodulators. The excitatory action is produced by glutamate, aspartate, and other biogenic catecholamines. Inhibitory action is produced by GABA and glycine. The neuromodulators are circulating steroid hormones, locally released adenosine, and other purines. The neurotransmitters are discussed in the section on 'Functional Aspects'.

Amino Acids

There is a wide spread of GABA, glycine, and glutamate regulation seen in CNS. GABA releases correlate with the frequency of the nerve stimulation, which produce increased Cl^- ion conductance to produce inhibition through hyper-polarization and mediates presynaptic inhibition. GABA ergic system present in the cerebral cortex, olfactory bulb, hippocampus, and lateral septal muscles. GABA receptors exist in A and B types. Glycine is another inhibitory amino acid, prominent in the brain stem and the spinal cord. Glutamate and aspartate are found abundantly in the brain, and they are extremely powerful excitatory neurotransmitter acts through *N*-methyl *D*-aspartate (NMDA) receptor. Activation of NMDA receptors produces long-term potentiating in hippocampus and at high concentration, glutamate produces excitotoxicity leading to neurotoxic signs.

Adrenergic Pathway in CNS

The cell bodies of noradrenergic neurons occur in small clusters in pons and medulla and send extensively branched axons to many prominent clusters in locus ceruleus. There is a close relationship between moods and states of arousal; depressed individuals are usually lethargic and unresponsive to external stimuli. The catecholamine hypothesis of affective disorders suggested that depression results from a functional deficiency of nor-adrenaline in certain parts of the brain, while mania results from an excess, and the blood pressure regulation in CNS mediated through α_2 auto receptors.

Functional Aspects of Dopamine

Dopamine is a neurotransmitter as well as a leading precursor of noradrenaline. It is degraded in a similar fashion to noradrenaline. They are connected with nigrostriatal pathway, which is important in motor control, mesolimbic pathways running from groups of cells in the midbrain to parts of the limbic system. Parkinson's disease is associated with a deficiency of nigrostriatal dopaminergic neurons. Behavioural effects of an excess dopamine activity constitute stereotyped behaviour patterns and can be produced by dopamine releasing agents.

Functional Aspects of 5-HT

The precise localization of the 5-HT neurons in the brain stem and throughout the brain parts regulates the hallucinations, behavioural changes, sleep, wakefulness, mood, feeding behaviour, and control of sensory transmission. The 5-HT receptors are concentrated in the midline raphe nuclei in the pons and medulla projecting diffusely to cortex, limbic system, hypothalamus, and spinal cord similar to noradrenergic neuron. They exert inhibitory or excitatory effects on individual neurons, acting either presynaptically or postsynaptically.

Cholinergic Transmission in CNS

Acetylcholine is widely distributed in the basal forebrain nuclei, septohippocampal projections; short interneuron in striatum and nucleus accumbans. Both nicotinic and muscarinic acetylcholine receptors are found predominantly in the CNS. The former mediate the central effects of nicotine through nicotinic receptors mainly located in presynapse. Muscarinic receptors appear to mediate main behavioural effects associated with acetylcholine such as arousal, learning, and memory. Certain neurodegenerative diseases, that is, dementia and Parkinson's disease are associated with abnormalities of cholinergic pathways.

Other Neurotransmitters and Functions in CNS

Histamine is another neurotransmitter, histaminergic neurons originate in a small area of hypothalamus and have a wide distribution. Histamine is active on waking hours and histaminic receptor antagonists are strongly sedative and antiemetic.

In purines, adenosine triphosphate (ATP) and adenosine are present. ATP is converted into adenosine diphosphate (ADP) and adenosine mono phosphate (AMP). Adenosine mainly exerts inhibitory effects through

A_1 and A_2 receptors resulting in sedative, anti-convulsant, and neuro-protective effect; it also acts as a safety mechanism.

These neurotransmitters and the functional aspects are necessary to maintain the homeostasis in the brain and many drugs act on these functions to alter the CNS activity and produce sedative, hypnosis, antianxiety, depression, antiepileptic, and anaesthetic actions.

Chapter 2

Sedatives and Hypnotics

INTRODUCTION

Sedatives are central nervous system (CNS) depressant drugs that reduce excitement, tension, and produce relaxation. Hypnotics are drugs that depress the CNS and produce sleep similar to that of natural sleep. Both sedative and hypnotic action may reside in the same drug. At lower dose, the drug may act as sedative, while at a higher dose the same drug may act as hypnotic.

Agents used as sedatives and hypnotics include a large number of compounds of diverse chemical structure given in classification and pharmacological properties, which have the common ability to induce a non-selective, reversible depression of the CNS.

Sedative and hypnotic drugs are frequently used in preanaesthetic medication and as an adjunctive therapy in psychiatry. A large number of sedative and hypnotic drugs cross the placental barrier, consequently their chronic use during pregnancy may cause withdrawal effect in the newborn infant. Many of these substances are excreted into the breast milk, and hence, their chronic use during breast-feeding may cause sedation to the infant.

Sedatives and hypnotics are also used as the following:

- antianxiety agents
- anticonvulsants
- muscle relaxants
- general anaesthetics
- preanaesthetic medication
- antipsychiatrics
- to potentiate analgesic drugs
- adjuvant to anaesthesia
- a co-drug in the treatment of hypertension

The clinical pharmacology of the sedatives and hypnotics include the following:

Treatment of Anxiety States

The psychological behaviour and physiological responses that characterizes anxiety may be in many forms. Typically, the psychic awareness of anxiety is accompanied by an enhanced motor tension and autonomic hyperactivity. The benzodiazepines continue to be widely used for the management of anxiety states. Since anxiety symptoms may be relieved by many benzodiazepines, it is not easy to demonstrate the superiority of one individual drug over another.

Treatment of Sleep Problems

Nonpharmacological therapies are sometimes useful for sleep problems including proper diet and exercise, avoiding stimulants before retiring and ensuring a comfortable sleeping environment. In some cases, the patient will need and should be given a sedative and hypnotic. Benzodiazepines can cause a dose-dependent decrease in both rapid eyeball movement and non rapid eyeball movement and slowly cause sleep, although to a lesser extent than barbiturates. Zolpidem and zaleplon are less likely to change sleep pattern than the benzodiazepines.

Other Therapeutic Uses

Long-acting drugs such as chlordiazepoxide, diazepam, and to a lesser extent phenobarbital are administered in progressively decreasing doses to patients during withdrawal from psychological dependence on ethanol or other sedative hypnotics. Meprobamate and other benzodiazepines are frequently used as skeletal muscle relaxants.

MOLECULAR BASIS OF INHIBITORY NEUROTRANSMITTERS

Gamma-aminobutyric acid (GABA) is the main inhibitory transmitter in the brain. GABA is formed from glutamate by the action of glutamic acid decarboxylase. Its action is terminated by reuptake, but also by deamination catalyzed by GABA transaminase. There are two types of GABA receptors, that is, GABA_A and GABA_B. GABA_A receptors, which occur mainly postsynaptically, are directly coupled to chloride channels, opening of which reduces membrane excitability. Other drugs that interact with GABA receptors and channels include benzodiazepines, neurosteroids, including endogenous progesterone metabolites and other CNS depressants, such as barbiturates, which facilitate the action of GABA. GABA_B receptors are G protein-coupled receptors linked to the inhibition of cAMP formation. They cause pre and postsynaptic inhibition by inhibiting Ca²⁺ channel openings and increasing K⁺ conductance. Baclofen is a GABA_B receptor agonist used to treat spasticity. Glycine is another inhibitory transmitter functionally similar to GABA action.


CLASSIFICATION

Sedatives and hypnotics are classified on the basis of their chemical structure, as follows:

1. Barbiturates
2. Benzodiazepines
3. Acyclic hypnotics containing nitrogen
4. Cyclic hypnotics containing nitrogen
5. Alcohols and aldehydes
6. Acetylene derivatives

7. Miscellaneous
 - a. Inorganic salts
 - b. Acids and esters
 - c. Antihistaminic and anticholinergic agents
 - d. Suphones
 - e. Plant extracts
 - f. Endogenous substances
 - g. Other opioids: morphine, pethidine
 - h. Neuroleptics: chlorpromazine, triflupromazine
8. Newer agents

1. Barbiturates



Barbiturates are further classified on the basis of duration of their action.



a. Long-acting barbiturates (6 h or more than 6 h)

Name	R ¹	R ⁵	R ^{5'}
Barbital	-H	-C ₂ H ₅	-C ₂ H ₅
Phenobarbital	-H	-C ₂ H ₅	-C ₆ H ₅
Mephobarbital	-CH ₃	-C ₂ H ₅	-C ₆ H ₅
Metharbital	-CH ₃	-C ₂ H ₅	-C ₂ H ₅

b. Intermediate-acting barbiturates (3–6 h)

Name	R ¹	R ⁵	R ^{5'}
Amobarbital	-H	-C ₂ H ₅	—CH ₂ CH ₂ CH
Butobarbital	-H	-C ₂ H ₅	—CH(CH ₃)—CH ₂ —CH ₃
Aprobarbital	-H	CH ₂ =CH—CH ₂ —	(CH ₃) ₂ CH—
Talbutal	-H	CH ₂ =CH—CH ₂ —	CH ₃ CH ₂ CH(CH ₃)—
Butalbital	-H	CH ₂ =CH—CH ₂ —	(CH ₃) ₂ CHCH ₂ —
Hexobarbital	-CH ₃	-CH ₃	

c. Short-acting barbiturates (less than 3 h)


Name	R ¹	R ⁵	R ^{5'}
Pentobarbital	-H	-C ₂ H ₅	CH ₃ CH ₂ CH ₂ CH — CH ₃
Secobarbital	-H	CH ₂ =CH-CH ₂ -	CH ₃ (CH ₂) ₂ CH — CH ₃
Cyclobarbital	-H	-C ₂ H ₅	
Heptabarbital	-H	-C ₂ H ₅	



d. Ultra short-acting barbiturates (15 min)

Name	R ¹	R ⁵	R ^{5'}
Thiopentone	-H	-C ₂ H ₅	—CH(CH ₂) ₂ CH ₃ CH ₃


(At C - 2 = S instead of = O)

2. Benzodiazepines




Name	R ¹	R ²	R ³	R ⁷	R ^{2'}
Diazepam	-CH ₃	= O	-H	-Cl	-H
Oxazepam	-H	= O	-OH	-Cl	-H
Chlordesmethyl diazepam	-H	= O	-H	-Cl	-Cl
Fosazepam		= O	-H	-Cl	-H
Prazepam		= O	-H	-Cl	-H
Nitrazepam	-H	= O	-H	-NO ₂	-H
Nordiazepam	-H	= O	-H	-Cl	-H
Nimetazepam	-CH ₃	= O	-H	-NO ₂	-H
Flunitrazepam	-CH ₃	= O	-H	-NO ₂	-F
Flurazepam	-(CH ₂) ₂ N (C ₂ H ₅) ₂	= O	-H	-Cl	-F
Quazepam	-CH ₂ CF ₃	= S	-H	-Cl	-F
Halozepam	-CH ₂ CF ₃	= O	-H	-Cl	-H
Temazepam	-CH ₃	= O	-OH	-Cl	-H
Lorazepam	-H	= O	-OH	-Cl	-Cl
Clonazepam	-H	= O	-H	-NO ₂	-Cl
Doxefazepam	-CH ₂ OH	= O	-OH	-Cl	-F

Triazolo benzodiazepines




Name	R	R ₁
Alprazolam	-CH ₃	-H
Triazolam	-CH ₃	-Cl
Estazolam	-H	-H





Chlordiazepoxide

3. Acyclic hypnotics containing nitrogen (acyclic ureides)


a. Urethanes







b. Ureides



c. Carbamates







d. Amides






4. Cyclic hypnotics containing nitrogen






a. Piperidinediones





b. Quinazolinones





5. Alcohols and aldehydes





6. Actylene derivatives



7. Miscellaneous


a. Inorganic salts

KBr, magnesium sulphate




b. Acids and esters

Tryptophan, 5-hydroxy tryptophan

Etomidate






c. Antihistamines and anticholinergics




d. Sulphones


Toxic-not used

e. Plant extracts of*Radix valerianae**Rauwolfia serpentina**Avana sativa**Glandula lupuli***f. Endogenous substances: peptides****8. Newer agents****SYNTHESIS AND DRUG PROFILE****1. Barbiturates**

Barbiturates are derivatives of barbituric acid. Their hypnotic activity is conferred by the replacement of H-atom attached to the C-5 position by aryl or alkyl radicals. They are generally synthesized by adopting the following route of synthesis.


Mode of action: Barbiturates primarily act on GABA: benzodiazepine receptor Cl^- channel complex and potentiate GABA ergic inhibitory action by increasing the lifetime of Cl^- channel opening induced by GABA. Barbiturates do not bind to benzodiazepine receptor promptly, but it binds to another site on the same macromolecular complex to exert the GABA ergic facilitator actions. The barbiturate site appears to be located on α and β subunit. At high concentrations, barbiturates directly increases Cl^- conductance and inhibit Ca^{2+} dependent release of neurotransmitters and they also depress glutamate-induced neuronal depolarization.

Synthesis**Route I: From urea and malonic acid**

Route II: From chloroacetic acid


Metabolism of barbiturates: These drugs are metabolized in the liver and forms less lipophilic compounds. These are mediated through glucuronide or sulphate conjugation.

1. Oxidation of a substituent at C-5 forms alcohols or phenols, and these undergo further oxidation to form ketones or carboxylic acids. The barbiturates containing a propene at the fifth position inactivates CYP450 by alkylation of the porphyrin ring of CYP450.
2. The conjugation of heterocyclic nitrogen with glucuronic acid is due to the oxidative metabolism in the biotransformation of 5,5-disubstituted barbiturates (phenobarbital and amobarbital).
3. It undergoes oxidative *N*-dealkylation at nitrogen.
4. Oxidative desulphation of 2-thio barbiturates yields more hydrophilic barbiturates, which is excreted through urine.



Uses: They are used as sedative, hypnotic and anticonvulsant. They are administered through the intravenous (IV) route for inducing anaesthesia.

1. Barbitone sodium (Barbital sodium)




Sodium-5,5'-diethylbarbiturate

Properties and uses: Baritone sodium exists as white, crystalline powder or colourless crystals that is soluble in boiling water and in alcohol, but only slightly soluble in water. It forms water-soluble salts


with sodium hydroxide. It is a powerful hypnotic drug and generally used in the treatment of epileptic seizures.

Assay: Dissolve the substance in pyridine and to this add thymolphthalein solution and silver nitrate solution in pyridine and titrate the solution with 0.1 methanolic sodium hydroxide. Endpoint is the appearance of blue colour.

Synthesis




2. Phenobarbitone (Phenobarbital, Luminal)



Properties and uses: Phenobarbital sodium is a hygroscopic substance. It is a white, crystalline powder, freely soluble in water and also soluble in alcohol. It is used as sedative, hypnotic and antiepileptic (drug of choice in the treatment of grandmal and petitmal epilepsy). It is useful in nervous and related tension states. An overdose of it can result in coma, severe respiratory depression, hypotension leading to cardiovascular collapse, and renal failure.

Synthesis



Assay: Dissolve the sample in water and add 0.05 M sulphuric acid. Heat the mixture to boiling point and then cool it. Add methanol and shake until dissolution is complete. Perform a potentiometric titration using 0.1 M sodium hydroxide. After the first point of inflexion, interrupt the addition of sodium hydroxide, add 10 ml of pyridine, mix, and continue the titration. Read the volume added between the two points of inflexion.


Storage: It should be stored in well closed airtight container.

Dose: For sedation: Adult: 30–120 mg/day in 2–3 divided doses. Children: 6 mg/kg/day. For hypnotic: Adult: 100–320 mg at bedtime. Do not administer for more than 2 weeks for the treatment of insomnia.

Through IV route for preoperative sedation: Child: 1–3 mg/kg 1–1.5 h before procedure.


Dosage forms: Phenobarbital sodium tablets I.P., B.P., Phenobarbital sodium injection I.P., Phenobarbitone tablets I.P., Phenobarbital injection B.P., Paediatric phenobarbital oral solution B.P.

3. Methyl phenobarbitone (Mephobarbital)



5-Ethyl-1-methyl-5-phenyl barbituric acid


Synthesis



Properties and uses: It is a white, crystalline powder, odourless, with a bitter taste, and a saturated is solution acid to litmus. Soluble in water, alcohol, chloroform, and in solutions of alkali hydroxides or carbonates. Mephobarbitone is a strong sedative with anticonvulsant action, but a relatively mild hypnotic. Hence, it is used for the relief of anxiety, tension, and apprehension, and is an antiepileptic in the management of generalized tonic-clonic and absence seizures.


Dose: As a sedative 30–100 mg 3–4 times/day; as an anticonvulsant 400–600 mg daily.

4. Allobarbitone



5-5'- Diallyl barbituric acid


Synthesis



Uses: It can be used both as sedative and hypnotic at different dose intervals.


Dose: As a sedative 30 mg 3–4 times a day; as a hypnotic 100–200 mg at night.

6. Butabarbitalone (Neonal)



5-(1-methyl propyl)-5-ethyl barbituric acid


Synthesis



Properties and uses: It is used as a sedative and hypnotic, especially used for the short-term treatment of insomnia. Because of tolerance, barbiturates lose efficacy after two weeks of use.


Dose: 30 mg as a sedative and 100–200 mg at night as a hypnotic.

5. Hexobarbitone (Hexobarbital, Evipal, Sombulex)



5-Cyclohexenyl-1,5-dimethylpyrimidin-2,4,6-trione

Synthesis




Properties and uses: It is a white, crystalline powder, very slightly soluble in water, sparingly soluble in alcohol. It forms sodium salt with sodium hydroxide, which is soluble in water. It is used as hypnotic.

Assay: Dissolve the sample in ethanol; to this add thymolphthalein solution and silver nitrate solution in pyridine. Titrate with 0.1 Methanolic sodium hydroxide. Endpoint is the appearance of blue colour.


Dose: The usual dose for adult, oral hypnotic is 250–500 mg.

6. Pentobarbitone sodium (Pentobarbital sodium, Palapent, Sodital)



Sodium-5-ethyl-5-(1-methylbutyl) barbiturate

Synthesis



Properties and uses: It is hygroscopic in nature and a white crystalline powder, very soluble in water. It is used as a sedative or hypnotic for the short-term management of insomnia and is a preanaesthetic medication, used in the treatment of strychnine poisoning. It is also indicated in the anaesthetic doses and administered intravenously, for the control of certain convulsive syndromes. This barbiturate is thought to reduce cerebral blood flow and, thereby, decrease oedema and intracranial pressure.


Assay: Dissolve the sample in silver nitrate solution in pyridine and titrate with 0.1 methanolic sodium hydroxide until a pure blue colour is obtained, using 0.5 ml of thymolphthalein solution as indicator.

Storage: It should be stored in well-closed airtight containers.

Dose: The usual oral sedative dose for adult is 30 mg 2–4 times daily. Through I.M. route, for preoperative, sedative, 150–200 mg. Through IV route, anticonvulsant, 100 mg initially up to 400 mg.


Dosage forms: Pentobarbital tablets I.P., B.P.

7. Quinobarbitone sodium (secobarbital sodium)



Sodium-5-allyl-5-(1-methylbutyl) barbiturate

Synthesis



Properties and uses: It is a white, hygroscopic powder having a bitter taste, with pH between 9.7 and 10.5, soluble in water and alcohol. It is used in status epilepticus and in toxic reactions to strychnine and as local anaesthetic.

Dose: The usual adult dose is 50–200 mg.


SAR of Barbiturates

A good hypnotic barbituric acid derivative must have the following properties:

1. The acidity value within certain limits to give proper ratio of ionized (dissociated) and unionized forms, which is important to cross blood brain barrier (BBB). It takes approximately 40%–60% dissociation to enable a barbiturate to cross BBB and exert effects on CNS. Determination of the pKa can thus be predictive of the CNS activity.
2. Lipid water solubility (partition coefficient) should be in certain limits.

1. Acidity

On the basis of acidity values, barbiturates are divided into two classes:



Active class

- i. 5,5'-disubstituted barbituric acids
- ii. 5,5'-disubstituted thiobarbituric acids
- iii. 1,5,5'-trisubstituted barbituric acids


Inactive class

- i. 1-substituted barbituric acids
- ii. 5-substituted barbituric acids
- iii. 1,3-disubstituted barbituric acids
- iv. 1,5-disubstituted barbituric acids
- v. 1,3,5,5'-tetrasubstituted barbituric acids

They are inactive since they are not acidic. These classes of agents depend on metabolism to produce 1,5,5' trisubstituted barbituric acids, which are acidic. Attachment of alkyl substituent to both N¹ and N³ renders the drug nonacidic, making them inactive.

2. Lipid water solubility

Once the acidity value criteria is satisfied, the lipid-water solubility or partition co-efficient is calculated to find out whether the compound is active or not. The following structural skeleton is essential for hypnotic activity:




- The sum of the carbon atoms of both the substituents at c-5 should be between 6 and 10, in order to attain optimal hypnotic activity. This sum is also an index of the duration of action.

Sum of value	Duration of action
7–9	Rapid onset and shortest duration
5–7	Intermediate duration of action
4	Slowest onset and longest duration (two ethyl group or ethyl and phenyl)

- Within the same series, the branched chain has greatest lipid solubility and hypnotic activity, but has shorter duration of action.
- Branched cyclic or unsaturated chains at C-5 position, generally, reduce the duration of action, due to increased ease of metabolic conversion to more polar inactive metabolite.
- The greater the branching, more potent will be the drug.

Example: pentobarbital is more potent than amobarbital.




- However, the stereo-isomers possess approximately the same potencies.
- Within the series, the unsaturated analogues (i.e. alkyl, alkenyl, and cycloalkenyl) may result in greater potency than the saturated analogues, with the same number of carbon atoms.
- Alicyclic or aromatic substituted analogues are more potent than analogues of aliphatic substitutions with the same number of carbon atoms.
- Introduction of a halogen atom into the C-5 substituents increases potency.


- Introduction of a polar substituents (OH, NH₂, COOH, CO, RNH, and SO₃H) into the aromatic group at C-5 results in decreased lipid solubility and potency.
- Alkylation at 1 or 3 position may result in compounds having shorter onset and duration of action since *N*-methyl group reduces acidity value.
- Replacement of oxygen by sulphur atoms at C-4 and C-6 position reduces the hypnotic activity.
- Replacement of oxygen by sulphur atom at C-2 position leads to rapid onset and shorter duration of action.

II. Benzodiazepines


Mode of action: Benzodiazepine receptors are present in the brain and they form a part of GABA_A receptor's chloride ion channel macromolecular complex. Binding of benzodiazepines to these receptors produces activation of GABA_A receptor and increases chloride conductance by increasing the frequency of opening chloride ion channel. These in turn inhibit neuronal activity by hyper-polarization and de-polarization block.

Metabolism of Benzodiazepines: Compounds without the hydroxyl group are nonpolar, and undergoes hepatic oxidation. Compounds with hydroxyl groups have more polarity and are readily converted into the glucuronide conjugates and excreted easily. These compounds are also metabolized by 3-hydroxylation of benzodiazepine ring.



1. Diazepam (Calmose, Valium, Diazep)

7-Chloro-1-methyl-5-phenyl-1,4-benzodiazepin-2-one

Synthesis

Properties and uses: It is a white or almost white crystalline powder soluble in ethanol and very slightly soluble in water. It is used as a skeletal muscle relaxant, anticonvulsant and antianxiety agent. It may take a long time to achieve sedative and antianxiety effects, during which time the patient can usually be maintained by giving the drug once or twice a day. Patients on the drug should be cautioned not to drive an automobile or to operate dangerous machinery until a few days after the drug has been discontinued.


Assay: Dissolve the sample in acetic anhydride and titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: For short-term management of anxiety: Adult: 2 mg three times a day. Maximum: 30 mg daily. For insomnia associated with anxiety—Adult: 5–15 mg at bedtime. Sleepwalking; night terrors—Children and adolescents (up to 18 years): 1–5 mg at bedtime. Anaesthetic premedication—Adult: 5–15 mg given before general anaesthesia. Child: 1–12 month: 250 µg/kg; 1–5 year; 2.5 mg; 5–12 year; 5 mg. For adjunct in the management of seizures—Adult: 2–60 mg daily in divided doses. For muscle spasms—Adult: 2–15 mg daily in divided doses, increased up to 60 mg daily in severe spastic disorders. Maximum: 60 mg/day. Child: 1–12 month, 250 µg/kg; 1–5 years, 2.5 mg; 5–12 years, 5 mg; 12–18 year; 10 mg. Maximum: 40 mg/day. Elderly: Dose reduction may be required.

Dosage forms: Diazepam tablets I.P., B.P., Diazepam injection I.P., B.P., Diazepam capsules I.P., Diazepam oral solution B.P., Diazepam rectal solution B.P.

2. Nitrazepam (Dormin, Nipam, Nitorsun)



7-Nitro-5-phenyl-1,4-benzodiazepin-2-one

Properties and uses: It is a yellow crystalline powder slightly soluble in alcohol and insoluble in water. It is used as sedatives and hypnotics, and in the management of myoclonic seizures.


Assay: Dissolve the sample in acetic anhydride. Titrate the solution with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For short-term management of insomnia—Adult: 5 mg at night; can increase to 10 mg, if necessary. Elderly and debilitated patients: less than the normal adult dose. For infantile spasms: Child and infant, 125 µg/kg two times a day; gradually increase to 250–500 µg/kg two times a day.

Dosage forms: Nitrazepam tablets I.P., B.P., Nitrazepam oral suspension B.P.

Synthesis



3. Oxazepam (Serepax)



7-Chloro-3-hydroxy-5-phenyl-1,4-benzodiazepin-2-one

Properties and uses: It is a white or almost white crystalline powder slightly soluble in ethanol and insoluble in water. It is useful for the control of acute tremulousness, inebriation, or anxiety associated with alcohol withdrawal. Side effects that have been observed include rashes, nausea, lethargy, oedema, slurred speech, tremor, and altered libido. More severe reactions include leucopenia and jaundice.


Assay: Dissolve the sample in anhydrous acetic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For anxiety, alcohol withdrawal syndrome—Adult: 15–30 mg 3 or 4 times/day. Elderly or debilitated patients: Initially, 10 mg thrice/day; increase up to 10–20 mg 3 or 4 times/day, if necessary. For insomnia associated with anxiety: Adult: 15–25 mg given 1 h before bedtime. Up to 50 mg may be occasionally required.

Dosage forms: Oxazepam tablets B.P.

Synthesis




4. Lorazepam (Larposa, Lorvan)



7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,4-benzodiazepin-2-one

Synthesis




Properties and uses: It is a white or almost white crystalline powder, which is insoluble in water, sparingly soluble in ethanol, sparingly soluble in methylene chloride. It shows polymorphism. It is used as sedative and hypnotic. It has much more polarity than diazepam, for example, metabolism is relatively uncomplicated, and the duration of action is short.

Assay: Dissolve the sample in dimethylformamide. Titrate with 0.1 M tetrabutylammonium hydroxide and determine the endpoint potentiometrically.

Dose: For Anxiety—Adult: Usual dose 1–6 mg daily in 2 or 3 divided doses. Largest dose taken at night. Up to 10 mg daily has been used. Elderly: Initial dose of 1–2 mg daily in 2 or 3 divided doses. Adjust as necessary. For insomnia associated with anxiety; Adult: 1–4 mg as a single dose given at bedtime. Elderly: 1–2 mg initially, adjust as needed.


Dosage forms: Lorazepam injection B.P., Lorazepam tablets B.P.

5. Chlorazepate




7-Chloro-2-oxo-5-phenyl-1,4-benzodiazepin-3-carboxylic acid


Synthesis



Uses: It is used as a sedative and hypnotic.

6. Triazolobenzodiazepines



Synthesis: Estazolam, Triazolam, Alprazolam

Estazolam $\text{R} = \text{H}, \text{R}_1 = \text{H}$
 Triazolam $\text{R} = \text{Cl}, \text{R}_1 = \text{CH}_3$
 Alprazolam $\text{R} = \text{H}, \text{R}_1 = \text{CH}_3$

Metabolism of Alprazolam: The methyl group of this drug is metabolized by oxidation reaction to methyl alcohol and conjugation reaction takes place.

Properties and uses

Estazolam: A triazolobenzodiazepine derivative that structurally resembles alprazolam and triazolam. It is useful in the management of insomnia. It has an intermediate half-life and the peak plasma concentration reaches 1.5 to 2 h after oral administration. It undergoes hepatic microsomal oxidation and has an elimination half-life 2 to 15 h. It causes more serious toxicity and withdrawal reactions than other benzodiazepines.

Dose: The usual required dose is 2 mg.

Triazolam (Halcion): It is freely soluble in water and the metabolites, has little hypnotic action and is useful in the management of insomnia. The common adverse effects include drowsiness, dizziness, and headache.

Dose: The usual oral dose for an adult is 0.25–0.5 mg at bedtime.


Alprazolam: It is a white crystalline powder, practically insoluble in water, freely soluble in methylene chloride sparingly soluble in acetone and in alcohol. It shows polymorphism. It is useful in the short-term

management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and early morning awakenings. The duration of action is short and the drug is a highly potent anxiolytic in doses of milligram.

Assay of Alprazolam: Dissolve the sample in a mixture of 3 volumes of anhydrous acetic acid and 2 volumes of acetic anhydride. Titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically. Titrate to the second point of inflexion.

Storage: It should be stored in well-closed airtight containers and protected from light.


SAR of Benzodiazepines



- The presence of electron attracting substituents (Cl, F, Br, NO₂) at position C-7 is required for the activity, and the more electron attracting substituents leads to potent activity.
- Position 6, 8, and 9 should be unsubstituted for the activity.
- Phenyl (or) pyridyl at the C-5 position promotes activity. If the phenyl ring substituted with electron attracting groups at 2' or 2', 6' position, then the activity is increased.
- On the other hand, substituents at 3', 4', and 5' positions decreases activity greatly.
- Saturation of 4, 5 double bond or shift of it to the 3, 4 position decreases the activity.
- Alkyl substitution at position 3 decreases the activity, but the presence or absence of hydroxyl group is essential. Compounds without 3-hydroxyl group are nonpolar and usually have long half-life. Compounds with the 3-hydroxyl group have short half-life because of rapid conjugation with glucuronic acid.
- Substitution at N¹ by alkyl, halo alkyl, and amino alkyl group increases the activity.
- Reduction of carbonyl function at C-2 position to CH₂ yields less potent compound.
- Triazolo benzodiazepine (Alprazolam) is found to be more potent, they do not require any substitution at 7th position.


III. Acyclic hypnotics containing nitrogen

1. Meprobamate (Miltown, Equanil)



2-Methyl-2-propyl-1,3-propanediol dicarbamate

Synthesis




Properties and uses: It is a white or almost white amorphous or crystalline powder slightly soluble in water and freely soluble in alcohol. It is used in the treatment of anxiety disorders. It is also a centrally acting skeletal muscle relaxant. The agents in this group find use in a number of conditions, such as strains and sprains that may produce acute muscle spasm.


Assay: Dissolve the sample in 25% V/V solution of sulphuric acid and boil under a reflux condenser for 3 h. Cool and dissolve by cautiously adding 30 ml of water, cool again and place in a steam-distillation apparatus. Add 40 ml of strong sodium hydroxide solution and distil immediately by passing steam through the mixture. Collect the distillate into 40 ml of a 40 g/l solution of boric acid R until the total volume in the receiver reaches about 200 ml. Add 0.25 ml of methyl red mixed solution. Titrate with 0.1 M hydrochloric acid until the colour changes from green to violet.

Dose: The usual oral dose for an adult is 400 mg.

2. Ethinamate




Synthesis



IV. Cyclic Hypnotics Containing Nitrogen


1. Piperidinedione derivatives

a. Methypyrlone (Noludar)



3,3-Diethyl-5-methylpiperidine-2,4-dione


Synthesis



Properties and uses: Methypyrlone exists as white crystalline powder and soluble in water. Used as a hypnotic agent useful in the management of insomnia of varied etiology.


Dose: The usual adult dose is 200–600 mg for hypnotic; 50–100 mg for sedative.

b. Glutethimide



3-Ethyl-3-phenyl piperidine-2,6-dione

Synthesis




Properties and uses: It is used as a hypnotic drug to induce sleep without depressing respiration. Over dosage is less likely to depress respiration, but more likely to cause hypertension than most other barbiturates. Adverse reactions include a generalized rash, occasionally a purpuric or urticarial rash; exfoliative dermatitis has also been observed, rarely nausea, hangover, paradoxical excitation, and blurred vision have occurred. Some of these side effects may be due to the anticholinergic activity of this drug.



Dose: The usual adult dose is 250–500 mg.

2. Quinazolinone derivatives

a. Methaqualone (Mequin)



2-Methyl-3-o-tolylquinazolin-4(3H)-one

Synthesis**Route I. From: Anthranilic acid****Route II. From: *N*-Acetyl anthranilic acid**

Properties and uses: It is a white or almost white crystalline powder. It dissolves in dilute sulphuric acid and very slightly soluble in water and also soluble in alcohol. It is used as a hypnotic drug to induce sleep and as a daytime sedative. It may be administered along with an antihistaminic agent such as diphenhydramine.

Assay: Dissolve the sample in anhydrous acetic acid. Titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: The usual adult dose is 50–150 mg.

V. Alcohols and Aldehydes


Mode of action: These drugs elicit the action and is similar to the mechanism of barbiturates. These are general CNS depressants, which produce profound hypnosis.

Metabolism: These are metabolized by alcohol dehydrogenase enzyme. Chloralhydrate undergoes oxidation to chloral and then to an inactive metabolite, trichloroacetic acid, via aldehyde dehydrogenase, which also is extensively metabolized to aryl glucuronides via conjugation with glucuronic acid and then excreted in urine.

1. Chloral hydrate (Noctec)



Synthesis




Properties and uses: Colourless, transparent crystals, very soluble in water and freely soluble in alcohol. Used principally for the short-term treatment of insomnia, it is used pre-operatively to allay anxiety and to induce sedation/sleep. It is used post-operatively as an adjuvant to opiates and other analgesics to control pain. It has also been used to produce sleep prior to electroencephalogram (EEG) evaluations. It is also effective in reducing anxiety associated with withdrawal of alcohol and other drugs, such as opiates and barbiturates.

Assay: Dissolve the sample in water and add 1 M sodium hydroxide solution. Allow to stand for exactly 2 min and titrate with 0.5 M sulphuric acid, using phenolphthalein solution as indicator. Titrate the neutralized solution with 0.1 M silver nitrate, using potassium chromate solution as an indicator.

Storage: It should be stored in well closed airtight container.


Dose: The usual adult dose is 500–1000 mg for hypnotic and 250 mg for sedative.

2. Ethchlorvynol (Placidyl)



1-Chloro-3-ethyl-1-penten-4-yn-3-ol


Synthesis



Properties and uses: It also possesses muscle relaxant and anticonvulsant properties apart from CNS depressant action. Adverse effects include suppression of REM sleep, ataxia, and hypotension.


Dose: The usual adult dose is 500–1000 mg hypnotic and 100–200 mg sedative.

3. Paraldehyde



2, 4, 6-Trimethyl-1,3,5-trioxane

Synthesis




Properties and uses: It is a colourless or slightly yellow transparent liquid. It solidifies on cooling to form a crystalline mass. Miscible with alcohol and with essential oils, soluble in water, but less soluble in boiling water, it is exclusively used in the management of hospitalized patients undergoing alcohol withdrawal. Its CNS depressant activity resembles that of alcohol and chloral hydrates.

Storage: It should be stored in well-closed airtight containers and protected from light. If the substance has solidified, the whole contents of the container must be liquefied before use.


Dosage forms: Paraldehyde injection B.P.

4. Hydroxyzine hydrochloride



2-(2-(4-[(4-Chloro phenyl) phenyl methyl]-1-Piperazinyl)-ethoxy) ethanol dihydrochloride

Synthesis



Properties and uses: It is a hygroscopic crystalline powder, white or almost white in colour, freely soluble in water and in alcohol, very slightly soluble in acetone. It is useful in psychosomatic disturbances, nervous tension, and anxiety.


Assay: Dissolve the sample in 10 ml of anhydrous acetic acid and 40 ml of acetic anhydride. Titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Adult: I.M. injection as the hydrochloride in doses of 25–100 mg every 4–6 h; Children: 1 mg per kg body weight I.M. for pre and postoperative sedation.


VII. Miscellaneous Class

1. Triclofos sodium



2, 2, 2-Trichloro ethanol dihydrogen phosphate monosodium.

Synthesis




Properties and uses: It is a white or almost white powder, hygroscopic in nature. Freely soluble in water, slightly soluble in ethanol, practically insoluble in ether. Used as hypnotic.

Preparation: Triclofos oral solution B.P.


VIII. Newer Agents

1. Zaleplon (Zaplon, Zaso)




Properties and uses: Zaleplon is a nonbenzodiazepine pyrazolo pyrimidine derivative of a short-acting sedative and hypnotic. It acts as a selective agonist at the benzodiazepine α_1 receptor subunit on the GABA_A receptor complex in the brain. Subunit modulation of the GABA-BZD receptor is hypothesized to be responsible for its hypnotic properties.

Synthesis




Dose: For insomnia—Adult: 10 mg before bedtime. Maximum: 20 mg daily. Elder less than 65 year: 5 mg before bedtime. Maximum 10 mg daily.

2. Zopiclone (Ziclone, Zopicon, Zonap)



Synthesis




Properties and uses: It is a white or slightly yellowish powder, insoluble in water, freely soluble in methylene chloride, sparingly soluble in acetone, insoluble in alcohol. It dissolves in dilute mineral acids. It is a new hypnotic agent structurally unrelated to barbiturates and benzodiazepines. It binds to the GABA_A benzodiazepine receptor complex.

Assay: Dissolve the sample in a mixture of 10 ml of anhydrous acetic acid and 40 ml of acetic anhydride. Titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: For short-term management of insomnia—Adult: 7.5 mg at bedtime. Elderly: Initially, 3.75 mg at bedtime


3. Zolpidem



Properties and uses: It is a white or almost white crystalline powder, hygroscopic in nature, slightly soluble in water, sparingly soluble in methanol, and insoluble in methylene chloride. It is an imidazopyridine agent and is an agonist at the benzodiazepine α_1 receptor subunit of the GABA_A receptor, used for the management of

insomnia. The selective binding at α_1 receptors Subunits of GABA_A may explain the relative absence of myo-relaxant and anticonvulsant effects as well as the preservation of deep sleep in human.

Synthesis



Assay: Dissolve the sample in a mixture of 20 ml of anhydrous acetic acid and 20 ml of acetic anhydride. Titrate with 0.1 M perchloric acid and determine the endpoint potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

PROBABLE QUESTIONS

1. Define and classify sedatives and hypnotics. Explain how the cyclic ureide barbituric acid may be prepared from (a) urea and malonyl dichloride and (b) urea and diethyl malonate.
2. Why the thiobarbiturates get metabolized in vivo faster than the barbiturates? Explain.
3. Explain the SAR of benzodiazepines.
4. How does the long-acting barbiturate phenobarbitone sodium can be synthesized.
5. Name the barbiturate having allyl group at C-5 in the barbituric acid. Write its synthesis and uses.
6. Mention a drug having pyrimidine nucleus used as sedative and hypnotic. Write its structure, chemical name, synthesis, and uses.
7. A class of barbiturates find their use in the treatment of insomnia and preoperative medication. Name two potent drugs and discuss the synthesis of any one of them.
8. Write a note on triazolo benzodiazepines used as sedative and hypnotic.
9. Based on quinazolinone nucleus, a potent hypnotic drug was introduced. Name the compound and write its structure, synthesis, and uses.
10. Outline the metabolic pathway and mode of action of benzodiazepines and barbiturates.
11. Outline the synthesis of meprobamate and nitrazepam.
12. Write the structure, chemical name, and uses of a potent hypnotic drug having a benzodiazepine nucleus. Outline its synthesis and metabolic pathway.
13. Explain the following with suitable examples: (a) mode of action of barbiturates and (b) SAR of barbiturates.
14. A brand of barbiturates are usually employed to cause general anaesthesia and control convulsions. Name any one potent member and write its synthesis and metabolism in vivo.
15. Write a note on long-acting barbiturates.

SUGGESTED READINGS

1. Abraham DJ (ed) *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. Berger FM. 'Spinal cord depressant drugs'. *Pharmacol Rev* 1: 243–78, 1949.
3. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
4. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
5. Cheng CC and Roth B. In *Progress in Medicinal Chemistry*, Ellis GP and West GB (eds). New York: Appleton-Century-Croft, 1971.
6. Clarke FH (ed). *Ann Rep Med Chem*, Vol. 12. New York: Academic Press, 1997.
7. Cook L and Sepinwall J. In *Mechanism of Action of Benzodiazepines*, Costa E and Greengard P (eds). New York: Raven Press, 1975.
8. Doran WJ. 'Barbituric acid hypnotics' In *Medicinal Chemistry* Vol. 4, Blicke FF and Cox RH (eds). New York: John Wiley, 1959.
9. Dyson GM and May P. *May's Chemistry of Synthetic Drugs* (5th edn). London: Longmans, 1959.
10. Gennaro AR (ed). *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2005.

11. Gringauz A. *Introduction to Medicinal Chemistry*. New York: Wiley-VCH, 1997.
12. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi: The Controller of Publications, Civil lines, 1996.
13. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
14. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
15. Maynert EW and Van Dyke HB. 'The metabolism of barbiturate'. *Pharmac Rev* 1: 217–42, 1949.
16. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
17. Sternback LH et al. In *Drugs Affecting the Central Nervous System*, Vol. 2, Burger A (ed). New York: Marcel Dekker, 1985.

Chapter 3

General Anaesthetics

INTRODUCTION

General anaesthetics are a group of drugs that produce loss of consciousness, and therefore, loss of all sensations. The absolute loss of sensation is termed as anaesthesia. General anaesthetics bring about descending depression of the central nervous system (CNS), starting with the cerebral cortex, the basal ganglia, the cerebellum, and finally the spinal cord. These drugs are used in surgical operations to induce unconsciousness and, therefore, abolish the sensation of pain.

Horace Wills, a dentist, in 1844 successfully used N_2O as an anaesthetic for tooth extraction. Morton, a dentist, demonstrated ether as an anaesthetic agent and it became popular. In 1847, chloroform was used by Simpson in Britain for obstetrical purposes. The first intravenous anaesthetic, thiopentone, was introduced in 1935. In 1901, Mayer and Overton pointed out a direct parallelism between lipid/water partition coefficient of general anaesthetics and their anaesthetic property known as minimal alveolar concentration (MAC).

MAC is the lowest concentration of an anaesthetic in pulmonary alveoli that is needed to produce immobility in response to a painful stimulus in 50% of the individuals. MAC of a number of general anaesthetics shows excellent correlation with their oil/gas partition coefficients. However, this only reflects the capacity of anaesthetics to enter into the CNS and attain sufficient concentration in the neuronal membrane.

The basic molecular targets show that the ligand-gated ion channels are the major target of anaesthetic action. Many inhalation anaesthetics, such as barbiturates, benzodiazepines, and propofol potentiate the action of inhibitory transmitter GABA to open chloride channels. The action of glycine transmitter, which also activates chloride channels in the spinal cord and medulla, is augmented by barbiturates, propofol, and many other inhalation anaesthetics. N_2O and ketamine do not act on GABA or glycine, but they selectively inhibit the excitatory *N*-methyl *D*-aspartate (NMDA) type of glutamate receptor.

Types of General Anaesthetics

General anaesthetics are usually given through inhalation or by intravenous injection.

Inhalation anaesthetics: Nitrous oxide, a gas at ambient temperature and pressure, continues to be an important compound of many anaesthesia regimens. Halothane, enflurane, isoflurane, desflurane, sevoflurane, and methoxyflurane are volatile liquids.

Intravenous anaesthetics: Several drugs are used intravenously, alone, or in combination with other drugs to achieve an anaesthetic state for minute surgery of the patients in the intensive care unit. These drugs include the following:

Barbiturates (thiopental, methohexitol)
 Benzodiazepines (midazolam, diazepam)
 Opiod analgesics (morphine, fentanyl, sufentanil, alfentanil, remifentanil)
 Propofol
 Ketamine
 Miscellaneous:
 droperidol, etomidate, dexmedetomidine.

Mode of action: General anaesthetics target the ligand gated ion channels and produce the anaesthetic action. The GABA receptor gated chloride channels are the most important sites and opens to perform the inhibitory action. N_2O and ketamine do not affect the GABA or glycine gated Cl^- channel, but they selectively inhibit the excitatory NMDA-type of glutamate receptor, which belongs to calcium-gated channels in the neurons and leads to neuronal hyper-polarization.

STAGES OF ANAESTHESIA

Stage I (analgesia): The patient is conscious and experience sensations of warmth, remoteness, drifting, falling, and giddiness. There is a marked reduction in the perception of painful stimuli. This stage is often used in minor surgery.

Stage II (delirium): This stage begins with the loss of consciousness. Depression of higher centres produces variety of effects including excitement, involuntary activity, and increased skeletal muscle tone, and the respiration is typically irregular.

Stage III (surgical anaesthesia): This is the stage of unconsciousness and paralysis of reflexes, respiration is regular and blood pressure is maintained. All surgical procedures are carried out in this stage.

Stage IV (medullary paralysis): Respiratory and circulatory failures take place as a result of the depression of the vital centres of the medulla, and brain stem occurs.

CLASSIFICATION











I. Volatile/Inhalation anaesthetics

S. No.	Name	Structure
1	Chloroform	$CHCl_3$
2	Diethyl ether	$C_2H_5OC_2H_5$


(Continued)

(Continued)


S. No.	Name	Structure
3	Divinyl ether	$\text{H}_2\text{C} = \text{CHOCH} = \text{CH}_2$
4	Trichloro ethylene	$\begin{array}{c} \text{Cl} \\ \\ \text{Cl} - \text{C} = \text{C} - \text{Cl} \\ \\ \text{H} \end{array}$
5	Ethyl chloride	$\text{CH}_3\text{CH}_2\text{Cl}$
6	Cyclo propane	$\begin{array}{c} \text{H}_2 \\ \diagup \quad \diagdown \\ \text{C} \\ \diagdown \quad \diagup \\ \text{H}_2\text{C} - \text{CH}_2 \end{array}$
7	Halothane	CF_3CHClBr
8	Tribromo ethanol	$\text{Br}_3\text{CCH}_2\text{OH}$
9	Fluroxene	$\text{CF}_3\text{CH}_2\text{OCH} = \text{CH}_2$
10	Methoxy flurane	$\text{CHCl}_2\text{CF}_2\text{OCH}_3$
11	Enflurane	$\begin{array}{ccccc} \text{F} & \text{F} & & \text{F} & \\ & & & & \\ \text{H} - \text{C} & - \text{C} & - \text{O} - & \text{C} & - \text{H} \\ & & & & \\ \text{Cl} & \text{F} & & \text{F} & \end{array}$
12	Isoflurane	$\begin{array}{ccccc} \text{F} & \text{H} & & \text{F} & \\ & & & & \\ \text{F} - \text{C} & - \text{C} & - \text{O} - & \text{C} & - \text{H} \\ & & & & \\ \text{F} & \text{Cl} & & \text{F} & \end{array}$
13	Sevoflurane	$\begin{array}{ccccc} \text{F} & \text{H} & & \text{H} & \\ & & & & \\ \text{F} - \text{C} & - \text{C} & - \text{O} - & \text{C} & - \text{F} \\ & & & & \\ \text{F} & \text{CF}_3 & & \text{H} & \end{array}$

II. Nonvolatile or intravenous anaesthetics**a. Ultra short-acting barbiturates****Methohexital sodium****Thiopental sodium****b. Aryl cyclohexylamines****Ketamine****d. Narcotic analgesics****Alfentanil****e. Miscellaneous****Phencyclidine****Thiomylal sodium****Hexobarbital****c. Benzodiazepines****Midazolam****Fentanyl****Propanidid**

Etomidate




Propofol




SYNTHESIS AND DRUG PROFILE

I. Volatile/Inhalation anaesthetics



1. Ether (Diethyl ether)



Synthesis



(ii) Williamson's ether synthesis




Properties and uses: It is a clear, colourless liquid, volatile, highly flammable, soluble in water, miscible with alcohol, methylene chloride, and with fatty oils. Low molecular weight ethers display anaesthetic activity that increases along with toxicity as the chain length increases. Introduction of unsaturation into the aliphatic ether increases potency and also shortens induction and emergence.


Ether is an absolute anaesthetic with pungent, irritant odour. It is flammable and explosive at concentrations necessary for anaesthesia.

Storage: It should be stored in well-closed airtight containers and protected from light, stored at a temperature of 8°C–15°C.


2. Trichloro ethylene



Synthesis




Properties and uses: It may be used sporadically as a weak volatile anaesthetic, administered through inhalation. It possess an excellent analgesic property. It is frequently employed in short surgical operations, where a mild anaesthesia having potent analgesia is desired.




3. Halothane

Synthesis


Route I. From: Trichloro ethylene



Route II. From: Trichloro ethylene




Metabolism: It is metabolized to three major metabolic products, trifluoroacetic acid, *N*-trifluoro acetyl ethanolamine, and *N*-acetyl-*s*-(2-bromo,2 chloro-1,1-difluoro ethyl)-1-cysteine




Properties and uses: It is a clear, colourless, heavy, nonflammable liquid, slightly soluble in water, miscible with ethanol, and with trichloroethylene. Halothane lacks flammability. It may produce any depth of anaesthesia without causing hypoxia. Being a nonirritant, its inherent hypotensive effect retards capillary bleeding and renders a comparatively bloodless field. It is a potent, relatively safe general inhalation anaesthetic used in conjunction with N_2O . For skeletal muscle relaxation, it is used with succinyl choline or tubocurarine.

Storage: It should be stored in well-closed airtight containers, protected from light, at a temperature not exceeding 25°C in a nonreactive metal container.


4. Methoxy Flurane



Synthesis




Metabolism: It is metabolized in the liver to produce fluoride ions, oxalic acid, difluoro methoxyacetic acid, and dichloroacetic acid. The high concentration of fluoride ions causes renal damage.




Properties and uses: It is a clear, colourless liquid, nonflammable and nonexplosive in air or oxygen in anaesthetic concentrations. It is the most potent of the inhalational agents. It is employed to cause light anaesthesia with deep analgesic and muscle relaxation feature, which makes it convenient for surgical operations.


5. Enflurane



Synthesis




Metabolism: The principal metabolites are difluoromethoxy difluoroacetic acid and fluoride ion.




Properties and uses: It is a clear, colourless, volatile liquid with pleasant hydrocarbon-like odour. Soluble in water, miscible with organic solvents, chemically it is extremely stable. The induction of an emergence from anaesthesia and adjustment of anaesthetic depth during maintenance is smooth and moderately rapid. It is a noninflammable halogenated ether anaesthetic and provides rapid induction with no excitement.


6. Isoflurane



Synthesis




Metabolism: It is metabolized to trifluoroacetic acid and fluoride ion.



Properties and uses: It is a clear, colourless, heavy liquid, insoluble in water, miscible with ethanol, and trichloroethylene. It resembles isomer enflurane in its properties. It is not flammable in air or oxygen. The depth of anaesthesia can be rapidly adjusted with it. Used for induction and maintenance of general anaesthesia.

Storage: It should be stored in well-closed airtight containers and protected from light.


7. Sevoflurane




1,1,1,3,3,3-Hexafluoro-2- (fluoro methoxy) propane

Properties and uses: Low boiling liquid with a slight odour; miscible with most organic solvents including fats or oils; practically insoluble in water. It is a nonflammable, nonirritating agent. The physical properties of this compound result in a more rapid induction and termination of anaesthetic when observed with the currently used agents.


8. Cyclopropane (Trimethylene)



Synthesis



Properties and uses: It is nonirritant in nature and ensures rapid recovery from anaesthesia. The adverse effects are depressant effects on respiration, tendency to induce cardiac arrhythmias, and enhanced haemorrhage. Cyclopropane is an anaesthetic gas with a rapid onset of action. It may be used for analgesia, induction, or maintenance of anaesthesia.

9. Nitrous oxide (N₂O)


Properties and uses: It is a colourless gas, without appreciable odour to taste, soluble in water, freely soluble in alcohol, soluble in ether, or oils. This is the least toxic and least potent anaesthetic. It is a noninflammable, nonirritating, and a powerful analgesic agent. Nitrous oxide is a weak anaesthetic with good analgesic properties, and relatively no skeletal muscle relaxant properties. It is an inhalation anaesthetic of choice in dental surgery.

II. Nonvolatile or intravenous anaesthetics

a. Ultra short-acting barbiturates


Metabolism of Barbiturates: This is discussed in Section III, Chapter 'Sedatives and Hypnotics'.

1. Thiopentone sodium (Thiopental)



Sodium salt of 5-ethyl-5(1-methyl butyl)-2-thio barbiturate

Synthesis



Properties and uses: A yellowish-white powder, hygroscopic, freely soluble in water, and partly soluble in ethanol. These are usually administered intravenously for the production of complete anaesthesia of a short duration. It belongs to the category of ultra short-acting barbiturates. Onset is rapid (about 30 sec) and duration is brief (10–30 min). By rectal route it is administered as a solution, suspension, or suppositories as basal anaesthetic. It is also used as a sedative, hypnotic, and anticonvulsant.


Assay for sodium: Dissolve the sample in water, add 0.1 ml of methyl red solution, and titrate with 0.1 M hydrochloric acid until a red colour is obtained. Boil the mixture gently for 2 min, cool it, and, if necessary, continue the titration with 0.1 M hydrochloric acid until the red colour is again obtained.

Assay for thiopental: Dissolve the sample in water, add 2 ml of dilute sulphuric acid, and shake with chloroform. Filter and evaporate the filtrate to dryness on a water-bath. Dissolve the residue in 30 ml of previously neutralized dimethylformamide and add thymol blue in methanol. Titrate immediately with 0.1 M lithium methoxide until a blue colour is obtained.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dosage forms: Thiopental injection B.P.

2. Methohexital sodium




Sodium salt of 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbiturate

Synthesis




Properties and uses: White to off-white hygroscopic powder, essentially odourless, and the solution is alkaline to litmus, soluble in water. Methohexital produces more rapid recovery from unconsciousness than thiopental. It is more potent and has shorter duration of action. It is used for the induction of anaesthesia through the intravenous administration. It has two advantages over thiopental sodium. First, being it has less affinity towards fatty tissues and second, it has a greater potency. Its onset of action is quite speedy comparable to thiopental sodium while its recovery is more rapid. For these reasons, this intravenous anaesthetic is specifically useful for short surgical operations, such as oral surgery, gynaecological investigation, genitourinary procedures, and electroconvulsive therapy.

3. Thiomytal Sodium



Sodium salt of 5-allyl-5(1-methyl butyl)-2-thio barbiturate


Synthesis



Properties and uses: Thiomytal is a highly hydrophobic thiobarbiturate having its structural features very much related to thiopental. Its biological activities are almost identical to thiopental. Used as intravenous anaesthetic.


b. Arylcyclohexylamines

1. Ketamine HCl



2-(2-Chloro phenyl)-2-(methlamino) cyclohexanone

Synthesis



Properties and uses: It is a white or almost white crystalline powder, freely soluble in water, methanol, and ethanol. Its another name is 'dissociative anaesthetic' because it produces unpleasant hallucinations and strong feelings of dissociation from the environment. It is a rapidly acting nonbarbiturate general anaesthetic that produces anaesthesia and is characterized by profound analgesia.

Assay: Dissolve the substance in methanol and add 1.0 ml of 0.1 M hydrochloric acid, and perform potentiometric titration, using 0.1 M sodium hydroxide.


Storage: It should be stored in well-closed airtight containers, protected from light.

Dosage forms: Ketamine HCl injection I.P., B.P.

c. Benzodiazepines


Metabolism: This is discussed in Sec III, Chapter 'Sedatives and Hypnotics'.

1. Midazolam



8-Chloro-6-(2-fluorophenyl)-2-methyl-imidazo benzodiazepine

Synthesis




Properties and uses: It is a white or yellowish, crystalline powder, soluble in acetone, ethanol, and methanol, but insoluble in water. Midazolam has been used adjunctively with gaseous anaesthetics. The onset of CNS effect is slower than that of thiopental and it has a longer duration of action.

Assay: Dissolve the sample in anhydrous acetic acid and add acetic anhydride, titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Dosage forms: Midazolam injection B.P.

d. Narcotic analgesics


1. Fentanyl



N-(1-phenyl ethyl-4-piperidiny) propionanilide

Synthesis and drug profile is discussed in Sec IV, Chapter 'Narcotic Analgesics'.


2. Alfentanyl



N-[1-[2-(4,5-dihydro-5-oxo-tetrazol-1-yl)ethyl]-4-(methoxy methyl)-4-piperidiny]-*N*-phenyl propionamide


Properties and uses: It is closely related to fentanyl. It is a potent analgesic used as a primary anaesthetic or as an adjunct in the maintenance of anaesthesia. It has the same properties and side effects as fentanyl. It relieves moderate to severe break through pain.

Synthesis




e. Miscellaneous

1. Etomidate




Synthesis




Properties and uses: It contains a 4-carboxylic acid ester-substituted imidazole moiety, which is also present in a number of compounds that are structural variants of the triazolo and imidazolo benzodiazepines. It is a positive allosteric modulator of GABA receptors.

2. Propofol



2,6-Diisopropyl phenol

Synthesis



Properties and uses: It is colourless or is a very light yellow in colour, clear liquid, very slightly soluble in water, miscible with hexane and with methanol. Propofol is useful for induction and maintenance of anaesthesia.

Assay: It is assayed by adopting liquid chromatography technique

Storage: It should be stored in well-closed airtight containers and protected from light under an inert gas.

Dosage forms: Propofol injection B.P.

PROBABLE QUESTIONS

1. Define and classify general anaesthetics. Outline the synthesis of any two drugs synthesis that belongs to intravenous anaesthetics.
2. Write the different stages of anaesthesia and explain the mode of action of general anaesthetics.
3. How will you classify general anaesthetics? Write the structure, chemical name, and uses of two drugs from each class.
4. Write the synthesis of general anaesthetic having pyrimidine nucleus.
5. Name the three derivatives of barbiturates that are used abundantly as intravenous anaesthetics. Write their structure, chemical name, and uses.
6. Mention a benzodiazepine derivative used as a general anaesthetic. Write its chemical name and synthesis.
7. Write a note on fluorinated compounds employed as inhalation anaesthetics.
8. Outline the synthesis and assay of the following general anaesthetics
(a) Fluroxene and (b) Halothane
9. What are intravenous anaesthetics? Outline the synthesis of the following:
(a) Thiopental sodium, (b) Ketamine hydrochloride, and (c) Methohexital sodium

SUGGESTED READINGS

1. Abraham DJ (ed) *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 1995.
2. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.

3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
4. Collins VJ. *Principles of Anesthesiology*. Philadelphia: Lea and Febiger, 1966.
5. Eger EI. *Anaesthetic Uptake and Action*. Baltimore: Williams and Wilkins, 1974.
6. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
7. Griffiths MC (ed). *USAN and the USP Dictionary of Drug Names*. Rockville: United States Pharmacopeial Convention Inc, 1985.
8. Gringauz A. *Introduction to Medicinal Chemistry*. New York: Wiley-VCH, 1997.
9. Graham LP. *An Introduction to Medicinal Chemistry* (2nd edn). New York: Oxford University Press, 2002.
10. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
11. Lednicher D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
12. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
13. Macintosh RR and Bannister FB. *Essentials of General Anaesthesia*. London: Blackwell Scientific Publication, 1947.
14. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.

Chapter 4

Local Anaesthetics

INTRODUCTION

Local anaesthetics are drugs that when applied directly to the peripheral nervous tissue blocks nerve conduction and abolish all the sensations in that part supplied by the nerve. They are generally applied to the somatic nerves and capable of cutting on axons, cell body, dendrites, and synapses.

These are used in dentistry, in ophthalmology, in minor surgical operations, including endoscopy, and for relieving pain in certain medical conditions such as tumours growing in the spine. Local anaesthetics are also used topically for the temporary relief of pain from insect bites, burns, and other surface wounds.

Most local anaesthetic agents are weak bases, consisting of lipophilic groups connected by an intermediate chain to the tertiary amino groups. For therapeutic application, they are usually made available as salts to increase the solubility and the stability in the body. They exist either as the unchanged base or as a cation.

The clinically used local anaesthetics have minimal local irritant action and block sensory nerve endings, nerve trunks, neuromuscular junction, ganglionic synapse, and receptors that function through increased net (nerve) permeability. They also reduce the release of acetylcholine from motor nerve endings. Sensory and motor fibres are inherently and equally sensitive. The sensitivity is determined by the diameter of the fibres as well as by the fibre type. Diameters remaining the same, myelinated neurons are blocked earlier than nonmyelinated neurons. Autonomic fibres are generally more susceptible than somatic fibres. Among the somatic afferent order of blockade is pain, temperature, sense, touch and deep pressure sense, since pain is generally carried out by smaller diameter fibres than those carrying other sensations or motor impulses.

In clinical practice, a solution of local anaesthetic (except cocaine) often contains a vasoconstrictor (epinephrine, norepinephrine or phenylepinephrine). The vasoconstrictor serves dual purpose by decreasing the rate of absorption. It not only localizes the anaesthetic at the desired site, but also limits the rate at which it is absorbed into the circulation. The vasoconstrictor prolongs the action and lowers the systemic toxicity of local anaesthetics.

Mode of action: Local anaesthetics block both the generation and the conduction of the nerve impulse. The blockade probably results from the biochemical changes caused by the drug. Immediately after the nerve impulse had passed, the pores again become smaller. Sodium ions are pumped out of the fibre, at the same time potassium ions are transported into the fibre. Local anaesthetic decreases the permeability of cell membrane to sodium, thus preventing sodium depolarization.

Metabolism of local anaesthetics: Clinically available local anaesthetics are broadly divided into esters (e.g. procaine) and nonesters (e.g. lignocaine). The esters are hydrolyzed by esterases enzyme into *p*-amino benzoic acid and corresponding alcohols. The nonester types are primarily metabolized in the liver by CYP450, for example, lidocaine is converted primarily into 3-hydroxyl lidocaine to form 3-hydroxymono ethyl glycine-xylidine. Both may be excreted in their conjugated form. Lidocaine also metabolized into 4-hydroxy-2,6-dimethylanilide and 2-amino-3 methyl benzoic acid from the precursor metabolite 2,6-xylidine. The 2,6-xylidine is also directly excreted in its conjugated form, and it is formed from mono ethyl glycine xyloidine, which is an immediate metabolite of lidocaine.


CLASSIFICATION

Local anaesthetics are generally classified into the following groups :

1. Natural agents
 - a. Cocaine
2. Synthetic nitrogenous compounds
 - a. Derivatives of benzoic acid
 - b. Derivatives of para-amino benzoic acid
 - i. Freely soluble: Procaine, Amethocaine.
 - ii. Poorly soluble: Benzocaine, Orthocaine
 - c. Derivatives of acetanilide: Lignocaine, Mepivacaine, Bupivacaine, Prilocaine, Etidocaine.
 - d. Derivatives of quinoline: Cinchocaine, dimethisoquin
3. Synthetic non-nitrogenous agents: Benzyl alcohol, propanediol
4. Miscellaneous drugs with local action: Clove oil, phenol, chlorpromazine and certain antihistamines, for example, diphenhydramine

On the basis of chemical structure, local anaesthetics are classified as follows:


I. Benzoic acid derivatives







Name	R ₁	R ₂
Hexylcaine	-H	$\begin{array}{c} \text{H} \quad \text{H} \quad \text{H} \\ \quad \quad \\ -\text{C}-\text{C}-\text{N}-\text{C}_6\text{H}_{11} \\ \quad \\ \text{CH}_3 \quad \text{H} \end{array}$
Meprylcaine	-H	$\begin{array}{c} \text{H} \quad \text{CH}_3 \quad \text{H} \\ \quad \quad \\ -\text{C}-\text{C}-\text{N}-\text{CH}_2\text{CH}_2\text{CH}_3 \\ \quad \\ \text{H} \quad \text{CH}_3 \end{array}$

(Continued)

(Continued)




Name	R ₁	R ₂
Isobucaine	H	$ \begin{array}{ccccccc} & \text{H} & & \text{CH}_3 & \text{H} & & \text{H} \\ & & & & & & \\ - & \text{C} & - & \text{C} & - & \text{N} & - & \text{C} & - & \text{CH} \\ & & & & & & & & & \\ & \text{H} & & \text{CH}_3 & & & & \text{H} & & \text{CH}_3 \end{array} $
Piperocaine	-H	$ \begin{array}{ccccccc} & \text{H} & & \text{H} & & \text{H} & & \text{CH}_3 \\ & & & & & & & \\ - & \text{C} & - & \text{C} & - & \text{C} & - & \text{N} & \text{---} & \text{Cyclohexyl} \end{array} $
Cyclomethycaine		$ \begin{array}{ccccccc} & \text{H} & & \text{H} & & \text{H} & & & \\ & & & & & & & & \\ - & \text{C} & - & \text{C} & - & \text{C} & - & \text{N} & \text{---} & \text{Cyclohexyl} \\ & & & & & & & & & \\ & \text{H} & & \text{H} & & \text{H} & & & & \text{CH}_3 \end{array} $

II. *p*-Amino benzoic acid derivatives


Name	R ₁	R ₂	R ₃	R ₄	R ₅
Benzocaine	-H	-H	-H	-CH ₂ -CH ₃	-
Butamben	-H	-H	-H	-(CH ₂) ₃ CH ₃	-
Procaine	-H	-H	-H	-CH ₂ -CH ₂ -	
Chlorprocaine	-H	-H	-Cl	-CH ₂ -CH ₂ -	
Tetracaine	- ⁿ Butyl	-H	-H	-CH ₂ -CH ₂ -	






(Continued)

(Continued)

Name	R ₁	R ₂	R ₃	R ₄	R ₅
Butacaine	-H	-H	-H	-CH ₂ -CH ₂ -CH ₂	
Binoxinate	-H	ⁿ Butoxy	-H	-CH ₂ -CH ₂ -	
Propoxycaine	-H	-H	ⁿ Propoxy	-CH ₂ -CH ₂ -	


III. Anilide derivatives (2,6 Xylidines)




Name	R ₁	R ₂
Lidocaine/Lignocane	-CH ₃	
Mepivacaine	-CH ₃	
Prilocaine	-H	
Bupivacaine	-CH ₃	
Etidocaine	-CH ₃	

IV. Miscellaneous


a. Phenacaine




b. Dipiperdon HCl




c. Dimethizoquine




d. Dibucaine



e. Pramoxine HCl




f. Dyclonine HCl



SYNTHESIS AND DRUG PROFILE

I. Benzoic acid derivatives

a. Cocaine




Properties and uses: Cocaine is the first local anaesthetic discovered; it is an alkaloid obtained from the leaves of *Erythroxylon cocca*. It is a white crystalline powder (or colourless crystals), very soluble in water, freely soluble in alcohol, and slightly soluble in methylene chloride. Though it is considered too toxic for any anaesthetic procedure requiring injection, it is still employed topically as a 1% or 2% solution for the anaesthesia of the ear, nose, throat, rectum, and vagina because of its intense vasoconstrictive action.

Assay: Dissolve the substance in a mixture of 0.01 M hydrochloric acid and alcohol. Perform potentiometric titration using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.


Synthesis




Dose: Employed topically in a 1% or 2% solution for anaesthesia of the ear, nose, throat, rectum, and vagina.

Dosage forms: Cocaine eye drops B.P.

b. Hexylcaine hydrochloride (Synonym: Cyanine)




Synthesis



Properties and uses: It is a white powder, soluble in water, and chloroform. It is regarded as an all-purpose soluble local anaesthetic agent. The onset and duration of action is almost similar to that of lignocaine. It is mainly used as surface anaesthetic.


Dose: For infiltration anaesthesia, 1%; for nerve block anaesthesia, 1% and 2% solution; and for topical application to skin and mucous membrane, 1% to 5%.

c. Meprylcaine and Isobucaine HCl




Meprylcaine
 $R = -(CH_2)_2-CH_3$
 Isobucaine
 $R = -CH_2CH(CH_3)_2$

Synthesis





d. Cyclomethycaine sulphate



3-(2-Methyl piperidino)propyl-*p*-(cyclohexyloxy)benzoate sulphate


Synthesis

Route I. From: *p*-Chlorobenzoyl chlorideRoute II. From: *p*-Hydroxy benzoic acid

Properties and uses: It is a white crystalline powder, soluble in water, and chloroform. Used to relieve pain from damaged skin, mucous membrane of rectum, vagina, and urinary bladder.


Dose: The usual dose for topical purpose is 0.25% to 1% in suitable form.

e. Piperocaine (Synonym: Metycaine)



3-(α -Methyl piperidino) propyl benzoate


Synthesis




Properties and uses: Piperocaine is small, white, crystalline powder, soluble in water and chloroform. It is used as surface anesthesia for eyes, throat and caudal analgesia.

II. Para amino benzoic acid derivatives

a. Benzocaine (Americaine)



Synthesis




Properties and uses: It is a white crystalline powder or colourless crystals, freely soluble in alcohol, slightly soluble in water. Structurally, it lacks the terminal diethylamino group usually present in most of the anaesthetics, such as procaine. It is used to get rid of the pain caused by wounds, ulcers, and in mucous surface. It is nonirritant and nontoxic.

Assay: Dissolve the substance in a mixture of hydrochloric acid and water, and perform the determination of primary aromatic amino-nitrogen (diazotization method).


Storage: It should be stored in well-closed airtight container and protected from light.

Dose: Topical, 1% to 20% in ointment, cream, and aerosol for skin.

b. Butamben (Butesin)




Synthesis



Properties and uses: It is a local anaesthetic of relatively low solubility and used in a similar manner to benzocaine. It is more efficacious than its corresponding ethyl ester when applied to intact mucous membranes.


Dose: Topical, 1% to 2% in conjunction with other local anaesthetics in creams, ointments, sprays, and suppositories.

c. Procaine hydrochloride (Navocaine)




Synthesis


Route I. From: *p*-Amino benzoic acid



Route II. From: 2-Chloro ethyl 4-amino benzoate



Route III. From: 2-Chloro ethanol




Properties and uses: It is a white crystalline powder or colourless crystals, soluble in water and alcohol. It has the advantage of lacking of local irritation, minimal systemic toxicity, longer duration of action, and low cost. It can be effectively used for causing anaesthesia by infiltration, nerve block, epidural block, or spinal anaesthesia.

Assay: Dissolve the substance in dilute hydrochloric acid and perform the determination of primary aromatic amino nitrogen (Diazotization method).

Storage: It should be stored in well-closed airtight container, protected from light.

Dose: Usual infiltration, 50 ml of a 0.5% solution; usual peripheral nerve block, 25 ml of a 1% or 2% solution; usual epidural, 25 ml of a 1.5% solution.


d. Tetracaine (Anethaine, Pontocaino hydrochloride)




2-(Dimethyl amino) ethyl-*p*-(butyl amino) benzoate

Synthesis

Route I. From: 4-Amino benzoic acid



Route II. From: 4-Amino benzoic acid



Properties and uses: It is a white crystalline powder, slightly hygroscopic in nature, soluble in alcohol, and freely soluble in water. It is an all-purpose local anaesthetic drug used frequently in surface, infiltration block, caudal, and spinal anaesthesia. It is reported to be 10 times more toxic and potent than procaine. Its duration of action is twice than that of procaine.


Assay: Dissolve the substance in alcohol and add 0.01 M hydrochloric acid. Perform potentiometric titration, using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight container, protected from light.

Dose: Usually, subarachnoid 0.5 to 2 ml as a 0.5% solution; topically, 0.1 ml of a 0.5% solution to the conjunctiva.


Dosage forms: Tetracaine eye drops B.P.

e. Butacaine (Butyn sulphate)




3-(Di-butyl amino)-1-propane-*p*-amino benzoate

Synthesis




Dose: Several instillations of a 2% solution about 3 min apart allows most surgical procedures.

f. Binoxinate




2-(Diethyl amino) ethyl-4-amino-3-butyloxy-benzoate

Synthesis




g. Propoxycaine (Blockhain)



2-(Diethyl amino) ethyl-4-amino-2-propoxy benzoate


Synthesis



Properties and uses: Its local anaesthetic potency is reported to be 7 or 8 times more than that of procaine. It is a structural isomer of proparacaine, and is less toxic with slightly lower potency than proparacaine. It is mainly used for infiltration and nerve block anaesthesia.


Dose: Usually, 2 to 5 ml of 0.5% solution.

h. Proparacaine



2-(Diethyl amino) ethyl-3-amino-4-propoxy benzoate.


Synthesis



Properties and uses: An effective ester-type surface anaesthetic with potency about equal to that of tetracaine. It is a useful anaesthetic in ophthalmology and induces little or no initial irritation. It is useful for most ocular procedures that require topical anaesthesia such as cataract extraction, tonometry, removal of foreign bodies and sutures, gonioscopy, conjunctival scraping for diagnosis and short-operative procedures involving the cornea and conjunctiva.

SAR OF BENZOIC ACID DERIVATIVES


Most of these local anaesthetics are tertiary amines available as HCl salts with pKa in the range of 7.5–9.0. Any structural modification of the local anaesthetic that causes change in pKa will have pronounced effect to reach hypothetical receptor or the binding sites.



1. Lipophilic

- The clinically useful local anaesthetics of this class possess an aryl radical that is attached directly to the carbonyl group and are highly lipophilic. They appear to play an important role in the binding of local anaesthetics to the channel receptor protein.
- Placement of aryl group with substituents that increases the electron density of the carbonyl oxygen enhances the activity.

- Structural modification leads to change in physical and chemical properties. Electron withdrawing substituents in ortho or para or at both the positions leads to an increase of its local anaesthetic property.
- Amino (procaine, butacaine) alkyl amino (tetracaine) alkoxy (cyclomethycaine) group can contribute to electron density in the aromatic ring by both resonance and inductive effects. Hence the increase in local anaesthetic property.
- Any substitution that enhances zwitterion formation will be more potent. Hence *m*-position substitution decreases the activity.



- Tetracaine is more potent than procaine (40–50 times). Although the butyl group present in it increases lipid solubility, the potentiation is partly due to electron releasing property of the *n*-butyl group via inductive effect, which intend to increase the formation of the Zwitterion.
- Presence of electron withdrawing group such as Cl⁻ ortho to carbonyl pulls electron density away from carbonyl group, thus, making it more susceptible for nucleophilic attack by the esterase.

2. Intermediate

- In procaine series, anaesthetic potency decreases in the following order sulphur, oxygen, carbon, and nitrogen.
- Modifications also affect the duration of action and toxicity. In general, amides (X = N) are more resistant to metabolic hydrolysis than esters (X = O). Thioesters (X = S) may cause dermatitis.
- Placement of small alkyl groups (branching) around ester group (hexylcaine/meprylcaine) or the amide function also hinder hydrolysis, and hence, increase in duration of action.


3. Hydrophilic portion

- The amino alkyl group is not necessary for local anaesthetic activity, but it is used to form water soluble salts such as HCl salts.
- Tertiary amines are more useful agents. The secondary amines appear to have a longer duration of action, but they are more irritating. Primary amines are not active/cause irritation.
- The tertiary amino group may be diethyl amino, piperidine, or pyrrolidino, leading to a product that exhibit same degree of activity, essentially.
- The more hydrophilic morpholino group usually leads to diminished potency.
- In general, the local anaesthetic drug should have increased lipid solubility and lower pKa values that leads to rapid onset and lower toxicity.


III. Anilides

Agents of this class are more stable to hydrolysis. They are more potent, have lower frequency of side effects, and induce less irritation than benzoic acid derivatives.

a. Lidocaine HCl (Synonym: Lignocaine, Xylocaine)



Synthesis



Metabolism: Undergoes *N*-de-ethylation to yield mono-ethyl glycinexylide followed by amidase action to *N*-ethyl glycine and 2, 6-dimethylaniline.

Properties and uses: It is a white crystalline powder, very soluble in water, freely soluble in alcohol. It is a potent local anaesthetic. It is reported to be twice as active as procaine hydrochloride in the same concentrations. It has local vasodilating action, but usually used with vasoconstrictor adrenaline to prolong the local anaesthetic activity. It is also used as class I anti-arrhythmic agent.


Assay: Dissolve the substance in alcohol and add 0.01 M hydrochloric acid. Perform potentiometric titration using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Infiltration or epidural up to 60 ml (or 100 ml with epinephrine) as 0.5% solution.


Dosage forms: Lidocaine gel B.P, Lidocaine and Chlorhexidine gel B.P, Lidocaine injection B.P, Lidocaine and adrenaline injection/Lidocaine and Epinephrine injection B.P, Sterile Lidocaine solution B.P.

b. Bupivacaine (Marcaine)



1-Butyl-N-(2, 6-dimethyl phenyl)-2-piperidin carboxamide

Synthesis



Properties and uses: It is a white crystalline powder or colourless crystals, soluble in water, freely soluble in alcohol. It is a long-acting local anaesthetic of the amide type, similar to mepivacaine and lidocaine, but about four times more potent. The effect of bupivacaine last longer than lidocaine hydrochloride. It is long-acting local anaesthetic mainly employed for regional nerve block.


Assay: Dissolve the sample in a mixture of water and alcohol, to this add 0.01 M hydrochloric acid and carry out a potentiometric titration using 0.1 M ethanolic sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Regional nerve block, 0.25% to 0.5% solutions; Lumbar epidural block, 15 to 20 ml of 0.25% to 0.5% solution; Caudal block, 15 to 40 ml of 0.2% solution.

Dosage forms: Bupivacaine HCl injection I.P., Bupivacaine injection B.P., Bupivacaine and Adrenaline injection/Bupivacaine and Epinephrine injection B.P.


c. Mepivacaine (Carbocaine hydrochloride, Polocaine)



N-(2,6-dimethyl)-1-methyl-2-piperidin carboxamide

Properties and uses: It is a white crystalline powder, freely soluble in water and in alcohol, very slightly soluble in methylene chloride. The duration of action is significantly longer than that of lidocaine, even without adrenaline. It is of particular importance in subjects showing contraindication to adrenaline. It is a local anaesthetic used for infiltration, peridural, nerve block, and caudal anaesthesia.


Synthesis



Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and alcohol. Perform potentiometric titration using 0.1 M sodium hydroxide.

Dose: In filtration and nerve block, 20 ml of 1% or 2% solution in sterile saline; caudal and peridural, 15 to 30 ml of 1%; 10 to 25 ml of 1.5% or 10 to 20 ml of a 2% solution in modified Ringer's solution.


d. Prilocaine (Citanest hydrochloride)



2-(Propylamino)-*o*-propiono toluidine

Properties and uses: It is a white crystalline powder or colourless crystals, very slightly soluble in acetone, freely soluble in water and alcohol. It is a local anaesthetic of the amide type, which is employed for surface infiltration and nerve block anaesthesia. Its duration of action is in between the shorter-acting

Synthesis




lidocaine and longer-acting mepivacaine. The solution of prilocaine HCl is specifically used for such patients who cannot tolerate vasopressor agents, patients having cardiovascular disorders, diabetes, hypertension, and thyrotoxicosis.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and alcohol and perform potentiometric titration, using 0.1 M sodium hydroxide.

Dose: Usually, therapeutic nerve block, 3 to 5 ml of a 1% or 2% solution; infiltration, 20 to 30 ml of a 1% or 2% solution; peridural, caudal, regional, 15 to 20 ml of a 3% solution; infiltration and nerve block, 0.5 to 5 ml of a 4% solution.


Dosage forms: Prilocaine injection B.P.

e. Etidocaine (Duranset)



2- (Ethyl propyl amino)-2', 6'-butyroxylyde

Synthesis




Properties and uses: It is a white crystalline powder, soluble in water, freely soluble in alcohol. It is used clinically in epidural, infiltrative, and regional anaesthesia. It has greater potency and longer duration of action than lidocaine.

Dose: Solution for injection: 1% without epinephrine and 1.5% with epinephrine.


SAR of Anilides

General structure of anilides is represented as follows:



a. Aryl group

- The clinically useful local anaesthetics of this type possess a phenyl group attached to the sp^2 carbon atom through a nitrogen bridge.
- Placement of substituents on the phenyl ring with a methyl group in the 2 (or) 2 and 6-position enhances the activity. In addition, the methyl substituent provides steric hindrance to hydrolysis of the amide bond and enhances the coefficient of distribution.
- Any substitution on the aryl ring that enhances zwitterion formation will be more potent.



b. Substituent X


- 'X' may be carbon, oxygen, or nitrogen among them lidocaine series (X = O) has provided more useful products.

c. Amino alkyl group

- The amino function has the capacity for salt formation and is considered as the hydrophilic portion of the molecule.
- Tertiary amines (diethyl amine, piperidine) are more useful because the primary and secondary amines are more irritating to tissues.


IV. Miscellaneous class

a. Phenacaine (Holocaine hydrochloride)



N, N'-bis(4-Ethoxyphenyl) ethanindamide


Synthesis



Properties and uses: It exists as small white odourless and crystalline powder. Structurally, it is related to anilides in that the aromatic ring is attached to a sp^2 carbon through a nitrogen bridge. It is one of the oldest synthetic local anaesthetic. It is used mainly for producing local anaesthesia of the eye.


Dose: To the conjunctiva as 1%–2% ointment or as a 1% solution.

b. Dipiperodon HCl (Diothane)



3-(1-Piperidiny)-bis (phenylcarbamate)-1, 2-propandiol


Synthesis



Properties and uses: It exists as white crystals, soluble in water, and potent surface anaesthetic; used primarily for anus. Very toxic in nature.


Dose: Topically, 0.5% to 1% solution, to the mucous membranes.

c. Pramoxine HCl (Traonaolene)



4-(3(4-Butoxy phenoxy)propyl)morpholine.HCl


Synthesis



Properties and uses: White crystals or white crystalline powder, numbing taste, may have a slight aromatic odour. Soluble in chloroform, freely soluble in alcohol and water, very slightly soluble in ether. It is a surface anaesthetic, which possesses very low degree of toxicity and sensitization. It is applied locally as 1% solution in rectal surgery, itching, and minor burns. Structurally, it is unrelated to any of the amide type agents, simple ether linkage fulfils this function, and thus, exhibits the local anaesthetic activity.


Dose: It is applied locally as 1% solution in rectal surgery, itching, and minor burns.

d. Dyclonine (Dyclone)



1-(4-Butoxy phenyl)-3-(1-piperidinyl)-1-propanone.HCl


Synthesis



Properties and uses: Exists as white crystals or white crystalline powder and may have a slight odour. Soluble in water, alcohol, and chloroform, insoluble in ether and hexane. Dyclonine containing lozenges are used to relieve minor sore throat and mouth discomfort. It is used to anesthetize mucous membranes of mouth, trachea, and urethra prior to various endoscopic procedures.


Dose: A 5% solution is used to relieve pain associated with oral or anogenital lesion.

e. Dibucaine (Nupercaine)



2-Butoxy-N-(2-(diethylamino)ethyl)-4-quinoline carboxamide


Synthesis



Properties and uses: Exists as white powder with slightly characteristic odour, somewhat hygroscopic, and darkens on exposure to light. Soluble in water, alcohol, chloroform, and in ether. Its anaesthetic activity is similar to those of procaine or cocaine when injected. It is several times more potent than procaine when injected subcutaneously and five times more toxic than cocaine, when injected intravenously. It is the most potent toxic and long-acting local anaesthetics used as infiltration, surface and spinal anaesthesia.


Dose: Subarachnoid, 0.5 to 2 ml of 0.5% solution; usually, 1.5 ml of a 0.5% solution.

f. Dimethisoquin (Synonym: Quinisocaine, Quotane)



3-Butyl-1-(2-(dimethylamino)ethoxy)isoquinoline

Synthesis



Uses: It is a surface anaesthetic used as an ointment or lotion for relief from irritation, itching, pain, or burning.

Dose: Topically, to the skin as a 0.5% ointment or lotion 2 to 4 times/day.

PROBABLE QUESTIONS

1. Define and classify local anaesthetics with suitable examples. Outline the synthesis of any two drugs from different class.
2. Differentiate between the Local anaesthetics and the General anaesthetics. Is it necessary to include local anaesthetics as adjuncts in antiseptic creams used in severe burns and painful skin abrasions? Explain with typical examples.
3. Write the synthesis of local anaesthetics having the following functional group.
(a) Ether (b) Amide (c) Morpholine
4. Outline the synthetic route leads to Procaine using the starting material
(a) 2-Chloroethyl-*p*-amino benzoate
(b) 4-Aminobenzoic acid
(c) 4-Nitrobenzoic acid.
5. Justify why propoxycaine hydrochloride is more potent than procaine hydrochloride.
6. Mention a tropane derivative used as potent surface anaesthetic agent. Outline its synthesis starting from succinic aldehyde.
7. Write in detail about the SAR of Benzoic acid derivatives used as local anaesthetics.
8. Amides and esters constitute an important category of local anaesthetics. Mention the examples with their chemical structure; outline the synthesis of any one drug from each category.
9. Describe the synthesis of a quinoline analogue used as a local anaesthetic starting from isatin.
10. Write the mode of action and general metabolic pathway of local anaesthetics.
11. Write in brief about Anilides used as local anaesthetics.
12. Describe the synthesis of an isoquinoline analogue used as a local anaesthetic.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
4. Covino BG. 'Local anaesthetics'. In *Drugs in Anaesthesia*, pp. 261–91. London: Edward Arnold Publishers, 1987.
5. Geddes JC. 'Chemical structure of local anaesthetics'. *Br J Anaesth* 34: 1962.
6. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.

7. Hewer CL and Lee JA. 'A rare toxic effect of local anaesthesia with lignocaine'. In *Recent Advances in Anaesthesia and Analgesia* (8th edn), p. 121. London: Churchill, 1958.
8. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
9. Lofgren N. *Studies on Local Anaesthetics*. Stockholm: University of Stockholm, 1948.
10. Lechat P. 'Local anaesthetics'. In *International Encyclopedia of Pharmacology and Therapeutics I*. Oxford: Pergamon Press, 1971.
11. Lemke TL and Williams DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
12. Lednicher D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
13. Neal MJ. *Medical Pharmacology at a Glance* (3rd edn). London: Blackwell Scientific Publications, 1997.
14. Rang HP, Dale MM, and Ritter JM. *Pharmacology* (4th edn). Edinburgh: Churchill Livingstone, 1999.
15. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
16. Roth SH and Miller KW. *Molecular and Cellular Mechanisms of Anesthetics*. New York: Plenum Press, 1986.
17. Smith J and Williams H. *Introduction to the Principles of Drug Design*. Bristol: Wright-PSG, 1988.
18. Sneader W. *Drug Discovery: The Evolution of Modern Medicines*. Chichester, UK: John Wiley, 1985.
19. Speight JM and Holford P. *Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics* (4th edn). Auckland, New Zealand: ADIS Press, 1997.
20. Strichartz GR. *Local Anesthetics*. Berlin: Springer, 1987.
21. Thomas G. *Medicinal Chemistry: An Introduction*. Chichester, UK: John Wiley, 2000.
22. Takman BH and Adams HJ. 'Local anaesthetics'. In *Medicinal Chemistry* (4th edn), ME Wolff (ed). New York: John Wiley, 1980.
23. Trimer JS and Angnew WS. 'Molecular diversity of voltage-sensitive sodium channels'. *Ann Rev Physiol* 51: 401–418, 1989.
24. Voet D, Voet JG, and Pratt C. *Fundamentals of Biochemistry*. New York: Wiley, 1999.

Chapter 5

Tranquillizers

INTRODUCTION


Tranquillizers are used primarily for the treatment of symptoms of mental diseases. They cause sedation without inducing sleep. They are essentially used in the symptomatic treatment of psychosis, such as schizophrenia and organic psychosis. The symptoms of schizophrenia can be divided into two types, positive and negative. Positive symptoms are those that are not normally found in healthy individuals, including hallucinations, delusions, and thought disorder. Negative symptoms represent the loss of qualities normally present in healthy individuals, including impoverishment of thought, blunted emotion, attention deficit, and lack of motivation or initiative. In addition, many of these drugs also act as skeletal muscle relaxants, antihypertensives, antiemetics, and antiepileptics.

GENERAL MODE OF ACTION

All antipsychotics except clozapine have potent dopamine (D_2) receptor blocking action. Phenothiazines and thioxanthenes also block D_1 , D_3 , and D_4 receptors and have correlation with antipsychotic or tranquillizing property. Blockade of the dopaminergic projections to the temporal and the prefrontal area constitutes the limbic system, and in the mesocortical area, it is probably responsible for antipsychotic action. As an adaptive change, to blockades of D_2 receptor, the firing of DA neurons and DA turnover increases initially. However, over a period of time, this subsides and gives away diminished activity, especially in the basal ganglia corresponding to the emergency of Parkinsons disease. Clozapine and other atypical antipsychotics have significant 5-HT₂ and α_1 blocking action and are relatively selective for D_4 receptor. Thus, antipsychotic property depends on a specific profile of action of the drugs on several neurotransmitter receptors.

CLASSIFICATION

1. Phenothiazine derivatives




Name	R ₂	R ₁₀
Propyl dialkylamino side chain		
Promazine	-H	$-(CH_2)_3 N \begin{matrix} \diagup CH_3 \\ \diagdown CH_3 \end{matrix}$
Chlorpromazine	-Cl	$-(CH_2)_3 N \begin{matrix} \diagup CH_3 \\ \diagdown CH_3 \end{matrix}$
Triflupromazine	-CF ₃	$-(CH_2)_3 N \begin{matrix} \diagup CH_3 \\ \diagdown CH_3 \end{matrix}$
Ethyl piperidyl side chain		
Thioridazine	-SCH ₃	$-(CH_2)_2 - \begin{array}{c} \text{piperidine ring} \\ \\ CH_3 \end{array}$
Mesoridazine	O ← SCH ₃	$-(CH_2)_2 - \begin{array}{c} \text{piperidine ring} \\ \\ CH_3 \end{array}$
Propyl piperazine side chain		
Prochlorperazine	-Cl	$-(CH_2)_3 - \begin{array}{c} \text{piperazine ring} \end{array}$
Trifluperazine	-CF ₃	$-(CH_2)_3 - \begin{array}{c} \text{piperazine ring} \end{array}$
Thioethylperazine	-SCH ₂ CH ₃	$-(CH_2)_3 - \begin{array}{c} \text{piperazine ring} \end{array}$
Butaperazine	-(CH ₂) ₃ -CH ₃	$-(CH_2)_3 - \begin{array}{c} \text{piperazine ring} \end{array}$
Perphenazine	-Cl	$-(CH_2)_3 - \begin{array}{c} \text{piperazine ring} \\ \\ -CH_2CH_2OH \end{array}$
Fluphenazine	-CF ₃	$-(CH_2)_3 - \begin{array}{c} \text{piperazine ring} \\ \\ -CH_2CH_2OH \end{array}$

(Continued)


(Continued)

Name	R ₂	R ₁₀
Acetophenazine		
Carphenazine		


2. Benzodiazepines



Chlordiazepoxide




Oxazepam




Lorazepam


3. Fluro butyrophenones



Haloperidol




Trifluoperidol



Droperidol


Spiroperidol, Benperidol, Paraperidol

4. Rauwolfia alkaloids









Name	R ₁	R ₂
Reserpine		-OCH ₃
Rescinamine		-OCH ₃
Reserpidine		-H

5. Dihydroindolones




6. Thioxanthines




Name	R ₁	X
Chlorprothixene	-Cl	
Clopendithiol	-Cl	
Flupenthixol	-CF ₃	
Thiothixene		

7. Dibenzoxazepines





8. Dibenzodiazepines



9. Diphenyl butyl piperidines

- Pimozide
- Penfluridat

10. Benzisoxazoles and Benzisothiazoles



11. Thienbenzodiazepines

- Olanzapine

12. Propanediol carbamates

- Meprobamate


13. Miscellaneous

- Oxypertine
- Quetiapine
- Seretindole


SYNTHESIS AND DRUG PROFILE

I. Phenothiazines

a. General synthesis of propyl dialkylamino side chain derivatives



Synthesis



a. Promazine

Properties and uses: It is a white or almost white crystalline powder, slightly hygroscopic in nature. It is well soluble in water, alcohol, and methylene chloride. It has low clinical potency, medium extrapyramidal toxicity, high sedative effect, and high hypotensive action. It is used as dopamine receptor antagonist and neuroleptic.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and 50 ml of alcohol. Perform the potentiometric titration using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight container and protected from light.

Dosage forms: Promazine injection B.P., Promazine oral suspension B.P., Promazine tablets B.P.

Chlorpromazine (Cain, Chlorpromazine, Megatil)

Metabolism: It is demethylated, sulfoxidized, hydroxylated, and glucuronidated to yield 7-*o*-glu-nor chlorpromazine.

Properties and uses: It is a white or almost white crystalline powder, freely soluble in ethanol and well soluble in water. The drug has significant sedative and hypotensive properties, possibly reflecting central

and peripheral α_1 -noradrenergic blocking activity and also effects the peripheral anticholinergic activity, used as dopamine receptor antagonist and neuroleptic.

Assay: Dissolve the sample in a mixture of 0.1 M hydrochloric acid and ethanol. Perform potentiometric titration using 0.1 M sodium hydroxide.

Storage: It decomposes on exposure to air and light, hence, it should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 75–80 mg daily in divided doses for psychiatric patients. As an antiemetic, it is 25–50 mg.

Dosage forms: Chlorpromazine HCl injection I.P., Chlorpromazine tablets I.P., B.P., Chlorpromazine injection B.P., Chlorpromazine oral solution B.P.

Tiflupromazine


Properties and uses: It is a white to pale yellow, crystalline powder, hygroscopic in nature, soluble in alcohol and freely soluble in water. It has lower sedative and hypotensive effects than chlorpromazine, and greater milligram potency as an antipsychotic, used as dopamine receptor antagonist and neuroleptic.

Assay: Dissolve the sample in alcohol, to this add 0.01 M hydrochloric acid and perform potentiometric titration, using 0.1 M sodium hydroxide.


Storage: It should be stored in well-closed airtight container and protected from light.

Dosage forms: Trifluoperazine HCl injection I.P., Trifluoperazine HCl tablets I.P., Trifluoperazine tablets B.P.

b. General synthesis of ethyl piperidyl side chain derivatives



Synthesis



Uses: It is effective in the management and manifestations of psychotic disorders with minimal anti-emetic action.

Thioridazine (Melozone, Ridazin, Melleril)

Properties and uses: It is a white or almost white crystalline powder, soluble in ethanol, freely soluble in water and in methanol. The drug exerts minimum antiemetic activity and there by gives rise to minimal extrapyramidal stimulation. The drug has sedative and hypotensive activity in common with chlorpromazine. It is effective in the management and manifestations of psychotic disorders, used as Dopamine receptor antagonist and neuroleptic.

Assay: Dissolve the substance in a mixture of anhydrous acetic acid and acetic anhydride and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers, and protected from light.


Dose: For Schizophrenia: Adult: Initially, 50–100 three times/day and slowly titrated upwards at not more than 100 mg/week. Maximum of 800 mg daily in 2–4 divided doses. Child, 2–12 year: Initially, 0.5 mg/kg daily in divided doses, increased gradually until optimum effect is obtained. Maximum: 3 mg/kg daily.

For Depression: Adult: Initially, 25 mg thrice/day, titrated to 20–200 mg daily.


Mesoridazine

Properties and uses: It shares many properties with thioridazine, but no pigmentary retinopathy has been reported.

c. General synthesis of propyl piperazine side chain derivatives



Synthesis



Name	R	R ₁
Prochlorperazine	-Cl	-CH ₃
Trifluoperazine	-CF ₃	-CH ₃
Perphenazine	-Cl	-CH ₂ CH ₂ OH
Fluphenazine	-CF ₃	-CH ₂ CH ₂ OH
Acetophenazine	-COCH ₃	-CH ₂ CH ₂ OH
Carphenazine	-COC ₂ H ₅	-CH ₂ CH ₂ OH

b. Perphenazine

Properties and uses: It is a white or yellowish-white crystalline powder soluble in dilute solutions of hydrochloric acid, soluble in alcohol, freely soluble in methylene chloride, and insoluble in water. It is used as dopamine receptor antagonist and neuroleptic.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.1 M perchloric acid, and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight container and protected from light.

Dosage forms: Perphenazine tablets B.P.

Prochlorperazine (Vometil, Stemetil, Emidoxyn)

Properties and uses: It is a white or pale yellow crystalline powder, well soluble in water and alcohol. It is more potent on a milligram basis than its alkylamino counterpart, chlorpromazine because of the high prevalence of extra-pyramidal symptom (EPS). It is mainly used for anti-emetic effect, not for its anti-psychotic effect, used as dopamine receptor antagonist and neuroleptic.

Assay: Dissolve the sample in anhydrous acetic acid by warming on a water-bath and allow it to cool to room temperature. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight container and protected from light.

Dose: For nausea and vomiting: Adult: As mesylate: 12.5 mg by deep IM. If required, may give further doses via oral route. For psychosis: Adult: As mesylate: 12.5–25 mg by deep IM injection twice/day or thrice/day.

Dosage forms: Prochlorperazine maleate tablets I.P., Prochlorperazine mesylate injection I.P., Prochlorperazine tablets B.P., Prochlorperazine buccal tablets B.P.

Fluphenacin (Anatensol, Decanoate, Fpz, Prolinate)

Properties and uses: It is a white or almost white crystalline powder, slightly soluble in ethanol and in methylene chloride, but freely soluble in water, used as dopamine receptor antagonist and neuroleptic.


Assay: Dissolve the sample in a mixture of anhydrous formic acid and acetic anhydride and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight container and protected from light.

Dose: The usual dose is 1–2 mg daily for anxiety; up to 15 mg daily for schizophrenia.

Dosage form : Fluphenazine tablets B.P.

SAR of Phenothiazines



It is presumed that phenothiazines (neuroleptic) mediate their pharmacological effect mainly through interaction at D_2 type dopamine receptors. Examination of X-ray structures of dopamine and chlorpromazine substituted with chlorine shows that these two structures can be partly superimposed. Chlorpromazine base could be superimposed on aromatic ring of dopamine base with sulphur atom aligned with *p*-hydroxy of dopamine. These substances are chemically constituted by lipophilic linearly fused tricyclic system having hydrophilic basic amino alkyl side chain.

Activity of phenothiazines is determined by the following:

1. Nature of alkyl side chain at C-10.
2. Amino group of side chain.
3. Substituents on aromatic ring.


1. Modification of alkyl side chain

- Potency is maximum when there is three carbon between two 'N' atom (ring and side chain N).
- Introduction of methyl group at C-1 decreases antipsychotic activity and produces imipramine-like activity.
- If C-1 is incorporated into cyclopropane ring imipramine-like activity is obtained.
- When oxygen is introduced into C-1 results in potent antidepressant effect. Example: Chloracizine.
- Addition of $-CH_3$ at C-2 or C-3 has very little effect on activity.
- Bridging of position 3 of side chain to position 1 of phenothiazine nucleus decreases neuroleptic activity.

2. Amino group modification

- 3° nitrogen shows maximum potency and 2° or 1° nitrogen shows reduced or abolished activity. *N*-alkylation with more than one carbon decreases activity.
- Activity is decreased when dimethylamino group is replaced by pyrrolidinyl, morpholinyl, or thiomorpholinyl groups. However, piperidine or piperazine is more potent than dimethylamino group.
- Bridged piperidine derivatives retain high degree of activity although bulky.
- Introduction of OH, CH_3 , CH_3CH_2OH at C-4 of piperazine results in increased activity.

- Piperazine and phenothiazines may be esterified with long-chain fatty acids to produce slowly absorbed long-acting lipophilic prodrugs. Due to the slow release from oily deposition, significant activity is retained



Fluphenazine deconoate

- When *N*-4 piperazine substituents are as large as phenyl, ethyl, or *p*-amino phenyl ethyl (e.g. Azaspirane, Chlorspirane) are active.


3. Phenothiazine ring

- Substitution at C-2 position is optimal for neuroleptic activity. In general, potency at different positions increases in the following order $1 < 4 < 3 < 2$. Potency of the various groups increase in the following order $\text{OH} < \text{H} < \text{CN} < \text{CH}_3 < \text{Cl} < \text{CF}_3$.
- Disubstitution (or) trisubstitution of the C-2 substituted drugs results in harmful potency.
- CF_3 is more potent than Cl, but EPS appears, hence, chlorpromazine is much used, rather than triflupromazine.
- The electro-negative chlorine atom at C-2 is responsible for imparting asymmetry to this molecule and the attraction of the amine side chain towards the ring containing the chlorine atom indicate an important structural feature of such molecules.
- Oxidation of the sulphur at 5th position of antipsychotic phenothiazine decreases activity.

II. Benzodiazepines


Metabolism is discussed under 'Sedatives and Hypnotics' in Sec III.

a. Chlordiazepoxide (Cebrum, Cloxide, Librium)



7-Chloro-5-phenyl-2-methylamino-1,4-benzodiazepine-4-oxide

Synthesis




Properties and uses: It is a white or slightly yellow crystalline powder, sparingly soluble in ethanol and soluble in water. Chlordiazepoxide is also available commercially in anxiolytic products combined with anticholinergic and anti-depressant agents. The therapeutic value of these fixed combinations has not been established. Adverse reactions include drowsiness, ataxia, confusion, skin eruptions, oedema, menstrual irregularities, nausea and constipation, EPS and decreased libido. In some patients; blood dyscrasias (agranulocytosis), jaundice, and hepatic dysfunction have occasionally been reported. Used for the relief of anxiety and tension, withdrawal symptoms of acute alcoholism, and also used as sedative as well as muscle relaxant.

Assay: Dissolve the sample in water and titrate with 0.1 M silver nitrate. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight container and protected from light.

Dose: For Anxiety: Adult: 30 mg daily in divided doses, up to 100 mg daily in severe conditions. Elderly and debilitated patients: Dose reduction may be needed. For muscle spasms: Adult: 10–30 mg daily in divided doses. Elderly and debilitated patients: Dose reduction may be needed.

b. Oxazepam




7-Chloro-3-hydroxy-5-phenyl-1,4 benzodiazepin-2-one


Synthesis and drug profile are discussed under 'Sedatives and Hypnotics' in Sec III.

III. Fluoro butyrophenones

a. Haloperidol (Halidol, Hexidol, Cizoren)



Synthesis




Metabolism: It is metabolized by oxidative *N*-dealkylation. The principal metabolites are oxidative products, such as 4-fluorobenzoyl propionic acid and 4-fluorophenylacetic acid.


Properties and uses: It is useful in the management of psychotic reactions, hostility, and hyperactivity. It is a drug of choice for Tourett's syndrome. Haloperidol is an effective neuroleptic and also possesses antiemetic properties.

Dose: For restlessness and confusion: Adult 1–3 mg every 8 h. For psychoses: Adult: 0.5–5 mg twice or thrice/day, may increase up to 100 mg daily in severe or resistant cases. Usual maintenance: 3–10 mg daily. Child: >3 year: Initially, 25–50 µg/kg daily in two divided doses, increased gradually if necessary. Maximum: 10 mg/day.

b. Trifluoperidol




Synthesis




Uses: It is used for the treatment of schizophrenia and other psychosis, mania, and short-term adjunctive management of psychomotor agitation and excitement.

c. Droperidol



1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6 tetrahydro-4-pyridyl)-2-benzimidazolinone

Synthesis




Properties and uses: It is a white or almost white powder insoluble in water, sparingly soluble in alcohol, freely soluble in dimethylformamide and in methylene chloride. The drug exhibits relatively low therapeutic potency, medium extrapyramidal toxicity, high sedative effect, and above all high hypotensive action. It is frequently used in combination with the narcotic agents pre-anaesthetically. It is a neuroleptic used as an adjunct to anaesthesia to produce sedation and reduce incidence of nausea and vomiting. Also used as β_1 -adrenoceptor agonist α -adrenoceptor agonist.

Assay: Dissolve the sample in a mixture of 1 volume of anhydrous acetic acid and 7 volumes of methyl ethyl ketone. Titrate with 0.1 M perchloric acid, using naphthol benzene solution, and end point is the colour change from orange-yellow to green.

Storage: It should be stored in well-closed airtight container and protected from light.

Dosage forms: Droperidol injection B.P., Droperidol tablets B.P.


SAR of Butyrophenones



- Antipsychotic activity is seen when Ar group is an aromatic system in which fluoro-substituents at para-position enhances the activity.
- When X = carbonyl (C = O) optimal activity is seen, although other groups C(H)OH, C(H) aryl (pimozide) also afford good activity.
- When $n = 3$ activity is optimal, longer, or shorter chains decrease the activity.
- Aliphatic amino nitrogen is required and highest activity is seen when it is incorporated into a cyclic form
- Ar_1 group should be an aromatic and is needed; it should be attached directly to the fourth position or occasionally separated from it by one intervening atom.
- The Y group can vary and assist the activity.
- The empirical SARs could be constructed to suggest that the 4-aryl piperidino moiety is super impossible on the 2-phenyl ethyl amino moiety of dopamine and accordingly could promote affinity for D_2 and D_3 receptors.
- The long *N*-alkyl substituent could help to promote receptor affinity and produce receptor antagonism activity (or) inverse agonism.

IV. Thioxanthines

a. Chlorprothixene




3-(2-Chloro-thioxanthen-9-ylidene)-N,N'-dimethyl-1-propenamine

Properties and uses: It is a white or almost white crystalline powder, slightly soluble in methylene chloride, and soluble in water and alcohol. It is used in the treatment of acute and chronic schizophrenia, psychotic and other conditions in which anxiety, agitation, and tension predominate.

Metabolism: Thioxanthines are closely related to the phenothiazine in their pharmacologic effects and there seems to be at least one major difference in metabolism, most of the thioxanthine do not form ring hydroxylated derivatives.


Assay: Dissolve the substance in a mixture of 0.01 M hydrochloric acid and alcohol. Perform potentiometric titration, using 0.1 M sodium hydroxide.

Synthesis




Storage: It should be stored in well-closed airtight container and protected from light.

b. Clopenthixol




Synthesis




Uses: It is used in the treatment of schizophrenia and other psychotic states.

c. Thiothixene




Synthesis



Properties and uses: White, or nearly white crystalline powder with slight odour, and affected by light, soluble in water, anhydrous alcohol, or chloroform, practically insoluble in benzene, acetone, or ether. The substituent in the second position produces Z and E isomers. The Z isomers are the more active antipsychotic isomers. It was introduced as an antipsychotic agent useful in the management of schizophrenia and other psychotic states. It is also helpful in the management of secondary symptoms of schizophrenia, such as hallucinations, tension, and suspiciousness. It also shows antidepressant property.


V. Dihydro indolones

a. Molindone (Liclone, Moban)



3-Ethyl-2-methyl-5-(morpholinomethyl)-6,7-dihydro-indol-4-one

Synthesis




Properties and uses: Exists as white crystals, freely soluble in water or alcohol, it is a potent antipsychotic as trifluoperazine and all the side effects resemble those of the phenothiazines. It is used in the treatment of schizophrenia and other psychosis.

Dose: The usual dose is 15–25 mg/day.


VI. Dibenzoxazepinones

a. Loxapine succinate (Loxapac)



2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(1,4)oxazepine succinate

Synthesis




Properties and uses: Exist as white to off-white crystalline powder, slightly soluble in water or alcohol. It may give rise to possible anticholinergic and antiadrenergic activity. It must be employed with great caution in such patients who have either a history of glaucoma or urinary retention problems. It has resulted from the expansion of the six-member central ring of phenothiazine followed by isosteric replacement of one or more atoms with oxygen. Because of its seven-member central ring, the conformation of loxapine is more twisted than that of the phenothiazine rings. It is used for symptomatic control of schizophrenia.


Dose: The usual dose is 20–250 mg/day.

VII. Dibenzodiazepines

a. Clozapine (Lozapin, Sizopin, Clopaz)



Synthesis




Properties and uses: It is a yellow crystalline powder, dissolves in dilute acetic acid, insoluble in water, freely soluble in methylene chloride, and soluble in alcohol. It has more affinity for D_1 and less for D_2 dopamine receptors. It may have its unique profile due to the blockade of D_1 receptors and M_1 muscarinic activity. It has high potentially fatal agranulocytosis. Other adverse side effects include drowsiness, dizziness, and dose-related seizures. It is effective in individuals suffering from disorganization. For example, loose associations, inappropriate affect, incoherence, and reduction in rational thought processes.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Dose: For Schizophrenia: Adult: 12.5 mg 1–2 times on day 1 followed by 25 mg 1–2 times on day 2 increased gradually in increments of 25–50 mg up to a daily dose of 300 mg with 14–21 days. Subsequent increments of 50–100 mg may be made 1–2 times weekly. Usual dose is 200–450 mg/day. Maximum: 900 mg/day. Elderly: Initially, 12.5 mg on day 1 increased subsequently by increments of 25 mg. For psychosis in parkinsonism: Adult: Initially, 12.5 mg once daily at night, increased in steps of 12.5 mg up to two times each week, not >50 mg/day at the end of the second week. Usual dose: 25–37.5 mg daily. Maximum of 100 mg daily.


VIII. Benzisoxazoles

a. Risperidone (Respidon, Sizodon, Rispid)



3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one

Synthesis



Properties and uses: It is a white or almost white powder, dissolves in dilute acid solutions, insoluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol. It is a typical antipsychotic and neuroleptic. Its adverse effects include nasal congestion, orthostatic hypotension, insomnia, and possible EPS. Causes more EPS than other atypical agents. May cause weight gain and an increased tendency for glucose intolerance. Risperidone has structural features of hybrid molecules between butyrophenone and trazodone. It is a typical antipsychotic, effective against the negative symptoms of schizophrenia.


Assay: Dissolve the sample in 70 ml of a mixture of 1 volume of anhydrous acetic acid and 7 volumes of methyl ethyl ketone and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For Schizophrenia: Adult: Initially, 2 mg daily, may increase to 4 mg daily on the second day, adjusted further in increments or decrements of 1–2 mg daily at weekly intervals. Doses may be given in 1–2 divided doses. Maintenance: 4–6 mg daily. Maximum: 16 mg/day. For elderly: Initially, 0.5 mg two times a day gradually increased in increments of 0.5 mg twice a day. Maintenance: 1–2 mg twice a day.

IX. Miscellaneous

Quetiapine (Placidin, Q-Pin, Pincalm)




Synthesis



Properties and uses: It exists as white crystals. Quetiapine is used orally to treat psychotic disorders and symptoms, such as hallucinations, delusions, and hostility.


Dose: For Schizophrenia: Adult: Initially, 25 mg twice a day on day 1 increased to 50 mg twice a day on day 2, 100 mg twice a day on day 3, and 150 mg twice a day on day 4. Usual dose range: 300–450 mg daily. Maximum: 750 mg/day, For elderly: Initially, 25 mg daily, increased in steps of 25–50 mg daily according to response.

X. Ziprasidone (Azona, Zipsydon)




Synthesis


Step-I



Step-II




Condensation of product of *Step II* and *Step-I*



Properties and uses: It exists as a white to faint pink powder, hemihydrate. An atypical antipsychotic, this agent must be given with food twice daily for maximum effect. Adverse effects include somnolence and minor $Q T_c$ prolongation. Currently, this is the only atypical antipsychotic available in a parenteral (IM) formulation.


Dose: For Schizophrenia: Adult: As hydrochloride: ≥ 18 years: Initially 20 mg twice a day, increase if necessary at intervals of not less than two days, up to 80 mg twice a day. Maintenance: 20 mg twice a day. Elderly: Lower initial dose with slow titration and close monitoring.

c. Seretindole



1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl)piperidin-1-yl)ethyl)imidazolidin-2-one

Synthesis



PROBABLE QUESTIONS

1. What are tranquillizers? Write the mode of action and synthesis of any one benzodiazepine derivative.
2. Write note on flurobutyrophenones used as tranquillizers.
3. Classify the phenothiazines used as tranquillizers, based on their substituents. Write the mode of action, synthesis, and uses of Butaperazine.
4. Name some thioxanthines used as tranquillizers and write the synthesis and uses of Chlorprothixene.
5. Write the synthesis and drug profile of Chlorpromazine and Chlordiazepoxide.
6. Write the SAR of phenothiazines used as tranquillizers.
7. Write the synthesis and uses of Droperidol and Clozapine.

Chapter 6

Antidepressants

INTRODUCTION

Antidepressants are drugs, which enhance alertness and may result in an increased output of behaviour. They are used for the relief of symptoms of moderate and severe depressive disorder.

Depression is characterized by feelings of intense sadness or worry, agitation, self-depression, physical changes, such as insomnia, anorexia, loss of enthusiasm, and mental slowing. Major depression is one of the most common psychotic disorders. At any given moment, about 5%–6% of the population is depressed and estimated 10% of the people may become depressed during their lives. Depression is a heterogeneous disorder that has been characterized and classified into a variety of types.

1. Reactive or secondary depressor (occurs in response to illness and it is most common).
2. Endogenous depression (a genetically determined biochemical disorder).
3. Depression associated with bipolar effect (manic depression).

Endogenous depression occurs due to low concentration of various biogenic amines and other modulators of nervous transmission at neuronal level. Antidepressants are typically taken for at least 4–6 months.

Uses

Therapeutic uses of antidepressants are as follows:

- Moderate to severe depressive illness.
- Severe anxiety and panic attacks.
- Obsessive compulsive disorders.
- Chronic pain.
- Eating disorder.
- Post-traumatic stress disorder.

Antidepressants increase the availability of catecholamines at the appropriate receptor sites of the brain. Most of the antidepressants exerts important actions on the metabolism of monoamine neurotransmitters and their receptors particularly norepinephrine (NE) and serotonin. Their therapeutic activeness and actions together with strong evidence from genetic predisposition have lead to the speculation that the biological basis of major mood disorders may include abnormal function of monoamine neurotransmission disorders, including panic-agoraphobia, social and other phobias generalized anxiety and obsessive compulsive disorders that appear to


be responsive with selective serotonin reuptake inhibitor. Mania and their association with bipolar disorders are less common than major depression. Mania and its milder form is treated with anti-psychotics, anticonvulsants, or lithium salts, sometimes supplemented with a potent sedative in short term and lithium salts or any anticonvulsants with mood stabilizing property. Imipramine, Amitryptaline, and their *N*-de-methyl derivatives are widely used for major depression. The ability of monoamine oxidase (MAO) inhibitors were noted in 1950, and they are also used in therapy for major depressions, but has limitations due to the toxicities. Presently, selective serotonin reuptake inhibitors, such as Fluoxetine, Fluoxetine, Paroxetine, Sertaline, and Venlafaxine are used.

CLASSIFICATION

These drugs vary significantly in their chemical and pharmacological properties. One convenient way is to combine both aspects and classify accordingly.

I. Monoamine oxidase inhibitors (MAOIs)


a. Isocarboxazide




b. Iproniazid




c. Phenelzine




d. Pheniprazine




e. Tranylcypromine




f. Pargyline HCl




g. Clorgyline



h. Deprenyl



i. Nialamide




Harmine, Harmaline

α -methyl tryptamine, α -ethyl tryptamine

II. Tricyclic antidepressants (TCAs)


1. Imino dibenzyl derivatives




S. No.	Drugs	R	R ¹	R ²
1.	Imipramine	-H	-H	-CH ₃
2.	Desipramine	-H	-H	-H
3.	Trimipramine	-H	-CH ₃	-CH ₃
4.	Chlorimipramine	-Cl	-H	-CH ₃

2. Dibenzo cycloheptane derivatives


a. Amitriptyline



b. Nortriptyline




c. Protriptyline




3. Dibenzoxepine derivatives

a. Doxepin



4. Dibenzoxazepine derivatives




III. Second-generation antidepressants


- a. Bicyclic: Viloxamine, Zimeldine
- b. Tricyclic: Dibenzepine, Amoxapine, Imipramine
- c. Tetracyclic: Mianserin, Mianserin

IV. Selective serotonin reuptake inhibitors (SSRIs)


a. Citalopram(±) Isomer




b. Escitalopram (+) Isomer




c. Fluoxetine




d. Fluvoxamine



e. Paroxetine




f. Sertraline



V. Selective NE reuptake inhibitors

a. Venlafaxine



b. Nisoxetine

c. Roboxetine

VI. Benzodiazepines

a. Alprazolam

VII. Electro convulsive therapy

VIII. Miscellaneous


- i. β -Adreno receptor agonists salbutamol, clenbutral
- ii. Thyrotropine releasing hormone (TSH)
- iii. Others: trazadone, nomifenzine, bupropion, fluvoxamine

SYNTHESIS AND DRUG PROFILE

I. Monoamine oxidase inhibitors (MAOIs)


Mode of action: MAO is a family of enzymes located in the outer membrane of mitochondria. MAO inhibitors block the intracellular metabolism of biogenic amines, these results in increased amines concentration in the nerve terminals, whereas tricyclic antidepressants and others inhibit the reuptake of NE and serotonin by nerve terminals, this inturn facilitates adrenergic neurotransmission and produces an antidepressant action.


a. Phenelzine (Catron)



Synthesis

Route I. From: 2-Phenyl ethyl alcohol



Route II. From: Acetophenone



Properties and uses: It is a white powder or pearly platelets, insoluble in ethanol and in ether, but freely soluble in water. It is a MAOI with low sedative and antimuscarinic effects, causing weight gain. It is used primarily in the treatment of depression and certain phobic-anxiety states effective in neurotic or typical depressed patients.

Assay: Dissolve the substance in water, add sodium hydrogen carbonate, and 0.05 M iodine VS, close the flask and allow to stand for 90 min. To this add 20 ml of 2 M hydrochloric acid and titrate with 0.1 M sodium thiosulphate, using starch mucilage as an indicator.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 15–30 mg/day, orally 3 times a day.

Dosage forms: Phenelzine tablets B.P.


b. Isocarboxazide**Synthesis****Route I. From: Acetone and diethyl oxalate**

Route II. From: Benzyl alcohol




Properties and uses: It exists as white to off-white crystalline powder with slight characteristic odour, stable in dry air. Sparingly soluble in water, well soluble in ethanol, glycerol, or propylene glycol. An MAOI with low sedative and antimuscarinic effects causing weight gain, used in severe depressive state to whom tricyclic antidepressants (TCA) are contraindicated.

C. Tranyl cypromine (Synonym: Parnale)



Synthesis (From: Styrene)



Properties and uses: It is a white or almost white crystalline powder, slightly soluble in ethanol and in ether, but soluble in water. It can be regarded as a ring-closed derivative of amphetamine. It will produce severe hypertensive crisis if taken together with cheese. It is not to be used in cardiovascular disease. It has amphetamine-like action and releases NE centrally. This perhaps accounts for the relative rapidity of action with this


drug (in 48 h) in contrast to other MAO inhibitors, which have taken 2–3 weeks. It is used for hospitalized patients with endogenous depression, and who have not responded to other antidepressants. Can be indicated in elderly patients.

Assay: Assayed by nonaqueous titration and the end point determined potentiometrically.


Dose: Usual dose is 20–30 mg/day, orally in the morning and afternoon for 2 weeks.

Dosage forms: Tranyl cypromine tablets B.P.

e. Pargyline



Synthesis




Properties and uses: It possesses hypotensive and stimulant properties. It is recommended for the treatment of hypertension rather than for use in depressed states. It may act through a negative feedback on NE synthesis, and has a long duration of action. Patient receiving pargyline should not receive sympathomimetic amines.

IIa. Tricyclic antidepressants (TCAs)


Mode of action: Tricyclic antidepressants inhibit the active reuptake of biogenic amines, that is, NE and 5-HT into their respective neurons, and thus, potentiate them. Following the release of NE by depolarization in the presence of Ca^{2+} , NE interacts with postsynaptic α and β adrenergic receptors as well as presynaptic α_2 auto-receptors. Inactivation of transsynaptic communication occurs primarily by active transport (inhibited by tricyclics); secondary deamination by mitochondrial MAO, blockade and inactivation of NE by tricyclics, initially, leads to α_2 receptor mediated inhibition of the firing of neurons, and gradually on long-term administration of TCA, desensitize the α_2 -auto receptors and sensitizes the pre and postsynaptic NA/5-HT receptors and produces enhanced adrenergic and serotonergic transmission.

1. Imipramine (Synonym: Tofromil, Imavate, Microdep, Antidep, Depsol)



5-[3-(Dimethyl amino) Propyl]-10,11-dihydro-dibenz azepine.


Synthesis



Properties and uses: Imipramine HCl is the lead compound of the TCAs. It is also closely related to the antipsychotic phenothiazines compounds. The compound has a tendency towards a high 5-HT/NE uptake block ratio. It is useful in treating endogenous depression particularly manic-depressive and involutional psychosis. It is also used routinely to treat nocturnal enuresis (bed wetting) in children aged 6 years and above.


Dose: Usual dose is 50–150 mg daily, in divided doses.

2. Trimipramine (Surmontil)



5 [3-(Dimethyl amino) 2-methyl Propyl]-10,11-dihydro-dibenz azepine


Synthesis



Properties and uses: It exists as white crystals, has bitter taste and slightly soluble in water or in alcohol, but freely soluble in chloroform. Replacement of hydrogen with an α -methyl substituent produces a chiral carbon. It is used as a racemic mixture. Biological properties reportedly resemble those of imipramine.


Dose: For Depression: Adult: Initially 50–75 mg daily, increased gradually as necessary to 150–300 mg daily. It may be given in divided doses during day or as a single dose at night. For elderly: Initially 50–75 mg daily, increased gradually if necessary. Maximum: 100 mg daily.

3. Desipramine




5 [3-(Methyl amino) propyl]-10,11,-dihydro-dibenz azepine

Synthesis




Properties and uses: It exists as white to off-white crystalline powder, odourless, with bitter taste, unstable after long exposure to light, heat, and air, soluble in water, alcohol, chloroform, or ether. It has few anticholinergic effects or (a low level of sedation). Used as an antidepressant with less anxiolytic and sedative properties.

4. Clomipramine (Aneprnil)



3-Chloro-5-[3-(dimethyl amino) propyl]-10, 11-dihydro-dibenzazepine


Synthesis



Properties and uses: It is a TCA with high sedative and intense antimuscarinic effects, causing hypotension and weight gain. Initially, indicated only for obsessive-compulsive disorder.

Dose: Usual dose is 25 mg twice or thrice/day.

SAR of Dibenzazepines



Variation in the side chain

- Maximum potency occurs when the basic nitrogen is separated from tricyclic nucleus by a propylene bridge.
- Ethylene in between ring and side chain 'N' atom gives significant activity.
- Increase in the 'C' length from propylene leads to it becoming ineffective or produce toxic effects.
- Branching does not affect the activity. For example, Imipramine and Trimipramine have same activity.
- A carbonyl functionality in position 1 of the propyl side chain of imipramine have antidepressant like activity.
- Side chain with quinuclidine, morpholine nuclei claimed to be potent.
- The tertiary amine and secondary amine in the side chain are important because they significantly affect both the monoamine reuptake activity as well as interaction with other receptors. For example, tertiary amines are more potent inhibitors of 5-HT reuptake, while secondary amines are more potent in their inhibition of NE reuptake. Tertiary amines also have more potent activity to α_1 adrenergic, muscarinic, and histaminic receptors.

Variation in the ring substituents


- Presence of chloro-substituent at C-3 is less active than imipramine.
- Presence of dimethyl or keto at C-10 leads to the compounds becoming ineffective.
- Placement of methyl group at 2,8 position or chloro group at 3,7 resulted in compounds becoming ineffective.

Variation in the ring system

- Iminostilbenes are equally active.
- Piperazinyl derivatives are ineffective.


II b. Tricyclic antidepressants (TCAs)

a. Amitriptyline (Synonym: Envil, Amitril, Tryptomer, Amitone, Trilin)



5-(3-Dimethyl amino propyliden)-10,11-dihydro-dibenzocycloheptene

Synthesis



Properties and uses: It is a white or almost white powder or colourless crystals. Soluble in water, in alcohol, and in methylene chloride. It is one of the most anticholinergic and sedative of the TCAs, because it lacks the ring electron-enriching nitrogen atom of imipramine. Used for the treatment of depression associated with anxiety. It is also useful in the management of enuresis in children and adolescents.


Assay: Dissolve the sample in alcohol. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Usual dose is 50–75 mg daily on divided doses or at single dose at night.

Dosage forms: Amitriptyline HCl tablets I.P., Amitriptyline tablets B.P.


b. Nortriptyline (Synonym: Damelor, Aventyl HCl, Nordep, Nortin, Depival)




5-(3-Methyl amino propyliden)-10, 11-dihydro-dibenzo cycloheptene.

Synthesis

Route I. From: Phthalic anhydride



Nortriptyline**Route II. From 10, 11-dihydro cyclohepten-5-one**

Properties and uses: It is a white or almost white powder, soluble in ethanol and in methylene chloride, but sparingly soluble in water. A tricyclic, with moderate sedative and moderate antimuscarinic effects. It possesses antidepressant and tranquillizing properties, similar to those of the parent drug amitriptyline. It produces less anticholinergic, less sedative, and more stimulant action than amitriptyline.


Assay: Dissolve the sample in ethanol, add 0.1 M hydrochloric acid and perform potentiometric titration using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For depression: Adult: 75–100 mg daily in 3–4 divided doses, increase gradually up to 150 mg daily in severe depression. Child: Adolescent: 30–50 mg daily in divided doses. Elderly: 30–50 mg daily in divided doses.

Dosage forms: Nortriptyline HCl tablets I.P., Nortriptyline capsules B.P., Nortriptyline tablets B.P.

SAR of Dibenzo Cycloheptane Derivatives




- Placement of $-Cl$ at C-3 shows increase in activity, whereas, CH_3 at C-3 decreases CNS depression.
- Removal of *N*-methyl group of amitriptyline yielded nortriptyline, which is 2–5 times more potent than amitriptyline.
- Presence of double bond between 10 and 11 positions increases the activity.
- Unsaturation at C-5 enhances activity.
- When central ring size increases from 7 to 8 members (cyclo-octane), it is more effective.
- Several amitriptyline analogues in which replacement of C-11 with O, S, SO, SO_2 , and NH are clinically effective antidepressants.
- Nortriptyline with exocyclic double bond and protriptyline with endocyclic double bond differ in their metabolism patterns. Protriptyline is less metabolized in vitro leading to a prolonged half-life and lower dose requirement.
- Novel bridged derivatives are very powerful, for example, maprotiline is a potent antidepressant, and the time to steady-state concentration is up to 7 days.




II. c. Dibenzoxepine derivatives

1. Doxepin (Doxedep, Doxetar, Doxtin)



N-Dimethyl-3-[dibenz oxepin-11-ylidene] propylamine.

Synthesis



Properties and uses: It is a white or almost white crystalline powder, freely soluble in water, in alcohol, and in methylene chloride. One of the two carbon atoms of the ethylene bridge of the antidepressant may be replaced by oxygen. The side chain of amitriptyline can be attached resulting in the formation of doxepin. Used for the treatment of mild-to-moderate endogenous depression, Doxepin is a mixture of *cis* and *trans* isomers with *cis* isomer being more active. The drug is a NE and 5-HT uptake blocker, used as monoamine reuptake inhibitor and as tricyclic antidepressant.

Assay: Dissolve the substance in a mixture of anhydrous acetic acid and acetic anhydride and titrate with 0.1 M perchloric acid until the colour changes from blue to green by using crystal violet as an indicator.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 75–150 mg/day by oral or oral liquid.


Dosage forms: Doxepin HCl capsules I.P., Doxepin capsules B.P.

IV. Selective Serotonin Reuptake Inhibitors (SSRIs)

Mode of Action: SSRIs have analogous action to TCAs at serotonin containing neurons. Selective serotonin reuptake inhibitors, inhibits reuptake of serotonin. After serotonin is released from neuron, it is removed from the extracellular space by transporters or reuptake sites, located on the cell membrane, SSRIs blocks serotonin reuptake to remain active in the synaptic binding site for longer time. Following the release of serotonin in nerve terminals, it interacts with postsynaptic 5-HT₁₋₇ receptors and exerts their effects through a variety of phospholipase and cyclase-mediated mechanisms. Inhibitory auto receptors include 5-HT_{1A} and perhaps 5-HT₇ subtypes at serotonin cell bodies as well as 5-HT_{1D} receptors in the nerve terminals, and dendrites become desensitized following prolonged treatment with SSRIs and enhances the excitatory function.

Structurally, the SSRIs differ from the tricyclic in that the centre ring of tricyclic has been taken apart. The net effect is that the aryl amine similar to the grouping is present as in the tricyclics and the compound can compete for the substrate binding site of the serotonin transporter protein. As in the tricyclics the extra acyl group can add extra affinity and give favourable competition with the substrate serotonin.


9. Fluoxetine (Fludac, Platin, Prodep)




(±)-3-(*p*-Trifluoro methyl phenoxy)-*N*-methyl-3-phenyl-propylamine.

Synthesis

Route I. From: Beta (methyl amino) propiophenone



Route II. From: Acetophenone




Properties and uses: It is a white or almost white crystalline powder, soluble in methanol, sparingly soluble in water, and in methylene chloride. It is a selective serotonin reuptake inhibitor and antidepressant. It is used for the treatment of endogenous depression. It may be useful in treating obsessive-compulsive disorder, obesity, and alcoholism. It is a selective inhibitor of serotonin uptake in the CNS and has little effect on the control of NE or dopamine function.

Assay: Assayed by liquid chromatography method.


Dose: The usual dose is 20–80 mg/day.

Dosage forms: Fluoxetine capsules B.P., Fluoxetine oral solution B.P.

b. Fluvoxamine



Synthesis




Properties and uses: It is a white to almost white crystalline powder, sparingly soluble in water, freely soluble in ethanol, and in methanol. It is a selective serotonin reuptake inhibitor, antidepressant, and effective in treating depressive disorders. It may be relatively safe to use in depressed individuals with cardiovascular diseases. The most common adverse effects are nausea, headache, dry mouth, and insomnia.

Assay: It is assayed by titrating with 0.1 M perchloric acid (nonaqueous titration) and the end point is determined potentiometrically.

Storage: It should be stored in well-closed airtight containers.

Dosage forms: Fluvoxamine tablets B.P.


1. Sertraline




4-[3, 4-Dichloro phenyl] 1, 2, 3, 4-tetra hydro-N-methyl naphthalamine

Synthesis

Route I. From: 4-(3,4-Dichlorophenyl)-3,4-dihydro-1-naphthalenone




Route II. From: Benzene and 3,4-dichlorobenzoyl chloride



Properties and uses: Sertraline works by blocking presynaptic reuptake of serotonin and is considerably more potent in this effect than any antidepressant of this class. It is twice as potent in its inhibition of serotonin reuptake activity than in its inhibition of NE or dopamine uptake inhibitor. Used as selective serotonin reuptake inhibitor with low sedative and antimuscarinic activity, also used for panic disorder and premenstrual dysphoric disorder.


V. Selective Norepinephrine Reuptake Inhibitors (SNERIs)

a. Venlafaxine



(±) -1-[(2-Dimethylamino)-1-(4-methoxyphenyl) ethyl]-cyclohexanol

Synthesis



Properties and uses: It is a white or almost white powder and exhibits the property of polymorphism. Freely soluble in water and in methanol, soluble in anhydrous ethanol, slightly soluble, or practically insoluble in acetone. It is a phenylethylamine bicyclic compound with antidepressant effect similar to TCAs, but with fewer side effects. It is a selective inhibitor of 5-HT and NE reuptake. It also inhibits reuptake of dopamine, but to lesser extent.


Assay: Dissolve the substance in a mixture of 0.01 M hydrochloric acid and ethanol. Perform potentiometric titration with 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers.



VIII. Miscellaneous

a. Bupropion (Zyban)

Bupropion is a novel, nontricyclic antidepressant with a primary pharmacological action of monoamine uptake inhibition.




1-(3-chloro phenyl)-2-[(*t*-butylamino)propanone]

Synthesis**Route I. From: *m*-Chloro cyano benzene****Route II. From: 3-Chloro benzonitrile**


Properties and uses: It exists as a white solid, soluble in water or ethanol. A semisynthetic centrally acting opiod analgesic derived from thebaine, it is used for the relief of moderate to severe pain particularly associated with postoperative discomfort. It is approximately 30 times as potent as morphine and exerts its analgesic effect by binding to CNS opiod receptors. Bupropion is used to treat major depression, refractory depression, and seasonal effective disorder. It is also used to help people to stop smoking and to treat bipolar depression and attention defect disorder. It does not cause sedation and has minimal cardiovascular side effects. The most frequent side effect is agitation.

Dose: Initial dosing is 75–100 mg twice or thrice a day.


b. Trazodone (Tazodac, Trazalon, Trazonil)

Synthesis


Step I. Preparation of 1, 2, 4-triazolo pyridin-3-one



Step II. Preparation of 1-(3-chloro phenyl)-4-(3-chloro propyl) piperazine.



Condensation of *Step I* and *Step II* products



Properties and uses: It exists as white crystals, sparingly soluble in water or alcohol, soluble in chloroform. It is a heterocyclic with high sedative and no antimuscarinic effects. Antidepressant activity of trazodone is believed to be produced by blocking the reuptake of serotonin at the presynaptic neuronal membrane. Trazodone has no influence on the reuptake of NE or dopamine with the CNS. It has a sedative effect, which is believed to be produced by the α -adrenergic blocking action and modest histamine blockade.

Dose: The usual dose is 150–400 mg/day by oral.

PROBABLE QUESTIONS

1. Define and classify antidepressants and write the synthesis of any two of them. Mention their uses and metabolism.
2. Write the mode of action of MAO inhibitors, enumerate the various agents and write the synthesis and uses of Isocarboxazid.
3. Write in detail about Tricyclic antidepressants.
4. Write the synthesis, mode of action, and metabolic pathway of Amitriptyline and Imipramine.

5. Write a note on Selective serotonin reuptake inhibitors used as antidepressants.
6. Name some condensed seven-membered ring containing antidepressants and write the synthesis and uses of Doxepin.

SUGGESTED READINGS

1. Abraham DJ (ed) *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. Baldessarini RJ. *The Psychiatric Therapies*, TB Karasu (ed), pp. 119–70. Washington, DC: American Psychiatric Association, 1984.
3. Baldessarini RT. *Chemotherapy in Psychiatry: Principles and Practice* (2nd edn). Cambridge, MA: Harvard University, 1996.
4. Biel JH, Bopp B, and Mitchell BD. 'Chemistry and structure-activity relationships of psychotropic drugs'. In *Principles of Psychopharmacology* (2nd edn), WG Clark and J Del Guidone (eds) pp. 140–68. New York: Academic Press, 1978.
5. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
6. Brunton LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
7. Davis JM, Barter JT and Kane JM. 'Antipsychotic drugs'. In *Comprehensive Textbook of Psychiatry*, HJ Kaplan and BJ Sadock (eds), Vol. 2, pp. 15–91. Baltimore: Williams & Wilkins 1989.
8. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
9. Griffiths MC (ed). *USAN and the USP Dictionary of Drug Names*. Rockville: United States Pharmacopoeial Convention Inc, 1985.
10. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
11. Kane JM. 'The current status of neuroleptic therapy'. *J Clin Psychiatry* 50: 322, 1989.
12. Lednicher D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
13. Lemke TL and Williams DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
14. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
15. Strange PG. 'Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects'. *Pharmacol Rev* 53: 119, 2001.
16. Wise ID and Heffner TG. 'Antipsychotics'. *Ann Rept Med Chem* 26: 53–62, 49–58, 1991 (and references cited therein).

Chapter 7

CNS Stimulants

INTRODUCTION

Central nervous system (CNS) stimulants are drugs that stimulate the CNS. They fall into the following three broad categories:

1. Convulsants and respiratory stimulants.
2. Psychomotor stimulants.
3. Psychomimetic drugs or hallucinogenic drugs.

Convulsants or respiratory stimulants (analeptics): They have little effect on the mental function and appear to act mainly on the brain stem and spinal cord, producing reflex excitability, as increase in the activity of the respiratory and vasomotor centre and with higher doses it produce convulsions.

Psychomotor stimulants: They have a marked effect on mental function and behaviour, producing excitement, cessation of fatigue, and increase in motor activity.

Examples: (amphetamine, caffeine, and cocaine)

Psychomimetic drugs: They mainly affect through pattern, perception, and mood producing effects that superficially resemble the changes seen in schizophrenia.

Analeptics: Analeptics (Greek-restorative) also called respiratory stimulants are general CNS stimulants. Analeptics are drugs that when administered stimulate all the parts of CNS, especially the brain medulla, thereby counteracting the depressant activity due to the administration of excess CNS depressants. Some of the CNS stimulants are mainly used as analeptics. Analeptics is a Greek word that can be translated as having the meaning 'picking up' those who have been cast down. Analeptics stimulate the CNS system and in large doses, they cause generalized convulsions.

Classification

1.Those drugs acting directly on the CNS:

Cortical stimulants: Xanthine alkaloids, amphetamine, methyl amphetamine, methyl phenidate, and pipradol.

Medullary stimulants: Picrotoxin, nikethamide, amiphenazole, camphor, and carbon dioxide.






Spinal stimulants: Strychnine

2. Those that stimulate the CNS reflexly:

Lobeline, ammonia, veratrum, and nicotine.


According to the mode of action, analeptics may be divided into four groups. They are as follows:

- A. Respiratory stimulants
- B. Psychomotor stimulants
- C. Convulsant stimulants
- D. Psychomimetic drugs (hallucinogenic drugs)

A. Respiratory stimulants**a. Doxapram HCl****b. Nikethamide****c. Ethamivan****d. Bemigride****e. Almitrine dimesylate**


B. Psychomotor stimulants or central stimulants (sympathomimetics)

a. β -Phenylethylamine derivatives (Amphetamine and related drugs)




Name	R	R ₁	R ₂	R ₃	R ₄
Amphetamine(±)	-H	-H	-H	-H	-H
Dextroamphetamine(+)	-H	-H	-H	-H	-H
Methamphetamine(+)	-CH ₃	-H	-H	-H	-H
Phenetermine	-H	-H	-CH ₃	-H	-H
Benzphetamine	-CH ₃	-CH ₂ C ₆ H ₅	-H	-H	-H
Chloropheneteramine	-H	-H	-CH ₃	-H	4-Cl
Phenyl propanolamine	-H	-H	-H	-OH	-H
Fenfluramine	-H	-C ₂ H ₅	-H	-H	m-CF ₃
Cloretermine	-H	-H	-CH ₃	-H	O-Cl

b. Oxazolidinone derivatives




Name	R	R ¹
Pemoline	-H	-H
Tozalinone	-CH ₃	-CH ₃
Fenozolone	-H	-C ₂ H ₅

c. Morpholinones




Name	R
Phenmetrazine	-H
Phendimetrazine	-CH ₃

d. Methylxanthines











Name	R	R ¹
Caffeine	-CH ₃	-CH ₃
Theophylline	-CH ₃	-H
Theobromine	-H	-CH ₃
Etophylline	-CH ₃	-CH ₂ CH ₂ OH
Proxyphylline	-CH ₃	$\text{---H}_2\text{C}-\underset{\text{OH}}{\overset{\text{H}}{\text{C}}}-\text{CH}_3$
Pentoxiphylline	-C ₄ H ₈ -CO-CH ₃	-CH ₃

e. Aminophylline




f. Dyphylline



C. Convulsants and stimulants**a. Pentylene tetrazole****b. Picrotoxin****c. Strychnine****d. Bisuculline****e. Fluroethyl****D. Psychomimetic drugs (hallucinogenic drugs)****a. (+) Lysergic acid diethylamide****b. Indole derivatives**

Name	R
Psilocyn	—H
Psilocybin	—PO(OH) ₂

c. Phenylethylamine derivatives



Name


R

Mescaline

-H


3,4,5-Trimethoxy amphetamine
(TMA)-CH₃

d. Cannabis



e. Dissociate Agents


Phencyclidine HCl



SYNTHESIS AND DRUG PROFILE

I. Respiratory stimulants

a. Doxapram (Carbopram)




1-Ethyl-4-(2-morpholinoethyl)-3, 3-diphenylpyrrolidin-2-one hydrochloride

Properties and uses: It exists as white or almost white crystalline powder, soluble in water, in alcohol, and in methylene chloride. It is a respiratory stimulant possessing slight vasopressor characteristics. It stimulates the peripheral carotid chemoreceptor.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and alcohol. Perform potentiometric titration using 0.1 M sodium hydroxide


Synthesis



Dose: Usual dose for postanaesthetic: IV 0.5–1.0 mg/kg.


Dosage forms: Doxapram injection B.P.

b. Nikethamide (Coramine)




Properties and uses: It is an oily liquid or a crystalline mass, colourless, or slightly yellowish, miscible with water and with alcohol. It is a weak analeptic employed as respiratory stimulant.

Assay: Dissolve the sample in a mixture of acetic anhydride and anhydrous acetic acid. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.


Synthesis

Dose: 1 to 15 ml of 25% parenteral solution.

Dosage forms: Nikethamide injection B.P.

c. Bemigride


4-Ethyl-4-methylpiperidine-2,6-dione

Synthesis


Uses: This agent is used in the treatment of barbiturate intoxication. It causes a rapid stimulation of the CNS.

II. Psychomotor Stimulants

a. Amphetamine



Synthesis




Mode of action: Amphetamine increases synaptic dopamine and noradrenaline primarily by stimulating presynaptic release rather than by blockade of the reuptake as in the case of cocaine.

Uses: It is an anorectic and has been used in the weight control of obese individuals. It has potential for abuse and cardiovascular effects.

Dose: For narcolepsy, 10 mg/day, for obesity, 5–10 mg/day, 30–60 min before meals.


b. Fenfluramine (Pondialon)



Properties and uses: It is a white amorphous powder, sparingly soluble in water, used as respiratory stimulant.


Assay: Dissolve the sample in chloroform and acetone. Add mercuric acetate solution and titrate with 0.1 N perchloric acid.

Synthesis




Dose: By oral route for adults: 20 mg thrice a day, 30 min to 1 h before each meal.

c. Phentermine




Synthesis



Use: It is used as an appetite suppressant.


Dose: The usual dose is 15–30 mg at breakfast.

d. Methylphenidate HCl (Ritalin)



Methyl 2-phenyl-2-(piperidin-2-yl)acetate hydrochloride

Synthesis




Mode of action: It is similar to amphetamine, but superior in its pharmacological action. It increases the release of dopamine and noradrenaline, and it is useful in hyperkinetic children.

Properties and uses: It is a white fine crystalline powder, soluble in water, and sparingly soluble in chloroform and acetone. It is used as a potent CNS stimulant.


Dose: The usual dose by oral or parenteral is 10–60 mg/day.

e. Pemoline



2-Amino-5-phenyloxazol-4(5*H*)-one

Synthesis




Properties and uses: It is a white crystalline powder, slightly soluble in alcohol. It is used in the treatment of narcolepsy fatigue, mental depression, chronic schizophrenia, and as a mild stimulant in geriatric patients.

Xanthine Derivatives

The naturally occurring xanthine derivatives are caffeine, theophylline, and theobromine. These agents generally cause mild CNS stimulation, and relax smooth muscles, so it is used in the treatment of asthma. All xanthine derivatives produce diuresis by increasing glomerular filtration and blocking tubular reabsorption of sodium ions. It stimulates the medullary centre and overcomes fatigue.

Mode of action: These agents have mild stimulant action and increase the epinephrine secretion and enhance the neural activity in several areas of the brain. These agents act by producing antagonism of adenosine receptor. Adenosine is a neuromodulator, which influences numerous functions in the CNS and the blocking is responsible for stimulation.

a. Caffeine




1,3,7-Trimethyl-1*H*-purine-2,6(3*H*,7*H*)-dione

Properties and uses: It exists as a white crystalline powder or silky white crystals, sublimes readily, sparingly soluble in water, freely soluble in boiling water, and slightly soluble in ethanol. It dissolves in the concentrated solutions of alkali benzoates or salicylates. Caffeine acts on the higher centres of the CNS and produces a condition of wakefulness. It stimulates the respiratory centre, increases rate and depth of respiration. The diuretic action of caffeine is weaker than theophylline. Caffeine is used along with ergotamine in the treatment of migraine.


Assay: Dissolve the sample by heating in anhydrous acetic acid. Allow to cool, add acetic anhydride, and 20 ml of toluene. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Synthesis



Route I. From: Dimethylurea and cyanoacetic acid



Route II. From: Uric acid



Dosage forms: Aspirin and caffeine tablets B.P., Caffeine citrate injection B.P., Caffeine citrate oral solution B.P.

b. Theophylline and Theobromine (Theobid, Theopa, Broncordil)

Synthesis: They can be synthesized by adopting the above route described for caffeine with the suitable reagents.

i. Theophylline hydrate

Properties and uses: It exists as white, crystalline powder, slightly soluble in water, sparingly soluble in ethanol. It dissolves in solutions of alkali hydroxides, in ammonia, and in mineral acids. Used as nonselective phosphodiesterase inhibitor (xanthine) and in the treatment of reversible airways obstruction.

Assay: Dissolve the sample in water, add 0.1 M silver nitrate, and shake. Add bromothymol blue solution as indicator and titrate with 0.1 M sodium hydroxide.


Dose: For acute bronchospasm: Adult: As conventional tablet: 5 mg/kg every 6–8 h. Child: As conventional tablet: 5 mg/kg every 4–6 h. For chronic bronchospasm: Adult: As conventional dosage form: 300–1000 mg in divided doses, every 6–8 h daily. As modified-release preparations: 175–500 mg every 12 h.

Dosage forms: Aminophylline injection B.P., prolonged-release theophylline tablets B.P.

ii. Theobromine

Properties and use: It is a white powder, very slightly soluble in water and in ethanol, slightly soluble in ammonia. It dissolves in dilute solutions of alkali hydroxides and in mineral acids. Theobromine is used as diuretic and used in the treatment of angina pectoris and hypertension. It is a nonselective phosphodiesterase inhibitor (xanthine) and used in the treatment of reversible airways obstruction.

Assay: Dissolve the sample in boiling water, cool to 50°C–60°C and add 0.1 M silver nitrate and titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator, until a pink colour is obtained.

c. Aminophylline (Aminophylline, Minophyl)

Properties and uses: A white or slightly yellowish powder, sometimes granular, freely soluble in water (the solution becomes cloudy through absorption of carbon dioxide), practically insoluble in ethanol. It is used in the treatment of bronchial asthma, acts as a nonselective phosphodiesterase inhibitor and in the treatment of reversible airways obstruction.

Assay for Ethylenediamine

Dissolve the sample in water, to this add bromocresol green solution as indicator. Titrate with 0.1 M hydrochloric acid until a green colour is obtained.


Assay for Theophylline

Heat the weighed quantity of the sample to constant mass in an oven at 135°C. Dissolve the residue by heating in water; allow to cool, adding 0.1 M silver nitrate and shake. Add bromothymol blue solution as indicator and titrate with 0.1 M sodium hydroxide.

Dose: The usual dose is oral 300–600 mg/day.


Dosage forms: Aminophylline injection B.P.

d. Pentoxifylline (Flexital, Pentovas, Trental)



3,7-Dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione

Synthesis




Uses: It is used in the relief of bronchospasm in asthma.


Dose: The usual dose is 400 mg, thrice daily with meals.

III. Convulsant stimulants

a. Pentylene Tetrazole



5,6,7,8,9a-Hexahydro-1H-tetrazolo [1,5-a]azepine

Synthesis

Mode of action: It is a powerful CNS stimulant, believed to be acting by direct depolarization of the central neurons. However, it has also inhibited action on GABA channel openings. Low doses cause excitation, high doses cause convulsion.

Uses: It is used to induce convulsion in animals to locate epileptic foci in conjugation with the electroencephalograph.

b. Strychnine

Mode of action: It stimulates the entire cerebrospinal neuroaxis and produces convulsion. It produces reflex tonic-clonic and symmetrical convulsions. Strychnine acts by blocking postsynaptic inhibition produced by inhibitory transmitter glycine. One of the site is Renshaw cell-motor neurojunction in the spinal cord through which inhibition of antagonistic muscle is achieved. Due to the synaptic inhibition, all the nerve impulses become generalized resulting in apparent excitation and convulsions.

c. Picrotoxin


Mode of action: It is a potent convulsant, produces clonic spontaneous and asymmetrical convulsions. The convulsions are accompanied by vomiting, respiratory and vasomotor stimulation. It acts by blocking pre-synaptic inhibition mediated by GABA. However, it is not a competitive antagonist, it acts on the distinct site of GABA receptors and prevents the chloride channel opening. Thus, produces depolarization of neurons and excite the central nervous system.

IV. Psychomimetic drugs

These are characterized by the fact that they affect thought perception and mood, without causing marked psychomotor stimulation or depression.


These drugs fall broadly into two groups.

- **Those with a chemical resemblance to known neurotransmitter catecholamine:** These include LSD and psilocybin, which are related to 5-HT and mescaline that is similar in structure to amphetamine.
- **Drugs unrelated to monoamine neurotransmitter:** Cannabis and phencyclidine.

a. Lysergic acid diethylamide (LSD)

The chemical precursor lysergic acid occurs naturally in ergot, a microbial growth formed from the fungus *Claviceps purpurea*, which develops on various plants of the gramine, for example, rye LSD is a chiral molecule and the physiologically active isomer is (+). The 9, 10 double bond is essential for activity. LSD is a potent psychomimetic drug.

b. Psilocybin




Psilocyn R = H

Psilocybin R = $-\text{PO}(\text{OH})_2$

It occurs in a mushroom, *Psilocybe maxicana*. It is converted to psilocin in vivo, both have activity similar to LSD, but are much less potent.

c. Cannabis



Δ^1 -Tetrahydro cannabinol (THC/ (or) Δ^9 -THC

The dried flowering tops of the pistillate plants of *cannabis sativa* (moraceae) contain THC. The drug is used as a depressant with stimulant sensation. The phenolic OH is required for activity. It produces giddiness and increased hunger. Several other medicinal effects of marijuana include antinausea effect (for anticancer therapy), anticonvulsant, muscle-relaxing, and treatment of glaucoma.

PROBABLE QUESTIONS

1. Name any five potent CNS stimulants. Write their structures, chemical name, and uses.
2. Classify the CNS-stimulants and write the synthesis of one potent compound from each category.
3. Write note on respiratory stimulants
4. Write the structure of Propoxyphylline and Aminophylline. Explain why the former has better tolerance orally and intravenously than the latter.
5. Xanthines represent an important class of CNS stimulants. Write the structure, chemical name, and uses of any three potent drugs from this category and discuss the synthesis of any one of them.

6. Write the synthesis of the following drugs:
 - (a) Doxapram
 - (b) Nikethamide
7. Describe the synthesis of the following CNS-stimulants:
 - (i) Phentermine
 - (ii) Bemegride
 - (iii) Methylphenidate hydrochloride.
8. Describe a comprehensive account on the various CNS-stimulants used.
9. Write a note on naturally obtained CNS-stimulants.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
4. Fabing HD. 'The newer analeptic drugs'. *Med Clin North Am* 41(2): 339–551, 1957.
5. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
6. Griffiths MC (ed). *USAN and the USP Dictionary of Drug Names*. Rockville: United States Pharmacopeial Convention Inc, 1985.
7. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
8. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
9. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
10. Patrick GL. *An Introduction to Medicinal Chemistry*. Oxford, UK: Oxford University Press, 2001.
11. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: Pharmaceutical Press, 1997.

Chapter 8

Narcotic Analgesics

INTRODUCTION

Analgesics are agents that relieve pain by acting centrally to elevate pain threshold without disturbing consciousness or altering other sensory modalities. Certain analgesics like aminopyrine and phenylbutazone also possess anti-inflammatory properties. Such substances and the gold compounds are used in the treatment of arthritis.

Many drugs that are used to relieve pain are not analgesics; the general anaesthetics relieve pain by producing unconsciousness, local anaesthetics prevent pain by blocking peripheral nerve fibres, antispasmodics relieve pain by relaxing smooth muscles and the adrenal corticoids relieve pain associated with rheumatoid arthritis by anti-inflammatory action.

Analgesics are classified into two major categories:

1. Opioid analgesics or narcotic analgesics (centrally acting).
2. Nonopioid analgesics (peripherally acting).

Opioid Analgesics

Opioid analgesics are drugs that denote all naturally occurring, semisynthetic and synthetic drugs, which have a morphine-like action, namely, relief from pain and depression of CNS associated with the drug dependence.

Opium is a dark brown resinous material obtained from the poppy (*Papaver somniferum*) capsule. It has two types of alkaloids; Phenanthrene derivatives and Benzoisoquinoline derivatives. Opium has been known from 1500 BC. Sretturner, a pharmacist isolated the active principle of opium in 1806 and named it morphine.

Narcotic analgesic agents cause sleep in conjunction with their analgesic effect. If a narcotic is used for a long time, it may become habit-forming (causing mental or psychological dependence) and physical dependence may lead to withdrawal side effects.

Opioid drugs are not only used as analgesics, but also possess numerous other useful properties. For example, morphine is used to induce sleep in the presence of pain, diarrhoea, suppress cough, and facilitate anaesthesia.

The term opioid is used generally to designate collectively the drugs, which bind specifically to any of the subspecies of the receptors of morphine and produce morphine like actions. They tend to produce euphoria, which is an important factor in their addictive property that limits their use.

Other limitations include, respiratory depression, decreased gastrointestinal motility leading to constipation, increased biliary tract pressure, and pruritis due to histamine release.

GENERAL MODE OF ACTION

Three classical opoid receptors μ , κ , and δ (mu, kappa, and delta) have been extensively studied. Recently, N/OFQ (nociceptin/orphan) receptor, a fourth class has been identified. In addition, many subtypes have been identified in different species.

All these opoid receptors μ , κ , and δ are G protein coupled receptors situated on prejunctional neurons. They exert inhibitory modulations by decreasing the release of junctional transmitter (i.e. noradrenaline, dopamine, 5HT), and glutamate. Opoid receptors activation reduce intracellular cAMP formation and open K^+ channels or suppress voltage gated N type Ca^{2+} channels. These results in hyper-polarization in synaptic junctions and decrease the neurotransmitter release.

1. Mu (μ) receptors are responsible for supra-spinal analgesia mediated by μ_1 and spinal mediated by μ_2 . Respiratory depression and gastric motility reduction is mediated by μ_2 subtypes. μ receptor produces euphoria, physical dependence, and miosis.
2. Kappa receptors appear to mediate spinal analgesia through κ_1 subtypes and supra-spinal analgesia through κ_2 subtype. It produces respiratory depression, dysphoria, hallucination, miosis, sedation, and nicotinic effects.
3. Activation of δ receptors produces spinal analgesia, respiratory depression, affective behaviour, reinforcing actions, and reduced GI motility.

The σ (sigma) receptors are least considered because it is neither activated by morphine nor blocked by naloxone. However, certain narcotic analgesic drugs like pentazocine, butorphanol binds and produces dysphoria, psychotomimetic actions, tachycardia, and hallucinogenic effect (Fig. 8.1).






Figure 8.1 Opioid binding to ion channel associated μ receptors inhibit the influx of calcium ions into the presynaptic terminal and increase the outflow of K^+ ions from the postsynaptic membrane. This has the effect of reducing the release of the neurotransmitter glutamate and hyperpolarizing the postsynaptic membrane. Synaptic transmission is inhibited.

THERAPEUTIC USES

- Management of acute, chronic, and severe pain of acute myocardial infarction, obstetric analgesia.
- Cough suppression (codeine and dextromethorphan).
- Treatment of diarrhoea (diphenoxylate and loperamide).
- Management of acute pulmonary oedema.
- Preoperative medication and intraoperative adjunctive agent in anaesthesia (fentanyl, alfentanyl, and sufentanyl).
- Maintenance programmes for addicts (methadone).


CLASSIFICATION**I. Morphine and its analogues**

S. No.	Name	R	R'	R''
1	Morphine	-H	-H	-CH ₃
2	Ethyl morphine	-C ₂ H ₅	-H	-CH ₃
3	Codeine	-CH ₃	-H	-CH ₃
4	Heroin	-COCH ₃	-COCH ₃	-CH ₃
5	Nalorphine	-H	-H	-CH ₂ -CH=CH ₂

a. Hydromorphone derivatives


S. No.	Name	R	R'	R''
1	Hydromorphone	-OH	-H	-CH ₃
2	Oxy morphine	-H	-OH	-CH ₃
3	Hydrocodone	-OCH ₃	-H	-CH ₃
4	Oxycodone	-OCH ₃	-OH	-CH ₃

b. Dihydromorphine derivatives



Name	R
Dihydromorphine	-H
Dihydrocodeine	CH ₃










II. Meperidine analogues




S. No.	Name	R ₁	R ₂	R ₃
1.	Meperidine	-CH ₃	-C ₆ H ₅	-COOC ₂ H ₅
2.	Bemidone	-CH ₃	-C ₆ H ₄ OH	-COOC ₂ H ₅
3.	Properidone	-CH ₃	-C ₆ H ₅	-COCH(CH ₃) ₂


(Continued)

(Continued)


S. No.	Name	R ₁	R ₂	R ₃
4.	Ketobemidone	-CH ₃	-C ₆ H ₄ OH	-COC ₂ H ₅
5.	Anileridine	-CH ₂ -CH ₂ - 	-C ₆ H ₅	-COC ₂ H ₅
6.	Fentanyl	-CH ₂ -CH ₂ - 	-H	
7.	Lofentanil	-CH ₂ -CH ₂ - 	-COOCH ₃	
8.	Sufentanil	-CH ₂ -CH ₂ - 	-CH ₂ OCH ₃	
9.	Alfentanil	-CH ₂ -CH ₂ - 	-CH ₂ OCH ₃	
10.	Diphenoxylate	-CH ₂ -CH ₂ -C(Ph) ₂ CN	-C ₆ H ₅	-COOC ₂ H ₅
11.	Lopramide	-CH ₂ -CH ₂ -C(Ph) ₂ C(=O)N(CH ₃) ₂	-C ₆ H ₄ Cl	-OH


III. Methadone analogues




S.No	Drug	R ₁	R ₂	R ₃	R ₄
1.	Methadone	-Ph	-Ph	-COC ₂ H ₅	$\begin{array}{c} \text{---CH}_2\text{---CH---N} \begin{array}{l} \diagup \text{CH}_3 \\ \diagdown \text{CH}_3 \end{array} \\ \\ \text{CH}_3 \end{array}$
2.	Isomethadone	-Ph	-Ph	-COC ₂ H ₅	$\begin{array}{c} \text{---CH---CH}_2\text{---N} \begin{array}{l} \diagup \text{CH}_3 \\ \diagdown \text{CH}_3 \end{array} \\ \\ \text{CH}_3 \end{array}$
3.	Normethadone	-Ph	-Ph	-COC ₂ H ₅	$\text{---CH}_2\text{---CH}_2\text{---N} \begin{array}{l} \diagup \text{CH}_3 \\ \diagdown \text{CH}_3 \end{array}$
4.	Alpha acetyl methadone	-Ph	-Ph	$\begin{array}{c} \text{---CH---C}_2\text{H}_5 \\ \\ \text{OCOCH}_3 \end{array}$	$\begin{array}{c} \text{---CH}_2\text{---CH---N} \begin{array}{l} \diagup \text{CH}_3 \\ \diagdown \text{CH}_3 \end{array} \\ \\ \text{CH}_3 \end{array}$
5.	Dipanone	-Ph	-Ph	-COC ₂ H ₅	$\begin{array}{c} \text{---H}_2\text{C} \\ \diagdown \\ \text{H}_3\text{C} \end{array} \text{---N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{Cyclohexyl}$
6.	Dextromoramide	-Ph	-Ph	-CO---N 	$\begin{array}{c} \text{---CH---CH}_2\text{---N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{Morpholine} \\ \\ \text{CH}_3 \end{array}$
7.	Phenadoxone	-Ph	-Ph	-COC ₂ H ₅	$\begin{array}{c} \text{---H}_2\text{C} \\ \diagdown \\ \text{H}_3\text{C} \end{array} \text{---N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{Morpholine}$
8.	Propoxyphen	-Ph	-CH ₂ -C ₆ H ₅	-COC ₂ H ₅	$\begin{array}{c} \text{---CH---CH}_2\text{---N} \begin{array}{l} \diagup \text{CH}_3 \\ \diagdown \text{CH}_3 \end{array} \\ \\ \text{CH}_3 \end{array}$



IV. Morphinan analogues



Name	R	R'	R''
(i) Levorphanol tartarate	-H	-H	-CH ₃
(ii) Butorphanol tartarate	-H	-OH	-H ₂ C- 
(iii) Dextromethorphan	-CH ₃	-H	-CH ₃


V. Morphan analogues or benzazocin derivatives




S.no	Name	R	R ₁
1	Pentazocine	-CH ₂ -CH=C(CH ₃) ₂	-CH ₃
2	Phenazocaine	-CH ₂ -CH ₂ -C ₆ H ₅	-CH ₃
3	Cyclazocine	-CH ₂ - 	-CH ₃
4	Ketazocine	-CH ₂ - 	= O
5	Metazocine	-CH ₃	-CH ₃

VI. Miscellaneous


a. Tramadol



b. Tilidine



c. Sufentanil




d. Nexeridine

SYNTHESIS AND DRUG PROFILE

I. Morphine analogues

a. Morphine (Duraphine)



Metabolism of morphine: Morphine is conjugated by hepatic enzyme at phenolic (3-OH) position to form 3-glucuronide metabolite. Glucuronidation of morphine also leads to *N*-demethylation to normorphine, which has decreased opioid activity and it undergoes *N* and *O* conjugation and excreted. Compounds with *N*-alkyl groups larger than methyl get *N*-dealkylated as a major route of inactivation.

Properties and uses: It exists as a white or almost white crystalline powder or colourless, silky needles or cubical masses, efflorescent in a dry atmosphere. Soluble in water, slightly soluble in ethanol, and insoluble in toluene. It is used as an opioid receptor agonist and analgesic.

The diagram illustrates the multi-step synthesis of Morphine. It begins with the condensation of 3,4-Dimethoxy-phenylacetic acid and m-methoxyphenylethylamine to form an intermediate. This is followed by Bischler-Napieralski synthesis using POCl₃ at 140°C. The resulting tricyclic intermediate is then treated with Na-Hg/Alcohol. Subsequent Birch reduction using Na⁺(CH₃)₃C-OH leads to another intermediate. This intermediate is then treated with (i) CH₃I and (ii) NaOH. The resulting structure is then resolved by (+)-tartaric acid and (-)-form taken, followed by treatment with (ii) Br₂-CH₃COOH to form 7-Bromo codeinone. Reduction of 7-Bromo codeinone with LiAlH₄/THF under reflux yields Codeine. Finally, demethylation of Codeine using C₅H₅N/HCl yields Morphine. The synthesis also includes a side reaction where the intermediate is treated with 10% HCl under reflux to form (±)-Dihydro thebainone, which then undergoes ring closure to form another intermediate.


Assay: Dissolve the sample in a mixture of 0.01M hydrochloric acid and ethanol. Perform potentiometric titration, using 0.1M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: The usual, adult, oral dose is 10 to 30 mg 6 times/day.

Dosage forms: Chloroform and Morphine tincture I.P., B.P., Morphine suppositories I.P., B.P., Morphine sulphate injection I.P.

b. Levorphanol (Levo-Dromoran)




Synthesis




Properties and uses: It exists as white, odourless, crystalline powder, soluble in water and alcohol, insoluble in chloroform and ether. It is a potent narcotic analgesic having actions and structure similar to that of morphine. It is used effectively for the management of both moderate and severe pain. The *d*-isomer shows antitussive property.

Dose: By oral for severe pain, 1.5 to 4.5 mg 1 or 2 times daily; by S.C, I.M., usual single dose is 2 to 4 mg.

c. Buprenorphine (Tidigescic, Norphin, Buprinor)



Synthesis




Properties and uses: It exists as a white or almost white crystalline powder. Insoluble in cyclohexane, sparingly soluble in water, freely soluble in methanol, and alcohol. Buprenorphine is a more complex molecule than morphine, which would interact with the opioid receptor (analgesic) and because of its complex structure it would not interact with other receptors that produce side effects, and used as potent analgesic.

Assay: Dissolve the substance in anhydrous acetic acid and add acetic anhydride to this. Titrate against 0.1 M perchloric acid and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight container and protected from light.

Dose: The usual dose is 0.3 mg I.M. every 6 h.

d. Etorphine



Synthesis



Properties and uses: It is a white or almost white microcrystalline powder, very slightly soluble in chloroform, insoluble in ether, sparingly soluble in water and in ethanol. Etorphine is thousand times more potent than morphine, which could be interpreted as having a better or a tighter fit to receptors. It is used primarily in veterinary medicine to immobilize large animals.

Preparations: Etorphine and Acepromazine injection B.P., Etorphine and Levomepromazine injection B.P.


Assay: Assayed by nonaqueous titration, to a solution of a sample, add mercury (II) acetate solution and titrate against 0.1M perchloric acid, using crystal violet solution as indicator.

Storage: It should be stored in well-closed airtight containers and protected from light.

SAR of Morphine

SAR of Morphine was studied by

1. Modification of alicyclic ring
2. Modification of aromatic ring
3. Modification of 3° Nitrogen



1. Modification on alicyclic ring

- The alcoholic hydroxyl group at C-6 when methylated, esterified, oxydized, removed, or replaced by halogen analgesic activity as well as toxicity of the compound increased.
- The reduction of C-6 keto group to C-6 β hydroxyl in oxymorphone gives Nalbupine, it shows antagonistic action of μ receptors.
- The saturation of the double bond at C-7 position gives more potent compound. Examples, Dihydro morphine and Dihydro codeine.
- The 14 β hydroxyl group generally enhances μ agonistic properties and decreases antitussive activity. However, activity varies with the overall substitution on the structure.
- Bridging of C-6 and C-14 through ethylene linkage gives potent derivatives.
- Reaction of thebaine with dienophile (i.e diel's alder reaction) results in 6, 14 endo etheno tetrahydro thebaine derivatives, which are commonly called 'oripavines'. Some oripavines are extremely potent μ agonist, for example, Etorphine and Buprenorphine are the best known. These derivatives are about thousand times more potent than morphine as μ agonist.

2. Modification on phenyl ring

- An aromatic phenyl ring is essential for activity.
- Modification on phenolic hydroxyl group decreases the activity.
- Any other substitution on phenyl ring diminishes activity.

3. Modification of 3° nitrogen



- A tertiary amine is usually necessary for good opioid activity.
- The size of the N substitution can dictate the compounds potency and its agonists and its reverse antagonistic property.

- The *N*-methyl substitution is having good agonistic property, when increased the size of the substitution by 3–5 carbons results in antagonistic activity. Still larger substituent on *N* returns agonistic property of opioids, for example, *N*-phenyl ethyl substitution is ten times more potent than *N*-methyl groups.
- *N*-allyl and *N*-cylo alkyl group leads to narcotic antagonistic property.

4. Epoxide Bridge

- Removal of 3,4 epoxide bridge in morphine structure result in the compound that is referred to as morphinans.
- The morphinans are prepared synthetically. As the synthetic procedure yielded compound is a racemic mixture, only levo isomer possesses opioid activity while the dextro isomer has useful antitussive activity, for example, Levorphanol and Butorphanol.
- Levorphanol is a more potent analgesic than morphine.


Summarized SAR of Morphine Analogues is given below:

Functional group	Modification	Observed Effects
Phenolic hydroxyl –OH	(i) –OH–H (ii) –OH to –COCH ₃ (iii) –OH to OCH ₃ (iv) OH to OC ₂ H ₅ (v) OH to 	Less analgesic effect Less analgesic effect Less analgesic effect Less analgesic effect Less analgesic effect
Alcoholic hydroxyl –OH	(i) OH to OCH ₃ (ii) OH to OC ₂ H ₅ (iii) OH to OCOCH ₃ (iv) OH to = O (v) OH to H	More active than morphine More active than morphine More active than morphine Less active than morphine More active than morphine
Alicyclic Unsaturated Linkage –CH = CH–	–CH = CH to –CH ₂ –CH ₂	More active than morphine
Tertiary nitrogen 	(i) N–CH ₃ to NH (ii) N–CH ₃ to N–CH ₂ –CH ₂ –Ph (iii) N–CH ₃ to <i>N</i> -allyl, propyl	Less active than morphine More active than morphine Morphine antagonist

I. Meperidine analogues

Metabolism: Meperidine (Pethidine) analogues results in rapid metabolism. Esterase cleaves the ester bond to leave the inactive 4-carboxylate derivatives. They also undergo *N*-demethylation to give normeperidine.


a. Pethidine hydrochloride (Meperidine HCl, Denerol, Mepadin)




4-Ethoxy carbonyl-1-methyl-4-phenyl piperidine

Synthesis

Route I. From: Benzyl chloride



Route II. From: Phenyl acetonitrile


Properties and uses: It is a white crystalline powder, soluble in water, and freely soluble in alcohol. It may be used for the relief of a variety of moderate to severe pain, including the pain of labour and postoperative pain. Pethidine has atropine-like action on smooth muscle. It is normally used to induce both sedation and analgesia simultaneously.

Assay: Dissolve the substance in alcohol and add 0.01 M hydrochloric acid. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: Usual dose is 50 to 100 mg I.M. Occasionally given orally.

Dosage forms: Pethidine HCl injection I.P. Pethidine HCl tablets I.P. Pethidine injection B.P., Pethidine tablets B.P.

Fentanyl Citrate (Durogesic)

Properties and uses: It is a white or almost white powder soluble in water, freely soluble in methanol, and sparingly soluble in alcohol. Fentanyl is related to pethidine and also to basic anilides with analgesic properties, and is characterized by high potency, rapid onset, and short duration of action. It is a potent narcotic

Synthesis



analgesic employed for the arrest of pain and it may also be employed as an adjuvant for all such drugs mostly used for regional and general anaesthesia.


Assay: Dissolve the substance in a mixture of 1 volume of anhydrous acetic acid and 7 volumes of methyl ethyl ketone. Titrate with 0.1 M perchloric acid using naphtholbenzein solution as indicator.

Storage: It should be stored in well-closed airtight container and protected from light.

Dose: By I.M. in preoperative medication 0.05 to 0.1 mg, 30 to 60 min before surgical treatment, for rapid analgesic action, 0.05 to 0.1 mg by IV.

Dosage forms: Fentanyl injection B.P.

c. Diphenoxylate hydrochloride




1-(3-Cyano-3,3-diphenyl propyl)-4-phenyl-4-piperidin ethyl carboxylate


Properties and uses: It is a white or almost white crystalline powder, sparingly soluble in alcohol, very slightly soluble in water, freely soluble in methylene chloride. It is a synthetic analogue of pethidine with some analgesic activity, but is mostly used in the treatment of diarrhoea associated with gastroenteritis, irritable bowel, acute infections, hypermotility, ulcerative colitis, and sometimes even in food poisoning.

Assay: Dissolve the sample in alcohol and add 0.01M hydrochloric acid. Perform potentiometric titration, using 0.1 M ethanolic sodium hydroxide.


Storage: It should be stored in well-closed airtight containers and protected from light.

Synthesis**Route I. From: Ethyl-4-phenyl piperidine-4-carboxylate**

Route II. From: Diphenylacetonitrile



d. Anileridine




1-[2-(4-Amino phenyl) ethyl]-4-Phenyl-4-piperidin carboxylic acid ethyl ester

Properties and uses: It is a narcotic analgesic, having related chemical structure to that of pethidine. Anileridine is more active than merperidine and has the same uses and limitations.


Dose: The usual oral dose is 25 mg every 6 h.

Synthesis


Route I. From: 4-Phenyl piperidin-4-ethyl carboxylate




Route II. From: Benzyl cyanide or 2-Phenylacetone nitrile



e. Ketobemidone




Synthesis



Properties and uses: It is a white or almost white crystalline powder, soluble in alcohol, slightly soluble in methylene chloride, and freely soluble in water. Used as an opioid receptor agonist and analgesic.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and 50 ml of alcohol. Perform potentiometric titration using 0.1M sodium hydroxide.

f. Loperamide



4-((4-Chlorophenyl) hydroxy-1-((3-*N,N*-dimethylamino carbonyl)1,1-diphenyl) propyl) piperidine


Properties and uses: It is a white or almost white powder, slightly soluble in water, freely soluble in alcohol and methanol. It is used as a safe and effective opioid derivative with peripheral μ opioid and weak anticholinergic property.

Assay: Dissolve the sample in alcohol and add 0.01 M hydrochloric acid, perform potentiometric titration, using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Loperamide capsules B.P.


g. Alphaprodine




1,3-dimethyl-4-phenyl-4-(piperidine) propanoate

Uses: It is an effective analgesic similar to meperidine.


h. Lofentanil



Synthesis




SAR of Meperidine Analogues



- Placement of *m*-hydroxyl group on the phenyl ring increases activity. The effect is more significant on the keto compound than on the pyridine.
- Substitution of carbethoxy group in meperidine by acyloxy group provides better analgesic as well as spasmolytic activity (alpha prodine).
- The presence of phenyl and ester group at 4th position of 1-methylpiperidine results in optimum activity.
- The replacement of C-4 phenyl group of meperidine by hydrogen, alkyl, other aryl, aralkyl, and hetero cyclic groups reduces analgesic activity.
- Replacement of phenyl group by phenyl ethyl derivatives is seen to be about three times as active as the meperidine. The amino analogue, anileridine is about four, times more active.
- Contraction of piperidine ring to the pyrrolidine gives a more active compound, but causes abuse liability. For example, alphaprodine and procilidine.
- Enlargement of piperidine ring to a 7-membered hexa hydroazepine yield active compounds with low incidence of side effects. For example, Proheptazine.
- The C-3 methyl analogue with an ester group at the C-4 position like lofentanil 8,400 times more potent than meperidine as an analgesic.
- In fentanyl, the phenyl and acyl groups are separated by nitrogen. It is 50 times stronger than morphine with minimal side effects. Its short duration of action makes it well suited for use in anaesthesia.
- The *p*-chloro analogue (loperamide) has been shown to bind to opiate receptors in the brain, but it cannot penetrate the blood-brain barrier sufficiently to produce analgesia.
- Diphenoxylate, a structural hybrid of meperidine and methadone type, devoid of analgesic activities. It is effective as an intestinal spasmolytic and is used in the treatment of diarrhoea.


III. Methadone analogues

a. Methadone



6-Dimethylamino-4,4-diphenylheptan-3-one

Synthesis



Metabolism: Methadone metabolizes to form an active α -dinormethadol and dinor-L- α -acetylmethadol (LAAM), then it undergoes *N*-demethylation to form inactive pyrrolidines and pyrrolines which are excreted in urine.


Properties and uses: It is a white or almost white crystalline powder, freely soluble in ethanol and soluble in water. Even methadone, which looks structurally different from other opioid agonists, has steric forces that produce a configuration that closely resembles the opioid agonists. Methadone is more active and more toxic than morphine. It can be used for the relief of many types of pain. In addition, it is used as narcotic substitute treatment because it prevents morphine abstinence syndrome. The toxicity of methadone is three to ten times that of morphine, but its analgesic effect is twice that of morphine and ten times that of meperidine.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and anhydrous ethanol by using 0.1 M sodium hydroxide to perform potentiometric titration.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dosage forms: Methadone HCl injection I.P., Methadone HCl tablets I.P., Methadone injection B.P., Methadone Linctus B.P., Methadone oral solution (1 mg/ml), B.P., Methadone tablets B.P.

b. Dextromoramide



3-Methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl)butan-1-one

Synthesis




Properties and uses: It is a white amorphous or crystalline powder, soluble in water and sparingly soluble in alcohol. Used as an opioid receptor agonist, and thus, acts as an analgesic.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.05 M perchloric acid using naphthol-benzene solution as indicator.


Dosage forms: Dextromoramide tablets B.P.

c. Dextropropoxyphene (Propoxyphene hydrochloride, Neurovon, Proxytab, Spasma Neurovon)



4-(Dimethyl amino)-3-methyl-1, 2-diphenyl-2-butanolpropionate ester hydrochloride

Synthesis



Properties and uses: It is a white or almost white crystalline powder, very soluble in water and freely soluble in alcohol. It has no anti-inflammatory or antipyretic action and has little antitussive activity despite the fact that its levo isomer is used for this purpose. It is used to control mild-to-moderate pain and used along with other analgesics having anti-inflammatory and antipyretic properties, such as paracetamol and aspirin.

Assay: Dissolve the sample in acetic anhydride and titrate with 0.1M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 65 mg, 3 or 4 times/day.


Dosage forms: Co-proxamol tablets B.P.

SAR of Diphenyl Heptanone (Methadone Series)

- The reduction of keto and acetylation of resulting hydroxyl group gives the acetyl methadol, the useful anti-diarrhoeal opioids, for example, diphenoxylate and loperamide.
- Removal of any of the phenyl group sharply decreases the activity.
- Placement of *m*-hydroxy group in the phenyl ring decreases analgesic activity.
- The levo-isomer of methadone and isomethadone are twice as effective as their racemic mixture.
- Substitution of terminal dimethylamino group by piperidine group decreases activity.
- Substitution of propionyl group by hydrogen, hydroxyl or acetoxyl decreases the activity, whereas amide analogue, pyrrolidinoyl and terminal morpholino moiety enhance the activity by several times.

Morphan derivatives

a. Pentazocine (Fortstar, Fortwin, Zocin)



Properties and uses: It is a white or almost white powder sparingly soluble in water, soluble in ethanol, and sparingly soluble in methylene chloride. A synthetic analgesic agent, when administered orally in a 50 mg dose, it appears to be equivalent in analgesic effectiveness to 60 mg of codeine. Pentazocine in a parenteral dose of 30 mg or an oral dose of 50 mg is about as effective as 10 mg of morphine in most patients. There is some evidence that the analgesic action resides principally in the (–) isomer, and a dose of 25 mg is approximately equivalent to 10 mg of morphine sulphate.

Assay: Dissolve the sample in ethanol and add 0.01 M hydrochloric acid. Titrate against 0.1 M sodium hydroxide and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight containers and protected from light.




Dose: By parenteral, 20 to 60 mg (as lactate); usually 30 mg 6 to 8 times/day; daily dose must not exceed 360 mg.

Dosage forms: Pentazocaine injection I.P., Pentazocaine HCl tablets I.P., Pentazocine capsules B.P., Pentazocine tablets B.P.

Synthesis


Route I. From: 4-Methoxy phenyl acetyl chloride




Route II. From: 1-Bromo-3-methyl 2 butene**b. Cyclazocin****Synthesis**

Uses: It is a potent narcotic antagonist that has shown analgesic activity in humans at 1 mg doses.


c. Phenazocine




Synthesis



SAR of Benzomorphan Derivatives (Benzazocines)



- Pentazocine produces analgesia because of its agonistic action on kappa opioid receptors. Pentazocine is a weak antagonistic at μ receptors.
- The trimethyl compound ($R_1 = R_2 = \text{CH}_3$) is more active than dimethyl ($R_1 = \text{H}, R_2 = \text{CH}_3$) compound.
- Placement of *N*-phenylethyl results in more activity than *N*-methyl compound.
- Placement of methyl group in 9th position increases the activity. However -OH group decreases the activity.
- *N*-allyl (or) *N*-cyclopropyl methyl group confers antagonistic activity. For example, Levallorphanol, Naloxone, and Naltrexone.

Miscellaneous**a. Tramadol hydrochloride** (Domadol, Stemadol, Tramazac)


Properties and uses: It is a white crystalline powder, freely soluble in water and in methanol, very slightly soluble in acetone. The drug possesses opioid activity, but has other analgesic activity that is not reserved by naloxone. It is also used as noradrenaline reuptake inhibitor.

Assay: Dissolve the sample in a mixture of anhydrous acetic acid and add acetic anhydride. Titrate with 0.1 M perchloric acid, and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: I.M. or I.V. injection 50 to 100 mg; as suppository 100 mg.

Dosage forms: Tramadol capsules B.P.

b. Tilidine HCl (Valoron, Tilidine)


Properties and uses: It is a white or almost white crystalline powder, freely soluble in water, methylene chloride, and alcohol. It is a narcotic analgesic employed in the treatment of moderate to severe pain.

Assay: Dissolve the substance in a mixture of anhydrous acetic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 50 to 100 mg 4 times/day.

c. Sufentanil



Properties and uses: It is a white or almost white powder soluble in water and in alcohol, freely soluble in methanol. It is a structural analogue of fentanyl, used in anaesthesia and as a narcotic analgesic.

Assay: Dissolve the sample in a mixture of 1 volume of anhydrous acetic acid and 7 volumes of methyl ethyl ketone and titrate with 0.1M perchloric acid, using naphtholbenzein solution as indicator.

Storage: It should be stored in well-closed airtight containers and protected from light.



NARCOTIC ANTAGONISTS


The euphoria accompanying with use of heroin and other narcotics reinforces repeated drug-seeking behaviour as psychological dependence develops. Once tolerance develops, the opiate-dependent individual avoids painful withdrawal symptoms by continuously increasing the amounts of opiate consumed.

Narcotic antagonists: Prevents or abolishes excessive respiratory depression caused by the administration of morphine or related compounds. They act by competing for the same analgesic receptor sites. They are structurally related to morphine with the exception of the group attached to nitrogen.

CLASSIFICATION

- i. Pure antagonists (e.g. naloxone, naltrexone).
- ii. Partial agonists of nalorphine type (e.g. Nalorphine, levallorphan, and cyclazocine).
- iii. Partial agonists of morphine type (e.g. propiram, profadol).






Nalorphine precipitates withdrawal symptoms and produces behavioural disturbances in addition to the antagonism action. Naloxane is a pure antagonist with no morphine like effect. It blocks the euphoric effect of heroin when given before it.


Naltrexone became clinically available in 1985 as a new narcotic antagonist. Its action resembles those of naloxone, but naltrexone is well absorbed orally, and is long acting. Necessitating only a dose of 50–100 mg. therefore, it is useful in narcotic treatment programmes, where it is desired to maintain an individual on chronic therapy with a narcotic antagonist. In an individual taking naltrexone, subsequent injection of an opiate will produce little or no effect. Naltrexone appears to be particularly effective for the treatment of narcotic dependence in addicts who have more to gain by being drug free rather than drug-dependent. Naltrexone is at least 17 times more potent than nalorphine in morphine-dependent humans and twice as potent as naloxone in precipitating withdrawal symptoms.

a. Nalorphine (Nalline)



Synthesis


From: Morphine



Properties and uses: Nalorphine has a direct antagonistic effect against morphine, meperidine, methadone, and levorphanol. It has little antagonist effect towards barbiturate or general anaesthetic depression. However, it has strong analgesic properties, but it is not acceptable for such use owing to the high incidence of undesirable psychotic effects.


Dose: By I.V. 2 to 10 mg per dose; usually, 5 mg repeated twice at 3 min intervals, if required.

b. Naloxone (Narcotan, Nex)



Synthesis

From: Thebaine



Properties and uses: It is white or almost white hygroscopic crystalline powder, Soluble in water, soluble in ethanol, and insoluble in toluene. It is almost seven times more active than nalorphine in antagonizing the effects of morphine. It shows no withdrawal effects after long-term administration. It lacks not only the analgesic activity shown by other antagonists, but also all of the other agonist effects. At higher doses, Naloxone may be useful in the treatment of shock and spinal cord injury.


Assay: Dissolve the sample in ethanol and add 0.01 M hydrochloric acid. Perform potentiometric titration using 0.1 M ethanolic sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: Usual dose by parenterally 0.4 mg (1 ml)/day

Dosage forms: Naloxone injection B.P., Neonatal naloxone injection B.P.

c. **Naltrexone** (Naltima)



Synthesis




Properties and uses: It is a white or almost white powder, hygroscopic insoluble in methylene chloride, freely soluble in water, and slightly soluble in ethanol. Its opioid antagonist activity is reported to be two to nine times that of naloxone and 17 times that of nalorphine.

Assay: Dissolve the sample in ethanol, add 0.1 M hydrochloric acid. Perform potentiometric titration, using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: For opioid dependence: Adult: As hydrochloride: Initially, 25 mg; increase to 50 mg daily, if no withdrawal signs occur. Maintenance: 350 mg weekly given as 50 mg daily or divided in 3 doses (given for 3 days in a week) for improved compliance. As an adjunct in the management of alcohol dependence: Adult: As hydrochloride: 50 mg daily.


d. Levallorphan




Properties and uses: Levallorphan resembles nalorphine in its pharmacological action and is about five times more effective as a narcotic antagonist. It is useful in combination with analgesics, such as meperidine, alphaprodine, and levorphanol to prevent the respiratory depression usually associated with these drugs.

Synthesis

Route I. From: Morphinan



Route II. From: Cyclohexanone



PROBABLE QUESTIONS

1. What are the three important alkaloids isolated from *Papaver somniferum*? Write the structure, chemical name, and uses of morphine.
2. What are narcotic analgesics? Classify with suitable examples and explain the general mode of action.
3. Classify narcotic analgesics by giving at least two typical examples in each class with its structure, chemical name, and uses. Write any two drugs synthesis from different class.
4. Discuss the morphine analogues and give the synthesis of any one of them.
5. Write the structure, chemical name, and uses of any two important members of morphinan analogues. Outline the synthesis of one of them.
6. Based on the morphan nucleus, i.e. a bridged perhyrazocine, three drugs have been synthesized, namely, Metazocine, Cyclazocine, and Pentazocine. Write their structure, chemical name, and uses.
7. How will you synthesize Pentazocine?
8. The 4-phenylpiperidine analogue led to the synthesis of much simpler compounds having potent analgesic properties. Discuss the synthesis of any one compound stated below:
 - (a) Meperidine hydrochloride
 - (b) Fentanyl citrate
9. Write the names of any two important drugs based on phenylpropylamine analogues and describe the synthesis of one of them.
10. Write a brief note on Narcotic antagonists. Outline the synthesis of Nalorphine hydrochloride.
11. Write the SAR of Morphine and Meperidine derivatives
12. Write a note on methadone analogues.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New jersey: John Wiley, 2007.
2. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
4. Eddy NB and May EL. *Synthetic Analgesics (Part II) 6,7-Benzomorphans*. New York: Pergamon Press, 1966.
5. Griffiths MC. *USAN and the USP Dictionary of Drug Names*. Rockville : United States Pharmacopeial Convention Inc, 1985.
6. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincot Williams and Wilkins, 2006.
7. Hellerbach J, Schnider O, Besendor H, and Pellmount B. *Synthetic Analgetics. Part IIa, Morphinans*. New York: Pergamon Press, 1966.
8. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
9. Janssen PAJ. *Synthetic Analgesics. Part I Diphenyl-Propylamines*. New York: Pergamon Press, 1960.

10. Kosterlitz HW, Collier HO, and Vilareal JE. *Agonist and Antagonist Actions of Narcotic Analgesic Drugs*. Baltimore: University Park Press, 1973.
11. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
12. Lemke TL and Williams DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
13. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
14. Stevens G de. *Analgesics*. New York: Academic Press, 1965.

Chapter 9

Anticonvulsants

INTRODUCTION

Anticonvulsants are drugs that are used to arrest convulsions or seizures caused in epilepsy. The term epilepsy, based on the Greek word epilambian (meaning to seize), has been first mentioned by Hippocrates. Epilepsy is a disease that occurs due to central nervous system (CNS) disorder, which is characterized by seizures and convulsions or abnormal body movements with the loss of consciousness.

Approximately 1% of world's population has epilepsy, the second most common neurological disorder after stroke. Up to 1990, approximately 16 antiseizure drugs were available and 13 of them can be classified into five similar chemical groups, that is, barbiturates, hydantoins, oxazolidinediones, succinamides, and acetyl ureas. These groups have a common and similar heterocyclic ring structure with a variety of substituents for the drugs with this basic structure; the substituents on this heterocyclic ring determine the pharmacological class, either antimaximal electro shock or antipentylene-tetrazole. The remaining drugs, carbamazepine, valproic acid, and benzodiazepines, are structurally dissimilar and the newer drugs used are felbamate, gabapentin, lamotrigine, oxcarbazepine, tigabatrane, topiramate, vigabatrin, and levetiracetam. The anticonvulsant therapy mediated by these drugs is through different aspects of neurotransmission inhibition in the brain:

- By inhibiting sodium channels (phenytoin).
- By inhibiting gamma amino butyric acid (GABA) transaminase enzyme (vigabatrin).
- By inhibition of T-type calcium currents (ethosuximide, valproate).
- By GABA agonistic activity (benzodiazepine).

Three principle types of epilepsy are found. They are as follows:

Grandmal: In which the seizures last from 2 to 5 min, being characterized by a sudden loss of consciousness, tonic and clonic convulsions of all muscles associated with urinary incontinence.

Petitmal: The seizures last from 5 to 30 sec, being characterized by brief attacks of unconsciousness, usually occur in children at the age of 4 to 8 years.

Psychomotor seizures: Characterized by attacks without convulsions and lasts from 2 to 3 min.


The ideal antiepileptic drug should completely suppress seizures in doses that do not cause sedation or other undesired CNS toxicity. It should be well tolerated and highly effective against various types of seizures and devoid of undesirable side effects on vital organs and functions.

CLASSIFICATION

- I. Barbiturates
- II. Hydantoins
- III. Oxazolidinedione derivatives
- IV. Succinimides
- V. Phenyl acetyl ureas
- VI. Benzodiazepines
- VII. Carbonic anhydrase inhibitors
- VIII. GABA analogues
- IX. Iminostilbenes
- X. Miscellaneous
- XI. Newer—anticonvulsants


I. Barbiturates

Most of the barbiturates are sedatives and hypnotics. Only a few of them show anticonvulsant characters. Three important barbiturates that show anticonvulsant properties are the following:



Name	R'	R ₅	R ₅ '
Phenobarbitone	–H	–Ph	–Et
Mephobarbiton	–CH ₃	–Ph	–Et
Metharbital	–CH ₃	–Et	–Et


II. Hydantoins



The hydantoins are close structural relatives of barbituric acid, differing due to the lack of C-6 oxo group. The lack of this carbonyl group decreases the acidity. So it is a weaker acid than that of barbiturates.

Name	R ³	R ⁵	R ₅ '
Phenytoin	-H	-C ₆ H ₅	-C ₆ H ₅
Phenyl ethyl hydantoin	-H	-C ₂ H ₅	-C ₆ H ₅
Mephenytoin	-CH ₃	-C ₂ H ₅	-C ₆ H ₅
Ethotoin	-C ₂ H ₅	-H	-C ₆ H ₅


III. Oxazolidinediones



Replacement of the -NH group at position 1 of the hydantoin systems with oxygen atom yields the oxazolidine-2,4-dione system, trimethadione is only clinically used.


Name	R ³	R ⁵	R ^{5'}
Trimethadione (or) Troxidone	-CH ₃	-CH ₃	-CH ₃
Paramethadione	-CH ₃	-CH ₃	-C ₂ H ₅
Malidione	-CH ₂ -CH=CH ₂	-CH ₃	-H
Dimidone	-C ₂ H ₅	-CH ₃	-CH ₃

IV. Succinimides




Name	R ¹	R ³	R ^{3'}
Phensuximide	-CH ₃	-H	-C ₆ H ₅
Methsuximide	-CH ₃	-CH ₃	-C ₆ H ₅
Ethosuximide	-H	-CH ₃	-C ₂ H ₅

V. Acetyl urea derivatives or phenyl acetyl ureas




Name	R ¹
Phenacemide	-H
Phenyl ethyl acetyl urea	-C ₂ H ₅

VI. Benzodiazepines




Nitrazepam




Clonazepam

VII. Carbonic anhydrase inhibitors







Acetazolamide

Ethoxazolamide




Sulthiame



VIII. Gamma amino butyric acid (GABA) analogues








IX. Iminostilbenes




X. Miscellaneous




XI. Newer anticonvulsants






Nafimidone



Ralitoline



Topiramate

Drugs used for treating epileptic disorders are listed in Table 9.1

Table 9.1 Drugs used for treating epileptic disorders.

Disorder	Primary Drugs	Adjunctive Drugs
Partial seizures: Simple, complex, partial with secondarily generalized.	Carbamazepine, Phenytoin, Phenobarbital, Primidone, Valproate,	Lomotrigine, Gabapentin, Tiagabin, Topiramide,
Generalized seizures: Absence seizures	Ethosuximide, Valproate, Clonazepam	Lamotrigine
Myoclonic seizures	Valproate, Clonazepam	
Atonic seizures	Valproate	Lamotrigine
Tonic-clonic seizures (Not preceded by partial seizures)	Carbamazepine, Phenytoin, Gabapentin, Phenobarbital, Primidone, Valproate.	Gabapentin, Lamotrigine
Status Epileptics	Diazepam, Lorazepam, Followed by Phenytoin, Fosphenytoin	

Pharmacological Classification

Anticonvulsant drugs can be classified as follows:

- Centrally acting: General anaesthetics, paraldehyde, barbiturates, and diazepam.
- Acting mainly on the spinal cord: Mephenesin.
- Peripheral skeletal muscle relaxants: *d*-Tubocurarine and succinyl choline.

SYNTHESIS AND DRUG PROFILE


I. Barbiturates

Mode of action: The mechanism is facilitated by GABA receptor mediated synaptic inhibition, opens the chloride channels, and inhibits the calcium dependent release of neurotransmitters. In addition, at very

high concentrations, barbiturates depress sodium and potassium channels and reduce the abnormal discharge of electrical impulse.

Metabolism of barbiturates is discussed in Section III, Chapter Sedatives and Hypnotics.

a. Phenobarbital (Gardenal, Phenetone, Phenorbarb)




5-Ethyl-5-phenyl barbituric acid

Dose: The usual dose is 1 to 5 mg/kg daily.

Synthesis and drug profile is discussed in section III, Chapter Sedatives and Hypnotics.


b. Mephobarbitone or Methyl phenobarbital



5-Ethyl-1-methyl-5-phenyl-barbituric acid


Synthesis and drug profile is discussed in section III, Chapter 'Sedatives and Hypnotics.

c. Primidone (Mysoline)



5-Ethyl-2-hydro-5-phenyl-4,6-pyrimidine dione

Synthesis




Properties and uses: It is a white or almost white crystalline powder. It dissolves in alkaline solutions, slightly soluble in water and ethanol. It is an active antiepileptic but is less potent and less toxic than Phenobarbital. The most frequent side effects include ataxia and vertigo; these tend to disappear with continued or reduced therapy. It is an effective agent for treatment of all types of epilepsy except absence seizures. It is used in combination with Phenytoin or Carbamazepine.

Assay: Dissolve the sample in ethanol, cool, and dilute with the same solvent. Prepare a reference solution in the same manner using 60.0 mg of primidone. Measure the absorbance of the 2 solutions at the absorption maximum of 257 nm. Calculate the content of primidone from the absorbances measured and the concentrations of the solutions.

Dose: The usual dose is 500 mg/day, gradually increasing to a maximum of 2 g daily.

Dosage forms: Primidone oral suspension B.P., Primidone tablets B.P.

SAR of Barbiturates




1. Optimum activity is observed when the substitution at C-5 is phenyl.
2. The 5, 5'-diphenyl derivative have less activity than phenobarbitone.
3. N¹ and N³ substituents in some cases resulted in an increase in activity.

II. Hydantoins


Mode of action: Hydantoins prevent repetitive depolarization of normal brain cells during depolarization shift. This is achieved by prolonging the inactivated state of voltage gate sensitive sodium channels and governs the refractory period of specific neurons, moreover, reduces the calcium influx and inhibits the glutamate activity. Intracellular storaction of Na⁺ leads to the prevention of repetitive firing.

a. Phenytoin (Dilantin, Epsolin, Eptoin)



5, 5-Diphenylimidazolidine-2, 4-dione

Synthesis



Metabolism: Phenytoin is metabolized by CYP2C9 into a primary metabolite 5-(hydroxyl phenyl)-5-phenyl hydantoin (HPPH).

Properties and uses: It is a white crystalline powder, slightly hygroscopic, insoluble in methylene chloride, soluble in water and alcohol. Phenytoin is the first anticonvulsant in which it was clearly demonstrated that anticonvulsant activity could definitely be separated from sedative-hypnotic activity. A common side effect is gingival hyperplasia, a reaction that seldom occurs with mephenytoin, and apparently, never with cardiac arrhythmias. It is one of the most widely used antiepileptic agents and it is effective in most forms of epilepsy, except absence of seizures. Some cases of trigeminal and neuralgias respond well to phenytoin. It is also used in the treatment of cardiac arrhythmias.


Assay: Suspend the sample in water, add 0.05 M sulphuric acid and heat gently for 1 min, to this add methanol and cool. Perform the potentiometric titration, using 0.1 M sodium hydroxide. After reaching the first point of inflexion, interrupt the addition of 0.1 M sodium hydroxide, add 5 ml of silver nitrate solution in pyridine, mix, and continue the titration. Read the volume of 0.1 M sodium hydroxide added between the two points of inflexion.

Storage: It should be stored in well-closed airtight containers.

Dose: The usual dose is 50 to 100 mg.


Dosage forms: Phenytoin capsules B.P., Phenytoin injection B.P., Phenytoin tablets B.P.

b. Methoin or mephentoin



5-Ethyl-3-methyl-5-phenylimidazolidine-2,4-dione


Synthesis



Metabolism: It is converted into *N*-demethyl metabolite 5-phenyl-5-ethyl hydantoin.

Properties and uses: It is one of the first hydantoin introduced into therapy. It was introduced as a sedative-hypnotic and anticonvulsant under the name Nirvanol, but it was withdrawn because of toxicity.


SAR of Hydantoins



- 5-phenyl or other aromatic substitution is essential for activity.
- Alkyl substituent at position 5 may contribute to sedation, a property absent in phenytoin.
- Among other hypnotics 1,3-disubstituted hydantoin, exhibit activity against chemically induced convulsion, while it remains ineffective against electric shock induced convulsion.

III. Oxazolidinediones


General method for synthesis of oxazolidine dione derivatives




a. Trimethadione (Tridione)

Synthesis

Route-I. From Ethyl-2-hydroxypropanoate



Route- II. From: Propane-2-one


Metabolism: It is metabolized by *N*-demethylation to putative active metabolite dimethadone and it is further excreted unchanged.

Properties and uses: It is a colourless or almost colourless crystals, soluble in water and alcohol. It is first drug introduced specifically for treating absence seizures. It is important as a prototype structure for antiabsence seizure compounds. It is used as an antipetitmal agent. It causes nephrosis, aplastic anaemia and bone marrow depression.


Assay: Assayed by adopting gas chromatography technique.

Storage: It should be stored in well-closed airtight containers.

Dose: The usual dose is 900 mg to 2.4 g per day; usually 300 to 600 mg 2 to 4 times daily.

b. Paramethadione (Paradione)


5-Ethyl-3,5-dimethyl oxazolidine-2,4-dione

Synthesis

Properties and uses: It is an oily liquid, slightly soluble in water and freely soluble in ethanol. It is used as an anticonvulsant.

Dose: The usual dose is 300 mg to 2.4 g daily.

SAR of Oxazolidinediones




- Replacement of the -NH group at position 1 of the hydantoin system with an oxygen atom yields the oxazolidine-2,4-dione system.
- 3,5,5-Trimethadione (tridione) was the first drug introduced specifically for treating absence seizures. It is also important as a prototype structure.
- The nature of the substituent on C-5 is important, example, lower alkyl substituents towards antipetital activity while acyl substituents towards antigrandmal activity.
- The *N*-alkyl substituent does not alter or afford the activity since all the clinically used agents from this class undergo *N*-dealkylation in metabolism.

IV. Succinimides

Mode of action: Succinimides selectively acts on the transient current in calcium channels for the influx of calcium ions and inhibits the amplification of spikes.

a. Ethosuximide (Zarontin)



3-Ethyl-3-methyl-2, 5-pyrrolidinedione


Metabolism: It is metabolized into 3-(1-hydroxyethyl) compound.

Properties and uses: It is a white or an almost white powder or waxy solid. Freely soluble in water, ethanol, and methylene chloride. It conforms very well to the general structural pattern for antiabsence activity. The drug is more active and less toxic than Trimethadione. It is a calcium-T channel blocking drug, effective in the cure of petitmal epilepsy.

Assay: Dissolve the sample in dimethylformamide and titrate with 0.1 M tetrabutylammonium hydroxide. Determine the end point by potentiometric titration.

Storage: It should be stored in well-closed airtight containers.


Synthesis



Dose: The usual dose is 500 mg/day, in divided doses.


Dosage forms: Ethosuximide syrup I.P., Ethosuximide capsules I.P., B.P., Ethosuximide oral solution B.P.

b. Methsuximide (Celontin)



1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione

Synthesis




Metabolism: It is metabolized into *N*-demethylsuximide and the metabolite is also an active compound.

Properties and uses: It is more active than phensuximide, and used in the treatment of petitmal epilepsy.


Dose: The usual dose is, 300 mg/day; maintenance 0.3 to 1.2 g daily.

c. Phensuximide (Milontin)



1-Methyl-3-phenyl-2,5-pyrrolidinedione

Synthesis




Metabolism: *N*-demethylation occurs to yield active metabolite, both phensuximide and *N*-demethyl metabolites are inactivated by para hydroxylation and conjugation.

Properties and uses: It is a crystalline solid, soluble in water and freely soluble in ethanol. It has low potency and is therefore relegated to secondary status. The phenyl substituent confers some activity against generalized tonic-clonic and partial seizures. It is used in the treatment of petitmal epilepsy.

Dose: The usual dose is 500 mg to 1 g 2 to 3 times/day.


SAR of Succinimides




- The activity of antiepileptic agents, such as the oxazolidine 2,4-dione with substituted succinamides (CH_2 replace O) was logical choice for synthesis and evaluation.
- *N*-demethylation occurs to yield the putative active metabolite. Both phensuximide and the *N*-demethyl metabolite are inactivated by *p*-hydroxylation and conjugation.

V. Phenyl acetyl urea derivatives

a. Phenacemide (Phenurone)




Synthesis



Uses: Used mainly in psychomotor epilepsy.

Dose: The usual dose is 0.5 g, orally, 3 times/day with meals.

SAR of Phenacemide



Name	R
Phenacemide	-H
Phenyl ethyl acetyl urea	-C ₂ H ₅

Various substituents that are tested on the phenyl acetyl urea and their SAR is discussed as given:


1. Among aliphatic acetyl ureas the highest anticonvulsant activity is found in those derived from the branched chain acids of about 7-carbon atoms.
2. With a further increase in molecular weight the anticonvulsant activity gradually terminates and hypnotic effect predominates.
3. Phenacemide is a most active agent among the aromatic acetyl urea.
4. Any substitution in nitrogen of phenacemide does not increase further the anticonvulsant activity.
5. The activity decreases with aromatic substituents of phenacemide with a gradual increase in hypnotic activity.

VI. Benzodiazepines

Mode of action: Benzodiazepines acts by enhancing pre and postsynaptic inhibition through benzodiazepine receptor, which is an integral part of GABA_A receptor Cl⁻ channel. It opens the Cl⁻ channel through GABA facilitatory action. These drugs also induce hyper-polarization and decrease firing rate of neurons.


Metabolism of Benzodiazepines is discussed in section III, Chapter Sedatives and Hypnotics.

a. Clobazam (Frisium, Lobazam, Cloba)



7-Chloro-1-methyl-5-phenyl-1,4-benzodiazepine-2,4-dione

Synthesis



Uses: It is used in the treatment of partial and generalized epilepsy.


Dose: The usual dose for adult is 20 to 30 mg daily.

VII. Carbonic anhydrase inhibitors - Discussed in Sec VI, Diuretics.

VIII. GABA analogues


Gamma-amino butyric acid (GABA) is an inhibitory neurotransmitter. It cannot cross the blood-brain barrier (BBB). This problem is overcome by enhancing the lipid solubility by the formation of Schiff's base of gabamide.

a. Progabide



4-[(4-Chlorophenyl) (5-fluoro-2-hydroxy phenyl)methylene]amino]butanamide


Synthesis



Mode of action: Progabide crosses the BBB readily and is bio-transformed into its active acid metabolite. It acts as agonists for GABA_A and GABA_B receptors.


Properties and uses: It is a nonhygroscopic, microcrystalline, yellow powder, sparingly soluble in water. Used in simple and complex partial seizures, generalized tonic-clonic seizures, and myoclonic seizures.

b. Vigabatrin



4-Amino-5-hexenoic acid (or) γ-Vinyl GABA


Synthesis



Mode of action: Vigabatrin readily crosses the BBB and raises brain GABA levels by virtual of GABA transaminase enzyme inhibitor. GABA-T is responsible for the metabolism of GABA.


Properties and uses: The S (+)-enantiomer potently inhibits GABA-transaminase compared to the R-enantiomer, which is almost inactive in this respect.

c. Tiagablin (Gabitril)



1-[4, 4-Bis (3-Methyl-2-thienyl)-3-butenyl]nipecotic acid

Synthesis




Mode of action: Tiagabin is a GABA reuptake inhibitor, which increases extracellular concentration of GABA, which in turn opens the chloride ion channels. These in turn inhibits neuronal activity by hyperpolarization and depolarization block.

Properties and uses: It exists as white crystalline powder, soluble in water and insoluble in hydrocarbons. It is proven to reduce partial seizures when given as adjunctive therapy. The most common adverse effects are dizziness, light headedness, asthma, and lack of energy.

Dose: The usual dose initially is 4 mg once daily.

d. Gabapentin (Gabantin, Gaba, Rejuron)



2-(1-(Aminomethyl)cyclohexyl) acetic acid

Mode of action: It is a lipid soluble GABA analogue. It does not bind with GABA_A receptor, causes no inhibition on GABA reuptake and is not a GABA_T (GABA amino transferase enzyme that metabolizes GABA to succinic semialdehyde) inhibitor, thus, the mechanism of action is unknown.


Properties and uses: It is a colourless, crystalline substance, soluble in water. It has been endorsed as an effective drug for the management of neuropathic pain.

Dose: For epilepsy (partial seizures with or without secondary generalization): Adult: Initially, 300 mg on the first day; 300 mg twice/day on the second day; and 300 mg thrice/day on the third day. Thereafter, the dose may increase until effective antiepileptic control is achieved. Usual maintenance range: 0.9–3.6 g daily, daily dose to be taken in three equally divided doses and maximum dosing interval of 12 h. Maximum: 4.8 g daily.

IX. Iminostilbenes


Mode of action: Similar to phenytoin, iminostilbenes limits the repetitive firing of action potential and appears to reduce the rate of recovery of voltage-gated sodium channel from inactivation.

a. Carbamazepine (Tegretol, Zen, Zepol)



Dibenzazepine-5-carboxamide

Synthesis



Metabolism: Metabolism proceeds largely through the epoxide form at the *cis*-stilbene double bond. The epoxide is further converted to 10s and 11s-*trans*-diol.

Properties and uses: It is a white or almost white crystalline powder and it shows polymorphism, slightly soluble in water, freely soluble in methylene chloride, but sparingly soluble in acetone and ethanol. Carbamazepine inhibits voltage-dependent sodium channels. Carbamazepine, a urea derivative, is a broad spectrum antiseizure agent, but is toxic, used to treat partial seizures and grandmal seizures. It is also useful in the treatment of pain associated with trigeminal neuralgia.


Assay: It is assayed by adopting liquid chromatography technique.

Storage: It should be stored in well-closed airtight containers.


Dosage forms: Carbamazepine tablets B.P.

X. Miscellaneous

a. Sodium Valproate (Epilex, Epival, Valparin)



Synthesis



Mode of action: Valproate produces reduction in calcium channel influx and it also prolongs the transient activation time of inactivated sodium channels. Another potential mechanism contributed is to involve in the metabolism of GABA, which is an inhibitory neurotransmitter, by stimulating the GABA synthetic enzyme glutamic acid decarboxylase and inhibits the GABA degradative enzyme GABA transaminase.

Metabolism of valproic acid: It is metabolized by a conjugation of carboxylic acid group and oxidation on one of the hydrocarbon chains.


Properties and uses: It is a white or almost white crystalline powder, hygroscopic, very soluble in water, slightly to freely soluble in alcohol. It has been reported that there is a strong correlation between the anticonvulsant potency of valproate and other branched-chain fatty acids and their ability to reduce the concentration of cerebral aspartate. It has been effective in partial, generalized, and absence seizures.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers.

Dosage forms: Sodium valproate oral solution I.P., B.P., Sodium valproate tablets I.P., B.P., Gastro-resistant sodium valproate tablets B.P.


SAR of Sodium Valproate



- The anticonvulsant activity increases with increased chain length.
- Introduction of a double bond decreases the activity.
- Introduction of a 2° or 3° alcohol group or replacement of carbonyl or hydroxyl have no effect.


XI. Newer anticonvulsants

a. Denzimol




N-[β-[4-(β-phenylethyl) phenyl]-β-hydroxyethyl]imidazole

Synthesis




Properties and uses: It is a racemic mixture, white, odourless, and crystalline powder, soluble in water and alcohol, used in complex partial seizures.

b. Denzinamide




Synthesis




Uses: Used in partial and petitmal seizures.

c. Fosphenytoin (Fosolin, Fosphen)



(2, 5-Dioxo-4, 4-diphenylimidazolidine-1-yl) methyl dihydrogen phosphate


Synthesis



Properties and uses: It is a pro-drug form of phenytoin, and is rapidly cleared by phosphatases in vivo to form phenytoin.


Dose: For tonic-clonic status epilepticus: Adult: As phenytoin Na equivalents (PSE): Loading dose: 15 mg/kg given, via IV infusion at a rate of 100–150 mg/min. Maintenance: Initially, 4–5 mg/kg/day by IM injection or IV infusion at a rate of 50–100 mg/min; subsequent doses depend on patient's response and plasma phenytoin levels.

d. Lamotrigine (Lamogine, Lamitor, Lamorig)



3, 5-Diamino-6-(2, 3-dichlorophenyl)-1, 2, 4-triazine

Synthesis




Metabolism: It is metabolized by *N*-glucuronidation and subsequent urinary elimination of its major metabolite quaternary 2-*N*-glucuronide and minor 5-amino-*N*-glucuronide.


Properties and uses: It is one of the most potent and long acting anticonvulsant, with potency similar to or greater than that of phenytoin. It may prove to be of therapeutic value in several CNS-degenerative disorders, such as brain ischaemia, stroke and senile dementia. No toxic side effects have been noted. It is used as an add-on therapy for the treatment of generalized seizures not satisfactorily controlled by other antiepileptics. It acts as sodium channel blocker used for the management of generalized tonic-clonic, petitmal, myoclonic seizures, and myoclonic jerks in children.

Dose: For monotherapy in epilepsy: Adult: Initially, 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 weeks; thereafter, increase the dose by a maximum of 50–100 mg every 1–2 week to usual maintenance dose of 100–200 mg daily, as a single dose or in two divided doses. Some patients may require up to 500 mg daily.

e. Nafimidone




Synthesis




Properties and uses: Its pharmacological effect includes protection against both tonic-clonic and partial seizures in rodents with an ED_{50} comparable to those of Phenytoin and Phenobarbital. Used in tonic-clonic and partial seizures.

f. Ralitoline




N-(2-Chloro-6-methyl phenyl)-(3-methyl-4-oxothiazolidine-2-ylidene) acetamide

Synthesis




Properties and uses: It is a sodium channel blocker used for the management of generalized seizures.

g. Topiramate (Epitop, Topamac, Topamate)



2,3:4,5-bis-*o*-(1-methyl ethylidene) -β-D-fructopyranose sulphamate


Synthesis



Properties and uses: It exists as white crystalline powder, includes efficacy against generalized seizures, absence, and myoclinic seizures.


Dose: The usual dose 40 mg/day in two divided dose.

h. Zonisamide



1, 2-Benzisoxazole-3-methane sulphonamide

Synthesis



Properties and uses: It exists as white needles, soluble in water, chloroform, hexane, methanol, ethanol, ethyl acetate and acetic acid. It also has weak carbonic anhydrase inhibiting activity, but this pharmacologic effect is not thought to be a major contributing factor in the antiseizure activity of zonisamide. Used as sodium channel blocker prevents tonic seizures.

PROBABLE QUESTIONS

1. Define and classify the drugs used for convulsive seizures. Write the structure, chemical name, and uses of one important compound from each class.
2. Write a note on the uses of barbiturates in convulsion therapy.
3. Explain Hydantoin as a potent anticonvulsant. Describe the synthesis and uses of Phenytoin.
4. Write a note on phenyl acetyl urea derived anticonvulsants.
5. Discuss paramethadione as a therapeutic agent used in petitmal epilepsy.
6. Name few newer anticonvulsants and describe the synthesis of any one of them.
7. Succinimides afford better tolerated and less toxic anticonvulsants. Justify the statement with the help of a detailed account of one of the potent compounds belonging to this category.
8. Name the anticonvulsant drug obtained by replacing 'O' at C-2 of Phenobarbital with 2H atom. Outline its synthesis and uses.
9. Describe an account of anticonvulsants having a dibenzodiazepine ring system with a carbamoyl moiety hooked on to the N-atom.
10. Describe the relative structural differences occurring amongst Phensuximide, Methsuximide, and Ethosuximide. Give their chemical names, uses, and advantages of one over the other.
11. Describe the mode of action of Hydantoin and Primidone in the body.
12. How do the mode of action of oxazolidinediones and succinimides differ from hydantoin?
13. Describe in detail about Benzodiazepines-derived anticonvulsants which possess a broad-spectrum activity.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
4. Casford NDP, Mc Donald IA, and Schweiger EJ. 'Recent progress in antiepileptic drug research'. *Ann Rep Med Chem* 33 : 61, 1998.
5. Gale K. 'GABA and epilepsy: Basic concepts from preclinical research'. *Epilepsia* 33 (Suppl) 5: 53–512, 1992.
6. Gennaro AR (ed). *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
7. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
8. Kupferberg HJ. 'Strategies for identifying and developing new anticonvulsant drugs'. *Pharm Weekblad (Sci Ed)* 14(34): 132–38, 1992.
9. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
10. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
11. Mercier J. 'Anticonvulsant drug'. In *Encyclopedia of Pharmacology and Therapeutics* (2 Volumes). Oxford: Pergamon Press, 1973.
12. Mac Donald RL and Mclean MJ. 'Anticonvulsant drugs: Mechanisms of action'. *Adv Neurol* 44: 713–35, 1986.
13. Nanavati SM and Silverman RB. 'Design of potential anticonvulsants'. *J Med Chem* 32(24):13–21, 1989.
14. Pandeya SN and Dimmrock JR. 'Recent evaluations of theosemicarbozones and semicarbozones and related compounds for antieoplastic and anticonvulsant activities'. *Pharmazie* 48: 659–66, 1993.
15. Peter RJ and Rogawski MA. 'From serendipity to rational discovery'. *Epilepsia New Antiepileptic Drugs* 33(Suppl)1: 51–56, 1992.
16. Reynolds EF. *Martindale: The Extra Pharmacopoeia* (31st edn). London: Royal Pharmaceutical Society, 1996.
17. Reynolds EF (ed). *Martindale: The Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
18. Tomah JEP and Goodman LS. 'Anticonvulsants'. *Pharma Rev* 28: 409, 1948.
19. Toman JEP and Taylor JD. 'Mechanism of action and metabolism of anticonvulsants'. *Epilepsia I*: 31–48, 1952.
20. Vajda FJE. 'New anticonvulsants'. *Neuropharmacology* 514: 519–25, 1992.
21. Vida JA. 'Anticonvulsants'. In *Medicinal Chemistry: A Series of Monographs* Vol. 15. New York: Academic Press, 1977.
22. Woodbury DM, Penry JK, and Schmidt RP. *Antiepileptic Drugs*. New York: Raven Press, 1972.

Chapter 10

Antiparkinsonism Agents

INTRODUCTION

Parkinsonism, as a clinical entity, was first described by James Parkinson in 1817. It is a syndrome having the features of akinesia, muscular rigidity, tremor, excessive salivation, seborrhoea, mood changes (especially depression), and liver damage that may be present in certain patients.

The pathophysiologic basis of this idiopathic disorder may relate to exposure of some unrecognized neurotoxin or any generation of free radicals. Normally the high concentrations of dopamine in basal ganglia of the brain is reduced in the case of Parkinson's disease and pharmacological attempts to restore dopaminergic activity with levodopa and dopamine agonist that have been successful in alternating many of the clinical features of this disorder. An alternative or complementary approach has been to restore the normal balance of cholinergic and dopaminergic influences on basal ganglia with antimuscarinic drugs.

The functional circuits between the cortex, basal ganglia, thalamus, and the neurotransmitters are indicated further. In Parkinson's disease, there is a degeneration of neurons in pars compacta of the substantia nigra, leading to hyper activity in indirect pathways and increased glutamatergic activity by subthalamic nucleus (Fig. 10.1).

General mode of action: Parkinson's disease is a progressive neurodegenerative disorder with motor defects due to the imbalance between the dopaminergic (inhibitory- D_2 and excitatory- D_1 receptors). These are amplified by K^+ channels and Ca^{2+} channels, respectively. Parkinson's disease is characterized by dopamine deficiency. Levodopa is considered to act through D_1 and D_2 receptors present in the striatum and it regulates the activity of the two pathways having opposite effects on thalamic input to the motor cortex to produce the smooth kinetic movements.

Other categories of antiparkinsonian drugs influence the metabolism of dopamine and levodopa. In peripheri, levodopa is converted in to 3-ortho methyl dopa in the presence of *catechol-O-methyl transferase* (COMT) and to dopamine in the presence of dopa decarboxylase. These metabolic pathways are inhibited by tolcapone, entacapone, and carbidopa, benzaserizide, respectively.

In brain, dopamine is converted into homovanillic acid catalyzed by *monoamine oxidase B* (MAO-B). This is inhibited by MAO-B inhibitors selegiline and the dopamine is protected to remain in the neurons to regulate the inhibitory and excitatory balance.




Figure 10.1 Functional circuits.


CLASSIFICATION

The drugs used in the treatment of parkinsonism can be classified as follows:

I. Drugs affecting brain dopamine


i. Drugs that increase brain levels of dopamine

a. Levodopa




ii. Drugs that decrease dopamine metabolism


a. Carbidopa



b. Benserazide




c. Droxidopa




iii. Dopamine releasers


a. Amantadine HCl




iv. Dopamine receptor stimulation: Dopaminergic agonists




Name	R	R ¹
Bromocriptine	-Br	
Lisuride	-H	
Ergoline	-H	






v. Dopamine conservation, MAO-B Inhibitor

a. Selegiline HCl



II. Anticholinergic agents


i. Piperidine analogues



S. no	Name	R ₁	R ₂
1	Biperiden		
2	Cycrimine		
3	Trihexyphenidyl hydrochloride		


ii. Pyrrolidine analogues

a. Procyclidine HCl




iii. Phenothiazine analogues

a. Ethopropazine HCl



Antihistamines with central anticholinergic activity

b. Diphenhydramine




III. Miscellaneous drugs

- Antidepressants: Amitriptyline, trazadone
- α -tocopherol (vitamine E)
- Glutamate release inhibitor: Lamotrigine
- Glutamate receptor antagonist: Remacemide
- Glial-derived neurotrophic factor: GDNF
- Benztropine
- Orphenadrine citrate
- Chlorphenoxamine HCl

SYNTHESIS AND DRUG PROFILE

I. Drugs affecting brain dopamine


a. Levodopa (Bidopal, Benspar, Madopar)




2-Amino-3-(3,4-dihydroxyphenyl) propanoic acid

Synthesis

Route-I. From: 4-Methylbenzene-1,2-diol



Route-II. From: 4-Methylbenzene-1,2-diol



Metabolism: Levodopa is rapidly absorbed by active transport in gastro intestinal (GI) tract and once absorbed, 95% is decarboxylated in the periphery to the dopamine, which is further metabolized to dihydrophenylacetic acid and homovanillic acid, which are excreted through urine.

Properties and uses: It is a white or almost white crystalline powder, freely soluble in 1 M hydrochloric acid, slightly soluble in water and insoluble in ethanol. Used as dopamine precursor and in the treatment

of Parkinson's disease. It is also used to treat the parkinsonism-like neurological syndrome of manganese intoxication, in which there is also a deficiency of dopamine in the basal ganglia. Levodopa is a precursor of melanin and may activate latent malignant melanoma. The effects of levodopa on bradykinesia and rigidity are more rapid and complete than the effects on tremor.


Assay: Dissolve the sample in anhydrous formic acid by heating, if necessary. To this add anhydrous acetic acid, dioxan, and crystal violet and titrate with 0.1 M perchloric acid. End point is the appearance of green colour.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The initial oral dose is 100 mg to 1 g/day in divided doses with meals; maintenance dose is 2.5 to 6 g daily and must not exceed 8 g.


Dosage forms: Levodopa capsules I.P., B.P., Levodopa tablets I.P., B.P., Co-beneldopa capsules B.P., Dispersible co-beneldopa tablets B.P., Co-careldopa tablets B.P.

b. Carbidopa (Lodosyn)



3-(3,4-Di-hydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid

Synthesis



Metabolism of Carbidopa: It is a synthetic amino acid precursor of (–) norepinephrine, which is absorbed from the gut and metabolized to norepinephrine. It is further metabolized by COMT and MAO to form metanephrine and normetanephrine. Further they undergo for the metabolism by MAO to 3-methoxy-4-hydroxy mandilic acid.


Properties and uses: It is a white or yellowish-white powder, dissolves in dilute mineral acids, slightly soluble in water, sparingly soluble in alcohol, insoluble in methylene chloride. It has no direct therapeutic actions on its own, but rather is used only to protect levodopa and L-5-hydroxytryptophan. Both of which are decarboxylated by aromatic amino acid decarboxylase. When it is given concomitantly with levodopa, only about 25% as much levodopa is needed. The onset of response is more rapid.

Assay: Dissolve the substance in anhydrous acetic acid and titrate with 0.1 M Perchloric acid. Determine the end point potentiometrically

Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Co-carbidopa tablets I.P., B.P.

c. Amantadine HCl (Symmetrel)



Mode of action: Amantadine appears to act by promoting presynaptic synthesis and release of dopamine in the brain. It acts on glutamate receptors through which dopaminergic system exerts the possible influence on regulating the D_1 and D_2 receptors.


Properties and uses: It is a white or almost white crystalline powder, and it sublimates when heated. Freely soluble in water and in alcohol. Amantadine an organic cage amine, is an antiviral agent useful in preventing and treating influenza A_2 . It possesses both antiparkinsonism and antiviral activity.

Assay: Dissolve the sample in a mixture of 0.01 M Hydrochloric acid. Perform potentiometric titration, using 0.1 M sodium hydroxide.

Dose: In the treatment of Parkinsonism initial dose is 100 mg/day, increased to 100 mg twice daily, after one week.

Dosage forms: Amantadine HCl capsules I.P., Amantadine capsules B.P., Amantadine oral solution B.P.

d. Bromocryptine mesylate (Parlodel, Proctinal, Sicriptin)



Properties and uses: It is a white or slightly coloured fine crystalline powder, insoluble in water, soluble in methanol and ethanol, sparingly soluble in methylene chloride. It is an ergot derivative. Bromocriptine mimics the action of dopamine. Addition of a bromine atom renders the alkaloid criptine a potent dopaminergic agonist at D_2 receptor and an antagonist at D_1 sites. It is used as an adjunct to levodopa.


Assay: Dissolve the sample in a mixture of 10 volumes of anhydrous acetic acid and 70 volumes of acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: Bromocriptine is very sensitive to light, and hence, it should be stored in well-closed airtight container, protected from light.


Dosage forms: Bromocriptine mesylate tablets I.P., Bromocriptine mesylate capsules I.P., Bromocriptine capsules B.P., Bromocriptine tablets B.P.

II. Anticholinergic agents

a. Trihexyphenidyl HCl (Triphen, Parkin, Pacitane)



Synthesis




Properties and uses: It is a white crystalline powder, slightly soluble in water, sparingly soluble in alcohol, and methylene chloride. This drug introduced in 1958, has ganglion-blocking activity, its peripheral atropine-like activity predominates. Its therapeutic activity is based on the later activity. It is more effective than levodopa against Parkinson's tremor.

Assay: Dissolve the sample in alcohol and add 0.01 M hydrochloric acid. Perform potentiometric titration using 0.1 M sodium hydroxide.

Dose: The initial oral dose is 1 mg on first day, followed by 2 mg daily after 3 to 5 days; maintenance dose is 6 to 10 mg/day in 3 to 4 divided doses but not exceeding 20 mg/day.


Dosage forms: Trihexyphenidyl tablets B.P.

b. **Biperiden HCl** (Akineton hydrochloride)



1-(Bicyclo hept-2-en-1-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol

Synthesis




Properties and uses: It is a white crystalline powder, very slightly soluble in methylene chloride, slightly soluble in water, and in alcohol. It reduces tremor, akinesia, and muscle rigidity, drooling and sweating.

Dose: In the treatment of parkinsonism, 2 mg for 3 or 4 times/day.

Assay: Dissolve the sample in alcohol and titrate with 0.1 M alcoholic potassium hydroxide. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


c. **Procyclidine HCl** (Kemadrin, Picidin, Prodine)



Dose: The initial oral dose is 7.5 mg/day in 3 or 4 divided doses after meals; maintenance dose is usually 20 to 30 mg/day.


Synthesis and drug profile is discussed under 'Anticholinergic Drugs' in sec III.

d. **Ethopropazine HCl** (Parsidol)



10-[2-(Diethylamino)propyl]phenothiazine hydrochloride

Synthesis



Mode of action: These drugs act by reducing the unbalanced cholinergic activity in the striatum of parkinsonian patients.

Properties and uses: Drowsiness is common and the drug can cause muscle cramps and hypertension. Used especially for control of rigidity. It is an useful adjunct to antiparkinson's agents.

Dose: The usual oral dose is initially 50 mg/day, slowly increased to 500 mg/day in divided doses.

PROBABLE QUESTIONS

1. Define and classify antiparkinsonism agents. Describe the synthesis and uses of any two.
2. Write the general mode of action of antiparkinsonism agents and the synthesis of Dopamine.
3. Outline the synthesis of Ethopropazine and Biperiden.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill Inc., 2006.
4. Burger A. *Drugs Affecting the Central Nervous System Medicinal Research*, Vol. 2. New York: Dekker, 1968.
5. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
6. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
7. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
8. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.

Chapter 11

Skeletal Muscle Relaxants

INTRODUCTION

Skeletal muscle relaxants are drugs that are able to reduce unwanted spasm or spasticity without interfering with consciousness and normal voluntary movements. These drugs may find an important application in various neurological or muscular skeletal disorders.

Drugs that cause depression of the motor functions leading to a relaxation of voluntary muscles are known as muscle relaxants. Drugs that act on the skeletal muscles fall into two major therapeutic groups, those used during surgical procedures and in intensive care units to cause paralysis (i.e. neuromuscular blockers) and those used to reduce spasticity in a variety of neurological conditions (i.e. spasmolytic). Neuromuscular blockers inhibit the transmission at the neuromuscular end plate and blocks central nervous system control. These components are used primarily as adjuvant to general anaesthesia.

In the 16th century, European explorers found that the natives of Amazon Basin of South America were using an arrow poison (Curare) that produced death by skeletal muscle paralysis. The active compound from curare, *d*-tubocurarine, and its synthetic derivatives had an enormous influence on the practice of anaesthesia and surgery.

In practice, the blockade of end plate function is accomplished by two basic mechanisms. Pharmacological blockade of physiological agonist acetylcholine is characteristic of the neuromuscular blocking drugs. These drugs prevent access of transmitters to the receptor and prevent depolarization. The prototype of this nondepolarizing subgroup is *d*-tubocurarine. Blocking of transmission can also be produced by an excess of depolarizing agonist, namely, acetylcholine and the depolarizing blocking drug, succinylcholine.

Skeletal muscle contractions occur when there is a release of acetylcholine from presynaptic vesicles, and acts on the postjunctional acetylcholinergic receptors in the motor end plate. An autoimmune disease, myasthenia gravis, associated with skeletal muscle relaxation is produced due to the loss of acetylcholinergic receptors in the neuromuscular junction. In normal physiological conditions, relaxation can be produced by the skeletal muscle relaxant, which binds to antagonize the action of acetylcholine on neuromuscular junction's acetylcholine receptors.

CLASSIFICATION

I. Neuromuscular blocking drugs

a. Nondepolarizing muscle relaxants


- Tubocurarine chloride
- Metocurine iodide
- Gallamine triethiodide
- Pancuronium bromide
- Hexafluoronium bromide
- Fazadinium bromide
- Alcuronium chloride
- Paucuronium bromide
- Stercuronium iodide

b. Depolarizing neuromuscular blocking drugs

- Suxamethonium chloride or Succinyl choline chloride
- Suxethonium chloride
- Decamethonium bromide


II. Centrally acting muscle relaxants

a. Carbamates




Meprobamate

b. Glycerol mono-ethers and analogues




Name	R	R ¹	R ²
Mephenasin	-CH ₃	-H	-H
Mephenesin carbamate	-CH ₃	-CONH ₂	-H
Guaifenesin	-OCH ₃	-H	-H
Methocarbamol	-OCH ₃	-CONH ₂	-H
Chlorphenesin carbamate	-H	-CONH ₂	-Cl

c. Substituted alkanediols




Metaxalone



Lorbamate or Carisoprodal


d. Benzoxazole analogues



Chlorozoxazone


e. Heterocyclic bases

i. Xilobam




Zoxazolamine

ii. Benzodiazepines




Nefopam




Fletazepam

f. Imidazole analogue




Dantrolene


g. Miscellaneous drugs



Baclofen



Orphenadrine



Cyclobenzaprine


SYNTHESIS AND DRUG PROFILE

I. Neuromuscular blocking agents


a. Nondepolarizing blockers

Mode of action: Nondepolarizing blockers have affinity for the cholinergic receptors at the muscle end plate. The receptor is a protein with five subunits arranged similar to a rosette, surrounding the sodium channel. The two subunits carry two acetylcholine binding sites; they have negatively charged groups, which combine with the cationic head of acetylcholine leads to the opening of sodium channel. Most of the nondepolarizing blockers have two or more quaternary nitrogen atoms, which provide the necessary attraction to the same site for binding, so acetylcholine released from the nerve ending cannot be able to bind to generate action potential and produces muscle relaxant property.

i. Gallamine triethiodide (Flaxedil)



Synthesis



Properties and uses: It is a white or almost white powder hygroscopic in nature. Insoluble in methylene chloride, soluble in water, and slightly soluble in alcohol. It is a nondepolarizing neuromuscular blocker used as adjuvant to anaesthesia, so as to achieve depot muscular relaxation.

Assay: Dissolve the sample in a mixture of anhydrous formic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For the treatment of limb muscle paralysis, initial dose by I.V. or I.M. 1 mg/kg of body weight; for abdominal surgery, 1.5 mg/kg of body weight; maintenance dose is 500 µg to 1mg every 30 to 60 min, intervals, if required. The dose must be reduced when used along with anaesthetics like ether, cyclopropane, etc.

Dosage forms: Gallamine triethiodide injection I.P., Gallamine injection B.P.


b. Depolarizing neuromuscular blockers

Mode of action: These drugs depolarize the muscle end plate potential by opening of Na^+ channels as acetylcholine initially produce twitching and fasciculation. They do not dissociate rapidly from the receptors, and produce prolonged partial depolarization of muscles and plates leading to inactivation of sodium channels due to the dropping of membrane potential.

ii. Succinyl Choline Chloride



Synthesis




Uses: It is used to relax the skeletal muscle for orthopaedic manipulation of endotracheal-intubation.

II. Centrally Acting Muscle Relaxants

General mode of action: These selectively depress spinal and supra-spinal polysynaptic reflexes involved in the regulation of muscle tone without significantly affecting mono synaptically mediated stretch reflex.

a. Carbamates

i. Meprobamate




Synthesis and drug profile is discussed under Sedatives and Hypnotics sec III


b. Glycerol monoethers and analogues

Synthesis of Mephnesin (Tolserol) and Guaifenesin

(i) Mephnesin




Synthesis



Metabolism of mephnesin derivatives: The major metabolite product of mephnesin is β -(*o*-toloxy)-lactic acid, which is inactive. Because of easy metabolism (oxidation) of mephnesin to the corresponding lactic acid, its carbamate or succinate derivatives show longer duration, although less active than the parent drug.

Dose: Mephnesin: Usual oral dose is 0.5 or 1g for 1 to 6 times per day as per requirement.

ii. Guaifenesin




3-(2-Methoxyphenoxy)propane-1,2-diol


Properties and uses: It is a white or almost white crystalline powder, soluble in alcohol, sparingly soluble in water and used as an expectorant.

Assay: The substance is dissolved in freshly prepared mixture of 1 volume of acetic anhydride and 7 volumes of pyridine boil under a reflux condenser and then cooled. To this add water and titrate with 1 M sodium hydroxide using phenolphthalein as indicator. End point is the appearance of pink colour.

iii. Methocarbamol (Robinax)




Synthesis




Uses: Used in Parkinsonism and also in cerebro-vascular mishaps.

Dose: Initial oral dose is 1.5 to 2 g, 4 times daily for the first 2 or 3 days followed by 2.25 to 4.5 g per day in 2 or 4 divided doses; I.V., 1 to 3 g per day administered at a rate not exceeding 0.3 g/min; by I.M., 1 g every 8 h.

iv. Chlorphenesin Carbamate (Maolate)



Synthesis





Uses: It is used to diminish skeletal muscle spasms resulting from osteoarthritis and vertebral disk syndrome.

Dose: The initial usual dose is 800 mg thrice/day and reduced to 400 mg four times/day, or less as required.

c. Substituted alkanediols



i. Metaxalone (Skelaxin)





Synthesis



Uses: It is used for local skeletal muscle spasms.

Dose: The usual dose is 800 mg 3 or 4 times/day.

ii. Lorbamate**Synthesis**

Uses: Used as a muscle relaxant.

iii. Xilobam**Synthesis**


d. Benzoxazole analogues**i. Chlorzoxazone** (New Panazox, Ontacplus)**Synthesis**

Uses: It is obtained by cyclization of the *o*-hydroxyl benzformamide. Used as skeletal muscle relaxant for the reduction of painful muscle spasm, such as mycositis sprains and acute or chronic back pain.


Dose: The usual initial dose is 500 mg 3 or 4 times/day, maintenance dose is 250 mg.

e. Heterocyclic bases


Mode of action of benzodiazepines: These drugs produce centrally mediated skeletal muscle relaxation by acting on the benzodiazepine receptors in midbrain reticular formation and on the limbic system. It acts on the benzodiazepine receptors, increases the chloride influx, and produces hyperpolarization and decreases the firing rate of neurons and inhibits the calcium dependent release of neurotransmitters.

i. Fletazepam


Synthesis




ii. Nefopam



Synthesis




f. Imidazoline analogues**i. Dantrolene (Dantrium)**

Mode of action: This does not affect the neuromuscular transmission of membrane action potential, but uncouples contraction from depolarization of muscle membrane. Depolarization triggered release of calcium from sarcoplasmic reticulum is reduced and the contraction of muscle is abolished.


Dose: The initial dose by oral route is 25 mg/day, slowly increased over a period of 7 weeks to 100 mg, 3 to 4 times/day.

Synthesis


Step I. Synthesis of 5-(4-nitrophenyl)-2-furalal



Step II. Synthesis of 4-Amino imidazolidin-2,4-dione



Step III. Condensation of product of Step I and II




Metabolism: It is slowly metabolized to give 5-hydroxy and acetamide metabolites.


Uses: Used for the control of the spasticity, resulting from spinal cord injury, stroke, and multiple sclerosis.

g. Miscellaneous

i. Cyclobenzaprine HCl




Synthesis




Uses: It is a centrally acting skeletal muscle relaxant that relieves acute and painful muscle spasm.

ii. Baclofen (Liofen, Lioresal)




Synthesis



Uses: Useful in treating spasticity associated with spinal cord tensions, as in multiple sclerosis.


Dose: The initial dose is 5 mg thrice/day increased by 15 mg/day every fourth day to 20 mg thrice/day.

ii. Orphenadrine Hydrochloride



N,N-Dimethyl-2-(phenyl(*o*-tolyl)methoxy)ethanamine

Synthesis



Uses: Used in the control of the symptoms of Parkinson's disease.

PROBABLE QUESTIONS

- How will you classify the neuromuscular blocking drugs? Write the structure, chemical name and uses of any one agent from each category.
- Explain the following: (a) Mode of action of nondepolarizing blockers and (b) depolarizing blockers.
- Classify the centrally-acting muscle relaxants and give the structure, chemical name, and uses of one important member of each class.
- Discuss the synthesis of a potent glycerol mono ether analogue.
- How will you synthesize meprobamate? Discuss the various steps sequentially.
- Name an important member of benzoxazole analogue employed as muscle relaxant. Outline its synthesis.
- Write the structure, chemical name, and uses of Dantrolene sodium.
- Discuss the synthesis of the following important muscle relaxants.
(a) Chlorphenesin carbamate (b) Methocarbamol
- Describe the mode of action of various types of muscle relaxants by giving specific examples.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. *British Pharmacopoeia*. London: Medicines and Healthcare Products Regulatory Agency, 2008.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill Inc., 2006.
4. Burger A. *Drugs Affecting the Central Nervous System, Medicinal Research*, Vol. 2. New York: Dekker, 1968.
5. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
6. Griffiths MC (ed). *USAN and the USP Dictionary of Drug Names*. Rockville: United States Pharmacopeial Convention Inc., 1985.
7. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
8. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
9. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: Wiley, 1995.
10. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.

Chapter 12

Alzheimer's Disease

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily manifesting as a loss of memory, senile dementia, intraneuronal neurofibrillary tangle formation, and cerebral parenchyma deposition of the β -amyloid protein in the form of amyloid plaques and these constitutes the most stereotypic cognitive deficits and neuro-pathological hallmarks of AD. The earliest striking symptom is loss of short-term memory (amnesia). Behavioural disturbances include agitation, aggression, and depressive mood; sleep disorder and anxiety. AD was the 7th leading cause of death in 2004 with 65,829 number of deaths. There are an estimated 24 million people with dementia worldwide.

Pathogenesis

It has referred that 11 amino acid sequence of β -amyloid protein is neurotoxic for primary neurons. The cognitive deficits of patients with AD are closely associated with dysfunction of central cholinergic neurotransmission. There is a selective neuronal loss especially on the basal forebrain, which project to hippocampus and neocortex. It is generally believed that there are reductions of muscarinic (mAChR) and nicotinic (nAChR) acetylcholine receptors, which are located on presynaptic cholinergic terminals. Acetylcholinesterase (AChE) has been shown to be promoting the assembly of β -amyloid plaques into fibrils and is suggested to play a pathogenic role in AD by forming a complex, which has higher toxic effect than β -amyloid protein. The oxidative deamination of amines generates neurotoxic agents, that is, NH_3 and H_2O_2 . Oxidative stress signalling is speculated in the pathology of AD and other neurodegenerative disorders. The free radicals produced during oxidative stress causes the DNA and RNA oxidation indicated by increased levels of 8-hydroxy-2-deoxyguanosine and 8-hydroxy guanosine, elevated level of protein carbonyl residue and the lipid peroxidation, which are marked by higher levels of thiobarbituric acid reacting substance (TBARS), malondialdehyde (MDA), 4-hydroxy transneoneal (HNE), and isoprostrane. It is hypothesized that β -amyloid protein accumulation and diffuse plaque formation is associated with local microglial activation, cytokine release, reactive astrocytosis, and a multiprotein inflammatory response. There is considerable evidence that the effects of β -amyloid initiated inflammatory and neurotoxic processes, including excessive generation of free radicals and peroxidative injury to proteins and other macromolecules in neurons.

Of all persons with AD, up to 25% of cases are thought to be part of a familial-based inheritance pattern, and therefore, are only determined based on family history or genetic test results. In general, these forms of AD are inherited as an autosomal dominant disorder. There are indications that loss of glutaminergic neurons and glutamate activity in AD patients correlates with the severity of dementia, and glutaminergic disruption may be involved in the cognitive symptoms of this disorder. There is increasing speculation that AD may be linked aetiologically to the accumulation of aluminium in the brain. AD patients have inconsistently shown low concentration of norepinephrine, dopamine, and dopamine β -hydroxylase. These are often considered to improve the fluency and creativity. Interactions between the serotonergic and cholinergic systems are deregulated and are believed to play a role in the mechanism underlying both major depression and AD.

Treatment

There is currently no cure for AD. Currently available medications offer relatively small symptomatic benefit for some patients, but do not slow down disease progression.

ACETYLCHOLINESTERASE INHIBITORS

Acetylcholinesterase (AChE) inhibition was thought to be important because there is a reduction in the activity of the cholinergic neurons. AChE-inhibitors reduce the rate at which acetylcholine (ACh) is broken down, and hence, increase in the concentration of ACh in the brain (combating the loss of ACh caused by the death of the cholinergic neurons). Tacrine—no longer clinically used; Donepezil—marketed as Aricept; Galantamine—marketed as Razadyne, Reminyl, or Nivalin; Rivastigmine—marketed as Exelon.


NMDA ANTAGONISTS

Recent evidence of the involvement of glutaminergic neuronal excitotoxicity in the aetiology of AD led to the development and introduction of memantine. Memantine is a novel NMDA receptor antagonist, and has been shown to be moderately clinically efficacious.

TACRINE


Properties and its uses: It is a parasympathomimetic and a centrally acting cholinesterase inhibitor (anti-cholinesterase). It was the first centrally acting cholinesterase inhibitor approved for the treatment of AD, and was marketed under the trade name Cognex.

a. Memantine




1-Amino-3, 5-dimethyl-adamantane

Synthesis



Properties and uses: It is the first in a novel class of AD medications acting on the glutaminergic system by blocking NMDA glutamate receptors.


b. Donepezil




2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydroinden-1-one

Properties and uses: It is marketed under the trade name, Aricept, and is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the treatment of AD where it is used to increase cortical acetylcholine.

c. Galantamine or galanthamine




Synthesis



Properties and uses: It is an alkaloid obtained from the bulbs and flowers of the *Caucasian snowdrop* (Voronov's snowdrop), *Galanthus woronowii* (Amaryllidaceae), and related genera such as *Narcissus* (daffodil), *Leucojum* (snowflake), and *Lycoris*, including *Lycoris radiata* (red spider lily). It is also synthetically prepared. The active ingredient that was isolated from a species traditionally used as a popular medicine in Eastern Europe. It has been used for decades in Eastern Europe especially in the symptomatic treatment of polio (poliomyelitis) and was later developed by Janssen Pharmaceuticals into the Alzheimer medication.

d. Rivastigmine



3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate

Properties and uses: It is (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.

PROBABLE QUESTIONS

1. What is Alzheimer's disease? Enumerate the various agents used in the treatment of Alzheimer's disease and write the synthesis of any one among them.
2. Write briefly about Acetylcholinesterase inhibitors used in the treatment of Alzheimer's disease.
3. Write note on NMDA antagonists used in Alzheimer's disease.

DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM

1	Autonomic Nervous System	351
----------	---------------------------------	------------

2	Adrenergic Drugs	356
----------	-------------------------	------------

3	Cholinergic Drugs	378
----------	--------------------------	------------

4	Adrenergic Blockers	398
----------	----------------------------	------------

5	Anticholinergic Drugs	419
----------	------------------------------	------------

"This page intentionally left blank"

Chapter 1

Autonomic Nervous System

INTRODUCTION

Autonomic nervous system (ANS) represents the unconscious regulation and controls the visceral function. It consists of afferent central connections, and autonomic efferents. The afferent nerves are the first link in the reflex of ANS, which carries nonmyelinated fibres from visceral parts to the cerebrospinal axis. Central connections refer to the integration of autonomic reflexes through hypothalamus and the nucleus solitary tract. Autonomic efferents are the principal peripheral connections that are divided into sympathetic and parasympathetic outflow. Neurotransmitter in all the pre and parasympathetic postganglionic fibres is acetylcholine and in sympathetic postganglionic release is norepinephrine. ANS is composed of (1) sympathetic system and (2) parasympathetic system.

Sympathetic System

Preganglionic nerves of the sympathetic system arise from the lateral gray horn of 12th thoracic segments and the first two lumbar segments of the spinal cord (thoracolumbar division). They form ganglia in the vertebral chain called paravertebral chain ganglion and supply the postganglionic fibres to effector organs. The principal neurotransmitter is adrenaline, so it is called adrenergic system.

NEUROTRANSMISSION

In adrenergic neurons (sympathetic postganglion), the neurotransmitter released is norepinephrine, which is also called noradrenaline. There are closely related catecholamines (CAs), that is, adrenaline and dopamine that has minor effects secreted by adrenal medulla and in limbic system basal ganglia, respectively.

CAs are synthesized from amino acid phenylalanine. Tyrosine hydroxylase is the rate-limiting enzyme and its inhibition by α -methyl-*p*-tyrosine leads the CAs to dissipate. Other endogenous transmitter, that is, 5-HT produced by aromatic L-amino acid decarboxylase converts DOPA into dopamine and methyl dopamine, and then, it is converted by dopamine β -hydroxylase to α -methyl norepinephrine. The steps involved in the synthesis of epinephrine and norepinephrine is depicted in Figure 1.1.




Figure 1.1 Biosynthesis of epinephrine and norepinephrine.

REGULATION OF CATECHOLAMINES

Noradrenaline is stored in the synaptic vesicles on the adrenergic nerve endings and released by exocytosis along with the stored adrenaline, ATP and dopamine β -hydroxylase. The CAs are metabolized by monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT) in the liver and other tissues into vanillyl mandelic acid (VMA) and 3-methoxy-4-hydroxy phenyl ethylene glycol with metaephrine and normetaephrine (Fig. 1.2).

ADRENERGIC RECEPTORS

They are membrane bound G-protein coupled receptors and classified as α (alpha) and β (beta) adrenoceptors.

α -RECEPTORS

They are further classified into α_1 and α_2 . The selective agonist for α_1 is phenylephrine and antagonist is prazosin. α_2 receptors are stimulated by clonidine selectively and antagonized by yohimbine. Elicitation of α_1 receptors increases phospholipase C, D, A_2 and inositol-triposphate/diacylglycerol IP_3/DAG which contracts smooth muscles, genitourinary tracts, and increase the secretions of glands and in the heart, it increases the force of contraction. α_2 receptor stimulation causes decrease in cyclic AMP, Ca^{2+} L type channels, and increases the IP_3/DAG . It decrease the insulin secretion, produces platelet aggregation, decreases the release of NE as it has auto-regulation mechanism, and causes the vascular smooth muscle contraction.




Figure 1.2 Metabolism of catecholamines.

β -RECEPTORS

The β receptors are further subdivided into three subtypes and distributed in the body, that is, β_1 (heart), β_2 (bronchi, smooth muscles), and β_3 (adipose tissue). Each has a selective agonist and antagonist. For β_1 receptors, the agonist is dobutamine and antagonists are atenolol and metoprolol. Agonists for β_2 are salbutamol and terbutaline and antagonist is propranolol.

The pharmacology of β receptors indicate the biochemical increase of adenylylase, L-Type calcium channels increment through β_1 causes increase in the force and rate of contraction of AV nodal conduction velocity. β_2 receptor stimulates bronchodilation through elicitation of adenylylase. β_3 stimulation increases adenylylase and causes lipolysis.

Parasympathetic System

Preganglionic neurons of parasympathetic system arise from III, VII, IX, and X cranial nerves and 2nd, 3rd, and 4th sacral portion of the vertebra, respectively, so its named as craniosacral outflow. Acetylcholine (ACh) is the principal neurotransmitter and also called as cholinergic neurons.

NEUROTRANSMISSION

ACh is released into the synaptic vesicles of effectors junction by an impulse across the neuroeffector junction. This leads to the action potential that is due to the difference in the ionic gradients of Na^+ and K^+ equilibrium, and in other tissues, it is mediated along with calcium ion. ACh is synthesized locally in the cholinergic nerve ending by adenosine-triphosphate (ATP) dependent system (Fig. 1.3). Choline is actively taken by the axonal membrane and acetylated with the help of ATP and co-enzyme-A by the choline acetylase.

REGULATION OF ACh

ACh is stored in the synaptic vesicles and is extruded by miniature end plate potential (MEPPS) of action potential. They are metabolized by enzymes acetyl cholinesterase and butyrylcholinesterase. These convert the ACh into choline and acetate. ACh esterase comprises of an anionic site that possesses a glutamate residue and an esteric site in which histidine imidazole ring and a serine -OH group are present.




Figure 1.3 Biosynthesis of acetylcholine.

Hydrolysis of Ach involves electrostatic attraction of positively charged N^+ of Ach to aromatic pocket of Ach esterase and nucleophilic attack by serine $-OH$ and activation. Hydrolysis, transfer acetyl group to serine $-OH$ group, leaving acetylated enzyme molecule and free choline.

CHOLINERGIC RECEPTORS

These receptors comprise of G-Protein coupled with muscarinic and ligand gated channelled nicotinic receptors.

MUSCARINIC RECEPTORS

These are selectively stimulated by muscarine. The action of muscarinic receptors may be excitatory or inhibitory. They are primarily located in the heart, blood vessels, smooth muscles, and gastrointestinal tract (GIT), sweat glands and urinary tract. There are five subtypes, that is, M_1 , M_2 , M_3 , M_4 , and M_5 . M_1 present in the autonomic ganglia causes depolarization and also histamine release and secretes acid from gastric glands. These functions are mediated through IP_3/DAG and increase in cytosolic Ca^{2+} . Specific antagonist is oxotremorine and agonists are pirenzepine and telenzipine. M_2 is found in the sinoatrial (SA) and atrioventricular (AV) node of the heart, which decreases the rate of impulse generation and velocity of conduction, respectively. In addition, it decreases the contractility. These functions mediated through K^+ channel opening decreased cAMP.



M_3 found in the visceral smooth muscle causes contraction, exocrine glands cause secretion, vascular endothelial release of nitric oxide (NO) causes vasodilatation. The mechanism of the receptor is IP_3/DAG elicitation and increase in Ca^{2+} . The antagonist is hexahydrosiladifenidol and the agonist is bethanacol. M_4 is similar to M_2 and the M_5 is similar to M_1 present in CNS.

NICOTINIC RECEPTORS

These receptors are selectively agonized by nicotine and blocked by D-tubocurarine or hexamethonium. The receptors are pentameric structured and further divided into N_M and N_N .

N_M present in neuromuscular junctions cause depolarization of muscle end plate leading to contraction of skeletal muscles. The transduction mechanism is through the opening of Na^+ and K^+ channels.

N_N is present in autonomic ganglia, in adrenal medulla, and in CNS. In the ganglia level it causes depolarization and mediates the postganglionic impulse. In adrenal medulla, it stimulates the CA release through the opening of Na^+ and Ca^+ channels.



Chapter 2

Adrenergic Drugs

INTRODUCTION

Sympathetic nervous system is an important regulator of the activities of the vital organs, such as heart and peripheral vasculature, especially in response to stress. The effect of sympathetic stimulation is mediated by the release of norepinephrine from the nerve terminals that serve to activate the adrenoreceptors on postsynaptic sites. Also, in response to a variety of stimuli, such as stress, the adrenal medulla releases epinephrine, and it is transported in the blood to the target tissues. Drugs that mimic the action of sympathetic system are called sympathomimetic drugs. Like cholinomimetic drugs, the sympathomimetics can be grouped by their mode of action and by the spectrum of receptors. Some of the drugs (e.g. epinephrine, norepinephrine) act by a direct mode, that is, they interact with and activate adrenoceptor. Others act indirectly; their actions are dependent on the release of endogenous catecholamine. These indirect agents may have either of the different mechanisms:

1. Displacement of stored catecholamine from adrenergic nerve ending (e.g. amphetamine and tyramine).
2. By inhibition of reuptake of catecholamine already released (e.g. cocaine and tricyclic antidepressants).
3. Some drugs have both direct and indirect action.

PHYSIOLOGICAL BASIS OF ADRENERGIC RECEPTOR FUNCTION

The important factors in this function are the response of any cell or organ to the sympathomimetic amines due to the density and proportion of α and β -adrenergic receptors, including their subtypes (discussed in the section IV, 'Introduction to ANS'). For example, norepinephrine has relatively little capacity to increase the bronchial airflow, the receptors in the bronchial smooth muscle are largely of β_2 subtype. In contrast, isoproterenol and epinephrine are potent bronchodilators. Cutaneous blood vessels physiologically express almost exclusively α receptors; thus, norepinephrine and epinephrine cause constriction of such

vessels, whereas isoproterenol has little effect. Most of the actions of sympathomimetics are broadly classified into seven types:

1. Peripheral excitatory action on certain types of smooth muscles (i.e. blood vessels supplying skin, kidney, mucous membrane, and glands).
2. A peripheral inhibitory action on certain other types of smooth muscles (i.e. gut, bronchial tree, and blood vessels supplying skeletal muscle).
3. Cardiac excitation leads to increase in the heart rate.
4. Metabolic action (i.e. glycogenolysis in tissues and muscle, liberation of fatty acids).
5. Endocrine actions (i.e. increase in release of hormones).
6. CNS stimulation (i.e. psychomotor stimulation, wakefulness, and respiratory stimulation).
7. A presynaptic action that results in either inhibition or excitation, physiologically the inhibitory action is more than excitatory motion.

Therapeutically these agents are classified into the following:

- Pressor agents: Noradrenaline, Ephedrine and Dopamine
- Cardiac stimulants: Adrenaline, Dobutamine and Isoprenaline
- Bronchodilators: Isoprenaline, Salbutamol, Terbutaline, Formeterol, etc
- Nasal decongestants: Phenylephrine, Naphazoline, Pseudoephedrine
- CNS stimulants: Amphetamine, Methamphetamine, Dexamphetamine, etc

Mechanism of Action of Sympathomimetics

β_1 ADRENERGIC RECEPTOR ACTION

The β adrenergic actions mediated through cyclic AMP (cAMP). Adrenaline activates membrane bound enzyme adenylcyclase through regulatory protein Gs. Adenosine-triphosphate (ATP) is broken into cAMP at the inner face. In the heart, proteins such as troponin and phospholamban, are phosphorylated and results in increased interaction with calcium at myofilaments, leading to increased force of contraction.

β_2 ADRENERGIC RECEPTOR ACTION

β_2 receptors are predominantly found in the respiratory system. The β_2 receptor agonist produces bronchodilation by binding with the β_2 receptors.

α_1 ADRENERGIC RECEPTOR ACTION

Stimulation of α_1 adrenergic receptors elicits a primary mode of signal transduction that involves the mobilization of intracellular Ca^{2+} from endoplasmic stores. This increase in intracellular Ca^{2+} is thought to result from the activation of phospholipase C_β isoforms through G_q family of G protein. The hydrolysis of membrane bound polyphosphoinositides through phospholipase C results in generation of diacylglycerol (DAG) and Inositol 1, 4, 5-triphosphate (IP_3). IP_3 stimulates the release of Ca^{2+} from intracellular stores. In smooth muscles increased intracellular Ca^{2+} cause contraction, mediated by Ca^{2+} sensitive protein kinases, that is, calmodulin dependent myosin light chain kinase.

α_2 ADRENERGIC RECEPTOR ACTION

α_2 adrenergic receptors activate G protein gated K^+ channels resulting in hyper-polarization. These α_2 receptors are also capable of inhibiting voltage gated Ca^{2+} channels mediated by G protein and also activates the

mitogen activated protein kinase (MAPK). These lead to activation of a variety of tyrosine kinase mediated downstream events, and these inhibit the release of norepinephrine from nerve endings and suppresses the sympathetic outflow to the brain.

GENERAL CLASSIFICATION OF ADRENERGIC AGONISTS

Adrenergic agents are divided into three classes

I. Direct-acting adrenergic agonists

They bind to and activate α_1 , α_2 , β_1 , and β_2 receptors. Naturally occurring molecules, which bind to these receptors include NE (a neurotransmitter which binds to α_1 , α_2 , and β_1 receptors), Epinephrine (a hormone produced in and secreted from the adrenal medulla, which binds to α_1 , α_2 , β_1 , and β_2 receptors, it is a nonselective adrenergic agonists), and Dopamine (also a neurotransmitter, which binds to α_1 , α_2 , and β_1 receptors).

Examples of drugs: xylometazoline, phenylephrine, methoxamine.

II. Indirect-acting adrenergic agonists

They produce NE-like actions by stimulating NE release and preventing its reuptake and produces activation.

Example: Tyramine.

III. Dual-acting adrenergic agonists

These agents act as direct and indirect adrenergic agonists (hence, dual-acting). They bind to adrenergic receptors and stimulate NE release.

Examples: Ephedrine, Amphetamine, Mephenteramine.

Classifications Based on Therapeutic Uses

Adrenergic drugs used for raising blood pressure (vaso-constrictors): Noradrenaline, Metaraminol

Drugs used for their inotropic action on the heart: Dopamine, Dobutamine, Xamoterol

Drugs used as central stimulants: Amphetamine (Benzedrine)

Drugs used as smooth muscle relaxants: Adrenaline (epinephrine), Isoprenaline, Isoxsuprine

Selective β_2 stimulant: Salbutamol

Drugs used in allergic reactions: Adrenaline, Ephedrine







Drugs used as local vaso-constrictors: Adrenaline, Phenylephrine, Naphazoline

Drugs used for suppressing the appetite: Fenfluramine, Phenteramine, Amphetamine

Classification Based on Chemical Structures



I. Catecholamines

Compounds with hydroxyl ($-OH$) substitution in the third and fourth position of the benzene ring are termed as catecholamines.


**a. Adrenaline****b. Noradrenaline****c. Dopamine****d. Isoprenaline****e. Dobutamine**

II. Noncatecholamines


Those compounds that lack the hydroxyl at third and fourth position of the benzene ring are noncatecholamines. They release noradrenaline or dopamine from the sympathetic neurons. This indirect action produces effects mainly resembling those of externally administered noradrenaline.

a. Amphetamine**b. Metaraminol**


c. Salbutamol




d. Ephedrine




e. Naphazoline




f. Phenylephrine




g. Isosuprine




h. Nylidrine



i. Xylometazoline




j. Terbutaline



SYNTHESIS AND DRUG PROFILE


I. Catecholamines

a. Adrenaline (Synonym: Epinephrine)



1-(3,4-Dihydroxy phenyl) -2-methylamino ethanol

Synthesis



Metabolism of adrenaline and noradrenaline (catecholamines): Endogenous and exogenous catecholamines are metabolized by two enzymes monoamino oxidase (MAO) and catechol-O-methyl transferase (COMT). MAO converts catecholamines to their corresponding aldehydes, and in the periphery, the aldehydes are rapidly metabolized by aldehyde dehydrogenase to the corresponding carboxylic acid. In case of noradrenaline, this yields dihydroxy mandelic acid (DOMA). The second major pathway for catecholamine metabolism involves the methylation on one of the catechol -OH groups to give methoxy derivatives. O-Methylation of noradrenaline gives rise to a metabolite normetanephrine. Normetanephrine undergoes metabolism by MAO and 3-methoxy-4-hydroxy mandelic acid [vanillyl mandelic acid (VMA)] is formed, which is the main final metabolite of adrenaline and noradrenaline.

Properties and uses: Adrenaline is a catecholamine and belongs to the family of biogenic amines. It is a white or creamy white, sphaero-crystalline powder. It dissolves in solutions of mineral acids, potassium hydroxide, and of sodium hydroxide, but sparingly soluble in water, insoluble in ethanol and ether. It is used as a sympathomimetic, broncholytic, and antiasthmatic. It is used to prevent bleeding during surgery or in case of inner organ bleeding. Because adrenaline leads to constriction of blood vessel, it is administered in combination with local anaesthetics. In this combination, anaesthetics have long-lasting effect and can be administered in smaller doses. It is used in the treatment of heart block or circulatory collapse and open-angle glaucoma. It is usually the drug of choice in acute allergic disorders and histamine reactions.

(R)-Epinephrine is 12 times more active than S form. It has a potent stimulatory effect on both α and β -adrenergic receptors and is light sensitive and easily oxidized on exposure.

Adrenaline is a potent stimulant for both α and β receptors, predominately on the β_1 receptor of myocardium and pacemaker. The mechanism of rise in blood pressure is by

- direct myocardial stimulant (positive inotropic action)
- increase in heart rate (positive chronotropic action)
- vasoconstrictor in the vascular beds.


Assay: It is assayed by nonaqueous titration, the solution of the substance is titrated with 0.1 M perchloric acid, using crystal violet indicator.

Storage: Epinephrine is light sensitive and easily oxidized on exposure to air because of the catechol ring system. The development of a pink to brown colour indicates oxidative breakdown. To minimize oxidation, solutions of the drug are stabilized by the addition of a reducing agent, such as sodium bisulphite. Adrenaline should be stored in well-closed airtight containers, which is preferably filled with nitrogen, and protected from light.

Dose: By subcutaneous, 0.2 to 0.5 mg in 0.1% solution; intramuscularly 1 to 3 mg in a 0.2% oil suspension, repeated as required.


Dosage forms: Adrenaline injection I.P., Adrenaline eye drops/epinephrine eye drops B.P., Dilute adrenaline injection (1 in 10,000)/dilute epinephrine injection (1 in 10,000) B.P.

b. Noradrenaline (Synonym: Norepinephrine, Nephridine)



L-1-(3,4 Dihydroxy phenyl)-2-amino ethanol

Synthesis




Properties and uses: It is a white or brownish-white, crystalline powder, slightly soluble in ethanol and soluble in water. It differs from adrenaline only by lacking the methyl substitution on the amino ethanol. L-isomer is pharmacologically active. Noradrenaline is a potent agonist for α_1 receptors and has relative actions on β_2 receptors. By acting on these receptors, the systolic and diastolic pressures, and usually, pulse pressure are increased. It increases the peripheral vascular resistance. Its principle use is to support blood pressure in various acute hypotensive states, especially in myocardial shock. It is used as a vasoconstrictor in some local anaesthetic solutions for dental use.

Assay: Dissolve the sample in acetic anhydride and add anhydrous formic acid. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically

Storage: It becomes coloured on exposure to air and light. It should be stored in well-closed airtight containers, preferably in a sealed tube under vacuum or under an inert gas and protected from light.


c. Dopamine (Domin, Dopacard)





2-(3,4-Dihydroxy Phenyl)-1-amino ethane

Synthesis

Route I. From: Veratrole



Route II. From: Catechol**Route III. From: 2-(3, 4-dinitrophenyl) ethanamine**

Properties and uses: It is a white or almost white crystalline powder, soluble in alcohol, sparingly soluble in acetone and methylene chloride, but freely soluble in water. It is used in the treatment of shock. It is ineffective orally in large parts because it is a substrate for both MAO and COMT. Dopamine exerts the CVS effects by interacting with D_1 -dopaminergic receptors especially in the renal, mesenteric, and coronary beds. At high concentrations, dopamine acts on β_1 adrenergic receptors and causes positive inotropic effects and also dopamine causes the release of norepinephrine.


Assay: Dissolve the sample in anhydrous formic acid and add acetic anhydride. Titrate with 0.1 M Perchloric acid and determine the end point potentiometrically

Storage: It should be stored in well-closed airtight containers, protected from light.

Dose: Acute heart failure: Adult: Initially, 1–5 $\mu\text{g/kg/min}$ increased gradually by up to 5–10 $\mu\text{g/kg/min}$ according to the patient's BP, cardiac output and urine output. Up to 20–50 $\mu\text{g/kg/min}$ may be required in seriously ill patients.


Dosage forms: Dopamine intravenous infusion B.P.

d. Isoprenaline (Synonym: **Isoproterenol**, Isoprim, Isosol, Neo-Epinin)



1-(3,4-Dihydroxy phenyl)-2-isopropylamino ethanol

Synthesis



Metabolism: It is metabolized in the liver and other tissues by catechol-O-methyl transferase, which transfer the $-\text{CH}_3$ group to the $-\text{OH}$ group. It acts as poor substrate for MAO and it undergoes sulphate conjugation.


Properties and uses: It is a white or almost white crystalline powder, freely soluble in water, sparingly soluble in alcohol, practically insoluble in methylene chloride. It is a synthetic Isopropyl analogue of adrenaline, acting almost exclusively at β -receptor. It stimulates the action of adrenaline and has the advantage of being effective when given orally. It is a nonselective β agonist and has strong β_1 and β_2 agonist activity. Its primary use is in the treatment of bronchial asthma. It is used as an antiarrhythmic agent and in the treatment of shock to increase heart rate.

Assay: Dissolve the sample in anhydrous formic acid and add acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight containers, protected from light.

Dose: Sublingual, 10 to 15 mg 3 to 4 times/day; I.M. or S.C. 0.01 to 0.2 mg; repeated as necessary; infusion, 1 to 2 mg per 500 ml of 5% dextrose infusion at such a rate so as to maintain blood pressure.

Dosage forms: Isoprenaline HCl injection I.P., Isoprenaline sulphate tablets I.P., Isoprenaline injection B.P.

e. Dobutamine (Cardiject, Dotamin, Kardia)

N-[1-Methyl-3-(4-hydroxy phenyl)propyl]3,4-dihydroxy phenyl ethylamine

Synthesis

Metabolism: It is metabolized by COMT and conjugation, but not by MAO.

Properties and uses: It is a white or almost white crystalline powder, sparingly soluble in water and alcohol, and soluble in methanol. It resembles dopamine chemically, but possesses a bulky aromatic residue on the amino group despite the absence of a β -OH group. This substitution gives a compound that possesses an asymmetric carbon atom. Thus, dobutamine exists as a pair of enantiomers possessing a distinct pharmacology. The (+) enantiomer is a potent agonist at both β_1 and β_2 receptors. The (–) enantiomer is 10 times less potent at β_1 and β_2 receptors. The (–) enantiomer is a potent agonist at α_1 receptors. It acts by directly interacting with α and β adrenergic receptors. Racemic dobutamine increases the inotropic action due to α_1 receptor when compared to chronotropic actions, and the effects are mediated by β receptors. It enhances the automaticity of SA node.

Storage: It should be stored in well-closed airtight containers, protected from light.


Assay: Dissolve the sample in anhydrous formic acid and add acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Dose: For acute heart failure: For adult: 2.5–10 µg/kg, up to 0.5–40 µg/kg according to patient's heart rate, cardiac output, BP and urine output. For cardiac stress test: Adult: 5 µg/kg/min for 8 min using a 1 mg/ml solution, dose is then increased at 5 µg/kg/min until 20 µg/kg/min, with each dose being infused for 8 min before the next increase.

Dosage forms: Dobutamine intravenous infusion B.P.

II. Noncatecholamines


a. Metaraminol (Aramine)




2-Amino-1-(3'-hydroxy phenyl) propanol

Synthesis

Route I. From: *m*-Hydroxy benzaldehyde




Route II. From: 1-(3-Hydroxyphenyl)propane-1-one

Properties and uses: It is a white crystalline powder, insoluble in ether, slightly soluble in ethanol, and freely soluble in water. It is structurally similar to phenylephrine. It enhances cardiac output, peripheral resistance, and blood pressure. It helps to increase the coronary blood flow thereby decreasing the heart rate. The drug is employed frequently in acute hypotensive states, such as anaphylactic shock or shock secondary to myocardial infarction and trauma.


Assay: It is assayed by nonaqueous titration: the solution of the substance is titrated with 0.1 M perchloric acid using crystal violet indicator.

Dose: By I.V. 0.5 to 5 mg in an emergency; by infusion, 15 to 100 mg/500 ml of dextrose injection or sodium chloride injection; By I.M. 2 to 12 mg.

Dosage forms: Metaraminol injection B.P.


b. Amphetamine (Synonym: Benzedrine)**Synthesis**

It is synthesized by reductive amination by phenyl acetone.



Properties and uses: The racemic mixture has a higher proportion of cardiovascular effects than the dextro isomer. For most medical uses, the dextrorotatory isomer is preferred. It is one of the most important sympathomimetic agents. CNS stimulant effect is due to stimulation of the cortex. The D-isomer is three to four times more potent than the L-isomer. It also has an anorexic action and can be used in the treatment of obesity.


c. Salbutamol (Synonym: Albuterol, Asthalin, Salbid)




4-Hydroxy-3-hydroxy methyl- α -[(tert butylamino)methyl]benzyl alcohol

Synthesis

Route I. From: Methyl-2-hydroxybenzoate



Route II. From: *o*-Hydroxy benzyl alcohol

Properties and uses: It is a white or almost white crystalline powder, sparingly soluble in water, but freely soluble in ethanol. It has strong β_2 adrenergic activity. It is useful in the treatment of acute myocardial infarction, severe left ventricular failure. It has been used to arrest premature labour and is effective in ocular hypotension by topical application. It is used only as a bronchodilator and is the drug of choice in the treatment of bronchial asthma.


Assay: Dissolve the substance in alcohol, to this add 0.1 M hydrochloric acid, titrate with 0.1 M sodium hydroxide using methyl red as indicator. End point is the appearance of yellow colour.

Storage: It should be stored in well-closed airtight containers, protected from light.

Dose: By oral inhalation the adult dose is 100 microgram, followed by a second dose after 5 min, if required.

Dosage forms: Salbutamol tablets and inhaler I.P., Salbutamol pressurized inhalation B.P.

d. Ephedrine (Epipres)




2-Methylamino-1-phenyl propan-1-ol

Metabolism: It is metabolized by COMT.

Properties and uses: Occurs as a waxy solid and as crystals, and has a characteristic pronounced odour. It is soluble in alcohol, water, and organic solvent. Ephedrine has two asymmetric carbon atom and four optical isomers. The erythroacetate is called Ephedrine. It has both α and β -adrenergic agonistic effect. It is used in a variety of conditions, such as allergic disorder, colds, hypotension conditions, and narcolepsy. Also, occasionally, used to treat enuresis to dilate the pupil.


Synthesis




Assay: A sample is dissolved in alcohol and to this add 0.1N HCl. The solution is titrated with 0.1N NaOH, using methyl red as indicator.

Dose: The usual dose is 10 to 25 mg every 3 to 4 h.

e. Naphazoline (Ocucel Eye Drops)



Synthesis




Properties and uses: It is a white crystalline, odourless, and bitter compound. The salt is soluble in water and in alcohol. They essentially exist in an ionized form at physiological pH because of the very basic nature of the imidazoline ring (pK_a 9 to 10). It is a **directly acting sympathomimetic drug, which is mostly used as a local vaso-constrictor for the relief of nasal congestion due to allergic or infarction manifestations.** It is also employed as an ophthalmic solution for the relief of ocular congestion and blepharospasm.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and alcohol. Titrate with 0.1 M sodium hydroxide and determine the end point by potentiometric titration.

Storage: It should be stored in well-closed airtight containers, protected from light.

Dose: For nasal mucosa, 2 drops of 0.05% solution; for conjunctivity, 1 to 2 drops of a 0.1% solution after every 3 to 4 hours.


f. Phenylephrine




1-(3-Hydroxy phenyl)-2-methylamino ethanol

Synthesis

Route I. From: 3-Chloro acetyl phenol



Route II. From: Phenol



Properties and uses: It is a white or almost white crystalline powder, freely soluble in ethanol and water. Phenylephrine differs from adrenaline only by lacking the 4th OH group on the benzene ring, and


subsequently, resistant to COMT and has predominantly α_1 agonist effect. The L-isomer, causes marked arterial vaso-constriction and is active when given orally. It finds its main use in the relief of nasal congestion and as a mydriatic. It is also used to prolong the action of local anaesthetics.

Assay: Dissolve the sample in a mixture of 0.1 M hydrochloric acid and ethanol. Titrate with 0.1 M ethanolic sodium hydroxide and determine the end point by potentiometric titration.

Dose: By topical, intranasal, adults dose is 2 to 3 drops or 1 or 2 sprays of 0.2 to 0.5% solution; Intramuscular, adults, for mild to moderate hypotension: 2 to 5 mg repeated every 10 to 15 min.


Dosage forms: Phenylephrine eye drops B.P., Phenylephrine injection B.P.

1. g. Isoxsupurine (Duvadilam, Suprox, Tidilan)



4-(1-Hydroxy-2-(1-phenoxypropyl-amino)propyl) phenol

Synthesis




Properties and uses: It is a white or almost white crystalline powder, insoluble in methylene chloride, sparingly soluble in water and alcohol. **It is used in the treatment of cerebral and peripheral vascular disease.** It has also been employed in the treatment of Ménière's disease and similar disorders of the internal ear.

Assay: Dissolve the sample in alcohol and add 0.1 M hydrochloric acid. Perform potentiometric titration using 0.1 M sodium hydroxide.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Orally 20 mg 4 times/day; I.V. infusion as a solution containing 100 mg in 500 ml of sodium chloride solution.

h. **Nylidrine HCl** (Synonym: Arlidin)




Synthesis



Dose: The usual dose initially by oral route 6 mg three times/day, which may be enhanced to 36 or 48 mg/day in divided doses.

i. **Xylometazoline** (Synonym: Otrivin, Otrinoz, Decon)


Synthesis



Properties and uses: It is a potent sympathomimetic agent, having marked and pronounced α -adrenergic pharmacologic profile. It is found to act as a vasoconstrictor, when applied topically to mucous membranes particularly. It is frequently employed as a local vaso-constrictor for nasal congestion caused by sinusitis or rhinitis.


Dose: By intranasal, 1 drop of a 0.1% solution in adult; or a spray of 0.05% solution.

j. **Terbutaline** (Synonym: Bricanyl, Brethine, Asmaril)



Properties and uses: It exists as a gray-white crystalline powder, odourless and with a bitter taste, soluble in water and alcohol. The drug exhibits the properties of a direct-acting sympathomimetic agent, having predominantly β_2 adrenergic activity, and has a selective action on the β_2 receptors (i.e. β_2 agonist). It is used only as a bronchodilator and in the treatment of asthma. It possesses strong β -agonistic activity.


Synthesis



Dose: Uncomplicated premature labour: Adult 5mg/min for 20 min, increased every 20 min, steps of 2.5 $\mu\text{g}/\text{min}$ until contractions have ceased (usually 10 $\mu\text{g}/\text{min}$ sufficient), continue for 1 h, then decrease every 20 min in steps of 2.5 $\mu\text{g}/\text{min}$ to lowest dose that maintains suppression, continue at this level for 12 h. Maximum dose is 20 $\mu\text{g}/\text{min}$. Switch to oral at 2.5–10 mg every 4–6 h, if indicated and tolerated. Continue as long as needed to prolong pregnancy.

STRUCTURAL-ACTIVITY RELATIONSHIP

Many of the sympathomimetic drugs contain β -phenyl ethylamine as parent structure.



I. Phenyl ring substitution

- Substitution on the meta and para positions of the aromatic ring and on the amino, α , and β positions of the ethylamine side chain influences the mechanism of sympathomimetic action and the receptor selectivity of the drug.
- Maximal activity is seen in β -phenyl ethylamine derivatives, containing hydroxyl groups in the meta and para positions of the aromatic ring (catechol) and a β -hydroxyl group of the correct stereochemical configuration on the ethylamine portion of the molecule.
- Although the catechol moiety is an important structural feature to obtain maximal agonistic activity at adrenergic receptors, it can be replaced with other substituted phenyl moieties to provide selective adrenergic agonism.
- For example, replacement of the catechol function of isoproterenol with the resorcinol structure gives the drug metaproterenol, which is a selective β_2 -receptor agonist.
- In an other approach, replacement of the meta hydroxyl of the catechol structure with a hydroxymethyl group afforded Salbutamol, which shows selectivity to the β_2 receptor.
- The naturally occurring noradrenaline has 3, 4-dihydroxy benzene ring (catechol) active at both α and β receptors. However, it has poor oral activity because it is rapidly metabolized by COMT, the change in substitution pattern 3, 5-dihydroxy as in metaproterenol gives good oral activity. This is due to its resistance to metabolism by COMT. It also provides selectivity for β_2 receptors.

II. Substitution at nitrogen

- Amino group in phenylethylamines is important for direct agonistic activity.
- The amino group should be separated from the aromatic ring by two carbon atoms found among the potent direct-acting agonists.
- As the bulk of the nitrogen substituent increases, α -receptor agonistic activity decreases and β -receptor activity increases. Thus, NE that is an effective β_1 -receptor agonist is also a potent α -agonist, while epinephrine is a potent agonist at α , β_1 , and β_2 receptors. *N*-tertiary butyl group enhances β_2 selectivity. As the size increases from hydrogen in noradrenaline to methyl in adrenaline, isopropyl in isoproterenol, the activity of α receptor decreases and β receptor increases.
- Primary and secondary amines are more potent direct-acting agonists than 3° or 4° amines.

III. Substitution on the carbon side chain

- Methyl or ethyl substitution on the α -carbon of the ethylamine side chain reduces direct receptor agonist activity at both α and β receptors.
- Importantly, an α -alkyl group increases the duration of action of the phenylethylamine agonist by making the compound resistant to metabolic deamination by MAO.
- α -substitution also significantly affects receptor selectivity.
- Another effect of α -substitution is the introduction of a chiral centre, which has pronounced effects on the stereo-chemical requirements for activity.

Chapter 3

Cholinergic Drugs

INTRODUCTION

Acetylcholine receptor stimulants and cholinesterase inhibitors together comprise a large group of drugs, called as cholinergic drugs that mimic the actions of acetylcholine. Cholinoceptor stimulants are classified pharmacologically by the spectrum of action depending on the type of receptor, muscarinic, or nicotinic.

SPECTRUM OF CHOLINOMIMETIC DRUGS

Early studies of parasympathetic nervous system showed that the alkaloid muscarine mimicked the effects of parasympathetic nerve discharge, that is, the effects were parasympathomimetic. Application of muscarine to ganglion and to autonomic effector tissue (smooth muscle, heart, exocrine glands) showed that para-sympathomimetic action of the alkaloid occurred through an action on receptors at effector cells, which are not in those of ganglia. Low concentrations of alkaloid nicotine stimulates autonomic ganglia and skeletal neuromuscular junction, but not autonomic effector cells. The ganglion and skeletal muscle receptors were, therefore, labelled nicotinic. Cholinoceptor are a protein linked (muscarinic) or ion channel (nicotinic) families, which functions on the basis of their trans-membrane signalling mechanism (Fig. 3.1).

Direct-acting Cholinoceptor Stimulants

The direct-acting cholinomimetic drugs can be divided on the basis of their chemical structure into esters of choline (including acetylcholine) and alkaloids (muscarine and nicotine). A few drugs are highly selective for specific muscarinic and nicotinic receptor. Many have effects on both receptors, for example, acetylcholine.

MECHANISM OF ACTION OF DIRECTLY ACTING CHOLINERGIC DRUGS

These drugs mediate the actions through muscarinic and nicotinic receptor subtypes. Stimulation of M_1 or M_3 receptors causes hydrolysis of polyphosphoinositides and mobilization of intracellular Ca^{2+} , as a consequence of interaction with a G protein and phospholipase C is activated, which phosphorylates the target protein. In contrast, M_2 and M_4 inhibit adenylcyclase and regulate specific ion channels, that is, enhancement




Figure 3.1 Major groups of cholinoreceptors-activating drugs, and target tissue.

of K^+ conductance in cardiac arterial tissue. Cholinergic stimulation affects cardiac function directly by inhibiting the effects of adrenergic activation. As a part, it decreases the cAMP formation and reduction on L-Type Ca^{2+} channel activity. In arterial muscles, acetylcholine decreases the strength of contraction. This effect is due to M_2 receptor mediated action of G protein regulated K^+ channels. Increased K^+ permeability leads to hyperpolarization and shortens the duration of action potentials.

Indirect Acting Cholinomimetic Drugs

The actions of acetylcholine released from autonomic and somatic motor nerves are terminated by enzymatic destruction of the molecule. Hydrolysis is accomplished by acetylcholinesterase. The indirect acting drugs have primary effect on the active site of this enzyme, although some also have direct actions at nicotinic receptors. The common differences between members of the group are chemical and pharmacokinetic, but their pharmacodynamic properties are identical.

MECHANISM OF ACTION OF INDIRECTLY ACTING CHOLINERGIC DRUGS (ANTICHOLINESTERASE AGENTS)

Acetylcholinesterase (AChE) is a serine dependent isoenzyme capable of hydrolyzing Ach to choline and acetic acid. The active site of AChE comprises two distinct regions, an anionic site that possess a glutamate residue and an esteratic site in which histidine imidazole ring and serine $-OH$ group are present. Catalytic hydrolysis occurs, thereby the acetyl group is transferred to the serine $-OH$ group, leaving an acetylated enzyme molecule and a molecule of free choline. Spontaneous hydrolysis of the serine acetyl group occurs rapidly.

There are two main categories of AChE inhibitors:

1. The amine or ammonium AChE inhibitors react reversibly with enzymes, these compounds reversibly acylate the esteratic serine hydroxyl, their duration of action are few minutes to few hours.
2. The organophosphate type AChE inhibitors form an irreversible firm bond with the enzymes (esteratic site) and their duration of action are few weeks to months.


CLASSIFICATION

These agents mimic the actions of acetylcholine at parasympathetic system and based on their mechanism of action, they are classified as follows:


I. Directly acting cholinergic drugs

A. Choline esters


i. Acetyl choline




ii. Methacholine



iii. Carbachol




iv. Bethanechol




B. Cholinomimetic alkaloids

i. Pilocarpine



ii. Muscarine




iii. Arecholine


II. Indirectly acting cholinergic drugs

A Reversible cholinesterase inhibitors


i. Physostigmine (Eserine)




ii. Neostigmine bromide (Pristigmine)




iii. Pyridostigmine bromide (Mestinon)




iv. Edrophonium chloride



v. Ambenonium chloride (mytelase)




vi. Demecarium (Humorsol)




vii. Distigmine (Ubretid)

B. Irreversible cholinesterase inhibitors


a. Pralidoxime chloride




b. Echothiopate iodide




c. Malathion



d. Isofluorophate



e. Parathion




SYNTHESIS AND DRUG PROFILE

I. Direct-acting cholinergic drugs


The direct-acting agents exert their effects by stimulating muscarinic/nicotinic receptors.

i. Acetylcholine chloride (Miochol)



(2-Acetoxy ethyl)-trimethyl ammonium chloride

Synthesis




Properties and uses: It is a white or almost white crystalline powder or colourless crystals, very hygroscopic in nature, slightly soluble in methylene chloride, soluble in water and alcohol. It is a topical ophthalmic drug to induce miosis, during certain intraocular surgical procedures, such as cataract surgery, ridectomy, penetrating keratoplasty, and other anterior-segment surgery. Systemically administered Ach is rapidly hydrolyzed by acetylcholinesterase, hence, it has no clinical use. It is a cardiac depressant and effective vasodilator.

Assay: Dissolve the sample in water and neutralize with 0.01 M sodium hydroxide using phenolphthalein solution as indicator. Add 0.1 M sodium hydroxide solution, allow it to stand for 30 min and titrate with 0.1 M hydrochloric acid.

Storage: It should be stored in well closed ampoules and protected from light.


Dose: Topically as a 1% solution.

ii. Methacholine chloride (Provocholine)



(2-Acetoxy) trimethyl propanaminium chloride

Synthesis




Properties and uses: It is highly deliquescent, has faint fishy odour, and aqueous solutions are neutral, soluble in water, alcohol, and CHCl_3 . It is used to treat Reynaud's syndrome and glaucoma.

Dose: For usual paroxysmal tachycardia, 10 to 25 mg; by S.C. for peripheral vascular disease 10 to 25 mg.

I. (a) Cholinomimetic Alkaloids

i. Carbachol (Synonym: Carbachol, Moistat)




2-[(Amino carbonyl oxy)-N,N,N-trimethyl ethan ammonium chloride

Properties and uses: It is a white crystalline, hygroscopic powder, soluble in water, sparingly soluble in alcohol, insoluble in acetone. It is an ester of carbamic acid, the terminal methyl group of Ach is replaced by amino group. It possesses both muscarinic and nicotinic properties by cholinergic receptor stimulation. It is more slowly hydrolyzed by acetylcholinesterase. It is used for its miotic actions in the treatment of glaucoma to reduce intraocular pressure.


Assay: Dissolve the sample in a mixture of anhydrous acetic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Synthesis

Route I: From Ethylene chlorohydrin




Route II: From Carbamic acid



Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Topically 0.1 ml of 0.75 to 3% solution.

ii. **Bethanechol chloride** (Synonym: Urecholine, Myotonachol, Bethacol, Urotonin)






2-[(Amino carbonyl) oxy] *N, N, N* trimethyl propan ammonium chloride

Properties and uses: It is a white crystalline hygroscopic powder, and it exhibits polymorphism, soluble in water and alcohol. It has pharmacological properties similar to those of methacholine. The presence of $-\text{CH}_3$ gives prolonged activity due to steric hindrance. It produces smooth muscle contractions. It is not well absorbed from the gastro-intestinal tract. It can be given subcutaneously, but not by intramuscular (IM) or intravenous (IV) because of its severe side effects. It is used to relieve urinary retention and abdominal distention after surgery. This is one of the postvagotomy gastric drug.

Synthesis

Route I. From: propylene chlorhydrin




Route II. From: Beta methyl choline chloride**Route III. From: Carbamic acid**

Dose: By oral 5 to 30 mg 3 or 4 times/day; By S.C. 2.5 to 10 mg 3 or 4 times/day.


I. (b) Cholinomimetic alkaloids

i. Pilocarpine (Pilicar, Carpine, Locarp)



3-Ethyl-4-[(1-methyl-imidazole-5-yl)methyl] tetrahydro-2-furanone

Synthesis



Properties and uses: It is a white or almost white crystalline powder or colourless crystals, hygroscopic, very soluble in water and in alcohol. Pilocarpine is an alkaloid obtained from the dried leaflets of *Pilocarpus jaborandi* and *Pilocarpus microphyllus* in which it occurs to the extent of about 0.5% together with other alkaloids. Pilocarpine is a nonselective agonist on the muscarinic receptors. It acts on M_3 receptors in smooth muscles and cause contractions in the gut, trachea, and eyes. It is used for the treatment of symptoms of dry mouth caused by radiotherapy for cancer of head and neck and the symptoms associated with Sjogren's syndrome.

Assay: Dissolve the sample in alcohol and add 0.01 M hydrochloric acid. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers, and protected from light.


Dose: Topically 0.1 ml of 0.5 to 6% solution into the conjunctival sac 1 to 5 times/day.

Dosage forms: Pilocarpine hydrochloride eye drops B.P.

II. Indirectly acting cholinergic drugs

A. Reversible blockers

i. Physostigmine (Isopto-Eserine)




Properties and uses: It exists as a white or almost white crystalline powder, hygroscopic, very soluble in water, and freely soluble in alcohol. It gradually becomes red when exposed to air and light; the colour develops more quickly when the substance is also exposed to moisture. Aqueous solutions are unstable. It melts at about 145°C with decomposition. It is an alkaloid obtained from the dried ripe seeds of *Physostigma venenosum*. It occurs as a white, odourless, microcrystalline powder, slightly soluble in H_2O , freely soluble in alcohol, $CHCl_3$, and fixed oils. Physostigmine is an oldest anticholinesterase agent. It is used in the treatment of glaucoma. It can penetrate the blood brain barrier and is employed to antagonize the toxic CNS effects of antimuscarinic drugs, tricyclic depressants, H_1 antihistamines, and benzodiazepines. It is also used in the treatment of Alzheimer's disease.

Assay: Dissolve the sample in a mixture of anhydrous acetic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight glass container and protected from light.

Synthesis



Dose: Topically for open-angle glaucoma, 0.1 ml of 0.25 to 5% solution instilled into the conjunctival sac 2 or 4 times/day.


ii. Neostigmine Bromide (Synonym: Prostigmine, Myostigmin, Tilstigmin)




3-[[[(Dimethyl amino) carbonyl] oxy]-N, N, N-trimethyl benzene ammonium bromide.

Synthesis

Route I. From: Meta nitro aniline



Route II. From: *m*-Chloro-*N,N*-dimethyl amino benzene


Properties and uses: It exists as white, odourless, crystalline powder with a bitter taste, freely soluble in water, alcohol, and insoluble in ether. Its solutions are neutral to litmus. It acts as a cholinesterase inhibitor.

Assay: Dissolve the sample in anhydrous formic acid, and then add acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight container and protected from light.

Dosage forms: Neostigmine bromide tablets I.P., Neostigmine methyl sulphate injection I.P., Neostigmine tablets B.P.

iii. Pyridostigmine Bromide (Synonym: Mestion, Pyrido, Trostigmin)




3-[[(Dimethyl amino) carbonyl] oxy]-1- methyl-pyridinium bromide

Properties and uses: It exists as white, crystalline powder with a characteristic odour and bitter taste, soluble in water, alcohol, chloroform, slightly soluble in hexane, and insoluble in ether. It is hygroscopic in nature. It is used in the treatment of myasthenia gravis and it antagonizes the effects of neuromuscular blocking (NMB) agents.


Assay: Dissolve the sample in anhydrous acetic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Synthesis

Route I. From: 3-Pyridinol



Route II. From: Pyridine-3-sulphonic acid




Storage: It should be stored in well-closed airtight container, protected from light. The sterile substance should be stored in airtight, tamper-proof containers, and protected from light.

Dose: Initially, 60 mg every 4 to 8 h, but 120 to 300 mg 6 times/day is the usual dose.


Dosage forms: Pyridostigmine tablets B.P.

iv. Edrophonium Chloride (Tensilon)


Ethyl (*m*-hydroxy phenyl) dimethyl ammonium chloride

Synthesis

Route I. From: Meta dimethylamino phenol



Route II. From: 3-Aminophenol



Properties and uses: It exists as a white crystalline powder, soluble in water and alcohol, insoluble in methylene chloride. On parenteral administration, edrophonium has a more rapid onset and shorter duration of action than neostigmine, pyridostigmine, or ambenonium. It is used as an antiarrhythmic drug in paroxysmal atrial tachycardia. It is also used in the diagnosis of myasthenia gravis.

Assay: Dissolve the sample in a mixture of equal volumes of acetic anhydride and anhydrous acetic acid. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: By I.V. 2 to 10 mg; usually 2 mg is injected initially and if no adverse reaction takes place within 30 sec, the remaining 8 mg may be injected.

Dosage form: Edrophonium injection B.P.


II (B) Irreversible blockers

i. Pralidoxime Chloride




2-Formyl-1-methyl pyridinium chloride oxime

Synthesis




Properties and uses: It exists as a white to pale yellow crystalline powder, odourless, soluble in water. Used as an antidote for parathion and related pesticides poison.

ii. Echothiophate



2-[(Diethoxyphosphonyl) thio] *N,N,N*-trimethyl ethan ammonium iodide

Synthesis




Properties and uses: It exists as white crystalline hygroscopic solid with slight mercaptane-like odour, soluble in water, methanol, or dehydrated alcohol, but insoluble in organic solvents. It is a long-acting irreversible anti-AchE drug, used in the treatment of glaucoma.

Dose: Topically for adult in the treatment of glaucoma, 1 drop of 0.03% to 0.25% solution.

STRUCTURE ACTIVITY RELATIONSHIP

- Acetylcholine can exist in a number of conformations. Four of these conformations are synplanar, synclinal, anticlinal, and antiplanar.
- The most active isomer is the (+) *trans* enantiomer and it is identical to synclinal conformation of acetylcholine.

- The muscarinic receptors and acetylcholinesterase display stereoselectivity, the (S) enantiomer of methacholine is equipotent with acetylcholine, while the R (–) enantiomer is about 20-fold less potent.



I. Modification of Quaternary Ammonium Group

- The quaternary ammonium group is essential for intrinsic activity, and contributes to the affinity of the molecule for the receptors, partially through the binding energy and partially because of its action as a detecting group.
- The trimethyl ammonium group is the optimal functional moiety for the activity, although some exceptions are known (e.g. pilocarpine, nicotine, and oxotremorine), and it shows maximal muscarinic activity.
- Placement of primary, secondary, or tertiary amines leads to decrease in activity.

II. Modification of acyloxy group

- The ester group of ACh contributes to the binding of the compound to the muscarinic receptor.
- Replacement of methyl group by ethyl or large alkyl groups produces inactive compounds.
- Esters of aromatic or higher molecular weight acids possess cholinergic antagonist activity.

III. Modification of ethylene bridge

- The methyl ester is rapidly hydrolyzed by cholinesterase to choline and acetic acid. To reduce susceptibility to hydrolysis, carbamate esters of choline (carbachol) were synthesized and were found to be more stable than carboxylate esters.
- Placement of α -substitution in choline moiety results in a reduction of both nicotinic and muscarinic activity, but muscarinic activity to a greater extent.
- Incorporation of β -substitution leads to reduction of nicotinic activity to greater extent.
- Replacement of ester group with ether or ketone produces chemically stable and potent compounds.

Chapter 4

Adrenergic Blockers

INTRODUCTION

Adrenergic blockers are also called as antiadrenergic drugs or sympatholytics. Adrenergic blocking agents prevent the response of effector organs to endogenous as well as exogenous adrenaline and noradrenaline. These drugs block the actions of adrenergic drugs at alpha (α) or beta (β) adrenergic receptors.

Many types of adrenergic antagonists are used and several of these are clinically useful in medicine, particularly in the treatment of cardiovascular diseases. Drugs that decrease the amount of norepinephrine released as a consequence of sympathetic nerve stimulation as well as drugs that inhibit sympathetic nervous activity by suppressing sympathetic outflow is also widely used in medications. Almost all of these agents are competitive antagonists in their interactions with either α or β adrenergic receptors, and one exception is phenoxybenzamine, an irreversible antagonist that binds covalently to α -adrenergic receptors. These are due to important structural differences among the various types of adrenergic receptors. Selective β_1 antagonist drugs are used to act on the heart and selective β_2 antagonist drugs are used to act on the respiratory system.

PHYSIOLOGICAL BASIS OF ADRENERGIC RECEPTOR ANTAGONISTS

Blockade of vasoconstrictor α_1 receptors reduces peripheral resistance and causes reduced cardiac output leads to decreased blood pressure. The α blockers abolish the pressor action of adrenaline, which then produces fall in the blood pressure due to β_2 mediated vasodilatation called *Dale's vasomotor reversal*. Pressor action of selective α -agonists is suppressed. Reflex tachycardia occurs due to the presynaptic α_2 receptors. Nasal stuffiness and miosis result due to the blockade of α_2 receptors. The therapeutic application of drugs coming under the adrenergic antagonists are receptor oriented, especially β blockers are used as antihypertensive, α adrenergic antagonists are used to control the peripheral vascular resistance.

Mechanism of Action of α -Adrenergic Blockers

α -Adrenergic receptor response in clinical relevance include α_1 receptor mediated contraction of arterial and venous smooth muscle. α_2 adrenergic receptors are involved in suppressing sympathetic output, increasing vagal tone, facilitating platelet aggregation, inhibiting the release of norepinephrine, and acetylcholine from nerve endings. Blockade of α_1 receptors inhibits vasoconstriction induced by endogenous catecholamines. Vasodilatation may occur in both arteriolar resistance vessels and veins. α_2 receptor regulates both central and peripheral sympathetic neurons. Acceleration of presynaptic α_2 receptors inhibits the norepinephrine release. In some vascular beds, these drugs promote vasodilatation through the release of nitric oxide (endothelial relaxing factor). Phenoxybenzamine inhibits the uptake of catecholamine from the nerve terminals. Phentolamine and tolazoline are competitive α adrenergic antagonists and block the receptor for 5-HT and it causes the release of histamine from the mast cells, which is a potent vasodilator.

Mechanism of Action of β -Adrenergic Receptor Blockers


β adrenergic receptor antagonists slow the heart rate and decrease the myocardial contractility, these prolongs the systolic conduction and disturbs the ventricular fibres. Dimensions of the ventricle is decreased, oxygen consumption is decreased, and thereby decreases the heart rate and aortic pressure. In blood vessels, these drugs reduces the noradrenaline release from the sympathetic terminals and decrease the renin from kidney due to the blockade of β receptors.

CLASSIFICATION


I. Alpha receptor blocking agents

a. Beta halo alkyl amines


i. Dibenamine



ii. Phenoxy benzamine




b. Natural and dehydrogenated ergot alkaloids




S.No	Name	R ₁	R ₂
1.	Ergotamine	-CH ₃	-CH ₂ C ₆ H ₅
2.	Ergocristine	-CH(CH ₃) ₂	-CH ₂ C ₆ H ₅
3.	Ergocriptine	-CH(CH ₃) ₂	-CH ₂ ·CH(CH ₃) ₂
4.	Ergocornine	-CH(CH ₃) ₂	-CH(CH ₃) ₂

c. Imidazole derivatives

i. Tolazoline






ii. Phentolamine



d. Quinazolines

i. Prazosin





ii. Terazosin**iii. Doxazosin****e. Miscellaneous**

Indoramine


Yohimbine

Chlorpromazine


II. Beta-receptor blocking agents**a. β -Blockers with membrane stabilizing activity and intrinsic sympathomimetic property****i. Oxprenalol****ii. Pindalol**

b. Specific β -blockers


i. Timolol




ii. Nodalol

c. β -blockers with membrane stabilizing activity


i. Propranolol

d. β -blockers with cardio selective action


i. Acebutolol




ii. Atenolol




iii. Metoprolol




iv. Esmolol

e. β -Blockers with α -blocking property

i. Labetolol




ii. Carvediol




SYNTHESIS AND DRUG PROFILE

I. Alpha-receptor blocking agents

i. Dibenamine


*N*-(2-Chloro ethyl)-*N*-Dibenzylamine

Synthesis



Uses: Used as an antihypertensive agent.

ii. Phenoxybenzamine (Dibenzylamine)




Properties and uses: Colourless, crystalline compound soluble in alcohol, water, and chloroform. Irreversible antagonist with nonselective actions, a major use of phenoxybenzamine is in the treatment of pheochromocytoma (tumours of the adrenal medulla). It is used to treat peripheral vascular diseases, such as Raynaud's syndrome. It has also been used in the case of shock and frostbite to improve blood flow to peripheral tissues. Used in the treatment of shock and in the treatment of pulmonary oedema.

Assay: It is assayed by nonaqueous titration: the solution of the sample is titrated with 0.1 M perchloric acid using oracet blue B as indicator.


Dose: The usual dose initially 10 mg/day, increased gradually to 60 mg/day in divided doses.

Dosage forms: Phenoxybenzamine capsules B.P.

Synthesis




iii. Tolazoline (Synonym: Priscoline)



Synthesis


Route I. From: Phenyl acetonitrile



Properties and uses: It is a white, bitter taste, crystalline compound with a slight aromatic odour, soluble in water, alcohol, and chloroform, but sparingly soluble in ether. It is an **imidazolidine derivative**. It is a **competitive alpha adrenergic antagonist** and possesses similar affinity for α_1 and α_2 receptors. It is a **vasodilator** and has a **sympathomimetic effect to stimulate the heart and causes mydriasis**. It is of some use in the treatment of Raynaud's disease, cerebral vascular accidents. It has been used in the treatment of **persistent pulmonary hypertension of the newborn**.

Dose: By I.M., I.V., S.C., for adults: 25 mg slowly, then increased upto 50 to 75 mg twice/day to 2 or 3 times/week.


iv. Phentolamine mesylate




3-[(4,5-Dihydro-1-imidazole-2-yl)methyl](4-methyl-phenyl)amino phenol

Synthesis

Route I: From 3-(*p*-Toluidino) phenol



Route II: From 2-chloroacetyl chloride


Properties and uses: It is a white, odourless, bitter powder, soluble in water and alcohol. Phentolamine is a nonselective α -adrenoreceptor antagonist with an immediate onset and short duration of action. In addition to α -blocking activity, it has weak muscarinic activity in the gastrointestinal tract and weak to mild histaminergic activity in the stomach. It is an α -adrenergic blocker used in urgent heart failure.

Assay: Dissolve the sample in 2-propanol and titrate under a current of nitrogen with 0.1 M tetrabutylammonium hydroxide in 2-propanol. Determine the end point potentiometrically, using a glass electrode as an indicator electrode and a calomel electrode containing a saturated solution of tetramethylammonium chloride in 2-propanol as the comparison electrode.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Phentolamine mesylate injection I.P., Phentolamine injection B.P.

v. Prazosin (Minipress, Prazopress)



1-(4-Amino-6-7-dimethoxy-2-quinazolinyl)-
4-(-2-furanyl carbonyl)-piperazine

Properties and uses: It is a white crystalline powder, soluble in water and alcohol. A selective α -antagonist, prazosin, reduces peripheral vascular resistance and lowers arterial blood pressure in both supine and erect patients. Dizziness, headache, and palpitations can occur. Used to treat hypertension of any degree. It has been used in decreasing cardiac overload.


Assay: Dissolve the sample in acetic anhydride and add anhydrous formic acid. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: For hypertension: the adult dose as hydrochloride: Initially, 500 μ g twice to thrice/day for 3–7 days, increased to 1 mg two times to three times for the next 3–7 days if tolerated and gradually increased thereafter according to the patient's response. Maximum dose is 20 mg/day.

Synthesis

Route I. From: 4, 5-Dimethoxy anthranilamide




Route II. From: 4,5-Dimethoxy anthranilic acid

For heart failure: The adult dose as hydrochloride is initially, 500 μg twice to thrice/day, gradually increased according to response, maintenance dose is 4–20 mg day.

For Raynaud's syndrome: Benign prostatic hyperplasia (BPH): The adult dose initially is 500 μg twice/day, increased to a maintenance dose of <2 mg twice/day.


Dosage forms: Prazosin tablets I.P., B.P.

vi. Terazosin (Olyster, Teralfa, Terapress)



2[[4-(Tetrahydro-2-furanyl)-carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinolinamine

Synthesis




Properties and uses: It is a white or slightly yellow crystalline powder, insoluble in acetone, sparingly soluble in water, slightly soluble in methanol and ethanol. This α_1 -adrenergic receptor blocker has a longer half life (12 h) and longer duration of action (24 h) than prazosin, but is otherwise, similar to prazosin. Because the α_1 -selective drugs have little action on presynaptic receptors, they do not increase norepinephrine concentrations and reflex sympathetic activity (tachycardia) is less likely to occur.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid methanol. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For hypertension: The initial dose for adult is 1 mg at bed time, gradually increased two to three times a day according to the patient's response. Maintenance dose is 2–10 mg once daily. Maximum effect observed with 20 mg/day in 1 or 2 divided doses.

vii. Doxazosin (Alfazosin, Doxacard, Duracard)



1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl piperazine

Synthesis



Properties and uses: It is a water soluble analogue of prazosin and terazosin. It is a white or almost white crystalline powder. It shows polymorphism and some forms may be hygroscopic. Slightly soluble in water, methanol, insoluble in acetone, but soluble in a mixture of water and tetrahydrofuran. It is a new selective α_1 -adrenergic receptor antagonist similar to prazosin. Doxazosin, possibly, may prevent influx of extracellular calcium and cause relaxation of vascular smooth muscle. Headache and dizziness are the two most prevalent adverse effects.


Assay: It is assayed by using liquid chromatography technique.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For hypertension: For adult as mesylate, initial dose is 1 mg at bed time increase after 1–2 week according to response. Maintenance dose is 4 mg once daily, maximum dose is 16 mg/ day.

II. Beta receptor blocking agents

i. **Propranolol** (Synonym: Inderal, Ipran, Manopralol, Beetacap)



Synthesis




Properties and uses: It is a white or almost white powder, soluble in water and in ethanol. Currently, it is approved for hypertension associated cardiac arrhythmia, angina pectoris, due to coronary atherosclerosis and prophylaxis of migraine headache. It is a nonselective β -adrenergic antagonist and it has equal affinity for β_1 and β_2 receptors.


Assay: Dissolve the sample in ethanol and titrate with 0.1 M sodium hydroxide. Determine the end point potentiometrically.

Dose: The oral adult dose for arrhythmias is 10 to 30 mg 3 to 4 times/day.

Dosage forms: Prolonged-release propranolol capsules B.P., Propranolol injection B.P., Propranolol tablets B.P.

ii. Acebutalol (Sectral)



Synthesis

Properties and uses: It is a white or almost white crystalline powder, slightly soluble in acetone and methylene chloride, but freely soluble in water and ethanol. It is one of the very few β -blockers with mild ISA and does not cause bradycardia as propranolol does. Acebutalol and betaxolol possess membrane stabilizing activity, but the activity is much weaker than that seen with propranolol.


Assay: Dissolve the sample in ethanol and add 0.1 M hydrochloric acid. Perform potentiometric titration by titrating with 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers, protected from light.

Dose: A dose of 400 mg/day given once daily.



Dosage forms: Acebutalol HCl tablets I.P., Acebutolol capsules B.P., Acebutolol tablets B.P.

iii. **Atenolol** (Atenex, Aten, Betacard)



Synthesis

Route I. From: 2-(4-Hydroxyphenyl) acetic acid

Route II. From: *p*-Hydroxy phenyl acetamide


Properties and uses: It is a white or almost white powder, sparingly soluble in water, but soluble in ethanol. It is a β_1 selective drug with low lipid solubility. Mainly used in the treatment of essential hypertension.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Dose: The usual dose is 50 mg/day once daily.


Dosage forms: Atenolol tablets I.P., B.P., Atenolol injection B.P., Atenolol oral solution B.P., Co-tenidone tablets B.P.


iv. Metoprolol (Betaloc, Lopresor, Metolar)



Synthesis

Route I. From: *p*-(2-Chloroethyl) phenol




Route II: From *p*-(2-Methoxy ethyl) phenol

Properties and uses: It is white, odourless powder, bitter in taste, soluble in water, alcohol, and chloroform, but insoluble in acetone and ether. It is a β_1 selective antagonist used in the treatment of hypertension.

Dose: The usual initial oral dose is 100 mg given preferably once daily.

v. β -Blockers with α -blocking property

i. Labetolol (Labesol, Normadate)



Properties and uses: It is a white or almost white powder, sparingly soluble in water and alcohol, but insoluble in methylene chloride. Labetolol is a phenyl ethanol amine derivative that is a competitive inhibitor at

both β_1 and β_2 adrenergic receptors and at the α_1 -adrenergic receptor. It is more potent β antagonist than α antagonist, since it has two asymmetric carbon atoms (1 and 1'), it exists as a mixture of four isomers. It is the mixture that is used clinically in treating hypertension. The different isomers, however, possess different α - and β -antagonistic activities.


Assay: Dissolve the sample in a mixture of anhydrous formic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Dose: The usual initial dose is 100 or 200 mg twice/day with food.

Dosage forms: Labetalol injection B.P., Labetalol tablets B.P.


ii. Carvedilol (Cardivas, Carvedil, Carvipress)

It acts on both β and α -adrenergic receptors. Only δ isomer is β -blocking, and both enantiomers have α -blocking activity.



1-(Carbazol-4-yloxy)-3-[2-(2-methoxy phenoxy)ethyl amino]-2-propanol

Synthesis



Properties and uses: It is a white or almost white crystalline powder, insoluble in water and dilute acids, but soluble in alcohol. It shows polymorphism. Used in treating hypertension and congestive heart failure.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Dose: For hypertension: Adult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg twice/day increased to 12.5 mg twice/day after 1–2 week, increased further if necessary to 50 mg once daily or in divided doses. For elderly: 12.5 mg once daily.


For angina pectoris: Adult: Initially, 12.5 mg twice/day increased to 25 mg twice/day after 2 days.

For heart failure: Adult: Initially, 3.125 mg twice/day, doubled to 6.25 mg twice/day after 2 weeks, if tolerated.

For left ventricular dysfunction: After myocardial infarction: Adult: Initially: 6.25 mg twice/day, if tolerated, after 3–10 days, increase to 12.5 mg twice/day and then to a target dose of 25 mg twice/day.

STRUCTURE-ACTIVITY RELATIONSHIP

Propranolol has become one of the most thoroughly studied and widely used drug in the therapeutic armamentarium; it is the standard against which all other β antagonists are compared.



- The aromatic ring and its substituent is the primary determinant of β_1 antagonistic activity. The aryl group also affects the absorption, excretion, and metabolism of the β blockers.
- β blockers are structurally similar to β agonist. The catechol ring can be replaced by a variety of ring system without loss of antagonistic activity.
- Replacement of catechol hydroxyl group with chlorine of phenyl ring system retains β blocking activity. Example: pronethalol, dichloroisoproterenol.
- *N,N*-disubstitution decreases the β blocking activity, and the activity is maintained when the phenyl ethyl, hydroxy phenyl ethyl, or methoxy phenyl ethyl groups are added to amine as a part of the molecule.
- The two carbon chains are essential for activity.
- The introduction of $-OCH_2$ group into the molecule between the aromatic ring and the ethyl amine side chain provides β blocking agents, for example, propranolol.
- As in the sympathomimetics, bulky aliphatic groups, such as the tert-butyl and isopropyl groups are normally found on the amino function of the aryloxypropanolamine β receptor antagonists. It must be a secondary amine for optimal activity.
- As with the sympathomimetic agents, the configuration of the hydroxyl bearing carbon of the aryloxypropanolamine side chain play a critical role in the interaction of β antagonist drugs with β receptor. The carbon must possess the (S) configuration for optimal affinity to the β receptor. The enantiomer with the (R) configuration is typically 100 times less potent.

Chapter 5

Anticholinergic Drugs

INTRODUCTION

The parasympatholytics or cholinergic blocking agents include atropine and related alkaloids obtained from plants, such as *Atropa belladonna*, *A. accuminata*, *Hyosyamus niger*, *Scopolola carniolica*, *Datura stramonium*, and synthetic or semisynthetic atropine substitutes. These drugs in the therapeutic doses predominantly block the muscarinic actions of acetylcholine, but the ganglionic and skeletal neuromuscular actions of acetylcholine are not affected.

Cholinergic receptor blocking drugs or antagonists are divided into muscarinic and nicotinic subgroups on the basis of their specific receptor affinities. The antinicotinic drugs consist of ganglion blockers and neuromuscular junction blockers. The ganglion-blocking drugs have little clinical use. Muscarinic antagonists are often called as parasympatholytics. There are naturally occurring compounds with antimuscarinic effects that have been known and used in medicines and cosmetics as well as in poisons. Atropine is a prototype of these drugs. Many similar plant alkaloids are known and hundreds of synthetic antimuscarinic compounds have been prepared.

Muscarinic receptor antagonists prevent the effects of acetylcholine by blocking its binding to muscarinic cholinergic receptors at neuroeffector sites on smooth muscles, cardiac muscles and gland cells; in peripheral ganglia; and in the central nervous system. In general, M receptor antagonists cause little effect on the N receptor sites. However, quaternary ammonium analogues of atropine and related drugs, generally, exhibit a greater degree of nicotinic blocking activity, and consequently, are more likely to interfere with the ganglions on neuromuscular transmission. In the central nervous system (CNS) both muscarinic and nicotinic receptors are distributed at the spinal, subcortical, and cortical levels in the brain. At a high dose or a toxic dose, the actions in the CNS of the atropine and related drugs, generally, produce stimulation followed by depression.

Parasympathetic neuroeffector junctions in the different organs are not equally sensitive to even the nonselective muscarinic receptor antagonists. A small dose of atropine depresses salivary and bronchial secretion and sweating. With large doses, the pupil dilates, accommodation of lenses to near vision is inhibited. The heart rate is increased due to the vagal block. The actions of many of the clinically

available muscarinic receptor antagonists differ only quantitatively from those of atropine considered as the prototype. The currently available classes of drugs include the following:

1. Naturally occurring alkaloid-atropine and scopolamine (atropine from a plant *A. belladonna*).
2. Semisynthetic derivatives such as Homatropine, Atropine methonitrate, Ipratropium bromide, and Tiotropium bromide.
3. Synthetic congeners (show some selectivity for nicotinic and muscarinic receptors).

Out of these synthetic compounds, according to their various therapeutic uses, they have been segregated into mydriatics (cyclopentolate), antisecretory, and antispasmodics (propantheline, oxyphenonium, dicyclomine, and pirenzepine) and also antiparkinson's drugs (trihexyphenidyl, procyclidine, and biperiden). The cholinergic blocking agents can be grouped pharmacologically according to their location and type of cholinergic receptors into the following:

1. Parasympathetic postganglionic blocking agents or antimuscarinic agents.
Example: Atropine, Scopolamine.
2. Ganglionic blocking agents.
Example: Hexamethonium, Curare alkaloids, Pancuronium bromide.
3. Neuromuscular blocking agents.
Example: Tubocurarine, Metocurine.

DIFFERENCE BETWEEN THE QUATERNARY AND THE TERTIARY ANTIMUSCARINICS

Quaternary Amines

- These drugs do not pass through the blood brain barrier, and hence, lack CNS actions.
- Penetrate poorly into the eye from the blood stream or cornea.
- The quaternary compounds have greater affinity for nicotinic receptors, so that a great degree of ganglionic blockade may result.
- These are mostly excreted unchanged into the urine.

Tertiary Amines

- These drugs can penetrate the cell membranes in the nonionized form, and hence, can pass through the blood brain barrier. In the brain, they can exert both therapeutic and toxic actions.
- These drugs penetrate through the cornea and cause mydriasis and cycloplegia.
- They do not have nicotinic receptor affinity.
- These drugs are biotransformed in the liver.

Therapeutic Uses


1. Used topically to dilate the pupil and paralyze accommodation.
2. Used as a preanaesthetic medication, to inhibit excessive salivary, bronchial secretions, and to prevent bronchospasm and laryngospasm.

3. The antisecretory effects are also sought in the treatment of acute coryza, hay fever, and rhinitis.
4. Used in the treatment of bronchial asthma and peptic ulcer.
5. Used in the treatment of Parkinson's disease.


CLASSIFICATION

I. Solanaceous alkaloids and analogues


i. Atropine




ii. Scopolamine (Hyoscine)



iii. Homatropine




iv. Ipratropium bromide




II. Amino alcohol esters


i. Cyclopentolate




ii. Clidinium




iii. Dicyclomine




iv. Eucatropine HCl




v. Glycopyrrolate bromide



vi. Methantheline bromide




vii. Propantheline bromide




III. Amino ethers

i. Orphenadrine citrate




ii. Benztropine mesylate




IV. Amino alcohols


i. Biperiden



ii. Procyclidine HCl




iii. Trihexyl phenidyl




V. Amino amides

i. Tropicamide




ii. Isopropamide iodide



VI. Diamides


i. Ethopropazine HCl




ii. Diethazine

VII. Miscellaneous amines

i. Diphenmail methyl sulphate



ii. Pirenzepine




iii. Methixene HCl

iv. Glycopyrronium bromide

SYNTHESIS AND DRUG PROFILE

I. Solanaceous alkaloids and analogues


i. Atropine (Atp, Tropine)



8-Methyl-8-aza-bicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate

Properties and uses: It is a white crystalline powder or colourless crystals, freely soluble in alcohol and well soluble in water. It is the tropine ester of racemic tropic acid and is optically inactive. The greater molar potency of atropine helps it to block several moles of acetylcholine. The umbrella-like atropine molecule may mechanically or electrostatically inactivate adjacent receptors on the cell surface so that these receptors are also unavailable for acetylcholine or other parasympathomimetic stimulants. Atropine has all the actions and uses of antimuscarinic drugs.

Synthesis




Assay: Dissolve the sample in anhydrous acetic acid and warm it, if necessary. Cool the solution and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: In Bradycardia: Adult: 500 µg every 3–5 min totally 3 mg.

Dosage forms: Atropine methonitrate injection I.P., Atropine sulphate injection I.P., Atropine sulphate tablets I.P., Atropine sulphate ointment I.P., Atropine Eye drops B.P., Atropine Eye ointment B.P., Atropine injection B.P., Atropine tablets B.P., Morphine and Atropine injection B.P.

ii. Scopolamine




Synthesis




Properties and uses: It exists as colourless or white crystals or white granular powder, odourless, slightly efflorescent in dry air, and is an anhydrous salt, soluble in water or alcohol and in chloroform, insoluble in ether. Scopolamine is the levo component of the racemic mixture that is known as Hyoscine. It is effective in the prevention of motion sickness. It is a competitive blocking agent of the parasympathetic nervous system like atropine, but it differs markedly from atropine in its action on the higher nerve centres.

iii. Homatropine (Isopto)



Tropane-3 α -ol mandelate

Synthesis



Properties and uses: It is a white crystalline powder or colourless crystals, sparingly soluble in alcohol, but freely soluble in water. It is used topically on the ciliary structure of the eye and to effect mydriasis.


Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and alcohol. Perform potentiometric titration using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers, protected from light.

Dose: Topically for adult, to the conjunctiva, 1 drop of a 2%–5% solution given three times at 10 min intervals.


Dosage forms: Homatropine eye drops B.P.

iv. Ipratropium Bromide (Ipneb, Ipranaseaq, Ipratop)



(\pm)-endo-3-(3-Hydroxy-1-oxo-2-phenyl propyl)-8-methyl-8-(1-methyl ethyl-8-azoniabicyclo octane bromide

Synthesis



Properties and uses: It is a white or almost white crystalline powder, freely soluble in methanol, soluble in water, but slightly soluble in ethanol. It is used in the inhalation therapy to produce dilation of bronchial smooth muscle for acute asthmatic attacks. It produces broncho-dilation by competitive inhibition of cholinergic receptors bound to the smooth muscles of the bronchioles.


Assay: Dissolve the sample in water and add 3 ml of dilute nitric acid. Titrate with 0.1 M silver nitrate and determine the end point potentiometrically.

Dose: For inhalation reversible airways obstruction and COPD, maximum dose is 320 μ g daily as nebulized solution.

Dosage forms: Ipratropium Nebuliser solution B.P., Ipratropium powder for inhalation B.P., Ipratropium pressurized inhalation B.P.

SAR Solanaceous Alkaloids (Atropine Analogues)

Atropine




- The greater molar potency of atropine helps to block several moles of acetylcholine.
- The umbrella-like atropine molecule may mechanically or electrostatically inactivate adjacent receptors on the cell surface so that these receptors are also unavailable for acetylcholine or other parasympathomimetic stimulants.

- The circled portion of the atropine molecule depicts the segment resembling acetylcholine.
- The amine functional group is separated from the ester oxygen by more than two carbons, the conformation assumed by tropanol ring orients these two atoms such that the intervening distance is similar to that of acetylcholine. On the basis of the assumption that the size was a major factor in the blocking action, many substituted acetic acid ester of amino alcohol were prepared and evaluated for biological activity.
- The most potent compounds were those that possessed two lipophilic ring substituents on the carbon alpha to carbonyl of ester moiety for antimuscarinic activity.

II. Amino alcohol esters


i. Cyclopentolate HCl (Cyclopent, Cycilate, Dilate)




2-(Dimethylamino) ethyl-1-hydroxyl- α -phenyl cyclopentane acetate hydrochloride

Synthesis

Route I. From: Sodium phenyl acetate



Route II. From: Phenyl acetate ion




Properties and uses: It exists as white crystalline powder, soluble in water, methanol, and ethanol, but insoluble in toluene. Cyclopentolate is usually employed as eye drops to cause cycloplegia and mydriasis. It acts much faster than atropine and possesses a relatively shorter duration of action.

Assay: Dissolve the sample in a mixture of 0.1 M hydrochloric acid and alcohol. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Dose: Typically for adult, 1 drop of 1 or 2% solution to the conjunctiva; for refraction 1 drop of a 0.5% solution repeated after 5 to 15 min.


Dosage forms: Cyclopentolate eye drops B.P.

ii. Clidinium Bromide




3-OH-1-Methyl quinuclidium bromide benzilate

Synthesis




Uses: Used as a bronchodilator in asthmatic conditions. It has a longer lasting effect as compared to β -agonists.

iii. Dicyclamine HCl (Bentyl, Mesbentyl)



Synthesis




Properties and uses: It exists as a white, crystalline powder with a bitter taste, soluble in water and chloroform. Dicyclamine HCl behaves both as an antimuscarinic and a nonspecific antispasmodic agent. It

was first introduced in 1950 and had minimized the adverse effects associated with the atropine type of compounds. Dicyclomine has spasmolytic effect on various smooth muscle spasms particularly those associated with the gastrointestinal (GI) tract. It is also used in dysmenorrhoea, pylorospasm, and biliary dysfunction.


Dose: By oral or I.M. 10 to 20 mg per day in four divided dose.

iv. Glycopyrrolate Bromide




N,N-Dimethyl pyrrolidinium bromide-3- α -cyclopentyl mandelate

Synthesis



Properties and uses: It exists as a white, crystalline powder with a bitter taste, soluble in water and alcohol. It is used for suppressing gastric secretion and in the treatment of peptic ulcer and gastrointestinal disorder associated with spasm.



v. Propanthelin bromide (Probanthine, Spastheline)



(Ethyl) di isopropyl methyl ammonium bromide xanthene-9-carboxylate

Synthesis

Route I. From: Xanthene-9-carboxylic acid

Route II. From: *o*-phenoxy benzoic acid

Properties and uses: It is a white or yellowish-white powder, slightly hygroscopic, soluble in water, in alcohol, and in methylene chloride. It is beneficial for the treatment of peptic ulcer, due to the decreased gastric motility by this drug, and it may relieve the pain in this condition.

Assay: Dissolve the sample in acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight container, and protected from light.

Dose: The usual initial dose is 15 mg thrice/day before meals; and 30 mg at bed time.

Dosage forms: Propantheline bromide tablets I.P., Propantheline tablets B.P.


III. Amino ethers

i. Orphenadrine citrate (Orphipal)



N, N-Dimethyl-2-(*o*-methyl- α -phenyl benzyloxy) ethylamine citrate

Synthesis




Properties and uses: It is a white or almost white crystalline powder, sparingly soluble in water, slightly soluble in alcohol. It is used for the symptomatic treatment of Parkinson's disease. It is also used as a skeletal muscle relaxant.

Assay: Dissolve the sample in anhydrous acetic acid and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed containers. If the substance is sterile, it should be stored in a sterile, airtight, tamper-proof container, and protected from light.


Dose: The initial oral dose is 100 mg twice/day; I.M. or I.V. 60 mg every 12 hrs.

ii. Bzotropine Mesylate



3 α -(Diphenyl methoxy)-1 α H,5 α H-tropine methan sulphonate

Synthesis




Properties and uses: It is a white crystalline powder, insoluble in ether, but soluble in water and ethanol. It has anticholinergic, antihistaminic, and local anaesthetic activities. It is used in the treatment of Parkinson's disease.


Dosage forms: Benzatropine injection B.P., Benzatropine tablets B.P.

IV. Amino Alcohol

i. Biperiden (Akineton Hydrochloride)

 α -5-Norbornen-2-yl- α -phenyl-3-(piperidine-1-yl) propanol

Synthesis




Properties and uses: It is a white crystalline powder, slightly soluble in methylene chloride, in water, and in alcohol. It has a relatively strong musculotropic action, which is about equal to that of papaverine, in comparison with most synthetic anticholinergic drugs. It is used in all types of Parkinson's disease.

Assay: Dissolve the sample in alcohol and titrate with 0.1 M alcoholic potassium hydroxide and determine the end point potentiometrically

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: For parkinsonism, 2 mg 3 or 4 times/day.

ii. Procyclidine HCl (Kemadrin, Picidin, Prodrine)



1-Cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-1-propanol HCl

Synthesis




Properties and uses: It exists as white crystalline powder, and it has been used for peripheral effects that are similar to methantheline. Its clinical usefulness lies in its ability to relieve voluntary muscle spasticity through its central action. Procyclidine is used in the treatment of Parkinson's disease.

Assay: It is assayed by nonaqueous titration. The solution of the sample is titrated with 0.1 M perchloric acid using crystal violet as an indicator.


Dose: The initial oral dose is 7.5 mg/day in 3 or 4 divided doses after meals; maintenance dose is usually 20 to 30 mg per day.

Dosage forms: Procyclidine injection B.P., Procyclidine tablets B.P.

iii. Trihexylphenidyl (Pacitane, Parkin, Triphen)

 α -Cyclohexyl- α -phenyl-1-piperidine propanol

Synthesis



Properties and uses: It is a white crystalline powder, slightly soluble in water, sparingly soluble in alcohol and in methylene chloride. It is used as antispasmodic and antiparkinsonian agent. Trihexylphenidyl is more effective than levodopa against Parkinson's tremor.


Assay: Dissolve the sample in alcohol and add 0.01 M hydrochloric acid. Perform potentiometric titration using 0.1 M sodium hydroxide.

Dose: Initial oral dose is 1 mg on first day, followed by 2 mg daily after 3 to 5 days; maintenance dose, 6 to 10 mg/day in 3 to 4 divided doses but not exceeding 20 mg/day.

Dosage forms: Trihexylphenidyl tablets B.P.

V. Amino Amides

i. Tropicamide (Tropicamet, Tmide Ed, Optimide)




N-Ethyl-2-phenyl-*N*-(4-pyridylmethyl)-3-hydroxy-propionamide

Properties and uses: It is a white or almost white crystalline powder, soluble in alcohol and methylene chloride, but slightly soluble in water. Used to induce mydriasis and cycloplegia in ophthalmologic practice and it has short duration of action.


Assay: Dissolve the sample in anhydrous acetic acid, to this add naphtholbenzein solution, and titrate with 0.1 M perchloric acid. End point is the change of colour from orange to green.

Synthesis

Route I. From. Tropic acid



Route II. From: Tropic acid




Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual adult topical dose is 1 to 2 drops of a 0.5% or 1% solution to the conjunctiva; for mydriasis 0.5% solution is employed, and for cycloplegia 1% solution.

Dosage forms: Tropicamide eye drops I.P., B.P.

SAR of Muscarinic Antagonists



- For the potent cholinergic antagonist, the groups R^1 and R^2 must be hydrophobic in nature (usually, phenyl, cyclohexyl, or cyclopentyl).
- In the above general structure for amino alcohol, the substituent R^1 and R^2 should be a carbocyclic or a heterocyclic ring for maximal antagonistic potency.
- The ring may be identical, but the more potent compounds have different rings. The one ring is aromatic and other may be saturated or possessing only one olefine bond. Example: Propantheline.

- Their ability to do these effectively is because of the large group of R^1 and R^2 that enhance the binding to receptors since the antagonists are larger than agonists.
- The R^3 substituent may be a hydrogen atom, hydroxyl group, hydroxy methyl group or a carboxy amide, or it may be a component of R^1 and R^2 ring system. When the substituent is a hydroxyl group or hydroxy methyl group the antagonist is usually more potent. Due to the hydroxyl group presumably there might be an increase in the binding strength by participating in a hydrogen bond interaction at the receptor.
- The X substituent in the most potent anticholinergic agent is an ester, but an ester functional group is not absolutely necessary for muscarinic antagonistic activity.
- The N substituent is a quaternary ammonium salt in the most potent anticholinergic agents. Tertiary amine also possesses antagonist activity presumably by binding to the receptors in the cationic form. The alkyl substitution is usually methyl group, ethyl group, propyl, or isopropyl group.
- The distance between ring substituted carbon and amine nitrogen is apparently not critical, as much as the length of alkyl chain connecting this, may be from two to four carbons. The most potent anticholinergic agent has two methylene units in this chain.

PROBABLE QUESTIONS

1. Classify the various receptors involved in ANS. Write the structure, chemical name, and uses of one potent drug acting in each receptor.
2. How will you classify the sympathomimetic agents on the basis of chemical structure? Outline the synthesis of one catecholamine and one noncatecholamine used in the treatment of Bronchial asthma.
3. Write the structure, chemical name, and uses of any three important sympathomimetic drugs and discuss the synthesis of one such a compound selected by you.
4. Describe the synthesis and metabolic pathway of a sympathomimetic drug used in the treatment of Hypotensive shock.
5. What are sympathomimetic agents? Classify them and write the synthesis of any three drugs from different class.
6. What is epinephrine and norepinephrine? Outline their biosynthetic pathway and metabolism in the body.
7. Write in detail about the SAR of sympathomimetics.
8. Write the mode of action of sympathomimetics on alpha and beta receptors.
9. Write note on drugs used for their inotropic action on the heart.
10. Define and classify adrenergic blockers. Outline the synthesis and uses of any two of them from different class.
11. Outline the synthesis, mode of action, and uses of one important medicinal compound used as an autonomic drug belonging to the following categories:
 - (a) Alpha-adrenoreceptor blocking agent
 - (b) Beta-adrenoreceptor blocking agent

12. Name one compound belonging to the category of cholinomimetic drugs that are either directly acting or indirectly acting. Describe their synthesis and uses.
13. Write a comprehensive account of antimuscarinic agents by giving the structure, chemical name, and uses of one important representative from each category.
14. Write the mode of action of direct-acting cholinergic agents and indirect-acting cholinergic agents.
15. Define and classify cholinergic agents and write in detail about reversible cholinesterase inhibitors.
16. Write a brief note on cholinomimetic alkaloids.
17. Enumerate the importance of ganglionic blocking agents as autonomic drugs. Describe the synthesis of mecamlamine hydrochloride.
18. Write in brief about solanaceous alkaloids and its analogues.
19. Write the synthesis and uses of propanthelin bromide and trihexyphenidyl.
20. Write the SAR of muscarinic antagonists.
21. Write the structure, synthesis, chemical name, and uses of the following autonomic drugs:
 - (a) Carbachol
 - (b) Neostigmine
 - (c) Pralidoxime
22. Describe the mode of action of the following:
 - (a) Ganglionic blocking agents
 - (b) Antimuscarinic agents
23. Write a comprehensive account of the adrenergic neurone blocking agents with specific reference to:
 - (a) Bethanidine sulphate
 - (b) Guanethidine monosulphate

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. Bevan DR. 'Newer neuro muscular blocking agents'. *Pharmacol Toxicol* 74(3): 3–9, 1994.
3. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
4. *British Pharmacopoeia* Medicines and Healthcare Products Regulatory Agency. London, 2008.
5. Gennaro AR. *Remington: The Science and practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
6. Goyal RK. 'Muscarinic receptor subtypes: Physiology and clinical implication'. *N Engl J Med* 321: 1022, 1989.
7. Gringauz A. *Introduction to Medicinal Chemistry*. New York: Wiley-VCH, 1997.
8. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
9. Lednicer D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: Wiley, 1995.
10. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.

11. Nathanson NM. 'Molecular properties of the muscarinic acetylcholine receptor'. *Am Rev Neuro Sci* 10: 197, 1987.
12. Nelson HS. 'Beta adrenergic agonists'. *Chest* 82: 335, 1982.
13. Rosendorff C. 'Beta blocking agents with vasodilator activity'. *J Hypertens* 11: 537, 1993.
14. Ruffolo RR (Jr). 'Fundamentals of receptor theory: Basis of shock research-circ'. *Shock* 37: 173, 1992.
15. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
16. Sargent PB. 'The diversity of neuronal nicotinic acetylcholine receptors'. *Ann Rev Neurosc* 16: 403, 1993.
17. Salem MR. 'Therapeutic uses of ganglionic blocking drugs'. *Int Anesthesiol Clin* 16: 171, 1978.

"This page intentionally left blank"

DRUGS ACTING ON CARDIOVASCULAR SYSTEM

1	Cardiovascular System	447
2	Antihypertensive Agents	449
3	Antiarrhythmic Drugs	476
4	Antihyperlipidemic Drugs	499
5	Antianginals	520

"This page intentionally left blank"

Chapter 1

Cardiovascular System

INTRODUCTION

Arterial pressure is the product of cardiac output (CO) and peripheral vascular resistance. Hypertension is the most common cardiovascular disease. The pressure elevated from the normal arterial pressure induced pathological changes in the vasculature that produces hypertrophy of left ventricle, which principally causes stroke, myocardial infarction, cardiac arrest, renal insufficiency, and dissecting aneurysm of the aorta. It is important to note that the risk of both fatal and nonfatal cardiovascular disease in adults is lowest with systolic B.P. less than 120 mm Hg and diastolic less than 80 mm Hg. In severe levels of hypertension (systolic ≥ 210 and/or diastolic ≥ 120), some patients develop arteriopathy characterized by endothelial injury and marked proliferation of cells in intima, leading to intimal thickening and causes occlusion. This may also lead to severe microangiopathic haemolytic anaemia. Effective antihypertensive therapy will almost completely prevent haemorrhagic stroke, cardiac failure, and renal insufficiency. The usual approach to a patient with diastolic B.P. in the range of 85–94 mm Hg is to use nonpharmacological therapy as the initial strategy, which includes the life-style strategy. As the arterial pressure is the product of peripheral vascular resistance (PVR) and cardiac output, it can be lowered by the action of drugs either on the peripheral vascular resistance or CO or both.

Aetiology of Hypertension

It is important to consider specific causes in each of the case, however, because some of them are amenable to definite surgical treatment, renal artery constriction, and contraction of aorta, pheochromocytoma, Cushing's disease, and primary aldosteronism. The patients in whom no specific cause of hypertension can be found are said to have essential hypertension. Elevated BP underlies epidemiological evidence that points to genetic inheritance, psychological stress, environmental, and dietary factors (increased salt and decreased potassium or calcium intake).

The heritability of essential hypertension is estimated to be about 30%. Mutations in several genes have been linked to various rare causes of hypertension. Functional variations of genes for angiotensinogen, angiotensin-converting enzyme, and β_2 adrenoceptor appear to contribute to some cases of essential hypertension.

Normal Regulation of Blood Pressure

According to hydraulic equation, arterial blood pressure is directly proportional to CO and PVR.

$$BP = CO \times PVR$$

BP is maintained by moment-to-moment regulation of CO and PVR, exerted at three anatomical sites, that is, arterioles, postcapillary venules, and heart.

The fourth anatomical control site, the kidney contributes to the maintenance of blood pressure regulating fluid in the body. Baroreceptor reflexes mediated by ANS are in combination with humoral mechanisms, including the renin-angiotensin-aldosterone system to co-ordinate function at these four control sites and to maintain normal B.P. regulation. All antihypertensive drugs act by interfering with the above-specified mechanism. They are as follows:

1. Diuretics
 - a. Thiazides and related agents
 - b. Loop diuretics
 - c. Potassium sparing diuretics
2. Sympatholytic drugs
 - a. Centrally acting agent
 - b. Adrenergic neuron blocking agent
 - c. β adrenergic antagonist
 - d. α adrenergic antagonist
 - e. Mixed α and β adrenergic antagonist
3. Vasodilators
 - a. Arterial vasodilators
 - b. Arterial and venous vasodilators
4. Angiotensin converting enzyme inhibitors
5. Angiotensin II receptor antagonists

Chapter 2

Antihypertensive Drugs

INTRODUCTION

Antihypertensive drugs are defined as the drugs that are used to decrease the elevated blood pressure (hypertension).

Hypertension

It is one of the common cardiovascular disorders and it is a state of the body in which the systolic blood pressure (BP) is 150 mm Hg or more and diastolic BP is 95 mm Hg or more. Hypertension may be classified into primary and secondary:

PRIMARY HYPERTENSION

It is other wise known as essential hypertension. It is characterized by the following:

- Elevation of diastolic BP.
- Normal cardiac output.
- An increase in peripheral resistance.

SECONDARY HYPERTENSION

Factors causing secondary hypertension are as follows:

- Acute or chronic renal disease.
- Hyperaldosteronism.
- Cushing's syndrome.
- Acromegaly.
- Pheochromocytoma.
- Oral contraceptives, steroids, estrogen, and sympathomimetics.

Antihypertensive drug therapy has improved remarkably in the last 50 years. Before 1950, less effective and less tolerated antihypertensive drugs were available. Veratrum and sodium thiocyanate could lower BP, but were toxic and difficult to use. The ganglion blockers that were developed in the 1950s were effective, but inconvenient. Reserpine was a breakthrough, but produced mental depression. The therapeutic potential of hydralazine was not tapped fully because of the marked side effects when it was used alone. Guanethidine introduced in 1961 was an improvement on the ganglion blockers. The antihypertensives of 1960–70s were methyldopa, β -blockers, thiazides, high-ceiling diuretics, and clonidine. The antihypertensives of 1980–90s are angiotensin II converting enzyme inhibitors and calcium channel blockers. Angiotensin receptor blockers (losartan) are the latest antihypertensives. Diuretics and related drugs are the choice in uncomplicated hypertension. These drugs reduce plasma and extra cellular fluid volume by 5%–15% that decrease cardiac output. The reduction in total peripheral resistance is most probably an indirect consequence of small persisting Na^+ and volume defect. Decreased intracellular Na^+ concentration in the vascular smooth muscle may decrease stiffness of vessels wall, increase compliance, and dampen responsiveness to constrictor stimuli of noradrenaline and angiotensin II.


Angiotensin-converting enzyme (ACE) inhibitors are one of the first choice drugs in all the grades of essential as well as renovascular hypertension. When it is used alone, 50% of the patients are benefited and the addition of a diuretic/ β blocker extends the efficacy to 90%. Angiotensin receptor blockers give peak action at 2–4 weeks. Calcium channel blockers such as dihydropyridines, phenylalkylamine, and benzothiazepine are equally effective antihypertensives. Beta adrenergic blockers give 30%–40% efficacy in mild-to-moderate cases.

CLASSIFICATION


I. Diuretics





a. Thiazides

i. Chlorthiazide




ii. Hydrochlorthiazide




iii. Cyclopenthiazide**iv. Bendroflumethiazide****b. Loop diuretics****i. Frusemide or furosemide****ii. Ethacrynic acid**

iii. Bumetanide




c. Potassium-sparing diuretics

i. Triamterene




ii. Spiranolactone (Aldosterone antagonists)




II. Drugs acting on sympathetic system


a. Centrally acting drugs

i. Clonidine




ii. α -Methyl dopa

iii. Guanabenz



b. Catecholamine depletors


Reserpine




c. Adrenergic blockers

i. β -adrenergic blockers


1. Propranolol




2. Atenolol




3. Metoprolol




4. Oxprenolol




5. Acebutalol




6. Timolol



7. Nadolol




8. Pindolol




ii. α -Adrenergic blockers


1. Phentolamine




2. Phenoxy benzamine hydrochloride




3. Tolazoline




4. Prazosin




5. Terazosin




6. Doxazosin

iii. Mixed α and β blockers (nonselective)

1. Labetalol




2. Carvedilol



iv. Imidazoline receptor agonist


1. Moxonidine




2. Rilmenidine

d. Aderenergic neuron blockers


i. Guanethidine




ii. Guanoxan



iii. Debrisoquine




iv. Bethanidine




e. Ganglion blockers

i. Quaternary ammonium compounds

1. Hexamethonium bromide




2. Pentolinium tartarate




ii. Secondary amines

1. Mecamylamine HCl



iii. Tertiary amines


1. Pempidine




2. Trimethoprim

III. Calcium channel blockers


i. Verapamil




ii. Nifedipine




iii. Diltiazem




iv. Felodipine




v. Amlodipine



vi. Nicardipine




vii. Nitrendipine




IV. Drugs acting on renin-angiotensin system

- Drugs that block renin release—Propranolol.
- Drugs that inhibit angiotensin II—Saralasin.
- Drugs that inhibit angiotensin II receptors.


i. Losartan




ii. Irbesartan




iii. Candesartan



iv. Telmiesartan



v. Valsartan




d. Drugs that inhibit aldosterone—Spironolactone


e. ACE inhibitors









i. Sulphahydryl containing ACE inhibitors

Captopril




ii. Dicarboxylate containing ACE inhibitors




S. No.	Name	R ₁	R ₂	Ring
1	Enalapril	-CH ₃	-C ₂ H ₅	
2	Enalaprilat	-CH ₃	-H	
3	Lisinopril	-(CH ₂) ₄ NH ₂	-H	
4	Ramipril	-CH ₃	-C ₂ H ₅	
5	Quinapril	-CH ₃	-C ₂ H ₅	
6	Trandolapril	-CH ₃	-C ₂ H ₅	
7	Spirapril	-CH ₃	-C ₂ H ₅	
8	Moexipril	-CH ₃	-C ₂ H ₅	

V. Vasodilators


i. Hydralazine




ii. Diazoxide



iii. Minoxidil



iv. Sodium Nitroprusside




VI. Miscellaneous

MAO inhibitors—Pargyline, Metyrosine, Pinacidil

SYNTHESIS AND DRUG PROFILE


I. Drugs acting on renin-angiotensin system

i. Captopril (Aceten, Capotril)



1-[(2S)-3-Mercapto-2-methyl-1-oxopropionyl] pyrrolidine-2-carboxylic acid

Synthesis



Properties and uses: It is a white or almost white crystalline powder and it dissolves in dilute sodium hydroxide and potassium hydroxide solution. It is also soluble in water, methylene chloride, and methanol.

The first orally effective ACE inhibitor to have been marketed, it is approved for use in the treatment of hypertension, heart failure, left ventricular dysfunction, and postmyocardial infarction.


Assay: Dissolve the sample in water and titrate with 0.05 M iodine. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers, and protected from light.

Dose: The usual dose is 12.5 or 25 mg twice daily.

Dosage forms: Captopril tablets B.P.


ii. **Enalapril** (Envas, Enace, Enam, Enapril)



1-[N (S)-1-Carboxy-3-phenyl propyl]-L-alanyl-L-proline-1'-ethyl ester

Properties and uses: It is a white or almost white, crystalline powder, and it dissolves in dilute solutions of alkali hydroxides, sparingly soluble in water, freely soluble in methanol, but insoluble in methylene chloride. A prodrug is converted to the active ACE inhibitor, enalaprilat. It is indicated for use in the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It produces well to excellent responses in patients with essential hypertension.

Synthesis




Assay: Dissolve the sample in water and titrate with 0.1 M sodium hydroxide. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 10–40 mg in one or two divided doses by oral route.

iii. Lisinopril (Hipril, Lipril, Linvas)



1-[N-2- [(S)-1-Carboxy-3-phenyl propyl]-L-lysyl]-L-proline dihydrate


Properties and uses: It is a white or almost white crystalline powder, and is insoluble in acetone and in ethanol, soluble in water, but sparingly soluble in methanol. It is used in the treatment of renovascular hypertension, essential, malignant hypertension, and also for ventricular congestive heart failure.

Assay: Dissolve the sample in water and titrate with 0.1 M sodium hydroxide. Determine the end point potentiometrically.


Dose: The usual dose is 10mg/day.

Dosage forms: Lisinopril tablets B.P.

Synthesis



iv. Ramipril (Hopace, Cardace, Race)




Properties and uses: It is a white or almost white crystalline powder, sparingly soluble in water, but freely soluble in methanol. It is used as an antihypertensive agent, and is also used in the treatment of nephropathy.


Assay: Dissolve the sample in methanol and add water. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Step I: Synthesis of Compound A



Step II: Synthesis of compound (3aS,6aS)-Octahydrocyclopenta[b]pyrrole-2-carboxylic acid (B)




Step III: Condensation of products of *Step I* (A) and *Step II* (3a*S*,6a*S*)-Octahydrocyclopenta[*b*] pyrrole-2-carboxylic acid



Dose: For hypertension: Adult: Initial, dose is 1.25 mg once daily given at bed time. Maintenance: 2.5–5 mg daily as a single dose, up to 10 mg daily as needed.

Dosage forms: Ramipril capsules B.P., Ramipril tablets B.P.


v. Quinapril




Properties and uses: It exists as white crystals. It is used as an antihypertensive agent and is also used in the treatment of congestive heart failure.

Dose: The initial oral dose is 10 mg once daily.

Synthesis




vi. Benazepril (Benace)



Properties and uses: It exists as a white crystalline powder that is soluble in water, ethanol, or methanol. It is beneficial for patients with congestive heart failure.


Dose: The Benazepril, administered at 10 mg/day is as efficacious as captopril at 50 mg/day, enalapril at 20 mg/day.

Synthesis




II. Angiotensin II Antagonist

i. Losartan




Properties and uses: It exists as white crystalline powder that is soluble in water, alcohol, acetonitrile, or 2-butanone. It is used as an antihypertensive agent and also in the treatment of heart failure.

ii. Irbesartan




Properties and uses: It exists as white crystals that are soluble in ethanol or methylene chloride. It is an angiotensin II receptor antagonist.

iii. Candesartan




Properties and uses: It exists as colourless crystals and is used as an angiotensin II receptor antagonist.

iv. Telmisartan



Properties and uses: It exists as a white solid, insoluble in water or in aqueous solutions. It is used as an antihypertensive agent.


v. Valsartan




Properties and uses: It exists as white crystals and it is a nonpeptide angiotensin II receptor antagonist.

III. Vasodilators

i. Hydralazine (Apresoline)



Synthesis



Properties and uses: It is a white or almost white crystalline powder, which is slightly soluble in methylene chloride, but soluble in water and slightly soluble in alcohol. It is one of the few drugs that cause substantial vasodilation in the kidney and it increases renal plasma flow even when the blood pressure drops considerably. The side effects of tachycardia and palpitations may precipitate attacks of angina pectoris. It is used in the treatment of moderate to severe hypertension.


Assay: Dissolve the substance in water and add 35 ml of hydrochloric acid. Titrate with 0.05 M potassium iodate and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 25 to 100 mg oral twice daily; 20 to 40 mg I.V. in emergency.


Dosage forms: Hydralazine HCl injection I.P., Hydralazine injection B.P., Hydralazine tablets B.P.

ii. **Minoxidil** (Mintop, Coverit, Multigain)



2, 4-Diamino-6-piperidino pyrimidine-3-oxide

Synthesis



Properties and uses: It is a white or almost white crystalline powder, which is slightly soluble in water, soluble in methanol and in propylene glycol. Minoxidil, which is a piperidino pyrimidine derivative directly relaxes arteriolar smooth muscle, and is indicated for patients with severe hypertension, who do not respond to other drugs. It is used as the last line of therapy to treat moderate to severe essential hypertension. It often is effective in hypertension refractory as compared to all other therapies. A side effect is excessive hair growth. Consequently, the drug is used topically to restore hair growth in androgenic alopecia and alopecia areata.


Assay: Dissolve in anhydrous acetic acid and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is initially 5 mg; can be increased to 40 mg/day.


Dosage forms: Minoxidil scalp application B.P.

iii. Diazoxide (Hyperstat)



7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide

Synthesis




Properties and uses: It is a white or almost white and fine crystalline powder that is soluble in dilute solutions of alkali hydroxides, in dimethylformamide, slightly soluble in alcohol, but insoluble in water. A potent vasodilator, especially in the intravenous route, it can be used intravenously as a hypotensive drug in acute hypertensive crisis. Vasodilation is primarily the result of arteriolar dilation, so that orthostatic hypotension is usually minimal. It is also used as antihyperglycemic agent.


Assay: Dissolve it by gentle heating in a mixture of water and dimethylformamide. Titrate with 0.1 M sodium hydroxide and determine the end-point potentiometrically.

Dose: The usual dose is 1 mg/kg every 10 min

Dosage forms: Diazoxide Injection B.P., Diazoxide Tablets B.P.

iv. Sodium Nitroprusside (Nipride)



Synthesis

Properties and uses: It is a reddish-brown powder or crystals, which are freely soluble in water, but slightly soluble in alcohol. A potent directly acting peripheral vasodilator, this drug has an immediate onset of effect and short duration of action, therefore, it is effective in treating hypertensive emergencies, but must be given by continuous intravenous infusion. Side effects of this drug include significant hypotension and cyanide or thiocyanate toxicity.

Assay: Dissolve the substance in water and add dilute sulphuric acid. Titrate with 0.1 M silver nitrate and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 1 mg/kg/min by I.V. infusion.

Dosage forms: Sodium nitro prusside intravenous infusion B.P.

Chapter 3

Antiarrhythmic Drugs

INTRODUCTION

Antiarrhythmic agents corrects the arrhythmia of the heart. Cardiac arrhythmias are frequent problems in clinical practice, occurring in up to 25% of the patients treated with digitalis, 50% of the anaesthetized patients, and over 8% of the patients with acute myocardial infarction. Many factors can precipitate or exacerbate arrhythmias, ischaemia, hypoxia, acidosis, alkalosis, electrolyte abnormalities, excessive catecholamine exposure, autonomic influences, drug toxicity, over stretching of cardiac fibres, and the presence of any diseased tissue. However, all the arrhythmias result from the following:

1. Disturbances in impulse formation
2. Disturbances in impulse conduction
3. Or both

The different types of cardiac arrhythmias are the following:

1. **Extra systole:** Premature beats due to abnormal automaticity or after depolarization, arising from atrioventricular (AV) node, atrium, or ventricle.
2. **Paroxysmal supraventricular tachycardia:** Sudden onset of atrial tachycardia mostly due to circus re-entry type within or around the AV node.
3. **Atrial flutter:** Higher impulse and the arterial beat up to 200–350/min.
4. **Atrial fibrillation:** Atrial fibres are activated asynchronously at the rate of 300–550/min.
5. **Ventricular tachycardia:** It is a run of four consecutive ventricular extra systoles. It may be sustained or unsustained arrhythmia due to discharge from ectopic focus.
6. **Torsades de pointes:** Twisting of valves leads to polymorphic ventricular change and produces asynchronous complexes.
7. **Ventricular fibrillation:** Fractional activation of ventricles resulting in incoordinated contraction of fibres with loss of pumping function.
8. **Atrio-ventricular block:** It is due to depression of the impulse conduction through AV node and bundle of His due to vagal influence and ischaemias.

CLASSIFICATION

Antiarrhythmic drugs are classified into four types, according to their electrophysiological properties. The drugs that are used for arrhythmias are sodium, potassium, and calcium channel blockers. Some have additional or even primary autonomic effects.

Class 1: These have primary action on Na^+ and K^+ across the cell membrane.


Class 2: These have primary action to suppress adrenergically mediated ectopic activity.

Class 3: These are the drugs that prolong the repolarization. Action potential is widened and effective refractory period is increased.


Class 4: Their primary action is to inhibit Ca^{2+} mediated currents.

Class I: Blockade of fast sodium ion channel by depressing phase of the action potential

a. Moderate to marked sodium channel blockade agents




b. Mild-to-moderate sodium channel blockade agents




Lid


ocaine



Mexiletine




Tocainide




Phenytoin


c. Marked sodium channel blockade agents




Flecainide



Encainide




Lorcainide




P


ropafenone




Aprindine




Indecainide




Pilsicainide

Class II: Beta Adrenergic Antagonists


Acebutalol




Esmolol




talol



Propranolol




Timolol




Pindolol


Class III: Repolarization prolongators



Amiodarone




Bretylium tosylate




Acecainide

-Dofetilide
-Ibutilide

Class IV: Calcium channel blockers



Verapamil



Diltiazem


SYNTHESIS AND DRUG PROFILE

Class I: Blockade of fast sodium ion channel by depressing phase of the action potential

Mode of action: These agents block the specific channels and decrease the threshold for excitability. It decreases the conduction velocity in fast response tissues and increases QRS duration. These drugs also inhibit the triggered activity arising from delayed after depolarization (DAD) or early after depolarization (EAD) and shifts the voltage dependence of recovery from inactivation to more negative potentials, thereby tending to increase the refractoriness.

I. a. Moderate to marked sodium channel blockade agents

i. Quinidine Sulphate



(6-Methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol

Metabolism: Once absorbed, quinidine is subjected to hepatic first-pass metabolism and is approximately 85% plasma protein bound, with an elimination half-life of approximately 6 h. It is metabolized mainly in the liver, and the renal excretion of unchanged drug also is significant (10%–50%). The metabolites are hydroxylated derivatives at either the quinoline ring through first-pass O-demethylation or at the quinuclidine ring through oxidation of the vinyl group. These metabolites possess only about one-third of the activity of quinidine.


Properties and uses: It exists as a white or almost white crystalline powder or silky colourless needles. It is insoluble in acetone and slightly soluble in water, but soluble in boiling water and alcohol. Quinidine is an alkaloid isolated from cinchona bark. It is dextrorotatory diastereoisomer of quinine. **Quinidine is very useful for long-term treatment of ventricular premature depolarization or to prevent recurrences of ventricular tachycardia after cardioversion of this arrhythmia.** Quinidine should not be used without prior digitalization. It can cause cinchonism, characterized by hearing loss, vomiting, and diarrhoea.

Assay: Dissolve the sample in acetic anhydride and titrate with 0.1 M perchloric acid, using naphtholbenzein as an indicator.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Quinidine sulphate tablets I.P., B.P., Quinidine HCl tablets I.P., Quinidine dihydrochloride I.P., Quinidine bisulphate tablet I.P.

ii. Procainamide HCl (Pronestyl)



Synthesis



Metabolism: Metabolites of procainamide include *p*-amino benzoic acid and *N*-acetyl procainamide. The acetylated metabolite also active antiarrhythmic agent. Metabolism is catalyzed by *N*-acetyl transferase.

Properties and uses: It is a white crystalline powder, odourless, and soluble in water, alcohol, slightly soluble in chloroform, very slightly soluble in ether. It was developed in the course of research for compounds structurally similar to procaine. It is also more stable in water than procaine. It is useful in suppressing arrhythmias of ventricular origin. It is also effective against premature atrial contractions and atrial fibrillations. It is used in the management of myotonia. It is also used in the treatment of arrhythmias in alcohol withdrawal.


Assay: Dissolve the sample in dilute hydrochloric acid and perform the determination of primary aromatic amino-nitrogen (Diazotization method).

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 3 to 6 g orally at intervals of 6 to 8 h.


Dosage forms: Procainamide injection B.P., Procainamide tablets B.P., Procainamide HCl injection I.P., Procainamide HCl tablets I.P.

iii. Disopyramide Phosphate (Norpace, Regubeat)



α -[(2-Diisopropylamino)ethyl]- α -phenyl-2-pyridine acetamide

Synthesis



Metabolism: Half of the drug is excreted unchanged, rest of the amount undergoes hepatic metabolism to form *N*-dealkylated compound.

Properties and uses: It is a white or almost white powder, which is soluble in water, sparingly soluble in alcohol, and insoluble in methylene chloride. Used as an antiarrhythmic agent.


Assay: Dissolve the sample in anhydrous acetic acid and add naphtholbenzein indicator. Titrate with 0.1 M perchloric acid until the colour changes from yellow to green.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Total daily dose is 400–500 mg; 100–150 mg four times/day.


Dosage forms: Disopyramide phosphate capsules B.P.

iv. **Moricizine HCl** (Ethmozine)



Ethyl-10-(3-morpholinopropanoyl)-phenothiazin-2-yl-carbamate hydrochloride


Synthesis



Properties and uses: These are white crystals, which are soluble in water or alcohol. It is used in the treatment of cardiac arrhythmia.

Dose: The usual dose is 600 mg/day in three divided doses. It infrequently causes gastrointestinal and CNS effects.


v. Tiracizine HCl



Properties and uses: Tiracizine hydrochloride is an antiarrhythmic drug reported to reduce excitability of cardiac cells through blockade of fast sodium channels.


I. b. Mild-to-moderate sodium channel blockers

i. Lidocaine



Synthesis and drug profile are discussed under sec III, 'Local Anaesthetics'.

ii. Phenytoin (Dilantin, Eptoin)




5,5-Diphenylimidazolidine-2,4-dione

Synthesis

Synthesis and drug profile are discussed under sec III, Chapter 'Anticonvulsants'.


Dose: Orally 15 mg/kg first day; 7.5 mg/kg on the second day, followed by 300 to 400 mg per day.

iii. Mexiletine HCl




1-(2,6-Dimethylphenoxy)propan-2-amine hydrochloride

synthesis





Properties and uses: It exists as white crystals, which is soluble in water and alcohol. It resembles lidocaine as it possesses a xylol moiety, but is otherwise different chemically. Mexiletine is most useful in suppressing symptomatic ventricular arrhythmias.

iv. Tocainide HCl (Tonocard)



Properties and uses: It exists as a white crystalline powder with bitter taste and soluble in water or in alcohol. Tocainide is another lidocaine congener and is similar to mexiletine in its electro-physiologic properties and antiarrhythmic action.

Dose: The usual dose is orally 400–1200 mg in two or three divided doses.

Synthesis**I. c. Marked sodium channel blockers****i. Flecainide (Tambocar)**

2, 5-Bis(2, 2, 2-trifluoroethoxy)-N-[(4-[2, 2, 2-trifluoroethoxy]piperidin-2-yl)methyl]benzamide

Properties and uses: It is a white or almost white crystalline powder, very hygroscopic, soluble in water and in ethanol, insoluble in dilute hydrochloric acid and soluble in dilute acetic acid. Flecaïnide represents the first fluorine containing newer group of antiarrhythmic drugs. It is indicated for use in patients with life threatening arrhythmias, such as sustained ventricular tachycardia.


Assay: Dissolve the sample in anhydrous acetic acid. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: The usual dose is orally, 100 mg twice daily with an average daily maintenance doses from 200 to 600 mg.

Dosage forms: Flecaïnide injection B.P., Flecaïnide tablets B.P.

Synthesis




ii. Encainide HCl




Uses: It is used in the treatment of cardiac dysfunction.

iii. Lorcainide HCl




Synthesis



Properties and uses: Lorcainide proved to be effective in reducing ventricular arrhythmias and tachycardias.

Dose: The usual dose is 100 mg, 2 or 3 times/day.


iv. Propafenone HCl (Rhythmnorm)



(±)2'-(2-Hydroxy-3-propylamino propoxy)-3-phenyl propiophenone hydrochloride

Properties and uses: It exists as white crystals, which is soluble in hot water and in alcohol. It is slightly soluble in cold water. It is a class I-c antiarrhythmic drug and contains a chiral centre, and is marketed as the racemic mixture. The racemic mixture of propafenone produces effects that can be attributed to both (S) and (R) enantiomers. The (R) and (S) enantiomers exert similar Na⁺ channel-blocking effects,

Synthesis




the (S) enantiomers also produces a β -adrenergic blockade. As a result, the (S) enantiomer is reported to be 40-fold more potent than the (R) enantiomers as an antiarrhythmic agent. The enantiomers also display stereoselective disposition characteristics. The (R) enantiomer is cleared more quickly. It is useful in supraventricular and ventricular tachycardias and tachyarrhythmias. It resembles the β adrenoceptor blockers of aryloxy propanol amines.

Assay: Dissolve the sample in anhydrous formic acid and add acetic anhydride. Titrate with 0.1 M perchloric acid, determine the end point potentiometrically.


Dose: Initially 150 mg thrice/day which can be gradually increased to twice the initial dose.

v. Aprindine HCl




N-(3-Diethylamino propionyl)-*N*-phenyl-2-indanamide hydrochloride

Synthesis



Properties and uses: Aprindine is a powerful antiarrhythmic drug that may reverse both supraventricular and ventricular arrhythmias.


vi. Indecainide HCl




9-[3-(Isopropylamino propyl)]-fluorene-9-carboxamide hydrochloride

Properties and uses: It has shown itself to be a highly efficacious and well-tolerated antiarrhythmic drug for the suppression of ventricular tachycardias.

Synthesis



vii. Pilsicainide HCl



N-(2,6-Dimethylphenyl)-2-(hexahydro-1*H*-pyrrolizin-7*a*-yl) acetamide


Properties and uses: Pilsicainide hydrochloride is a new pyrrolizidine lidocaine derivative with antiarrhythmic activity. It is effective in the treatment of premature ventricular contraction.

II. β -Adrenergic Receptor Blockers

Mode of action: These are the drugs that mediate the actions through β receptors. β -adrenergic receptor antagonists slow the heart rate and decrease the myocardial contractility; these also prolong the systolic conduction and disturb the ventricular fibres. Dimensions of the ventricle and oxygen consumption are

decreased, and thereby decreases the heart rate and aortic pressure. In blood vessels, these drugs reduce the noradrenaline release from the sympathetic terminals and decrease the rennin from the kidney due to the blockade of β receptors.


i. Acebutolol



Synthesis and drug profile are discussed under sec IV, 'Adrenergic Blockers'

Properties and uses: It is a white to off-white powder that is soluble in water and alcohol. It is a β_1 -selective adrenergic receptor blocker and is used for controlling ventricular pressure beats.


ii. Esmolol HCl (Cardesmo, Neotach)




Properties and uses: It is available as white crystals and it is used in the treatment of supraventricular tachycardia.

Dose: A loading dose of 500 $\mu\text{g/kg/min}$ is infused over 1 minute followed by a maintenance dose of 50 $\mu\text{g/kg/min}$.

Synthesis




iii. Sotalol (Sotagrad)



Properties and uses: It is a white or almost white powder that is insoluble in methylene chloride, but freely soluble in water and in alcohol. It contains a chiral centre and is marketed as a racemic mixture. Because of its enantiomers, its mechanism of action spans two of the antiarrhythmic drugs classes. The l (–) enantiomer has both β -blocking agent (Class II) and potassium channel-blocking (class III) activity. The d (+) enantiomer has class III properties similar to those of the (–) isomer, but its affinity for the β -adrenergic receptors is 30–60 times lower. The sotalol enantiomers produce different effects on the heart. Class III action of d-sotalol in the sinus node is associated with slowing of the sinus heart rate, whereas β -adrenergic blockade contributes to the decrease in the heart rate observed with l or d-sotalol. It is effective against both supraventricular and ventricular arrhythmias.

Synthesis



Assay: Dissolve the sample in anhydrous formic acid and add acetic anhydride. Titrate with 0.1 M perchloric acid, determine the end point potentiometrically.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: The usual dose is 80 to 320 mg twice a day oral.


III. Repolarization Prolongers

Mode of Action: The prolongation effect is mostly due to the blockade of K^+ channels, although enhanced inward Na^+ current also prolongs the action potentials increased inward current produces the QT prolongation. The cardiac block of K^+ channels increases action potential duration and reduces normal automaticity.

i. Amiodarone (Cardarone, Aldarone, Amiodar)



Synthesis



Properties and uses: It is a white to cream-coloured crystalline powder, which is sparingly soluble in water, soluble in alcohol and chloroform. It is an iodinated benzofuran derivative, which is effective in maintaining rhythms in patients who has direct current shock for atrial fibrillation. It is also used as an antianginal agent.


Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and ethanol. Perform potentiometric titration using 0.1 M sodium hydroxide.

Storage: It should be stored in well-closed airtight containers and protected from light at a temperature not exceeding 30°C .

Dose: The usual dose is 400 mg alternating with 600 mg daily for 1 to 3 weeks orally.


Dosage forms: Amiodarone intravenous infusion B.P., Amiodarone tablets B.P.

ii. Bretylium tosylate



2-Bromo-1-(*N*-ethyl-*N,N'*-dimethylamino methyl benzene salt with 4-methyl benzene sulphonic acid.

Synthesis



Properties and uses: It is a white crystalline powder and exhibits polymorphism. freely soluble in water, in ethanol, and in methanol. It is used as antiadrenergic, antiarrhythmic, and antihypertensive agent.


Assay: Dissolve the sample in 1,4-dioxan and titrate with 0.025 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dose: Administered by I.M. or by slow I.V. infusion of 5 to 10 mg/kg over 10 to 30 min.

Dosage forms: Bretylium injection B.P.

iii. Acecainide



Synthesis



Uses: It is effective in suppressing a variety of treatment of ventricular arrhythmias.

IV. Calcium Channel Blockers

This is discussed in detail under Antianginals.

i. Verapamil (Calaptin, Vasopten)

Dose: Daily oral dose is 180 to 480 mg in acute cases, 5 to 10 mg slow I.V. over 2 min.

ii. Diltiazem (Dilzem, Angizem, Cardisec)

Dose: The usual dose is 60–90 mg of diltiazem, which can be given every 6 h for prophylactic control against paroxysmal supraventricular tachycardia.

Chapter 4

Antihyperlipidaemic Agents

INTRODUCTION

The lipids of human plasma are transported into the macromolecular complex and termed as lipoproteins. A number of metabolic disorders that involve the elevation of any lipoprotein series are termed as hyperlipoproteinaemias or hyperlipidaemias. The two major clinical sequelae of the hyperlipoproteinaemia are the acute pancreatitis and atherosclerosis. Lipoproteins contain apolipoprotein (*apo*). Blood conveys lipids into the artery wall that have low-density lipoprotein.

The pharmacological agents that reduce the concentration of plasma lipids are called hypocholesterolaemic agents. An increase in the plasma lipids, particularly cholesterol is a common feature of atherosclerosis, a condition involving arterial damage, which may lead to ischaemic heart diseases, myocardial infarction, and cerebrovascular accidents.

Lipids are insoluble in water, and they are transported into the plasma as lipoproteins, an increase in the plasma concentration of these substances is called hyperlipidaemia or hyperlipoproteinaemia. Lipoproteins consist of a central core of hydrophobic lipids (triglycerides or cholesteryl esters) encased in a more hydrophilic coat of polar substances—phospholipids, free cholesterol, and associated proteins, that is, apoproteins.

Lipoproteins are classified into four types: high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and chylomicrons.

Hyperlipoproteinaemias can be the following:

Primary

1. **Due to a single gene defect:** It is familial and called monogenic or genetic.
2. **Multiple gene:** Dietary and physical activity related causes 'polygene' or multifactorial.

Secondary

These are associated with diabetes, myxoedema, nephritic syndrome, chronic alcoholism, and drugs (corticosteroids, oral contraceptives, β blockers), etc. Globally, in blood, the primary carrier of plasma is cholesterol esters and very low-density lipoproteins. The current pharmacotherapy includes the following:

1. HMG CoA reductase (or 3-hydroxy-3-methyl-glutaryl-CoA reductase or HMGR) inhibitors (statins).
2. Bile acid sequestrants (resins).

3. Drugs that activates lipoprotein lipase (fibric acid derivatives).
4. Drugs that inhibit lipolysis and triglyceride synthesis (nicotinic acid).

Combined therapeutic regimen is useful in the following cases:


- When LDL levels are insignificantly increased during treatment of hypercholesterolaemia with a resin.
- When LDL and VLDL levels are both elevated initially.
- When LDL and VLDL levels are normalized with a single agent.
- When elevated level of lipoprotein or HDL deficiency coexist with other hyperlipidaemias.

Fibric acid and bile acid sequestrants are useful in the treatment of familial hyperlipidaemia of which some are intolerant of niacin. HMG CoA reductase inhibitors and bile acid sequestrants synergistically control the familial hypercholesterolaemia, but they may not control the levels of VLDL in some patients with familial combined hyperlipoproteinaemia. Niacin and bile acid sequestrants effectively control LDL levels during resin therapy of familial combined hyperlipoproteinaemia or other disorders involving both increased VLDL and LDL levels. Reductase inhibitors and Ezetimibe are used in treating primary hypercholesterolaemia and has some use in the treatment of homozygous familial hypercholesterolaemia.

CLASSIFICATION

Antihypercholestaerolemic agents act either by reducing the production of lipoproteins or by their removal from blood.



I. HMG CoA—Reductase Inhibitors




S. No.	Drug	R ₁	R ₂	R ₃
1.	Metastatin		-H	-H
2.	Lovastatin		-H	-CH ₃

(Continued)


(Continued)

S. No.	Drug	R ₁	R ₂	R ₃
3.	Simvastatin		-CH ₃	-CH ₃
4.	Pravastatin		-H	-OH


i. Dalvastatin




ii. Fluvastatin




iii. Atorvastatin



iv. Cerivastatin




II. Fibric acid derivatives




S. No.	Drug	R ₁	R ₂
1.	Clofibrate	-Cl	-C ₂ H ₅
2.	Fenofibrate		-CH(CH ₃) ₂
3.	Ciprofibrate		-H
4.	Benzafibrate		-H

v. Gemfibrozil




III. Bile Acid Sequestrants


i. Cholestyramine



ii. Colestipol




iii. Berlex




IV. Inhibition of LDL oxidation

i. Probucol




V. Pyridine derivative


i. Nicotinic acid (Niacin)




VI. Miscellaneous

i. β -Sitosterol

ii. Dextrothyroxine



iii. Ezetimibe




SYNTHESIS AND DRUG PROFILE

I. HMG CoA-Reductase Inhibitors


Mode of action: These kinds of drugs competitively inhibit the conversion of 3-hydroxy-3-methyl glutaryl coenzyme (HMG CoA) to mevalonate, which is the rate-limiting step in cholesterol synthesis and results in receptor mediated uptake and catabolism of intermediate density lipoprotein and very low-density lipoprotein.

Synthesis of Cholesterol



Metabolism of HMG CoA-reductase inhibitors: Lovastatin and simvastatin are inactive prodrugs that must undergo in vivo hydrolysis to produce their effects. The active forms of these two compounds as well as most HMGRIs undergo extensive first pass metabolism. The CYP3A4 isoenzyme is responsible for the oxidative metabolism of atorvastatin, lovastatin, and simvastatin. In the case of atorvastatin, the ortho- and para-hydroxylated metabolites are equiactive with the parent compound and contribute significantly to the overall activity of drugs.

i. Simvastatin (Simvas, Zosta, Siravotin)



Properties and uses: It is a white or almost white crystalline powder, insoluble in water, well soluble in methylene chloride and in alcohol. It is used as an antihyperlipidaemic agent.

Assay: It is assayed by adopting liquid chromatography technique.


Storage: It should be stored in well-closed airtight containers under nitrogen and protected from light.

Dose: For hyperlipidaemias: Prevention of cardiovascular events: Adult: Initially, 10–20 mg/day, to be taken in the evening. May start with 40 mg once daily in patients with high cardiovascular risk. For patients with moderate cardiovascular risk, initiate with 10 mg once daily, may adjust dose at 4-weekly intervals. Maximum of 80 mg/day.

For homozygous familial hypercholesterolaemia: Adult: Initially, 40 mg once daily. May increase dose to 80 mg daily, given in three divided doses. Child: 10–17 years: Initially, 10 mg daily. May increase to 40 mg daily according to response.


Dosage forms: Simvastatin tablets B.P.

ii. Fluvastatin




Properties and uses: It exists as a white to pale yellow hygroscopic powder, soluble in methanol and water or ethanol. It is used as an antihyperlipidaemic agent.


iii. Dalvastatin



Synthesis



iv. Lovastatin



Properties and uses: It is a white or almost white crystalline powder, insoluble in water, soluble in acetone, and sparingly soluble in ethanol. Used as HMG Co-A reductase inhibitor and lipid-regulating drug.

Assay: It is assayed by adopting liquid chromatography technique.


Storage: It should be stored in well-closed airtight containers under nitrogen at a temperature of 2°C to 8°C.

II. Fibric acid derivatives

Mode of action: These drugs activate receptors called α -peroxisome proliferator-activated receptors, which enhance the synthesis of lipoprotein lipase and increase the degradation of very low-density lipoprotein. This also enhances the fatty acid oxidation.

Metabolism of fibrates: The prodrug fenofibrate undergoes rapid hydrolysis to produce fenofibric acid. This active metabolite can then be further metabolized by oxidative or conjugate pathways.


v. Clofibrate



Ethyl 2-(4-chlorophenoxy)-2-methylpropionate


Properties and uses: It is a colourless to pale yellow liquid with acid taste, insoluble in water. It is a drug of choice in the treatment of type III, IV, and V hyperlipoproteinaemias.

Synthesis



Dosage forms: Clofibrate capsules B.P.

vi. Gemfibrosil (Gempar, Lopid, Normolip)




Metabolism: It is similar to fenofibric acid. It may undergo oxidation or conjugation. Oxidation of aromatic methyl group produces inactive hydroxymethyl and carboxylic acid analogues. As a drug class, fibrate and their oxidized analogues are primarily excreted as glucuronide conjugate in urine. Oxidation requires the CYP3A4 isoenzymes. However, because of the ability of these compounds to be conjugated and eliminated either with or without oxidation, drug interaction with other compounds affecting the CYP3A4 system are less important here than other drug classes.

Properties and uses: It is a white or almost white waxy and crystalline powder, insoluble in water, soluble in methylene chloride, in ethanol, and in methanol. It was used first in the treatment of hyperlipoproteinemia in the mid-1970s. Its mechanism of action and use are similar to those of clofibrate. It is used in the treatment of hyperlipidaemia. It is also useful in type V hyperlipoproteinaemia.

Assay: Dissolve the sample in methanol, to this add water and 0.1 M hydrochloric acid, and perform potentiometric titration, using 0.1 M sodium hydroxide.

Synthesis




Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: (Adults only) 600 mg twice daily, taken 30 min before morning and evening meals.

Dosage forms: Gemfibrozil capsules B.P., Gemfibrozil tablets B.P.


vii. Benzafibrate (Beza-Xl, Bezalip)



2-[P-[2-(*p*-Chloro benzamido) ethyl] phenoxy]-2-methyl propanoic acid


Properties and uses: Benzafibrate is more potent than clofibrate and reduces HDL and LDL to a greater extent. It is a highly potent antihyperlipidaemic agent.

Synthesis




Dose: For hyperlipidaemias: Adult: 200 mg thrice a day, may increase dose gradually over 5–7 days. Maintenance: 200 mg twice a day. As modified-release preparation: 400 mg daily.

viii. Ciprofibrate



2-(4-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid

Synthesis




Properties and uses: It is a white or slightly yellow crystalline powder, insoluble in water, soluble in anhydrous ethanol, and in toluene. It is a more potent lipid-lowering agent than clofibrate, used in the treatment of hyperlipidaemic conditions.

Assay: Dissolve the sample in a mixture of water and anhydrous ethanol. Titrate with 0.1 M sodium hydroxide and determining the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

ix. Fenofibrate (Lipicard, Stanlip, Fibril)




Properties and uses: It is a white or almost white crystalline powder, slightly soluble in ethanol, insoluble in water, and soluble in methylene chloride. Fenofibrate is a more potent hypocholesterolemic and triglycerides lowering agent.

Assay: It is assayed by adopting liquid chromatography technique.

Storage: It should be stored in well-closed airtight containers and protected from light.


Synthesis



Dose: For hyperlipidaemias: Adult: Dose depends on the formulation used. For standard micronized formulations: Initially, 67 mg thrice a day or 200 mg once daily. For nonmicronized formulations: Initially, 200–300 mg daily in divided doses. Usual range: 200–400 mg daily. For formulations with improved bioavailability, doses between 40 and 160 mg daily may be used. Child: 5 mg/kg daily.

III. Bile acid sequestrants

i. Cholestyramine resin



Mode of action: It is a styrene copolymer with divinyl benzene and quaternary ammonium functional group. The resin is insoluble in water, remains unchanged in the intestinal tract, unaffected by digestive enzymes, and is not absorbed. These are basic ion exchange resins, which binds with bile acids, interferes in the enterohepatic circulation, and leads to the excretion of cholesterol in faeces. This also indirectly leads to the enhanced hepatic metabolism of cholesterol to bile acids, so more LDL receptors are exposed on liver cells and the plasma intermediate density and very low-density lipoprotein clearance is more.


Properties and uses: It is a white or almost white fine powder, and is hygroscopic, insoluble in water, in methylene chloride and in ethanol, used as lipid-regulating drug.

Assay: It is assayed by adopting liquid chromatography technique.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Colestyramine oral powder B.P.

ii. Colestipol




Properties and uses: It exists as yellow to orange beads, hygroscopic in nature. It swells, but does not dissolve in water and dilute aqueous solutions of acids and alkali, insoluble in ethanol and in dichloromethane. It is an insoluble copolymer of diethylene triamine and epichlorohydrin, containing secondary and tertiary amine functionalities. It is potent in reducing cholesterol levels. It is effective in the treatment of type II hyperlipoproteinaemias.

Storage: Colestipol hydrochloride should be stored in airtight containers.

Dosage forms: Colestipol granules B.P.

IV. LDL Oxidation Inhibitors

Probucol (Lorelco)




4, 4' [Methyl ethylidene] bis (thio) bis [2, 6-bis (1, 1-dimethylethyl)] Phenol

Properties and uses: It is a chemical agent that was developed for the plastic and rubber industry in 1960s. Probucol is a more potent cholesterol-lowering agent of a series of alkylidene dithio bisphenols. It is used as an antihyperlipoproteinaemic agent.


Dose: Adults only: 250–500 mg twice daily taken with morning and evening meals.

Synthesis



V. Pyridine derivatives

i. Nicotinic acid





Pyridine-3-carboxylic acid

Mode of action: Nicotinic acid inhibits the lipolysis of triglycerides by hormone sensitive lipase, which reduces transport of the free fatty acids to liver and decreases hepatic triglycerides synthesis. Reduction of triglycerides synthesis decreases the production of hepatic VLDL.

Metabolism: Nicotinic acid is a B-complex vitamin that is converted to nicotinamide, NAD^+ , and NADP^+ . The latter two compounds are coenzymes, and required for the oxidation/reduction reaction in a variety of biochemical pathways. Nicotinic acid is metabolized to a number of inactive compounds, including nicotinuric acid and *N*-methylated derivatives.


Properties and uses: It is a white, crystalline powder and it dissolves in dilute solutions of the alkali hydroxides and carbonates, soluble in boiling water and in boiling alcohol, sparingly soluble in water. It is used as an antihyperlipidaemic agent.

Synthesis**Method I: From 3-Methyl pyridine****Method II: From Nicotine**


Assay: Dissolve the sample in water and titrate with 0.1 M sodium hydroxide, using phenolphthalein solution as indicator. End point is the appearance of a pink colour.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dosage forms: Nicotinic acid tablets I.P., B.P.

VI. Miscellaneous Agents**i. β -Sitosterol**3- β -stigmasterol-5-en-3-ol

Properties and uses: β -sitosterol lowers plasma concentrations of LDL, and has no effect on VLDL. The sitosterol is believed to lower plasma levels of cholesterol by interfering with its absorption. It is used as an anticholesteremic agent and also used in the treatment of prostatic adenoma.


ii. Dextrothyroxine*o*-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine

Synthesis



Uses: Used as antihyperlipidaemic agent.

iii. Ezetimibe



Metabolism of ezetimibe: It is metabolized rapidly and extensively in the intestinal wall and the liver to its active metabolite, a corresponding phenol glucuronide. This glucuronide is re-excreted in the bile back to its active site. A small amount of Ezetimibe undergoes oxidation to convert the benzylic hydroxyl group to a ketone. Ezetimibe does not appear to exert any significant effect on the activity of CYP450 enzyme.

Uses: Used as an antihyperlipidaemic agent.

Chapter 5

Antianginals

INTRODUCTION

Angina is caused by an accumulation of metabolites in the striated muscles and is associated with severe chest pain that occurs when the coronary flow is inadequate to supply oxygen required for the heart. Angina pectoris is the most common condition affecting significant number of population, involving tissue ischaemia in which vasodilators are used. Ischaemic heart disease is the most common serious health problem today. By far, the most frequent cause of angina is atheromatous obstruction of large coronary vessels (atherosclerotic angina and classic angina). However, in the transient spasm, localized portions of these vessels can also cause myocardial ischaemia and pain (spastic angina or variant angina). In theory, the imbalance between oxygen delivery and myocardial oxygen demand can be corrected by decreasing oxygen demand or by increasing delivery (by increasing coronary flow). Oxygen demand can be reduced by decreasing the cardiac work or according to recent studies, by shifting myocardial metabolism to substrates that require less oxygen per unit of adenosine triphosphate (ATP) production. In variant angina, spasm of coronary vessels can be reversed by nitrates or calcium channel blockers. It should be emphasized that all the vasodilators are effective in angina and, conversely, that some agents useful in angina (e.g. propranolol) are not vasodilators. Unstable angina, an acute coronary syndrome, is said to be present when there are episodes of angina at rest and when there is a change in character, frequency, and duration of chest pain as well as precipitating factors in patients with previously stable angina. In most cases, formation of nonocclusive thrombi at the site of a fissured or ulcerated plaque is the mechanism.

PRINCIPLES OF THERAPY FOR ANGINA

Pharmacological therapy to prevent myocardial infarction and death is with antiplatelet agents (aspirin, clopidogrel) and lipid lowering agents. Recently, angiotensin-converting enzyme (ACE) inhibitors have also reported to reduce the risk from coronary artery disease. In unstable angina and non-STsegment elevation myocardial infarction, and in coronary stenting, antilipid drugs, heparin, and antiplatelet agents are recommended.


Angina of effort: For therapy of chronic stable angina, long-acting nitrates, calcium channel blockers, or β blockers are chosen. The combination therapy has shown to be more effective than individual drugs used alone.

Vasospastic angina: Nitrites and calcium channel blockers are effective drugs for reducing and preventing ischaemic episodes in patients with variant angina. In approximately 70% of the patients treated with nitrites or calcium channel blockers, angina attacks are completely abolished.



Unstable and acute coronary syndromes: In patients with unstable angina with recurrent ischaemic episodes at rest, recurrent thrombotic occlusions of the offending coronary artery occur as the result of fissuring of atherosclerotic plaques and platelet aggregation. Anticoagulant and antiplatelet drugs play an important role in these cases.

CLASSIFICATION


I. Nitrites and Nitrates




Amyl nitrite




Nitroglycerine




Erythryl tetranitrate



Pentaerythritol tetranitrate




Isosorbide dinitrate

II. β -Adrenergic blocking agents

Propranolol


III. Calcium channel blockers

a. 1,4-Dihydro Pyridines




S. No.	Compound	R ₁	R ₂	R ₃	X
1	Amlodipine	-CH ₂ O(CH ₂) ₂ NH ₂	-C ₂ H ₅	-CH ₃	2-Cl
2	Felodipine	-CH ₃	-C ₂ H ₅	-CH ₃	2,3-Cl
3	Nifedipine	-CH ₃	-CH ₃	-CH ₃	2-NO ₂
4	Nitrendipine	-CH ₃	-CH ₃	-C ₂ H ₅	3-NO ₂
5	Nimodipine	-CH ₃	-CH ₂ CH ₂ OCH ₃	-CH(CH ₃) ₂	3-NO ₂
6	Nisoldipine	-CH ₃	-CH ₂ CH(CH ₃) ₂	-CH ₃	2-NO ₂


i. Isradipine




ii. Benidipine




iii. Nicardipine



iv. Lacidipine




v. Manidipine HCl




b. Diphenyl alkylamines

i. Verapamil




c. Benzothiazepine derivatives

i. Diltiazem






d. Diamino propanol ethers

i. Bepridil




IV. Cardiovascular glycosides






V. Miscellaneous


i. Dipyridamole




ii. Cyclandelate



iii. Aspirin



iv. Mioflazine



SYNTHESIS AND DRUG PROFILE

I. Nitrites and Nitrates

Mode of action: These types of drugs are rapidly denitrated enzymatically in the smooth cells to release the reactive free radical nitric oxide (NO), which activates cytosolic guanyl cyclase and increases the cyclic guanosine mono phosphate (cGMP) that causes dephosphorylation of myosin light chain kinase (MLCK) through cGMP dependent protein kinase. The reduction in phosphorylated MLCK interferes with myosin and fails to cause contraction. Relaxation also occurs due to reduced Ca^{2+} entry.


Metabolism: All organic nitrates are subjected to first-pass metabolism, not only by the action of glutathione nitrate reductase in the liver, but also in the extra hepatic tissues. Some metabolites of long-acting nitrates are active as vasodilators. An example of this is isosorbate dinitrate, which is metabolized primarily in the liver by glutathione nitrate reductase, which also participates in the metabolism of other organic nitrates, catalyzing the denitration of the parent drugs to yield two metabolites, 2- and 5-isosorbate mononitrate.

i. Amylnitrite (Vaporole)



Dose: The usual dose of amyl nitrite 0.18 or 0.3 ml.


Synthesis




Properties and uses: It is a clear yellowish liquid with an ethereal, fruity odour, and pungent, aromatic taste. It is insoluble in water, but miscible with alcohol, chloroform, or ether. It is a mixture of isomeric amyl nitrites, but is principally isoamyl nitrite. It is mainly used to treat angina pectoris. It is also effective in the emergency management of cyanide poisoning by causing the oxidation of haemoglobin to the compound methemoglobin.

Dose: The usual dose of amyl nitrite 0.18 or 0.3 ml.

ii. Nitroglycerine




Synthesis




Properties and uses: It is a colourless, odourless liquid with a sweet taste. Glyceryl trinitrate is the trinitrate ester of glycerol. Nitroglycerine is used in angina pectoris and extensively as an explosive in dynamite. A solution of the ester, if spilled or allowed to evaporate, will leave a residue of nitroglycerine. To prevent an explosion of the residue, the ester must be decomposed by addition of alkali. Even then the material dispensed is so dilute that the risk of explosions does not exist.

iii. Erythrityl tetranitrate (Cardilate)




Synthesis




Properties and uses: Erythrityl tetranitrate is a white powder with a slight odour of nitric oxide and bitter taste. It is soluble in acetone and alcohol, but insoluble in water. It is used in the treatment of angina pectoris and to reduce blood pressure in arterial hypertension.

Dose: 10 mg thrice/day by oral tablet.

iv. Pentaerythritol tetranitrate



Synthesis




Properties and uses: It is a white or slightly yellowish powder that is practically insoluble in water, soluble in acetone, and slightly soluble in alcohol. It is used in the treatment of angina pectoris. It relaxes the smooth muscle of smaller vessels in the coronary vascular tree.

Assay: It is assayed by adopting liquid chromatography technique.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: 40–80 mg every 4–6 h, orally.

v. Nicorandil (Nicoram, Corflo, Zynicor)




Synthesis




Properties and uses: The cardiac unloading effect of this drug contributes to its antianginal action.

Dose: Orally for angina pectoris: Adult: 10 mg twice/day, increase if necessary. Usual dose: 10–20 mg twice/day. May use 5 mg twice/day for patients prone to headache. Maximum dose is 30 mg twice/day.

vi. Isosorbide dinitrate (Isordil, Orbitrate)



Synthesis



Properties and uses: It is a fine white crystalline powder, slightly soluble in water, well soluble in acetone, but sparingly soluble in alcohol. It is effective in the treatment of acute angina attack.

Assay: It is assayed by adopting liquid chromatography technique.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: Sublingual: 5–10 mg every 2–3 h, Oral: 5–60 mg every 4–6 h; chewable tablet: 5–10 mg every 2–4 h.

Dosage forms: Isosorbide dinitrate tablet B.P.

II. β -Adrenergic blocking agents

i. Propranolol HCl



Synthesis and drug profile is given under sec IV Chapter, Anti adrenergic agents.


III. Calcium channel blockers

Mode of action: Calcium channel blockers act on the Ca^{2+} channel receptors, block the release of calcium, and, therefore, the calcium interaction with a protein calmodulin to form calcium calmodulin complex is decreased. This leads to the decreased activation of myosin light chain phosphorylation, which promotes muscle contraction by interacting between actin and myosin.

Metabolism: Prehepatic first-pass metabolism by CYP3A4 enzyme occurs with some orally administered calcium channel blockers, especially verapamil, with its low bioavailability of 20%–35%. The bioavailability of diltiazem is 40%–67%, nicardipine is 35%, nifedipine is 45%–70%; and amlodipine is 64%–90%. Verapamil is metabolized by CYP3A4 *N*-demethylation to its principal metabolite, norverapamil, which retains approximately 20% of the activity of verapamil, and by *O*-demethylation (CYP2D6) into inactive metabolites. Diltiazem is metabolized by enzyme hydrolysis of its primary metabolite, diacetyl derivative, which retains approximately 25%–50% of the activity of Diltiazem.

Diltiazem undergoes *N*-demethylation by CYP3A4 and *O*-demethylation by CYP2D6. The *N*-demethylated metabolic pathways results in a mechanism-based inhibition of CYP3A4. The major metabolites are detected after oral and continuous intravenous administration, but not following rapid intravenous administration.

i. Amlodipine (Amlodac, Stamlo, Amlong)



3-Ethyl-5-methyl-2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate


Properties and uses: It is a white or almost white powder, slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol and 2-propanol. Used as an antianginal and antihypertensive agent

Assay: It is assayed by adopting liquid chromatography technique.


Storage: It should be stored in well-closed airtight containers and protected from light.

Dose: 2.5 to 10 mg/day amlodipine was equal to or superior to 160–320 mg/day verapamil, 50 to 100 mg/day captopril.

Synthesis




ii. Nifedipine (Cacigard, Nicardia Retard, Depin)




3,5-Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Synthesis (Hantzsch synthesis)


Step I. Preparation of methyl-[2-acetyl-3-(2-nitrophenyl)]-2-propenoate



Step II. Preparation of Methyl-3-amino-2-butenone



Step III. Condensation of Steps I and II products.



Properties and uses: It is a yellow crystalline powder, sparingly soluble in ethanol, insoluble in water, but freely soluble in acetone. It is used in the treatment of vasospastic angina and hypertension.


Assay: Dissolve the sample in a mixture of 2-methyl-2-propanol and perchloric acid solution. Titrate with 0.1 M cerium sulphate using ferroin as indicator. End point is the disappearance of pink colour.

Storage: When exposed to daylight and artificial light of certain wavelengths, it readily converts into a nitrosophenylpyridine derivative. Exposure to ultraviolet light leads to the formation of a nitrophenylpyridine derivative. Hence, it should be stored in well-closed airtight containers and protected from light.




Dose: For angina pectoris: Adult: Long-acting preparation: 10–40 mg twice/day or 30–90 mg once daily.

Dosage forms: Nifedipine capsules I.P., B.P, Nifedipine tablets I.P.

III. Nitrendipine



3-Ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate


Synthesis*Step I.* Preparation of methyl-[2-acetyl-3-(nitrophenyl)]-2-propenoate*Step II.* Preparation of ethyl-3-amino-2-butenone*Step III.* Condensation of Steps I and II products

Properties and uses: It is a yellow crystalline powder exhibiting polymorphism, sparingly soluble in ethanol and methanol, insoluble in water, but freely soluble in ethyl acetate. It is used as a vasodilator and also used in the treatment of mild-to-moderate essential hypertension.


Assay: Dissolve the sample with gentle heating if necessary in a mixture of 2-methyl-2-propanol and perchloric acid solution. Titrate with 0.1 M cerium sulphate, using 0.1 ml of ferroin as indicator.

Storage: Exposure to ultraviolet light leads to the formation of a nitrophenylpyridine derivative. Hence, it should be stored in well-closed airtight containers and protected from light.

IV. Felodipine (Felogard, Plendil, Renedil)



Synthesis




Properties and uses: It is a white or light yellow, crystalline powder, practically insoluble in water, freely soluble in acetone, ethanol, methanol, and in methylene chloride. It is used in the treatment of angina and essential hypertension.

Assay: Dissolve the sample in a mixture of 2-methyl-2-propanol and perchloric acid solution. Add ferroin as an indicator and titrate with 0.1 M cerium sulphate until the pink colour disappears.

Dose: 2.5 to 20 mg alone or in combination with beta-blocker or 5 to 10 mg given once daily.


Storage: It should be stored in well-closed airtight containers and protected from light.

V. Nicardipine



Properties and uses: It exists as white crystals and are used in the treatment of angina and essential hypertension.

VI. Isradipine



3-Isobutyl 5-methyl 4-(benzo[1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate


Properties and uses: It is a yellow crystalline powder, practically insoluble in water, freely soluble in acetone and soluble in methanol. It is used in the treatment of angina.

Assay: It is assayed by adopting liquid chromatography technique.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dosage forms: Isradipine tablets B.P.

SAR of Dihydropyridines




- 1, 4-Dihydro pyridine ring is essential for activity. Substitution at N or oxidation or reduction of the ring reduces or abolishes the activity.
- A phenyl substitution at the 4th position is optimum for the activity. Substitution at para or unsubstituted phenyl ring reduces the activity.
- The 3rd and 5th position ester group optimizes activity. Placement of electron withdrawing substitution results in agonistic activity.
- When the ester at C₃ and C₅ are nonidentical, the C₄ become chiral and stereo selectivity is observed. S-enantiomers found to be more effective.

i. Verapamil




Synthesis


Step I. Synthesis of 3,4-Dimethoxy-2-isopropyl valeronitrile



Step II. Preparation of 3,4 Dimethoxy phenyl ethyl N-methyl-3-chloro propylamine



Step III. Condensation of product of Step I and II




Properties and uses: It is a white crystalline powder, soluble in water, freely soluble in methanol, and sparingly soluble in alcohol. It is used in the treatment of angina pectoris, arrhythmias from ischaemic myocardial syndromes, and supraventricular arrhythmias.

Assay: Dissolve the sample in ethanol and add 0.01 M hydrochloric acid. Titrate with 0.1 M sodium hydroxide and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Dosage forms: Verapamil HCl injection I.P., Verapamil HCl tablets I.P., Verapamil injection B.P., Verapamil tablets B.P., Prolonged-release Verapamil tablets B.P.

ii. Diltiazem



5-(2-(Dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,5]thiazepin-3-yl acetate

Synthesis




Properties and uses: It is a white crystalline powder, freely soluble in water, in methanol, and in methylene chloride, slightly soluble in ethanol. Diltiazem has two chiral centres (C_2 and C_3), the levorotatory *cis* antipode is more active form. It is used in the treatment of angina pectoris and also used as antiarrhythmic agent.

Assay: Dissolve the sample in a mixture of anhydrous formic acid and acetic anhydride. Titrate with 0.1 M perchloric acid and determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.


Second-Generation Alkyl Amine Type Calcium Channel Blockers

i. Bepridil



N-benzyl-*N*-(3-isobutoxy-2-(pyrrolidin-1-yl)propyl)benzenamine

Synthesis



Properties and uses: Bepridil exists as white crystals and is used as a vasodilator and antianginal agent.


Dose: The usual dose is 5 mg/kg.

IV. Cardiovascular agents

Cardiovascular agents have their major pharmacological action in the ability to alter the cardiovascular function, cardiac glycosides, and certain other agents have positive inotropic effects. They are useful in the treatment of congestive heart failure. Several cardiac glycosides have been studied, which include glycosides of digitalis, squill, and strophanthus. Among all of them, the most predominant one is digitalis. *Digitalis lanata* and *D. purpurea* are the richest sources of cardiac glycoside. On hydrolysis (acid or alkali or enzymatic) they yield the corresponding steroidal aglycone and glycone (sugar). The cardiac activity resides in the aglycone portion, but the sugar moiety provides favourable solubility and distribution characteristics.

Uses: Cardiac glycosides are used to slow down the heart in the atrial arrhythmias, particularly atrial fibrillation. These drugs are also given in the case of congestive heart failure.

i. Digoxin




Properties and uses: It is a white or almost white powder or colourless crystals. It is freely soluble in a mixture of methanol and methylene chloride, slightly soluble in ethanol, but insoluble in water. **It is used in the treatment of congestive heart failure with atrial fibrillation.**

Assay: It is assayed by adopting liquid chromatography technique.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Paediatric digoxin oral solution I.P., B.P., Digoxin tablets I.P., B.P., Digoxin injection I.P., B.P., Paediatric Digoxin Injection B.P.

ii. Digitoxin



Metabolism: Digitoxin is not extensively metabolized. It is transported from the intestinal enterocyte along with epithelium into the intestinal lumen by *p*-glycoprotein, which is also expressed in the kidney and liver. Digitoxin is essentially metabolized by the liver to form a variety of metabolites, including (digitoxose) 2-digitoxigenin, (digitoxose) 1-digitoxigenin, and (digitoxose) 1-digitoxigenin.


Properties and uses: It is a white or almost white powder, which is freely soluble in a mixture of methanol and methylene chloride, slightly soluble in alcohol and methanol, but insoluble in water. Digitoxin has action and uses similar to those of digoxin.

Assay: Dissolve the sample in alcohol. Dilute with alcohol and prepare a reference solution in the same manner, using digitoxin. To 5.0 ml of each solution add alkaline sodium picrate solution, allow to remain protected from bright light for 30 min and measure the absorbance of each solution at the maximum of 495 nm, using as the compensation liquid a mixture of 5.0 ml of alcohol and 3.0 ml of alkaline sodium picrate solution prepared at the same time. Calculate the content of Digitoxin from the absorbances measured and the concentrations of the solutions.

Storage: It should be stored in well-closed airtight container and protected from light.


Dosage forms: Digitoxin tablets B.P.

iii. Deslanoside



Properties and uses: It is a derivative of Lanatoside-C. It has action and uses similar to those of digoxin.


iv. Ouabain



Uses: It has action and uses similar to those of digoxin.


V. Miscellaneous

i. Dipyridamole



2,2-bis [diethanol amino]-4,8-dipiperidine pyrimido-[5,4-d]-pyrimidine

Synthesis



Properties and uses: It is a bright yellow crystalline powder, which dissolves in dilute solutions of mineral acids, but insoluble in water, soluble in acetone and ethanol. The drug inhibits adenosine deaminase in erythrocytes and interacts with the uptake of vasodilator adenosine by erythrocytes. These actions potentiate the

effect of prostacyclin, which acts as an inhibitor to platelet aggregation. It is a long-acting vasodilator. Its vasodilating effect is selective for the coronary system. It is also used to treat angina pectoris.

Assay: Dissolve the sample in methanol and titrate with 0.1 M perchloric acid. Determine the end point potentiometrically.

Storage: It should be stored in well-closed airtight containers and protected from light.

Dosage forms: Dipyridamole tablets B.P.

PROBABLE QUESTIONS

1. Write a note on diuretics used in the treatment of hypertension.
2. What is Angiotensin write some examples used as ACE inhibitors. Outline the synthesis and metabolism of any two of them.
3. Leaves of *Digitalis lanata* gave two important cardiac glycosides. Write their structure, chemical name, and uses.
4. How will you classify the antihypertensive drugs? Support your answer by giving the structure, chemical name and uses of two potent compounds from each category.
5. Clonidine, hydralazine, methyl dopa, and diazoxide are potent antihypertensive drugs. Write the structure, synthesis, and uses of any two compounds.
6. Describe the mode of action of some potent antihypertensive drugs being employed. Write their structures and chemical names.
7. Write in brief about beta blockers used in bronchial asthma.
8. Write a note on vasodilators used in the treatment of hypertension.
9. Write in detail about antiarrhythmic agents used as cardiovascular drugs. Support your answer with suitable examples.
10. Describe the mode and action of the different antiarrhythmic agents used in the treatment of hypertension.
11. Describe the synthesis of any one of the calcium channel blockers
12. Write the synthesis, mode of action, and uses of the following:
 - (a) Disopyramide phosphate
 - (b) Procainamide hydrochloride
13. Describe the synthesis, drug metabolism, and uses of Propranolol hydrochloride.
14. Outline the synthesis of verapamil hydrochloride and describe its mode of action.
15. Write in brief about the organic nitrites and nitrates used in the treatment of angina pectoris.
16. Write the mode of action and synthesis of isosorbide dinitrate and diltiazem.
17. Define and classify antihyperlipidaemics with suitable examples. Write the synthesis and uses of any two of them.
18. Write the mode of action and metabolism of HMG COA reductase inhibitors. Mention few drugs and outline the synthesis of any one of them.
19. Write note on fibric acid derivatives.
20. Classify antiarrhythmics and write in brief about the beta adrenergic blockers used in cardiac arrhythmia.
21. Write the synthesis and uses of the following: (i) Flecainide (ii) Bretylium tosylate.

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. Block JH and Beale JM. *Wilson Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry* (11th edn). New York: Lippincott Williams and Wilkins, 2004.
3. *British Pharmacopoeia*. Medicines and Healthcare Products Regulatory Agency. London, 2008.
4. Brogden RN and Todd PA. 'Disopyramide'. *Drugs*: 34: 151, 1987.
5. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
6. Costrini NV and Thomson WM. *Manual of Medical Therapeutics* (22nd edn). Boston: Little Brown, 1977.
7. Fitton A and Buckley MT. 'Moricizine: A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias'. *Drugs* 40: 138, 1990.
8. Gums, J. 'Use of ACE inhibitors in the treatment of cardiovascular disease'. *American Pharmacy* 432 (6): 62–70, 1992.
9. Gennaro AR. *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
10. Greenlee WJ and Siegl PKS. 'Angiotensin/renin modulators'. *Ann Rept Med Chem* 27: 59–68, 1992.
11. Griffiths MC (ed). *USAN and the USP Dictionary of Drug Names*. Rockville: United States Pharmacopeial Convention Inc., 1985.
12. Harrison DG and Bates JN. 'The nitrovasodilators: New ideas about old drugs'. *Circulation* 87: 1461–467, 1993.
13. Inomata N, Ishishara T, and Akaike N. 'Different time courses of the blockade of sodium current by lignocaine and SUN 1165 in single myocytes isolated from guinea-pig atrium'. *Br J Pharmacol* 98: 149, 1989.
14. *Indian Pharmacopoeia*. Ministry of Health and Family Welfare. New Delhi, 1996.
15. Keefe DLD, Kates RE, and Harrison DC. 'New antiarrhythmic drugs: Their place in therapy'. *Drugs* 22: 63–400, 1981.
16. Kelley RA and Smith TW. 'Endogenous cardiac glycosides'. *Adv Pharmacol* 25: 263–88, 1994.
17. Lawton G, Paciorck PM, and Waterduel JF. 'The design and biological profile of ACE inhibitors'. In *Advances in Drug Research*, B Testa (ed). pp. 161–220. London: Academic Press, 1992.
18. Lednicher D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
19. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
20. Redshaw S. *Angiotensin-Converting Enzyme (Ace) Inhibitors and the Design of Cilazapril in Medicinal Chemistry* (2nd edn), pp. 163–85. London: Academic Press, 1993.
21. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.
22. Roden DM and Woosley RL. 'Flecainide, tocainide'. *N Engl J Med* 315: 36–41, 1986.
23. Schwartz A. 'Molecular and cellular aspects of calcium channel antagonism'. *Am J Cardiol* 70: 6F–8F, 1992.
24. Thomas R, Cray P, and Andrews J. 'Digitalis: Its mode of action, receptor, and SAR'. In *Advances in drug Research* Vol. 19, pp. 313–562. London: Academic Press, 1990.
25. Weast CN and Pinson JB. 'Angiotension-converting enzyme inhibitors'. *Pharm Perspect Amb Care* 3: 76, 1991.

"This page intentionally left blank"

DRUGS ACTING ON URINARY SYSTEM

1	Urinary System	549
----------	----------------	------------

2	Diuretics	551
----------	-----------	------------

"This page intentionally left blank"

Chapter 1

Urinary System

INTRODUCTION

The kidneys do the major work of urinary system. The structural and functional units of kidneys are nephron. The clinical importance of urinary system includes hypertension, heart failure, renal failure, nephritic syndrome, and cirrhosis. The haemodynamics of renal system has a capability to alter the afore-said pathological conditions.

Functions of Renal System

The functions of renal system are as follows:

Regulation of blood ionic compounds: The kidneys help to regulate the blood ions, i.e., sodium (Na^+), potassium (K^+), calcium (Ca^{2+}), chloride (Cl^-) and phosphate ions (HPO_4^{2-})

Regulation of blood pH: The kidneys excrete a variable amount of hydrogen ions (H^+) into the urine and conserve bicarbonate (HCO_3^-) ions, which regulate pH of blood.

Regulation of fluid volume: The kidneys adjust blood volume by eliminating water in urine.

Regulation of blood pressure (BP): BP is regulated by the kidneys through an enzyme called renin secreted by juxta glomerular cells, which activates the renin-angiotensin-aldosterone (RAA) pathway. Increased renin causes increase in BP.

Maintenance of blood osmolarity: The kidneys produce two hormones, calcitrol and erythropoietin. Calcitrol, the active form of vitamin D helps to regulate calcitrol homeostasis and erythropoietin stimulates the production of red blood cells (RBCs).

Regulation of blood glucose level: The kidneys can use the amino acid of glutamine in gluconeogenesis and release blood to maintain sugar level.

Excretion of metabolite waste products and foreign substances: Metabolic products like ammonia, urea, bilirubin, creatinine, uric acid, and other substances, i.e., toxins of exogenous compounds and drug metabolites, etc., are excreted through urine.

Renal haemodynamics is altered by diuretics in clinical medicine. The therapeutic applications of diuretics are mainly concerned with hypertension and heart failure.

The normal renal physiological process includes glomerular filtration and tubular reabsorption.

PRINCIPLE OF GLOMERULAR FILTRATION

In glomerular capillaries, a portion of plasma water is formed through a filter, which functions due to the fenestrated capillary epithelial cells and the filtration diaphragm formed by epithelial cells; solutes of small size flow with filtered water into the urinary space whereas formed elements and macromolecules are retained by the filtration barrier. The glomerular filtration depends on the hydrostatic pressure in Bowman's capsule space. Glomerular filtration rate (GFR) averages 125 ml/min in males and 105 ml/min in females. The mechanism regulates GFR in two ways—(i) by adjusting blood flow into and out of glomerulus and (ii) by altering glomerular capillary surface area available for filtration.

PRINCIPLE OF TUBULAR REABSORPTION AND SECRETION

The volume of fluid entering the proximal convoluted tubules in half an hour is more than the total blood plasma volume—normally about 99% of filtered water is reabsorbed. Solute that are reabsorbed by both active and passive process include glucose, amino acids, urea, and ions, i.e., Na^+ , K^+ , Ca^{2+} , Cl^- , HCO_3^- (bicarbonates), and HPO_4^{2-} (phosphates). Once the fluid passes through the proximal convoluted tubule, the cells that are located more distally, tune the reabsorption processes to maintain homeostatic balance of water and selected ions. Most of the small proteins and peptides that pass through the filter is also reabsorbed by pinocytosis. In tubular secretion, the transfer materials from the blood and tubule cells enter into tubular fluid includes hydrogen ions (H^+), potassium (K^+), ammonium (NH_4^+), creatinine, and certain drugs like penicillin. The general membrane transports are Na^+ -ATPase pump, in basolateral membrane, which hydrolyzes ATP resulting in transport of Na^+ into intracellular and interstitial spaces. Na^+ may diffuse across the luminal membrane through sodium channels into epithelial cell down through the electrochemical gradient, which is established by basolateral Na^+ - K^+ -ATPases. In addition, free enzyme available in electrochemical gradient for Na^+ is trapped by integral protein of luminal membrane resulting in co-transporters of various solutes against their electrochemical gradient by symports (e.g. Na^+ -glucose, Na^+ - H_2PO_4 , and Na^+ -amino acid). Na^+ exits basolateral membrane into intercellular and interstitial spaces through Na^+ pump; their accumulation creates small osmotic pressure difference across the epithelial cell. In water-permeable epithelium, water moves into the intracellular spaces driven by osmotic pressure difference. Movement of water into intracellular space concentrates other solutes in the tubular fluid, resulting in an electrochemical gradient for these substances across the epithelium. Membrane permeable solutes then move down their electrochemical gradients into the intracellular spaces through both transcellular (e.g. simple diffusion, symports, antiports, uniports, and channels) and paracellular pathways. Membrane impermeable solutes that remain in the tubular lumen are excreted in the urine with an obligatory amount of water. As water and solutes accumulate in intracellular space the hydrostatic pressure increases, providing a driving force for bulk water flow.

There are other mechanisms that secrete organic acid and organic base secretions. Nine different organic acids and five different organic base transporters exist. Other regulations include cation and anion by Ca^{2+} -ATPase, Na^+ -Pi (sodium inorganic phosphate) symport, Na^+ - Mg^{2+} antiport, and Mg^{2+} ATPase.

The rate of urinary excretion can be expressed by the following equation:

$$\text{Urinary output} = \text{Glomerular filtration} + \text{Tubular secretion} - \text{Tubular reabsorption}$$

Chapter 2

Diuretics

INTRODUCTION

Diuretics increase the rate of urine flow and sodium excretion, and are used to adjust the volume or composition of body fluids in a variety of clinical situations, including hypertension, heart failure, renal failure, nephritic syndrome, and cirrhosis. The normal fluid filtration in human body is 180 litres, and about 1.5 litres of urine is formed in 24 hrs.

The diuretics act primarily by inhibiting tubular reabsorption; just 1% decrease in tubular reabsorption would produce more than double urine output. The action depends upon the drug by acting on various symport and antiport present in the nephron. All the transports depend on the basolateral membrane porters, especially in tubular reabsorption, which is divided into four sites:

1. Proximal tubule (PT)
2. Ascending limb of loop of henle (AscLH)
3. Cortical diluting segment of loop of henle
4. Distal tubule (DT)
5. Collecting duct

Proximal tubule: Transport of Na^+ and K^+ coupled with active reabsorption of glucose, aminoacids, other organic anions, and PO_4^{3-} are transported through specific symporters. The exchange with H^+ happens in the PT cells, which secrete H^+ with the help of carbonic anhydrase (CAse). H^+ ion exchanges with Na^+ - H^+ antiporter located in the luminal membrane and forms H_2CO_3 by combining with HCO_3^- . This H_2CO_3 is broken into H_2O + CO_2 by brush border CAse; both H_2O and CO_2 diffuse inside the cell and recombine to form H_2CO_3 with H^+ . The dissociated HCO_3^- in the cell is transported to cortical extracellular fluid (ECF) by basolateral membrane, Na^+ - HCO_3^- symporter resulting in the net reabsorption of NaHCO_3 . The HCO_3^- acetate, PO_4^- amino acid, and other anion reabsorption produces a passive driving force for Cl^- to diffuse through the para-cellular pathway.

Ascending limb of loop of Henle: In the medullary portion, a distinct terminal membrane carrier transports ions in the stoichiometric ratio of Na^+ - K^+ - 2Cl^- and is nonelectrogenic. The Na^+ that enters the cell is pumped to the ECF by Na^+ - K^+ ATPase at the basolateral membrane. In addition, a Na^+ - Cl^- symporter moves Cl^- down its electrochemical gradient in the ECF and moves Na^+ along.

Cortical diluting segment of loop of Henle: Absorbs salt through Na^+ - Cl^- symport.


Distal tubule and collecting duct: In DT and collecting duct Na^+ is again actively reabsorbed; the cation-anion balance being maintained partly by passive Cl^- diffusion and partly by secretion of K^+ and H^+ . Absorption of Na^+ at this site occurs through a specific amiloride sensitive Na^+ channel, and is controlled to a large extent by aldosterone. The luminal membrane provides an active secretory pump for H^+ , which is again governed by the movement of Na^+ in reverse diffusion.

These are the processes of renal physiology for the reabsorption of water and minerals into the body. Blocking of the symporters and antiports with various drugs provides the diuretic effect according to the site of action.

CLASSIFICATION

Diuretics may be classified under the following two categories:

I. Mercurial diuretics




Name	R	R ₁	X
Mersalyl		-CH ₃	Theophylline
Mercurophyllin		-CH ₃	Theophylline
Mercaptomerin		-CH ₃	-SCH ₂ COOH
Chloromerodrin	-NH ₂	-CH ₃	-Cl
Merethoxyline		-CH ₂ CH ₂ OCH ₃	-OH
Meralluride	NaOOCCH ₂ CH ₂ CONH-	-CH ₃	-OH

II. Nonmercurial diuretics


The nonmercurial diuretics may be classified on the basis of their chemical structure as follows:

a. Thiazide derivatives








Name	R ₁	R ₂
Chlorthiazide	-H	-Cl
Benzthiazide	-CH ₂ -S-CH ₂ -C ₆ H ₅	-Cl
Flumethiazide	-H	-CF ₃

b. Hydrothiazides









Name	R ₁	R ₂	R ₃
Hydrochlorothiazide	-H	-H	-Cl
Bendroflumethiazide	-H	-CH ₂ C ₆ H ₅	-CF ₃
Cyclothiazide	-H		-Cl
Hydro flumethiazide	-H	-H	-CF ₃
Cyclopentthiazide	-H		-Cl
Trichloromethiazide	-H	-CHCl ₂	-Cl
Buthiazide	-H	-CH ₂ CH(CH ₃) ₂	-Cl
Methyclothiazide	-CH ₃	-CH ₂ Cl	-Cl
Polythiazide	-CH ₃	-CH ₂ -S-CH ₂ -CF ₃	-Cl

c. CAse inhibitors




d. Sulphonamide diuretics







Xipamide (Salicylanilide)




Clorexolone (Oxoisindoles)

e. Aldosterone inhibitors


Spironolactone




Canrenone




Canrenoate



Amphenone B




Metyrapone




Eplerenone

f. Pteridine derivatives and related compounds




Triamterene




Amiloride


g. sulphomoyl benzoic acid derivatives




Furosemide



Bumetanide




Toresemide




Piretanide

h. Phenoxyacetic acid derivatives




Ethacrynic acid




Ticrynafene

i. Purine or Xanthine derivatives




Name	R ₁	R ₃	R ₇
Caffeine	-CH ₃	-CH ₃	-CH ₃
Theophylline	-CH ₃	-CH ₃	-H
Theobromine	-H	-CH ₃	-CH ₃

Aminophylline




Xanturil




j. Osmotic diuretics


Sodium and potassium salt, urea, sucrose, mannitol, trometamol, sodium acid phosphate, potassium acetate, and glycerine are the osmotic diuretics.



Urea




Isosorbide



Mannitol

k. Acidic diuretics

Ammonium chloride is an acidic diuretic.


l. Uricosuric diuretics**i. Indacrinone****m. Miscellaneous**

Example: Muzolimine

SYNTHESIS AND DRUG PROFILE

I. Mercurial diuretics

Calomel was used by Paracelsus in the 16th century as a diuretic. Most mercurial diuretics have the same general structure, which is a chain of at least three carbon atoms with one atom of mercury at one end of the chain. The group R is hydrophilic in nature, which determines the distribution and late excretion of the compound. The nature of α substituent affects the toxicity of the compound, irritation at the site of injection, and rate of absorption.







X—OH, halide or heterocyclic moiety

Y—Substituted side chain or aromatic function

R—Methyl group

Mode of action: These drugs primarily inhibit $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$ co-transporter in the ascending limb of Henle's loop and produce acidic urine. It involves in the interactions with sulphhydryl enzymes in kidney tubules.

i. Mercaptomerin sodium

Synthesis**ii. Chloromerodrin****Synthesis**

Uses: It is used in the treatment of congestive heart failure due to oedema, chronic nephritis, ascites of liver diseases, and nephrotic oedema.


Dose: The usual oral dose is 18.3 to 73.2 mg per day (\equiv 10 to 40 mg of mercury per day).

II. Nonmercurial diuretics

II. a. Thiazides


Mode of action of thiazides and hydrothiazides: The sites of action for these drugs are cortical diluting segment or DT. Here they inhibit Na^+ - Cl^- symport at the luminal membrane.

i. Chlorthiazide



6-Chloro-1,2,4-benzothiazine-7-sulphonamide-1,1-dioxide


Synthesis



Properties and uses: Chlorthiazide is a white crystalline powder, soluble in dilute solutions of alkali hydroxides, slightly soluble in water and in alcohol and sparingly soluble in acetone. It is a prototype benzothiadiazine derivative, used in the treatment of oedema associated with congestive heart failure, renal, and hepatic disorders.


Assay: Dissolve the sample in dimethylformamide and titrate against 0.1 M tetrabutylammonium hydroxide in 2-propanol. Determine the end point potentiometrically.

ii. Benzthiazide (Exna, Aquataq)



3-[(Benzylthio)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide

Synthesis




Properties and uses: It is a white crystalline powder with a characteristic odour and taste. Benzthiazide is soluble in water, alcohol, chloroform or ether, and in alkaline solutions. It is used in the treatment of oedema associated with congestive heart failure, renal, and hepatic disorders.


Dose: Usually as diuretic initial dose is 50 to 200 mg per day; maintenance, 50 to 150 mg per day; usual, antihypertensive, initial, 50 mg twice/day; maintenance, maximal dose of 50 mg thrice daily.

II. b. Hydrothiazides

i. Hydrochlorthiazide (Hydride, Aquazide, Bpzide)



Synthesis




Properties and uses: Hydrochlorthiazide is a white crystalline powder, which is soluble in acetone and dilute alkali hydroxide solutions, but sparingly soluble in alcohol. It is similar to chlorothiazide, but it is ten times more potent. Used in the treatment of oedema associated with congestive heart failure, renal, and hepatic disorders.

Assay: Dissolve the sample in dimethyl sulfoxide and titrate against 0.1 M tetrabutylammonium hydroxide in 2-propanol. Determine the end point potentiometrically.

Dose: 25 to 200 mg per day; usually 50 mg once or twice daily.


Dosage forms: Hydrochlorthiazide tablets I.P., B.P., Co-amlozide oral solution B.P., Co-amlozide tablets B.P., Co-triamterzide tablets B.P.

ii. Hydroflumethiazide (Naturetin, Neonaclex)



3,4-Dihydro-6(trifluoromethyl)-2H-1,2,4-benzothiazine-7-sulphonamide-1,1-dioxide

Synthesis




Properties and uses: Hydroflumethiazide is a white crystalline powder, practically insoluble in water and ether, soluble in ethanol. It is a potent oral thiazide diuretic, used in the management of oedema associated with cardiac failure, premenstrual tension, and hepatic cirrhosis.

Assay: Dissolve the sample in anhydrous pyridine and titrate against 0.1 M tetrabutylammonium hydroxide. Determine the end point potentiometrically.

Dose: 25 to 200 mg, usually 50 to 100 mg daily.


Dosage forms: Hydroflumethiazide tablets B.P.

iii. Bendroflumethiazide (Diucardin, Saluron)



3-Benzyl-3,4-dihydro-6(trifluoromethyl)-2H-1,2,4-benzothiazine-7-sulphonamide-1,1-dioxide

Synthesis




Properties and uses: Bendroflumethiazide is a white crystalline powder, practically insoluble in water, soluble in acetone and ethanol. A potent orally effective thiazide diuretic possesses both diuretic and anti-hypertensive actions.

Assay: Dissolve the sample in dimethyl sulphoxide and titrate against 0.1 M tetrabutylammonium hydroxide in 2-propanol. Determine the end point potentiometrically.


Dose: Initial, diuretic 5 to 20 mg per day; maintenance, 2.5 to 5 mg daily; as antihypertensive, initially 5 to 20 mg per day, maintenance, 2.5 to 15 mg per day.

Dosage forms: Bendroflumethiazide tablets B.P.

iv. Cyclothiazide (Anhydron, Fludil)




Synthesis



Properties and uses: It exists as white, odourless powder, soluble in alcohol or methanol but insoluble in water, chloroform, or ether. Used as both diuretic and antihypertensive.



Dose: Usual initial dose as diuretic, 1 to 2 mg/day; maintenance, 1 to 2 mg on alternate days, or 2 or 3 times/week; as antihypertensive, 2 mg 1 to 3 times daily.

v. Cyclopenthiazide (Navidrex)



6-Chloro-3-(cyclopentylmethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide

Synthesis




Properties and uses: Cyclopenthiazide is a white powder, practically insoluble in water, soluble in acetone and ethanol, very slightly soluble in ether. It is used in the treatment of oedema associated with congestive heart failure and renal and hepatic disorders.

Assay: Dissolve the sample in butylamine and titrate against 0.1 M tetrabutylammonium hydroxide using magneson solution as indicator.

Dose: For oedema, usual, initial dose is 0.5 to 1 mg per day, reduced to 250 to 500 µg/day or 500 µg on alternate days; for hypertension, usually 250 to 500 µg/day either alone, or in conjunction with other antihypertensive agents.


Dosage forms: Cyclopenthiazide tablets B.P.

vi. Methyclothiazide (Enduron)



6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiazide-7-sulphonamide-1,1-dioxide


Synthesis



Properties and uses: It is a white crystalline powder, odourless, tasteless, soluble in water, alcohol, chloroform or ether, and acetone. It is effective as a diuretic and antihypertensive agent. It is about 100 times more potent than chlorothiazide.


Dose: Usual dose maintenance, as diuretic and antihypertensive is 2.5 to 10 mg once per day,

vii. Trichlormethiazide (Metahydrin, Naqua)



6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide


Synthesis



Properties and uses: It is a white crystalline powder, odourless, sometimes with a characteristic odour, soluble in water, alcohol, chloroform, or ether. It is used as an antihypertensive agent.

Dose: The usual dose is 2 to 4 mg twice daily; maintenance 2 to 4 mg once/day.

viii. Polythiazide (Renese)




Properties and uses: It is a white crystalline powder with characteristic odour, soluble in water, alcohol, chloroform, or ether, acetone and aqueous alkali carbonates or hydroxides. Used as potent diuretic and antihypertensive agent.

Assay: Dissolve the sample in methanol and measure the absorbance after suitable dilutions at the maxima of 268 nm using ultraviolet spectrophotometer.


Dose: As diuretic, usually 1 to 4 mg/ day; as antihypertensive, 2 to 4 mg as required.

Synthesis




Dosage forms: Polythiazide tablets B.P.

SAR of Thiazide Diuretics



- The 2nd position can tolerate the presence of small alkyl groups such as CH_3 .
- Substituents with hydrophobic character in the 3rd position increases saluretic activity 1000 times. Substituents include $-\text{CH}_2\text{Cl}$, $-\text{CHCl}_2$, $-\text{CH}_2\text{C}_6\text{H}_5$, $-\text{CH}_2\text{S}$, $-\text{CH}_2-\text{C}_6\text{H}_5$. The increase in saluretic activity correlates with the lipid solubility.
- Saturation of double bond between the 3rd and 4th position of nucleus increases the diuretic activity approximately 3-fold to 10-fold. Example— Hydrochlorthiazide.
- Hydrogen atom at the 2nd position is more acidic due to the presence of neighbouring electron withdrawing the sulphone group.


- A free sulphonamoyl or potentially free sulphonamoyl group at 7th position is essential for activity. N⁷-caproyl chlorthiazide is excreted as chorothiazide, the loss of sulphonamoyl group eliminates the diuretic effect, but not the antihypertensive action, example, diazoxide.
- Direct substitution of the 4th, 5th, or 8th position with an ethyl group usually results in diminished diuretic activity.
- Substitution of the 6th position with an activating group is essential for diuretic activity. The substituents include Cl, Br, and CF₃ groups.
- The acidic protons make positive the formation of water-soluble sodium salt that can be used for intravenous administration of the diuretics.




II. c. CAse inhibitors

Mode of action: CAse is an enzyme that is present in the PT that catalyses the reversible reaction, $\text{H}_2\text{O} + \text{CO}_2 \leftrightarrow \text{H}_2\text{CO}_3$. Carbonic acid spontaneously ionizes as $\text{H}_2\text{CO}_3 \rightleftharpoons \text{H}^+ + \text{HCO}_3^-$. CAse inhibitors reversibly inhibits CAse resulting in the slowing of hydration of CO_2 and decrease the availability of H^+ to exchange with luminal Na^+ through $\text{Na}^+ - \text{H}^+$ antiporter.

i. Acetazolamide (Acetamide, Diamox, Ana)



Synthesis




Properties and uses: Acetazolamide is a white crystalline powder, soluble in dilute alkali hydroxide solutions, slightly soluble in water and in alcohol. It is a CAse inhibitor effective for the adjunctive treatment of oedema due to congestive heart failure, drug induced oedema, absence and other centrencephalic epilepsies, chronic simple (open angled) glaucoma, secondary glaucoma when it is desired to lower intra-ocular pressure prior to surgery. Acetazolamide is employed in the treatment of drug-induced oedema, oedema caused by congestive heart failure, and petitmal epilepsy.

Assay: Dissolve the sample in dimethylformamide and titrate against 0.1 M ethanolic sodium hydroxide. Determine the end point potentiometrically.


Dose: Usual dose is 250 mg 2 to 4 times/day.

Dosage forms: Acetazolamide tablets I.P., B.P.

ii. Methazolamide (Neptazane)




Synthesis




Properties and uses: Methazolamide is available as white or yellow crystalline powder with a slight odour, which is soluble in water, in alcohol or in acetone and dimethyl formamide. It is a more potent CA inhibitor than the prototypic acetazolamide and it is seldom used as a diuretic. Methazolamide displays improved penetration into the eye, a property that contributes to its usefulness in the treatment of glaucoma. It is employed in the treatment of drug-induced oedema, oedema caused by congestive heart failure and petitmal epilepsy.

Dose: 100 to 600 mg per day; usually 50 to 100 mg 2 to 3 times/day.

iii. Ethoxazolamide (Carolrase)




Synthesis




Uses: It is mainly used in acute angle-closure glaucoma, chronic simple glaucoma, and secondary glaucoma.

Dose: Usually 125 mg 2 to 4 times per day.

iv. Diclofenamide (Daranide, Oratrol)



Synthesis




Properties and uses: It exists as white crystalline powder with a characteristic odour, soluble in water, sodium hydroxide, alcohol, and ether. Used as a diuretic and for the treatment of primary and the acute

phase of secondary glaucoma. It produces less acidotic refractoriness to diuretic action than acetazolamide. It is used for the treatment of both primary and secondary glaucoma.


Dose: 50 to 300 mg per day; usually 25 to 50 mg 1 to 3 times daily.

v. Disulfamide (Diluen)



5-Chlorotoluene-2,4-disulphonamide

Synthesis



Uses: It is used in the treatment of oedema.


Dose: For oedema, usual, initial dose is 200 mg per day for 5 days a week or on alternate days, reduced to 100 mg per day.

SAR of *CAse* Inhibitors

Two groups of *CAse* inhibitors are


1. Heterocyclic sulphonamides
2. Meta-disulphamoyl benzene derivatives

1. Heterocyclic sulphonamides



- The C-2 sulphonamoyl group is important for activity.
- The free sulphonamoyl moiety is necessary to bind with Zn^{++} in the enzyme; hence, substitution of sulphonamoyl group gives inactive compound.
- The moiety to which the sulphonamoyl group is attached must be aromatic in character.
- The heterocyclic sulphonamides with higher partition coefficient and lowest Pka value have greatest CAse inhibitory and diuretic activities. Example—acetazolamide, methazolamide.
- *N*-alkylation with methyl group on ring *N*- of acetazolamide yields active compound (methazolamide).


2. *m*-Disulphamoyl benzene derivatives



- *m*-Disulphamoyl benzene does not have diuretic activity.
- Substituted *m*-sulphonamoyl benzene exhibits diuretic activity.
- The unsubstituted sulphonamoyl moiety is essential for the activity; any substitution leads to affect the potency of the compound.
- The sulphonamoyl moiety can be replaced with similar electrophilic groups (e.g. carboxyl, carbamoyl) that may increase the potency of the compound.
- Maximum diuretic activity is obtained when 4th is substituted by Cl, Br, CF_3 , or NO_2 group.
- Substitution of amino group at 6th position increases aleuronic activity, but decreases CAse inhibitor activity.

II. d. Sulphonamide derivatives


i. Quinethazone (Hydromox)



Properties and uses: Quinethazone is a quinazoline derivative with the effect similar to 6-thiazide. It is a yellowish white, odourless, crystalline powder, soluble in water and alcohol and freely soluble in solutions of alkali hydroxides and carbonates. Replacement of the ring sulphone group in thiazide by carbonyl yields


quinazolones. These compounds have same diuretic response as the thiazides. The most potent compound of the series, quinethazone have high Na^+/K^+ excretion ratio. Used as both diuretics and anti-hypertensive.

Synthesis




Dose: 50 to 200 mg/day; usually 50 to 100 mg once daily.

ii. Chlorthalidone (Hygroton)



2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl) benzene sulphonamide


Synthesis



Properties and uses: Chlorthalidone is an orally effective nonthiazide diuretic. It is an adjunct in oedema associated with congestive heart failure and is used in the treatment of oedema associated with obesity, pregnancy, renal disease, hepatic cirrhosis, premenstrual syndrome, and in congestive heart failure.

Dose: As diuretic, 50 to 200 mg per day or alternate day; usually 100 mg once daily, as antihypertensive, 100 mg alternate day or 50 mg every day.


iii. Metolazone (Diulo, Zaroxolyn)



7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazoline sulphonamide


Properties and uses: Metolazone is a colourless, odourless, tasteless, crystalline powder, sparingly soluble in water or alcohol, but soluble in organic solvents. It is a quinazoline derived nonthiazide diuretic, exerts its diuretic effect in the PT and in the cortical segment of the ascending limb of henle or distal convoluted tubule. Patients with non-oedematous, stable chronic renal failure, and high dosage of metazoline increases urine flow significantly. It is used for hypertension and oedema accompanying congestive heart failure.

Synthesis




Dose: Usual, adult oral dose for oedema of cardiac failure is 5 to 10 mg once daily; oedema of renal disease, 5 to 20 mg once daily; mild essential hypertension, 2.5 to 5 mg once daily.

iv. Indapamide



3-(Aminosulphonyl)-4-chloro-*N*-(2,3-dihydro-2-methyl-1*H*-indol-1-yl)-benzamide

Synthesis




Properties and uses: Indapamide is a white powder, practically insoluble in water, and soluble in ethanol. It is an oral diuretic and antihypertensive related to the indolines. Used in oedema associated with congestive heart failure and hypertension.


Assay: It is assayed by adopting liquid chromatography technique.

Dosage forms: Indapamide tablets B.P.

v. Xipamide




Synthesis




Properties and uses: Used in the treatment of hypertension and oedema.

iii. Clorexolone



Uses: It is effective in the treatment of congestive heart failure and cirrhosis of the liver.


Synthesis




II. c. Aldosterone antagonists

Mode of action: Aldosterone inhibitors inhibit the aldosterone action on mineralocorticoid receptor, where aldosterone generates aldosterone-induced proteins along with $\text{Na}^+ \text{K}^+ \text{ATPase}$ and amiloride sensitive Na^+ channels that leads to the reabsorption of Na^+ . Aldosterone inhibitors limit the reabsorption by binding with mineralocorticoid receptor. Spironolactone is the only available aldosterone antagonist ; a metabolite of spironolactone, canrenone is also active.

i. Spironolactone (Aldactone)



Synthesis



Properties and uses: Spironolactone is a white or yellowish-white powder, practically insoluble in water and soluble in alcohol. It is a synthetic steroid that acts as a competitive antagonist of the potent, endogenous mineralocorticosteroid, aldosterone. It has a slower onset of action than triamterene or amiloride, but its natriuretic effect is slightly greater during long-term therapy. It is indicated in the treatment of essential hypertension, oedema associated with congestive heart failure, hepatic cirrhosis with ascites, the

nephritic syndrome and hypokalemia, and in the diagnosis of primary aldosteronism. It is useful in the treatment of cirrhosis of liver, aldosterone secreting tumours, and high-renin hypertension.

Assay: Dissolve the sample in methanol and measure the absorbance of the solution after suitable dilution at the maxima of 238 nm using ultraviolet-spectrophotometer.

Diuretic-induced hypokalemia: Adult: 25–100 mg daily. Child: Neonates: 1–2 mg/kg daily; 1month-12 years: 1–3mg/kg daily; 12–18 years: 50–100 mg daily. To be given in 1–2 divided dose. Elderly: Dosing adjustment may be required.


Hirsutism in women: Adult: 50–200 mg daily. Elderly: Dosing adjustment may be required.

Dosage forms: Spironolactone tablets I.P., B.P.

II. f. Potassium sparing diuretics (Pteridine derivatives and related compounds)


Mode of Action: These drugs act on Na^+ channel from the luminal side and block the actions. Thus, it reduces the lumen negative transepithelial potential difference, which governs K^+ and H^+ secretion.

i. Amiloride



N-Amidino-3,5-diamino-6-chloropyrazine carboxamide

Synthesis




Properties and uses: Amiloride hydrochloride is a pale-yellow to greenish-yellow powder, slightly soluble in water and in anhydrous ethanol. It is a potassium-conserving drug with natriuretic diuretic and antihypertensive activity. It is an aminopyrazine, considered an open chain analogue of triamterene. It blocks the reabsorption of sodium ion and the secretion of potassium ion. Amiloride is more potent than triamterene.

Assay: Dissolve the sample in a mixture of 0.01 M hydrochloric acid and ethanol and titrate against 0.1 M sodium hydroxide. Determine the end point potentiometrically.


Dosage forms: Amiloride tablets I.P., B.P., Co-amilofruse tablets B.P., Co-amilozide oral solution B.P., Co-amilozide tablets B.P.

ii. Triamterene (Ditide)



2,4,7-Triamino-6-phenylpteridine

Synthesis



Properties and uses: Triamterene is a yellow crystalline powder, very slightly soluble in water and alcohol. It is a pteridine with structural resemblance to folic acid. Replacement of phenyl group with small basic heterocyclic nucleus such as thiazole and pyridine produces highly active compounds. 2 and 7 phenyl isomers of triamterene were very potent K^+ blockers. Triamterene may be used alone in the treatment of mild oedema associated with congestive heart failure or cirrhosis of the liver with ascites. It is used in the treatment of oedema associated with nephritic syndrome, cirrhosis of liver and congestive heart failure.

Assay: Dissolve the sample in anhydrous formic acid, add anhydrous acetic acid and titrate against 0.1 M perchloric acid. Determine the end point potentiometrically.


Dose: 100 mg every alternate day to 300 mg per day; usually 100 mg once daily.

Dosage forms: Triamterene capsules I.P., B.P., Co-triamterzide tablets B.P.

II. g. High ceiling or Loop diuretics


Mode of action: A glycoprotein with 12 membrane-spanning domains has found its function as $\text{Na}^+ \text{-} \text{K}^+ \text{-} 2\text{Cl}^-$ *co-transporters*. Many epithelia in the loop of henle performing secretory\absorbing functions, loop diuretics attach to the chloride-binding site of these proteins to inhibit transport functions.

i. Bumetanide (Bumex)



3-Butylamino-4-phenoxy-5-sulphamoylbenzoic acid

Synthesis




Properties and uses: Bumetanide is a white crystalline powder, practically insoluble in water, soluble in acetone, alcohol, and dilute solutions of alkali hydroxides, slightly soluble in methylene chloride. It is a 3-aminobenzoic acid, metanilamide derivative that is a potent loop diuretic with efficacy and biochemical effects similar to those of furosemide. Used in chronic congestive heart failure, chronic renal failure, chronic hepatic disease, and in the nephritic syndrome. It is used in the treatment of renal insufficiency and for the control and management of acute drug poisoning.

Assay: Dissolve the sample in alcohol and titrate against 0.1 M sodium hydroxide using phenol red solution as indicator until a violet-red colour is obtained. Perform a blank titration.


Dose: By oral 0.5 to 2.0 mg once daily. Parenteral: 0.5 to 1.0 mg intravenously. An equivalent dose of bumetanide is only one fortieth that of furosemide, and its bioavailability is about twice.

Dosage forms: Bumetanide injection B.P., Bumetanide oral solution B.P., Bumetanide tablets B.P., Bumetanide and slow potassium tablets B.P.

ii. Furosemide



Synthesis



Properties and uses: Furosemide is a white crystalline powder, practically insoluble in water and in methylene chloride, soluble in acetone and in dilute solutions of alkali hydroxides, sparingly soluble in ethanol.

A diuretic chemically related to the sulphonamide diuretics. It is slightly more potent than the organo-mercurial agents, is orally effective, and its diuretic action is independent of alterations in body acid-base balance. It is used for the treatment of oedema associated with renal disease, nephritic syndrome, cirrhosis of the liver, and congestive heart failure.

Assay: Dissolve the sample in dimethylformamide and titrate against 0.1 M sodium hydroxide using bromothymol blue solution as indicator.


Dosage forms: Furosemide tablets I.P., B.P., Co-amlofruse tablets B.P., Furosemide injection B.P.

SAR of Loop Diuretics


They are either 5-sulphamoyl-2-amino benzoic acid or 5-sulphamoyl-3-amino benzoic acid derivatives.

1. The carbonyl group at C-1 provides optimal diuretic activity.
2. The substitution of activating group (X) in the position 4 by Cl, alkoxy, aniline, benzyl, or benzoyl group at 4th position increases the diuretic activity.
3. The presence of sulphamoyl group in the 5th position is essential for activity.
4. The two series of 5-sulphamoyl benzoic acid differ in the nature of the functional group that substituted in 2nd and 3rd position.
5. The presence of furfuryl, phenyl, and thienyl methyl group at 2nd amino group of 5-sulphomoyl -2-amino benzoic acid gives maximum diuretic activity.
6. The wide range of alkyl group can be substituted at 3rd amino group of 5-sulfamoyl-3-amino benzoic acid without modifying the optimal diuretic activity.
7. A molecule with a weakly acidic group to direct the drug to the kidney and an alkylating moiety to react with sulphhydryl groups and lipophilic groups seemed to provide the best combination of a diuretic in the class.

i. 5-Sulphamoyl-2-amino benzoic acid derivatives




ii. 5-Sulphamoyl-3-amino benzoic acid derivatives




II. h. Phenoxyacetic acid derivatives

i. Ethacrynic Acid



Synthesis



Properties and uses: It exists as a white crystalline powder that is odourless, soluble in alcohol, ether, or chloroform and in water, an aryloxyacetic acid derivative that is a potent, short-acting diuretic. It is used in the treatment of oedema caused by congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.

II. i. Xanthine diuretics

Synthesis and drug profile of Caffeine, Theophylline, and Theobromine are discussed under sec III, Chapter CNS Stimulants.


Properties

- The Xanthines (caffeine, theophylline, and theobromine) have a weak diuretic activity.
- They have been known for their diuretic action, but currently it is rarely used.
- Aminophylline (theophylline ethylene diamine) is the most used member.
- Theophylline exerts its diuretic action by inhibition of Na^+ reabsorption in the proximal convoluted tubule.
- These drugs increase renal plasma flow, promoting a higher glomerular filtration rate.
- Adverse effects are central nervous system (CNS) stimulation and vomiting.


II. j. Osmotic diuretics

Osmotic diuretics are nonelectrolytes, which are freely filtered at the glomerulus and are not significantly reabsorbed from the tubules, and presence of these agents in the urine causes an increase in the electrolytes and volume flow. Mannitol, urea, glycerol, and isosorbide are the four osmotic diuretics, which are freely filtered through the glomerulus and are insignificantly reabsorbed from the tubules; they mainly induce diuresis by inhibiting sodium and water reabsorption in the PTs and the henle's loop.

i. Mannitol



Synthesis



Properties and uses: Mannitol is a white crystalline powder or granules, soluble in water, very slightly soluble in ethanol. It is most widely used for acute renal failure, cardiovascular operation, and severe traumatic injury with nephrotoxic anticancer agents.

Assay: It is assayed by adopting the liquid chromatography technique


Dosage forms: Mannitol injection I.P., Mannitol intravenous infusion B.P.

ii. Urea




Properties and uses: It is a colourless white, prismatic crystals or a white crystalline powder, odourless with a saline taste, soluble in water, alcohol, methanol, or glycerol, but insoluble in chloroform or ether. It is administered intravenously in a solution containing (30% urea +5% to 10% dextrose).

iii. Glycerine




Properties and uses: It is used prior to ophthalmological procedures. Glycerine is an orally active diuretic and obtained from the production of soaps and fatty acids through hydrolysis or by hydration of propylene.

iv. Isosorbide



Sorbitol






Isosorbide

Properties and uses: Isosorbide is given orally to cause a reduction in intraocular pressure. Isosorbide is prepared by acid dehydration of sorbitol.

II. k. Acidifying salts

Some inorganic cations produce weak acidotic diuresis, such as ammonium chloride, ammonium nitrate, and calcium chloride. The mechanism of acidification is represented by the following equation.



Ammonium chloride is metabolized to urea in the liver with the formation of H^+ . The excess acid (H^+) is buffered by HCO_3^- to form carbon dioxide. This leads to an acidification of the urine. An excess Cl^- also occurs in the tubular lumen and takes Na^+ along with it to maintain electrical neutrality.

PROBABLE QUESTIONS

1. Describe Benzothiadiazines (Thiazides) as an important class of diuretics. Write the structure, chemical name, and uses of any four official compounds.
2. Define and classify diuretics and write in detail about potassium-sparing diuretics.
3. What are diuretics? Classify diuretics by citing the structure, chemical name, and uses of at least two compounds from each category.

4. Write in detail about Carbonic anhydrase inhibitors and aldosterone antagonists.
5. Why do the nonmercurial diuretics have an edge over the mercurial diuretics?
6. Acetazolamide, Methazolamide, Diclofenamide, and Disulfamide are potent carbonic anhydrase inhibitors employed as diuretics. Discuss the structural difference amongst these drugs and give the synthesis of any two compounds.
7. How will you synthesize chlorthalidone, a sulphonamide diuretic.
8. High-ceiling diuretics exert an intense diuresis of relatively short duration (4–6 h) with a rapid onset (30 min). Justify the statement with the help of at least two important members of this class of drugs.
9. Write the SAR of Carbonic anhydrase inhibitors.
10. Write a brief note on the following:
(a) Aminopteredines (b) Sapirolactone (c) Phenoxyacetic acid derivatives.
11. How will you synthesize: (a) Furosemide, (b) Disulphamide, and (c) Chloromeridine
12. With the help of some specific examples describe in detail about the following:
(a) Osmotic diuretics and (b) Loop diuretics.
13. Describe the mode of action of the following class of diuretics and mention few examples with their structure.
(a) Thiazides, (b) Carbonic anhydrase inhibitors, and (c) Mercurial diuretics

SUGGESTED READINGS

1. Abraham DJ (ed). *Burger's Medicinal Chemistry and Drug Discovery* (6th edn). New Jersey: John Wiley, 2007.
2. Berliner RW and Orloff J. 'Carbonic anhydrase inhibitors'. *Pharmacy Rev* 1956.
3. *British Pharmacopoeia*. London: Medicines and Healthcare Products Regulatory Agency, 2008.
4. Bruntan LL, Lazo JS, and Parker KL. *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* (11th edn). New York: McGraw Hill, 2006.
5. Gennaro AR (ed). *Remington: The Science and Practice of Pharmacy* (21st edn). New York: Lippincott Williams and Wilkins, 2006.
6. Griffiths MC (ed). *USAN and the USP Dictionary of Drug Names*. Rockville: United States Pharmacopeial Convention Inc., 1985.
7. *Indian Pharmacopoeia*. New Delhi: Ministry of Health and Family Welfare, 1996.
8. Lednicher D and Mitscher LA. *The Organic Chemistry of Drug Synthesis*. New York: John Wiley, 1995.
9. Lemke TL and William DA. *Foye's Principle of Medicinal Chemistry* (6th edn). New York: Lippincott Williams and Wilkins, 2008.
10. Merrill J. 'Use and abuse of diuretics'. *Med Clin North Am* 44: 1155, 1960.
11. Nogrady T. *Medicinal Chemistry: A Biochemical Approach* (2nd edn). London: Oxford University Press, 1988.
12. PapsechV and Schroeder EF. 'Nonmercurial diuretics'. In *Medicinal Chemistry*, FF Blixkw (ed), Vol. III, p. 175. New York: John Wiley, 1956.

13. Spragne JM. Diuretics. In *Molecular Modification in Drug Design*, RF Gould (ed), Advances in Chemistry Series 45. Washington DC: American Chemical Society, 1964.
14. Spragne JM. Diuretics. In *Topics of Medicinal Chemistry*, JL Rabinowitz and RM Myerson (eds), Vol 2. New York: Interscience Publishers, 1968.
15. Reynolds EF (ed). *Martindale the Extra Pharmacopoeia* (31st edn). London: The Pharmaceutical Press, 1997.

"This page intentionally left blank"

Index

(+) – *trans*-isomer 32
1, 10-Phenanthroline 28
2, 2'-Bipyridine 28
2D QSAR analysis 61
3,4,5-Trimethoxy amphetamine 233
3D-QSAR analysis 62
5-HT 86
5-Sulphamoyl 1-2-amino benzoic acid derivatives 583
8-Hydroxyquinoline 28
 α -Adrenergic blockers 455
 α -Dinormethadol 270
 α -Methyl dopa 453
 α -Receptors 352
 β -Adrenergic blockers 453
 β -Adrenergic blocking agents 522, 530
 β -Adrenergic receptors 356
 β -Receptors 354
 β -Sitosterol 504, 517

A

Acebutalol 402, 412, 454
ACE inhibitors 461
Acetazolamide 554, 568
Acetyl choline 380
Acetylcholine chloride 383
Acetylcholinesterase (AChE) 379
Acetylcholinesterase inhibitors 345
Acetyl urea derivatives or phenyl acetyl ureas 289
Achiral 33
Acid-base reaction 22
Acidic diuretics 558
Acidifying salts 587
Acids and esters 95
Activation–aggregation theory 52
Actylene derivatives 95
Acyclic hypnotics 116
Addictive property 247
Adenosine 86
Adrenergic neuron blockers 457
Adjunctive treatment of oedema 569

Adrenaline 351, 359, 360
Adrenergic blockers 453
Advantages and disadvantages of solid support reagents 68
Advantages of CADD 55
Advantages of QSAR 58
Aetiology of hypertension 447
Agonist 49
Agents 5
Alcohols and aldehydes 94, 120
Aldosterone antagonists 577
Aldosterone inhibitors 555
Alfazosin 410
Alfentanil 251
Alfentanil 133, 145
Allobarbitone 101
Almitrine dimesylate 230
Alpha-receptor blocking agents 403
Alpha acetyl methadone 252
Alphaprodine 268
Alpha receptor blocking agent 399
Alprazolam 92, 115
Alzheimer's disease (AD) 344
Amides 93
Amantadine HCl 319, 324
Ambenonium chloride 381
Amiloride 556, 579
Amino alcohol 436
Amino alcohol esters 422, 429
Amino alcohols 423
Amino amides 424, 439
Amino ethers 423, 434
Aminophylline 232, 557, 585
Amitriptyline 216
Amitriptyline 206
Amlodipine 459, 522, 531
Amobarbital 90
Amphenone B 555
Amphetamine 231, 237, 359, 368
Amphoteric surfactants 26
Amylnitrite 526
Anaesthesia 131

Analgesia 131
 Anaphylactic shock 368
 Angina 520
 Anileridine 251
 Anilide derivatives 153
 Anilides 166
 Anionic surfactants 26
 Anorexic action 369
 Antagonist 49
 Anthelmintic activity 23
 Antianginals 520
 Anticancer agents 586
 Anticholinergic agents 320, 325
 Antiepileptic 99
 Antihistamines and anticholinergics 95
 Antihypertensive 449
 Antimuscarinic agents 420
 Antitussive 257
 Anxiety states 89
 Approaches to lead discovery 44
 Approach with molecular connectivity 48
 Aprobarbital 90
 Arecholine 380
 Arsphenamine 2
 Arylcyclohexylamines 143
 Aryloxyacetic acid derivative 585
 Ascending limb of loop of Henle 551
 Aspartate 85
 Aspirin 525
 Atenolol 402, 413, 454
 Atherosclerotic angina 520
 Atorvastatin 501
 Atropine 421, 425, 428
 Autonomic nervous system 351
 Azacytidine 77
 Azosemide 583
 Benace 469
 Benazepril 469
 Bendroflumethiazide 451, 553
 Benidipine 523
 Benserazide 319
 Benzafibrate 511
 Benzalkonium chloride 26
 Benzisoxazoles 199
 Benzocaine 152, 158
 Benzodiazepine receptor 96
 Benzodiazepines 91, 108, 143, 289, 303, 331
 Benzoic acid derivatives 151, 154
 Benzothiazepine derivatives 524
 Benzoxazole analogues 331, 338
 Benzphetamine 231
 Benzthiazide 553, 560
 Benztropine Mesylate 423, 434, 435
 Bepridil 524, 540
 Berlex 503
 Beta-receptor blocking agents 401
 Betacard 413
 Beta halo alkyl amines 399
 Bethanechol 380
 Bethanechol chloride 386
 Bethanidine 457
 Bile acid sequestrants 503
 Binoxinate 153, 162
 Bio-activation 78
 Bio-precursors 71
 Biogenic catecholamines 85
 Bioinformatics 54
 Bioisosteres 36
 Bioisosterism 36
 Biotransformation 97
 Biperiden 423, 436
 Biperiden HCl 326
 Bisuculline 233
 Blood brain barrier 106
 Bootstrapping 61
 Bromocriptine 319
 Bromocryptine mesylate 324
 Bromovalurea 93
 Bronchial asthma 365
 Bronchodilators 356, 357
 Bumetanide 452, 556, 581, 584
 Bupivacaine 153, 166
 Buprenorphine 257
 Bupropion (Zyban) 225

B

Baclofen 89, 341
 Barbital 90
 Barbitone sodium (Barbital sodium) 98
 Barbiturates 90, 91, 96, 106, 287, 291
 Barbituricid 96
 Bemidone 250
 Bemigrade 230, 236

Butabarbital 90
Butacaine 153, 162
Butalbital 90
Butamben 152, 159
Butaperazine 179
Buthiazide 553
Butorphanol tartarate 253

C

CADD 54
Caffeine 232, 240, 557, 585
Calcium channel blockers 458, 522, 531
Calfactant 26
Calomel 558
cAMP 89
Candesartan 471
Cannabis 245
Canrenoate 555
Canrenone 555, 577
Caproyl chlorthiazide 568
Captopril 461, 463
Carbachol 380, 384
Carbamates 93, 330
Carbamazepine 307
Carbanazepine 290
Carbidopa 319, 323
Carbonic anhydrase inhibitors 289
Carbromal 93
Cardace 466
Cardiac stimulants 357
Cardiovascular agents 541
Cardiovascular glycosides 524
Carrier-linked pro-drugs 71
Carvedil 417
Carvedilol 417, 456
Carvediol 403
CAse inhibitors 554
Catacholamine depleters 453
Catechol-O-methyl transferase 365
Catecholamine 356
Catecholamines 358, 360
Cationic surfactants 26
Centrally acting drugs 452
Centrally acting muscle relaxants 330
Central nervous system (CNS) 85
Cerivastatin 502
Cetrimide 26
Cetyl pyridinium chloride 26
Charge transfer complex 53
Chelates 27
Chemical diversity 5
Chemometrics 56
Chloral hydrate 121
Chlorazepate 113
Chlordesmethyl diazepam 92
Chlordiazepoxide 180, 188
Chlorgyline 205
Chloroform 131
Chloromerodrin 552, 559
Chloropheneteramine 231
Chlorothalidone 554
Chlorphenesin carbamate 336
Chlorprocaine 152
Chlorpromazine 179, 183
Chlorprothixene 182, 193
Chlorthalidone 573
Chlorthiazide 450, 553, 560
Chlorzoxazone 338
Cholestyramine 503
Cholestyramine resin 514
Choline esters 380
Cholinergic receptors 355
Cholinergic transmission in CNS 86
Cholinomimetic alkaloids 380, 384, 388
Cholinomimetic drugs 378
Ciemmensson 364
Ciprofibrate 512
Cirrhosis 585
Citalopram 207
Classical bioisosteres 37
Classic angina 520
Clidinium 422, 430
Clobazam 303
Clofibrate 509
Clomipramine 214
Clonazepam 92
Clonidine 452
Clopamide 554
Clopenthixol 182, 194
Cloretermine 231
Clorexolone 576
Clorgyline 205
Clozapine 182, 197

CNS stimulants 357
 CNS stimulation 357
 Co-transporters 581, 588
 Cocaine 154
 Codeine 249
 Colestipol 503, 515
 Collecting duct 551
 Combinatorial chemistry 66
 Combinatorial compound libraries 67
 Comparative molecular field analysis (CoMFA) 62
 Comparative molecular similarity indices analysis (CoMSIA) 64
 Competitive antagonist 578
 Complexation 27
 Computer-aided drug design 7, 54
 Conformational isomers 31
 Correlation coefficient 60
 Cortical diluting segment of loop of henle 551
 Covalent bonding 52
 Craniosacral outflow 354
 Critical micelle concentration 25
 Cross-validation 61
 Cyclandelate 525
 Cyclazocine 253, 275
 Cyclic adenosine monophosphate 50
 Cyclobarbitol 91
 Cycloplegia 430
 Cyclobenzaprine 341
 Cyclomethycaine 152
 Cyclomethycaine sulphate 156
 Cyclopenthiazide 451, 553, 564
 Cyclopentolate 422
 Cyclopentolate HCL 429
 Cyclo propane 132, 139
 Cyclothiazide 553, 563
 CYP450 97, 151

D

d- and l-tartaric acid 33
 Dale's vasomotor reversal 398
 Dalvastatin 501, 508
 Dantrolene 340
 Debrisoquine 457
 Delirium 131
De novo approach 57
 Denzimol 290, 309

Denzinamide 310
 Depolarization 85, 96, 150
 Depolarizing neuromuscular blockers 333
 Depolarizing neuromuscular blocking drugs 330
 Deprenyl 205
 Design of analogues and prodrugs 43
 Design of lead and lead discovery 44
 Desipramine 213
 Dextroamphetamine 231
 Dextromethorphan 253
 Dextromoramide 252, 271
 Dextropropoxyphene 272
 Dextrothyroxine 504, 517
 Dezinamide 290
 Diamides 424
 Diamino propanol ethers 524
 Diastereomers 33
 Diazepam (calmpose, valium) 109
 Diazepam 92
 Diazotisation 364, 391
 Diazoxide 463, 474
 Dibenamine 399, 403
 Dibenzodiazepines 197
 Dibenzoazepine derivatives 207
 Dibucaine 154, 174
 Dichlorophenamide 554
 Diclofenamide 570
 Dicyclomine 422
 Dicyclomine HCl 431
 Dienophile 259
 Diethazine 425
 Diethylallylacetamide 93
 Diethyl ether 131
 Diethyl stilboesterol 30
 Digitoxin 541
 Digoxin 541
 Dihydromorphine derivatives 250
 Dihydropyridine/pyridinium 78
 Diltiazem 459, 524, 538
 Dimercaprol (BAL) 29
 Dimethisoquin 175
 Dimethizoquine 154
 Dimethylglyoxime 28
 Dimidone 288
 Dipanone 252
 Dipiperodon HCl 154, 172
 Diphenhydramine 321

Diphenmail methyl sulphate 425
Diphenoxylate 251
Diphenoxylate hydrochloride 264
Diphenyl alkamins 524
Dipole-dipole and ion-dipole interactions 52
Dipyridamole 525, 543
Direct-acting adrenergic agonists 358
Direct-acting cholinceptor
 stimulant 378
Dissociative anaesthetic 143
Distal tubule 551
Distigmine 382
Distomer 35
Disulfamide 554, 571
Disulphonamide 571
Diuretics 450, 551
Divinyl ether 132
Dobutamine 359, 366
Domacarium 382
Donepezil 346
Dopamine 86, 318, 321, 359, 363
Dopamine conservation, MAO-B inhibitor 320
Dopamine receptor stimulation: Dopaminergic
 agonists 319
Dopamine releasers 319
Doxapram 234
Doxapram HCl 230
Doxazosin 401, 410, 456
Doxefazepam 92
Doxepin 206, 219
Droperidol 180, 192
Droxidopa 319
Drug design 41
Drug designing 6
Drug design through conjunction 46
Drug design through disjunction 45
Drug discovery and design 2
Drug latention 71
Dual-acting adrenergic agonists 358
Dyclonine HCl 154
Dyphylline 232

E

Easson–Stedman hypothesis 34
Echothiopate 382
Echothiopate 396

Edrophonium chloride 381, 394
Electron-donating substituents 53
Electron-withdrawing substituents 53
Electrostatic bonding 52
Enalapril 462, 464
Enalaprilat 462
Enantiomers 32, 33
Enflurane 132, 137
Enzyme 50
Ephedrine 360
Eplerenone 555
Ergoline 319
Erythrityl tetranitrate 527
Escitalopram 207
Esmolol 403
Estazolam 92, 115
Ethacrynic acid 451, 584
Ethinamivan 230
Ethchlorvynol 121
Ether (Diethyl ether) 134
Ethinamate 117
Ethopropazine HCl 321, 327, 424
Ethosuximide 288, 298
Ethotoin 288
Ethoxozolamide 554, 570
Ethyl chloride 132
Ethylenediamine 28
Ethylenediamine tetra acetic acid 28
Ethyl morphine 249
Etidocaine 153, 169
Etomidate 95, 134, 146
Etopylline 232
Etorphine 258
Eucatropine HCl 422
Eudismic ratio 35
Euphoria 248
Eutomer 35
Ezetimibe 505, 519

F

F-value 61
Factors affecting the drug-receptor interaction 53
Fast neurotransmitters 50
Felodipine 459, 522, 535
Fenfluramine 231, 237
Fenozolone 231

Fentanyl 133, 145, 251
 Fentanyl citrate 262
 Ferguson principle 13
 Fibric acid derivatives 502, 509
 Fletazepam 338
 Flumethiazide 553
 Flunitrazepam 92
 Fluoroxene 132
 Fluoxetine 207, 221
 Fluvastatin 501
 Flupenthixol 182
 Fluphenazine 179
 Fluphenecin 186
 Flurazepam 92
 Fluroethyl 233
 Fluoroxene 132
 Fluvastatin 501, 506
 Fluvoxamine 207, 222
 Forces involved in drug receptors interaction 52
 Fosazepam 92
 Fosphenytoin 290, 310
 Fostosal 78
 Free-Wilson analysis 57
 Frusemide or furosemide 451
 Full agonist 49
 Functions of renal system 549
 Furosemide 556, 582, 583

G

G-protein-coupled receptors 49
 GABA agonistic activity 286
 GABA-transaminase 305
 GABA 85
 GABA_A 89
 GABA analogues 304
 GABA_B 89
 Gabapentin 290, 306
 Galantamine or galanthamine 346
 Gallamine triethiodide 332
 Gamma-aminobutyric acid (GABA) 89
 Gamma amino butyric acid (GABA) analogues 290
 Ganglion blockers 457
 Ganglionic blocking agents 420
 Gastroenteritis 264
 Gemfibrosil 510
 Gemfibrozil 502

Genetic function approximation (GFA) 60
 Genetic partial least squares (G/PLSs) 60
 Gene transcriptions 50
 Glaucoma 384
 Glomerular filtration 550, 585
 Glomerular filtration rate (GFR) 550
 Glutamate 85
 Glutethimide 119
 Glycerine 586
 Glycerol mono-ethers and analogues 330
 Glycine 85
 Glycopyrrolate bromide 422, 432
 Grandmal 286
 Guaifenesin 335
 Guanabenz 453
 Guanethidine 457
 Guanoxan 457

H

Hallucination 248
 Haloperidol 180, 190
 Halothane 132
 Halozepam 92
 Hammett's relationship 57
 Hangover 119
 Hansch analysis 57
 Henle's loop 585
 Hepatic cirrhosis 578
 Heptabarbital 91
 Heroin 249
 Hetacillin 74
 Heterocyclic bases 338
 Heterocyclic sulphonamides 571
 Hexabarbitone 103
 Hexamethonium bromide 457
 Hexamine 75
 Hexobarbital 90, 133
 Hexylcaine 151
 Hexylcaine hydrochloride 155
 High-dimensional QSAR analyses 58
 High throughput screening 66
 Histaminergic neurons 86
 HMG CoA-reductase inhibitors 500, 505
 Hoffmann degradation 579
 Homatropine 421, 427
 Homoveratrylamine 363

Hydantoins 287, 293
Hydralazine 462, 472
Hydrochlorothiazide 553
Hydrochlorthiazide 450, 561
Hydrocodone 250
Hydro flumethiazide 553, 562
Hydrogen bonding 15, 52
Hydromorphone derivatives 249
Hydromorphone 250
Hydrophobic forces 53
Hydrophilic 164
Hydrothiazides 553, 561
Hydroxyzine hydrochloride 122
Hyoscine 27
Hyperpolarization 85
Hypertension 449

I

Identification of biologically active materials 6
Imidazole analogue 331
Imidazole derivatives 400
Imidazoline analogues 340
Imidazoline receptor agonist 456
Imino dibenzyl derivatives 206
Iminostilbenes 290, 307
Imipramine 212
Indacrinone 558
Indapamide 554, 575
Inderal 411
Indirect-acting adrenergic agonists 358
Indirect acting of cholinomimetic drugs 379
Indole derivatives 233
Induced Fit Theory 51
Inert precursor 71
Inhalation anaesthetics 130
Inhibiting gamma amino butyric acid 286
Inhibiting sodium channels 286
Inhibition of T-type calcium currents 286
Inhibitory neurotransmitters 89
Inositol trisphosphate 50
Insomnia 118
Intermediate-acting barbiturates (3–6 h) 90
Intermolecular hydrogen bonding 15
Intramolecular bond formation 52
Intramolecular hydrogen bonding 15
Intravenous anaesthetics 131

Intrinsic activity 50, 51
Local anaesthetics 150
Ionotropic 358
Ipratropium bromide 421, 427
Iproniazid 205
Irbesartan 471
Irreversible blockers 395
Irreversible cholinesterase inhibitors 382
Irreversible covalent bonds 18
Isobucaine 152
Isocarboxazide 205, 209
Isofluorophate 382
Isoflurane 132, 138
Isomethadone 252
Isoprenaline 359, 365
Isopropamide iodide 424
Isosorbide dinitrate 529
Isosorbide 557, 587
Isosterism 36, 53
Isosupurine 360
Isoxsupurine 373
Isradipine 522, 536

K

Ketamine 133
Ketamine HCl 143
Ketazocine 253
Ketobemidone 251, 266
Kinase-linked receptors 49

L

l-Penicillamine 29
LAAM 270
Labesol 416
Labetalol 456
Labetolol 403, 416
Lacidipine 523
Lamotrigine 290, 311
Levallorphan 282
Levodopa 318, 321
Levorphanol 256
Levorphanol tartarate 253
Librium 44
Lidocaine/Lignocane 153

Lidocaine HCl 166
 Ligand-gated ion channels 49
 Ligands 27
 Lignocaine, Xylocaine 166
 Linear free energy 48
 Lipid water solubility 106
 Lipophilic 164
 Lisinopril 462, 465
 Lisuride 319
 Local anaesthetics 150
 Lofentanil 251, 268
 Long-acting barbiturates 90
 Loop diuretics 451
 Lopramide 251, 267
 Lopresor 413, 415
 Lorazepam 92, 112, 180
 Lorbamate 337
 Lorbamate or carisoprodal 331
 Losartan 460, 470
 Lovastatin 509
 Loxapine succinate 182, 196
 Lysergic acid diethylamide 233, 244

M

Malathion 382
 Malidione 288
 Malonic acid 96
 Manidipine HCl 523
 Mannich base 272
 Mannich reaction 272
 Mannitol 585
 MAO 366
 Mecamylamine HCl 458
 Mechanism of action of sympathomimetics 357
 Medullary paralysis 131
 Memantine 345
 Meperidine 250
 Meperidine analogues 250, 261
 Mephesisin 334
 Mephentyoin 288
 Mephobarbital 90
 Mephobarbiton 287
 Mephobarbitone 101, 292
 Mepivacaine 153, 167
 Meprobamate (Miltown) 116
 Meprobamate 334

Meprylcaine 151
 Meprylcaine and isobucaine HCl 156
 Meralluride 552
 Mercaptomerin 552
 Mercaptomerin sodium 558
 Mercurial diuretics 552, 558
 Mercurophyllin 552
 Merethoxyline 552
 Mersalyl 552
 Mescaline 234
 Mesoridazine 179
 Meta-disulphamoyl benzene 571
 Metabolism of adrenaline and noradrenaline (catecholamines) 361
 Metabolism of barbiturates 97
 Metabolism of benzodiazepines 108
 Metaprolol 402
 Metaraminol (Aramine) 367
 Metaraminol 359
 Metaxalone 331, 336
 Metazocine 253
 Methacholine 380
 Methadone 252
 Methadone analogues 250
 Methamphetamine 231
 Methantheline bromide 423
 Methaqualone 119
 Metharbital 90, 287
 Methazolamide 554, 569
 Methocarbamol 335
 Methohexital sodium 133, 141
 Methoin or mephentyoin 295
 Methoxy flurane 132, 137
 Methsuximide 288, 299
 Methyclothiazide 553, 565
 Methypylone 118
 Methylphenidate HCl 239
 Methyl phenobarbitone 101
 Methylxanthines 232
 Metolazone 554, 574
 Metoprolol 413, 415, 454
 Metyrapone 555
 Micelle 25
 Micelle formation 25
 Midazolam 133, 144
 Mineralocorticoid receptor 577
 Minipress 407
 Minoxidil 463, 473

Mintop 473
Mioflazine 526
Mixed Approach 58
Mixed α and β blockers (nonselective) 456
MLR analysis 59
Mode of action 96
Modern drug discovery 3
Moexipril 462
Molecular hybridization in drug design 46
Molecular orbital approach 48
Molindone 196
Morphan analogues or benzazocin derivatives 253
Morphan derivatives 273
Morphinan analogues 253
Morphine 249, 254
Morphine analogues 254
Morphine and its analogues 249
Morpholinones 232
Moxonidine 456
Multiple hydrogen bonding groups 16
Multiple linear regression 56
Muscarine 380
Muscarinic receptor antagonists 419
Muscarinic receptors 355
Muzolimine 558
Mydriatic 373
Myocardial infarction 368
Myostigmin 391

N

N-dealkylation 79
N-methyl D-aspartate (NMDA) receptor 85
N₂O 131
Nabumetone 79
Nadolol 454
Nafimidone 312
Nalorphine 249, 279
Naloxone 280
Naltrexone 281
Naphazoline 360, 371
Narcotic analgesics 145, 247
Narcotic antagonists 278
Nasal congestion 373
Nasal decongestants 357
Natriuretic 580
Natriuretic effect 578

Natural and dehydrogenated ergot alkaloids 400
Nefopam 339
Neostigmine Bromide 381, 391
Nephridine 362
Nephritic syndrome 580, 583
Neuromuscular blocking agents 332, 420
Neuromuscular blocking drugs 330
Neurotransmitters 85
Newer anticonvulsants 290
Nialamide 206
Nicardia 532
Nicardipine 459, 523, 536
Nicorandil 529
Nicotinic acid (Niacin) 504
Nicotinic acid 516
Nicotinic receptors 86, 355, 419
Nifedipine 458, 522, 532
Nigrostriatal dopaminergic neurons 86
Nikethamide 230, 235
Nimetazepam 92
Nimodipine 522
Nipam 110
Nirvanol 295
Nisoldipine 522
Nitrazepam 92,
Nitrazepam (Nipam) 110
Nitrendipine 460, 522, 534
Nitrites and nitrates 521, 526
Nitroglycerine 527
Nitrous oxide 140
NMDA Antagonists 345
Nodalol 402
Nonbenzodiazepine 124
Noncatecholamines 359, 367
Nonclassical bioisosteres 37, 38
Nondepolarizing muscle relaxants 330
Nonionic surfactants 26
Nonmercurial diuretics 553
Nonopioid analgesics 247
Nonrandom screening 44
Nonspecific conformational perturbations 51
Nonthiazide diuretic 574
Noradrenaline 359, 362
Noradrenergic neurons 86
Nordiazepam 92
Norepinephrine 362
Normethadone 252
Nortriptyline 217

Nortryptiline 206
 Nuclear receptors 49
 Nylidrine 360
 Nylidrine HCl 374

O

Obesity 369
 Occupation theory 50
 Opioid analgesics 247
 Opium 247
 Opioid receptors 248
 Optical isomerism 53
 Orbide 587
 Organophosphate 379
 Oripavines 259
 Orphenadrine citrate 423, 434
 Orphenadrine Hydrochloride 342
 Orthodox synthesis 66
 Osmotic diuretics 557
 Osomotic diuretics 585
 Outliers 61
 Oxanamide 93
 Oxazepam 92, 111, 180, 189
 Oxazolidinediones 288, 296
 Oxazolidinone derivatives 231
 Oxprenalol 401, 454
 Oxy morphone 250

P

p-Amino benzoic acid derivatives 152
 Para amino benzoic acid derivatives 158
 Paraldehyde 122
 Paramethadione 288, 297
 Parasympathetic system 351
 Parathion 382
 Pargyline 211
 Pargyline HCl 205
 Parkinson's disease 86
 Paroxetine 207
 Partial agonist 49
 Partial least square (PLS) 59
 Partition co-efficient 18, 106
 Pathogenesis 344
 Pemoline 231, 239

Plant-derived bioactive materials 4
 Pempidine 458
 Pentaerythritol tetranitrate 528
 Pentazocine 253, 273
 Pentobarbital 91
 Pentobarbitone sodium 104
 Pentolinium tartarate 457
 Pentoxyphylline 232, 243
 Pentylene tetrazole 233, 243
 Peripherally acting 247
 Peripheral vascular resistance (PVR) 447
 Perphenazine 179
 Perphenazine 186
 Pethidine 261
 Pethidine hydrochloride 261
 Petitmal 286
 Petitmal epilepsy 99
 Pharmacodynamic Studies 44
 Pharmacokinetic Studies 44
 Phenacaine 154, 171
 Phenacemide 289, 302
 Phenazocaine 253
 Phenazocine 276
 Phencyclidine 133
 Phencyclidine HCl 234
 Phenelzine 205, 208
 Phenetermine 231
 Pheniprazine 205
 Phenobarbital 90, 292
 Phenobarbitone (Phenobarbital) 99
 Phenobarbitone 287
 Phenodoxone 252
 Phenol 26
 Phenothiazine 23
 Phenothiazines 183
 Phenothiazine anaologues 321
 Phenoxy acetic acid 584
 Phenoxyacetic acid derivatives 556, 584
 Phenoxy benzamine 399, 404
 Phenoxy benzamine hydrochloride 455
 Phensuximide 288, 300
 Phentermine 238
 Phentolamine 400, 455
 Phentolamine mesylate 406
 Phenyl acetyl urea derivatives 302
 Phencyclidine 133
 Phenylephrine 360, 372
 Phenyl ethyl acetyl urea 289

Phenylethylamine derivatives 234
Phenyl ethyl hydantoin 288
Phenyl propanolamine 231
Phenytoin 288, 293
Physicochemical characteristics 11
Physicochemical properties 56
Physostigma 389
Physostigmine 381, 389
Picrotoxin 233, 244
Pilocarpine 380, 388
Pilocarpus 389
Pindalol 401, 454
Piperidine analogues 320
Piperidinedione derivatives 118
Piperidinediones 94
Piperocaine 152, 158
Pirenzepine 425
Piretanide 556, 584
Point attachment 34
Polonovsky rearrangement 112
Polymorphism 113
Polythiazide 553, 566
Poppy 247
Positive chronotropic 362
Positive inotropic 362
Potassium-sparing diuretics 452
Pralidoxime chloride 382, 395
Pramoxine HCl 154, 172
Prazepam 92
Prazosin 400, 407, 455
Predicted sum of squares (PRESS) 61
Pressor agents 357
Prilocaine 153, 168
Primary aldosteronism 579
Primary hypertension 449
Primidone 290, 292
Principal component analysis (PCA) 60
Pro-drug 71
Probucol 504, 515
Procaine 152
Procaine hydrochloride 160
Processes of drug discovery 1
Prochlorperazine 179, 186
Procyclidine HCl 320, 327, 424, 437
Progabide 290, 304
Promazine 179, 183
Prontosil 74
Propanolol 411

Propanidid 133
Propanthelin bromide 432
Propantheline bromide 423
Proparacaine 164
Properidone 250
Propofol 134, 147
Propoxycaïne (Blockhain) 163
Propoxycaïne 153
Propoxyphen 252
Propranolol 402, 411, 453
Propranolol HCl 530
Prostigmine 391
Protriptyline 206
Proximal tubule 551
Proxiphylline 232
Psilocybin 233
Psilocyn 233
Psilocybin 245
Psychomotor seizures 286
Pteridine 580
Pteridine derivatives 556
Purine or xanthine derivatives 556
Pyridine derivative 504, 516
Pyridostigmine bromide 381, 392
Pyrrolidine analogues 320

Q

Quantitative structure-activity relationship 56
Quantum mechanics 48
Quaternary amines 420
Quaternary ammonium compounds 457
Quazepam 92
Quetiapine 200
Quinapril 462, 468
Quinazoline 400, 572
Quinazolinones 94
Quinethazone 554, 572
Quinobarbitone sodium 105

R

Race 466
Ralitoline 313
Ramipril 462, 466
Random screening 44

Rate of receptor occupation 51
 Rate theory 51
 Rational approach to drug design 48
 Rational drug design 7
 Rational drug design approach 54
 Receptor 49
 Redox potential 22
 Regression methods 59
 Regulation of blood pressure 448
 Relative response 51
 Renin-angiotensin system 460
 Rescinnamine 181
 Reserpine 181
 Reserpine 181, 453
 Resins for SPS 68
 Reversible blockers 389
 Reversible cholinesterase inhibitors 381
 Reversible reaction 568
 Reynaud's syndrome 384
 Riboflavin 23
 Rilmenidine 457
 Risperidone 182, 199
 Rivastigmine 348

S

Salbutamol 360, 369
 Saponification 114, 440
 SAR of anilides 170
 SAR of barbiturates 106, 293
 SAR of benzodiazepines 116
 SAR of benzoic acid derivatives 164
 SAR of benzomorphan derivatives (benzazocines) 276
 SAR of butyrophenones 193
 SAR of CAse Inhibitors 571
 SAR of dibenzazepines 215
 SAR of dibenzo cycloheptane derivatives 219
 SAR of diphenyl heptanone 273
 SAR of hydantoins 295
 SAR of loop diuretics 583
 SAR of meperidine analogues 269
 SAR of morphine 259
 SAR of oxazolidinediones 298
 SAR of phenacetamide 302
 SAR of phenothiazines 187
 SAR of sodium valproate 309
 SAR of succinimides 301

SAR of thiazide diuretics 567
 Screening and designing 4
 Scopolamine 421, 426
 Secobarbital 91
 Secondary amines 458
 Secondary hypertension 449
 Second messengers 50
 Sectaral 412
 Selegiline HCl 320
 Semiquinone 23
 Seretindole 202
 Sertraline 207, 223
 Sevoflurane 132, 139
 Simple linear regression analysis 59
 Simvastatin 506
 Sleep problems 89
 Smooth muscle relaxants 358
 Sodium nitroprusside 463, 474
 Sodium valproate 290, 308
 Solanaceous alkaloids and analogues 421
 Solid phase synthesis 67
 Spasmolytic 432
 Specific conformational perturbations 51
 Specific β -blockers 402
 Spiranolactone 452
 Spirapril 462
 Spironolactone 555, 577
 Split-mix technique 67
 Stages of anaesthesia 131
 Standard error of the estimate (S) 60
 Statistical methods used in QSAR analysis 59
 Steps involved in QSAR studies 59
 Stepwise linear regression analysis 59
 Steric features of a drug 30, 53
 Streptomyces 5
 Structural elucidation 6
 Structurally nonspecific drugs 13
 Structurally specific drugs 13
 Structure-activity relationship 56
 Strychnine 244
 Strychnine 233
 Succinimides 288, 298
 Succinyl Choline Chloride 333
 Sufentanil 251, 254, 278
 Sulindac 72, 79
 Sulphasalazine 75
 Sulphomoyl benzoic acid derivatives 556
 Sulphonamide diuretics 554

Sulphones 96
Suppressing the appetite 358
Surface-active property 26
Surface anaesthetic 156
Surface tension 25
Surfactant 25
Surgical anaesthesia 131
Sympathetic system 351
Synthesis of mephenesin (Tolserol) and
guaifenesin 334

T

Tacrine 345
Talbutal 90
Tartaric 33
Telmiesartan 461
Telmisartan 471
Temazepam 92
Terapress 409
Terazosin 401, 409, 455
Terbutaline 360, 375
Tertiary amines 420, 458
Tetracaine 152, 161
Thebaine 280
Theobromine 232, 242, 557, 485
Theophylline 232, 557, 585
Theophylline and theobromine 242
Theophylline hydrate 242
Theories of receptors 50
Thermodynamic activity 13
Thiazide derivatives 553
Thiazides 450, 560
Thioethylperazine 179
Thiomylal sodium 133, 142
Thiopental sodium 133
Thiopentone 91
Thiopentone sodium 140
Thioridazine 179
Thiothixene 182, 195
Thoracolumbar division 351
Three-point attachment 351
Tiagabin 290, 305
Ticrynafen 556
Tilidine 254
Tilidine HCl 277
Timolol 402, 454

Tocopherol 321
Tolazoline 400, 405, 455
Topiramate 314
Toresemide 556
Tozalinone 231
Tramadol 254
Tramadol hydrochloride 277
Trandolapril 462
trans-diethylstilbesterol 43, 45
transaminase enzyme 286
Tranlycypromine 205, 210
Trazadone 226
Triamterene 452, 556, 580
Triazolam 92
Triazolo benzodiazepines 92, 114
Tribromo ethanol 132
Trichloromethiazide 553, 565
Trichloro ethylene 132
Triclofos sodium 123
Trifluoperazine 179
Trifluoperidol 180, 191
Triflupromazine 179
Trihexyphenidyl 438
Trihexyl phenidyl 424, 438
Trihexyphenidyl HCl 325
Trimethadione 288, 296
Trimethoxy amphetamine 234
Trimethophan 458
Trimethyl ammonium 31
Trimipramine 212
Tropicamide 424, 439
Troxidone 288
Tabocurarine 136
Tubcurarine chloride 330
Tubular reabsorption 550
Two-point attachment 34

U

Ulcerative colitis 264
Ultra short-acting barbiturates 140
Unstable angina 520
Urea 557
Ureides 93
Urethanes 93
Uricosuric diuretics 558
Urinary output 550

V

V. Ambenonium chloride 381
 Valnoctamide 93
 Valproic acid 308
 Valsartan 461, 472
 Van der Waal's or London Dispersion Forces 53
 Variant angina 520
 Vaso-constrictors 358
 Vasodilators 462, 472
 Vasospastic angina 521
 Venlafaxine 208, 224
 Verapamil 458, 524, 537
 Vigabatrin 290, 305
 Volatile/inhalation anaesthetics 134

W

Weak and reversible H-bonds 18
 Withdrawal side effects 247

X

Xanthine diuretics 585
 Xanturil 557
 Xilobam 331, 337
 Xipamide 576
 Xylometazoline 360, 375

Z

Zaleplon 96, 124
 Ziprasidone 182, 201
 Zolpiclone 96
 Zolpidem 96, 126
 Zonisamide 290, 314
 Zopiclone 125
 Zwitterion 165, 171